Patent application title: COMPOSITIONS AND METHODS RELATED TO PROFILING A PLURALITY OF CELLS BASED ON PEPTIDE BINDING
Inventors:
Renata Pasqualini (Houston, TX, US)
Renata Pasqualini (Houston, TX, US)
The Board Of Regents Of The University Of Texas (Austin, TX, US)
Wadih Arap (Houston, TX, US)
Mikhail Kolonin (Houston, TX, US)
Assignees:
The Board of Regents of the University of Texas System
IPC8 Class: AC07K764FI
USPC Class:
424 169
Class name: Radionuclide or intended radionuclide containing; adjuvant or carrier compositions; intermediate or preparatory compositions in an organic compound attached to peptide or protein of 2+ amino acid units (e.g., dipeptide, folate, fibrinogen, transferrin, sp. enzymes); derivative thereof
Publication date: 2013-04-11
Patent application number: 20130089498
Abstract:
Methods and compositions are described for classifying cells and/or
peptides that associate or bind with a particular characteristic pattern
to a plurality of cells or cell lines. Aspects of the invention also
include the use of peptide(s) having an appropriate binding
characteristic to deliver a drug to a cell or cell population.Claims:
1.-31. (canceled)
32. A method of targeting a therapeutic agent or an imaging agent to an EphA5 receptor positive cancer cell in a subject, the method comprising administering to the subject a pharmaceutical composition comprising: a) the EphA5 cell targeting moiety; and b) the therapeutic agent or the imaging agent.
33. The method of claim 32, wherein an EphA5 receptor is on a surface of the cancer cell.
34. The method of claim 32, wherein the subject is a human.
35. The method of claim 32, wherein the EphA5 cell targeting moiety comprises a peptide.
36. The method of claim 35, wherein the peptide is covalently modified.
37. The method of claim 35, wherein the peptide is cyclic.
38. The method of claim 32, wherein the EphA5 cell targeting moiety comprises an antibody.
39. The method of claim 38, wherein the antibody is specific for EphA5 receptor only when upregulated on a surface of the cancer cell.
40. The method of claim 32, wherein the therapeutic agent or the imaging agent comprises a radioisotope.
41. The method of claim 40,wherein the radioisotope is 213Bi, 103Pd, 133Xe, 131I, 68Ge, 57Co, 65Zn, 85Sr, 32P, 35S, 90Y, 153Sm, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn, 117Sn, 186Re, 166Ho or 188Re.
42. The method of claim 32, wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell.
43. The method of claim 32, wherein the therapeutic agent is an immunotherapeutic agent.
44. The method of claim 32, Wherein the therapeutic agent is a chemotherapeutic agent.
45. The method of claim 32, wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent.
46. A method of treating an EphA5 receptor positive cancer cell in a subject, the method comprising administering a pharmaceutical composition comprising: a) an EphA5 cell targeting moiety; and b) a therapeutic agent or an imaging agent, to the subject.
47. The method of claim 46, wherein an EphA5 receptor is on a surface of the cancer cell.
48. The method of claim 46, wherein the subject is a human.
49. The method of claim 46, wherein the EphA5 cell targeting moiety comprises a peptide.
50. The method of claim 49, wherein the peptide is covalently modified.
51. The method of claim 50, wherein the peptide is cyclic.
52. The method of claim 46, wherein the EphA5 cell targeting moiety comprises an antibody.
53. The method of claim 52, wherein the antibody is specific for an EphA5 receptor only when upregulated on a surface of the cancer cell.
54. The method of claim 46, wherein the therapeutic agent or imaging agent comprises a radioisotope.
55. The method of claim 54,wherein the radioisotope is 213Bi, 103Pd, 133Xe, 131I, 68Ge, 57Co, 65Zn, 85Sr, 32P, 35S, 90Y, 153Sm, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn, 117Sn, 186Re, 166Ho or 188Re.
56. The method of claim 46, wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell.
57. The method of claim 46, wherein the therapeutic agent is an immunotherapeutic agent.
58. The method of claim 46, wherein the therapeutic agent is a chemotherapeutic agent.
59. The method of claim 46, wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent.
Description:
[0001] The present application is a divisional of co-pending U.S.
application Ser. No. 12/826,327, filed Jun. 29, 2010, which is a
continuation of U.S. application Ser. No. 11/684,379, filed Mar. 9, 2007,
which claims the benfit of U.S. Provisional Patent Application No.
60/780,893, filed Mar. 9, 2006, the entire contents of each of which are
incorporated herein by reference in their entirety.
TECHNICAL FIELD
[0003] The present invention is directed generally to method and compositions related to molecular biology, virology, and oncology. In certain aspects it is directed to compositions comprising and methods of profiling and/or classifying a plurality of cells or cell lines based on peptide binding characteristics.
BRIEF SUMMARY OF THE INVENTION
[0004] An embodiment of the invention includes methods of profiling cell lines and/or identifying peptide sequences or structures that bind a target population or family of cells. The methods include providing a plurality of cell lines; contacting each cell line with a library of phage displaying random heterologous peptides on their surface; obtaining phage that bind each of the cell lines; identifying peptides that bind each cell line; and classifying each cell line based on the identified peptides. The method can further comprise classifying each identified peptide based on the cell lines that bind each identified peptide. In one aspect, the cell lines include cancer cell lines. Cancer cell lines may include, but are not limited to kidney, breast, colon, lung, prostate, brain, liver, pancreatic, uterine, neuronal, skin, head and neck, leukemic, lymphocytic, or ovarian cancer cell lines. In another aspect, the panel is cancer cell lines. In a particular aspect, the panel is a NCI 60 panel of cancer cell lines. The methods further include identifying a peptide that binds to a majority of the cancer cell lines or cancer cells of common origin. Furthermore, methods can also include analyzing the identified peptides to identify similarities with known receptor ligands.
[0005] In certain aspects, classifying the cell line is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map (CIM). In a particular aspect, classifying the identified peptide is performed by clustering analysis. Clustering analysis can be used to construct a clustered image map. In another aspect, the methods may also include identifying receptors for at least one of the identified peptides comprising the steps of providing an identified peptide; labeling the identified peptide; contacting an appropriate cell line with the labeled peptide; isolating a receptor-peptide complex; and identifying the receptor bound to the labeled peptide.
[0006] In another embodiment, a group of peptides comprising five or more peptides can be classified or identified as selectively bind to a sub-population of cell lines, wherein the peptides include, but are not limited to those listed in Table 3 and described herein. In certain aspects, a sub sequence of the peptide may be identified as conferring to the peptide a certain binding characteristic.
[0007] In still further embodiments, methods of the invention can be used to classify a cell or cell line. Methods of classifying a cell line include, but are not limited to steps comprising: contacting a cell with a group of selected peptides or polypeptides that differentially bind cells of a known origin; detecting the peptides that bind the cell line; and assessing the classification of the cell line based on the peptide(s) that bind the cell line. Thus, in certain aspects, classifying a cell may comprise determining whether as cell expresses a certain receptor polypeptide, is susceptible to a particular therapy or determining the tissue of origin for the cell. In certain aspects of the invention, a group of selected peptide for use according to the invention are further defined as cyclic or partially peptides, such as peptides comprising a disulfide bond. In certain cases, a group of selected peptides or polypeptides may comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more distinct peptides or polypeptides.
[0008] Thus, in a further specific embodiment there is provided a method for classifying a cell comprising obtaining or having a sample comprising a cell; contacting the cell with a group of peptides or polypeptides that differentially bind cells of a known origin or type; detecting the peptides that bind to the cell and classifying the cell based on the peptide binding. As described supra, in certain aspects, a group of selected peptides or polypeptides comprise amino acid sequences selected from those provided in Table 3. Thus, in certain cases a group of selected peptides or polypeptides comprise 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30 or more members that comprising an amino acid sequence according to Table 3. The skilled artisan will recognize that selected peptide or polypeptides of the invention may in some aspects be labeled for example with an enzyme, a fluorophor or a radio isotope.
[0009] In some aspects, a selected peptide or polypeptide may be a cyclic or partially polypeptide such as a peptide or polypeptide comprising a disulfide bond. In some preffered aspects, the cyclic region of a peptide or polypeptide comprises 5, 6, 7, 8, 9, 10 or more amino acids. For example, in certain aspects, a selected peptide or polypeptide comprises an amino acid sequence provided in Table 3 wherein the given amino acid sequence is comprised in the cyclic region of the polypeptide. Thus, it is contemplated that a selected peptide or polypeptide may comprise an amino acid sequence of Table 3 wherein the sequence is flanked by cysteine residues such that the cysteine residues may be linked by a disulfide bond.
[0010] In some aspects of the invention a method for classifying a cell according to the invention may comprise comparing the binding profile of a group of selected peptides or polypeptides to a cell to a similar binding profile from a cell with a known classification. Such a comparison may be performed directly or may performed by consulting a chart or database of binding profiles. For example, a chart or database of binding profiles may comprise binding profiles from cells of 5, 10, 15, 20, 25 or more different classifications. In certain aspects, a chart or database of binding profiles may comprise clustering analysis of the binding of selected peptides or polypeptide to cells of different classification. Thus, in some cases a chart or database of binding profiles may comprise a clustered image map (CIM). Thus, classifying a cell may be performed by for example clustering analysis.
[0011] In still further aspects of the invention there is provided a method for treating a subject comprising obtaining or having a sample from the subject comprising a cell; classifying the cell (e.g., by the methods described supra); and treating the subject with a therapeutic based upon the classification of the cell. For example, in some cases a subject may be defined as a cancer patient. In this case a cancer cell from the subject may be classified. Classification of the cell may for example comprising determining the tissue of origin, receptor status or susceptibility of the cell to particular anticancer therapy. Thus, based upon the classification of the cell the subject may be treated with an appropriate anticancer therapy. For example, methods of the invention may be used to classify a cell as susceptible or resistant to radiation therapy, immunotherapy, surgical therapy or chemotherapy. Furthermore, methods of the invention may be used to classify the cell as susceptible or resistant to a particular chemotherapeutic agent or class of chemotherapeutic agents. Thus, methods of the invention may involve classifying a cancer cell from a subject as susceptible or resistant to an anticancer therapy and treating the subject with one or more anticancer therapies that the cell is susceptible to.
[0012] In certain aspects the invention concerns obtaining or having a sample such as a cell. It is contemplated that in cases where a sample is from a subject the sample may be directly obtained or may be obtained by a third party and subsequently subjected to methods described herein. Furthermore, in certain aspects it is contemplated that methods of the invention may be defined as a method for aiding in the therapy of a subject comprising classify a cell from the subject (e.g., as having certain protein receptor expression or being from a tissue of a particular origin) and providing the classification information to a third party such as a medical professional to aid in the therapy of the subject.
[0013] In yet another embodiment of the invention includes a method of classifying a peptide(s). Methods of peptide classification include, but are not limited to steps comprising: contacting a plurality of cell lines with a library of peptides that differentially bind the cells; detecting the peptides that bind the cell line; and classifying the peptides based on the cells that bind the peptide.
[0014] In certain aspects an EphA5 receptor can be targeted by using a composition comprising a peptide sequence of CSGIGSGGC (SEQ ID NO:2) or CRFESSGGC (SEQ ID NO:3). The skilled artisan will further recognize that in certain aspects a peptide targeting sequence of the invention is cyclic. Thus, there is provided EphA5 receptor targeting composition comprising a cyclic polypeptide wherein the cyclic polypeptide comprises the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As exemplified herein in certain aspects an cyclic EphA5 targeting composition may comprise a peptide sequence according to SEQ ID NO:4 or SEQ ID NO:5 flanked by cysteine residues thereby forming a cyclic targeting agent via disulfide bonds between the cysteine residues. As used herein the termed flanked means that the indicated amino acid sequence are between two cysteine residues however it is contemplated that in some cases additional amino acids may also be comprised between the two cysteine residues.
[0015] A composition of the invention can be coupled (either non-covalently or covalently, or indirectly via an intermediate such as a liposome or directly) to a therapeutic or imaging agent. The therapeutic can include, but is not limited to a small molecule, a drug, or a therapeutic peptide. For example, in certain aspects, a therapeutic composition of the invention comprises a polypeptide. In these aspects the therapeutic Eph5A receptor targeting composition may comprise a fusion protein. Thus, in some very specific cases the therapeutic polypeptide may be a toxin or other cytotoxic molecule capable of inducing cell death in Eph5A receptor expressing cells. Imaging agents for use in the invention include but are not limited to MRI contrast agents, radio isotopes, fluorophors and mass tags (e.g., for detection via mass spectrometry).
[0016] In certain aspects there is provided an EphA5 receptor agonist comprising the amino acid sequence SGIGSGG (SEQ ID NO:4) or RFESSGG (SEQ ID NO:5). As described above in some cases the EphA5 receptor agonist is a cyclic peptide or polypeptide wherein the cyclic region comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5. Thus, in some case the agonist is a cyclic peptide or polypeptide comprising a disulfide bond such as a peptide or polypeptide wherein the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5 are flanked by cysteine residues (e.g., as in SEQ ID NO:2 or SEQ ID NO:3).
[0017] Thus, in still further aspects of the invention there is provided a method for treating an Eph5A receptor positive cell comprising administering to the cell an EphA5 receptor targeting therapeutic as described supra. Thus, in some aspects a method of the invention may be further defined as a methods for treating a subject comprising an EphA5 receptor positive cell by administering an effective amount of an EphA5 receptor targeting therapeutic. For example, in certain cases a subject may be a cancer patient comprising an EphA5 receptor positive positive cancer such as a lung cancer or neuronal cancer. In still further aspects there is provided a method for treating a subject with a an EphA5 receptor positive cancer by administering an EphA5 receptor targeting therapeutic wherein the therapeutic comprising a cytotoxic agent or an anticancer agent.
[0018] The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
[0019] The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or."
[0020] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawing, in which:
[0022] FIG. 1: Selectivity of broad-specificity tripeptides for clusters of NCI-60 cell lines. Two-dimensional hierarchical clustering was applied to the frequencies of 38 tripeptides (rows) encountered in CX7C peptides selected on NCI-60 cell lines (columns). Tripeptides selected on all but one cell line of common origin were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with the tripeptides. Tripeptide frequencies were mean subtracted and average linkage clustered with correlation metric. Amino acid color code: red, hydrophobic; green, neutral and polar; purple, basic. The color in each CIM segment ranges from blue (negative correlation) to red (positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histologic tumor origin (Monks et al., 1991, Weinstein et al., 1997. Bars underneath dendrogram, clusters of cells of similar tumor tissue origin (one exception allowed). Boxed, cluster of lung cancer-derived cell lines and associated/dissociated tripeptides.
[0023] FIGS. 2A-B: Identification of peptides mimicking EGFR ligands. FIG. 2A, EGFR-binding peptide sequences isolated from the SKOV-3 selected phage pool were matched in each orientation to protein sequences of biological human EGFR ligands (leader peptide sequence underlined). Matches displayed are peptides with three or more amino acids being identical (red) and one or more being from the same class (green) as the correspondingly positioned protein amino acids. Tripeptides listed in Table 1 (yellow). FIG. 2B, isolation of peptides targeting EGFR. Binding of SKOV3-selected phage pool to immobilized EGFR compared with BSA in rounds 1 and 2 of biopanning of SKOV3-selected phage pool on immobilized human EGFR.
[0024] FIGS. 3A-3B: Phage selection on immobilized EphA5 receptor. FIG. 3A, Ephrin-mimic phage displaying the enriched motif GGS were selected on EphA5-coated microtiter wells. Phage showing specific binding to EphA5 was analyzed for its distinctive binding to EphA5 compared to EphA4 receptor (FIG. 3B). BSA and fd-tet insertless phage were used as negative controls.
[0025] FIG. 4: EphA5 receptor expression in the NCI-60. From microarray analysis reported at dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894.
[0026] FIG. 5: EphA5 and EphA4 receptor expression by the lung cancer cell lines Hop92 and H460. The OVCAR3 cell line was used as negative control. 10× magnification.
[0027] FIG. 6: Specific binding of the CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage to lung cancer cells Hop92 and H460 but not to the ovarian cancer cell line OVCAR-3. Insertless phage (fd-tet) was used as negative control.
[0028] FIGS. 7A-B: A. Clustered image map relating all isolated NCI-60-binding tripeptides to NCI-60 cell lines. FIG. 7A, Two-dimensional hierarchical clustering was applied to the frequencies of 3,280 unique tripeptides (rows) found in cell-binding CX7C peptides selected on the NCI-60 cells (columns). Tripeptides were clustered based on their correlations with cell lines; cell lines were clustered based on their correlations with tripeptides. Tripeptide frequencies were mean-subtracted and average-linkage clustered with correlation metric (the data were transformed to the mean of 0; variance of 1). The color in each CIM segment ranges from blue (high negative correlation) to red (high positive correlation), as indicated by the scale bar. Cell lines are color-coded based on previously defined histological tumor origin. FIG. 7B, A control two-dimensional hierarchical clustering applied under the Poisson assumption to 3,280 randomly simulated tripeptide frequencies (rows) showed no obvious pattern, thus indicating that clusters in A were not generated at random.
[0029] FIG. 8: Targeted peptides mediate ligand-receptor cell internalization. CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage were permeabilized into A549 cells. No internalization was observed when cells were incubated with insertless phage
[0030] FIG. 9A-B: Biological effects of the peptides CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3 on lung cancer cells. Promotion of cell survivial and proliferative response of starved lung cancer cells to the ephrin mimic peptides, control peptide and complete culture medium (A549 (FIG. 9A), H460 cells (FIG. 9B)). Concentrations of peptide were optimized. Values in the Y-axis correspond to the number of viable cells under each experimental condition evaluated after a 72 h incubation period. Data bars represent the mean and corresponding standard error of the mean.
DETAILED DESCRIPTION OF THE INVENTION
[0031] A collection of 60 cell lines derived from human tumors (NCI-60) has been widely explored as a tool for anticancer drug discovery. In one aspect of the invention, the cell surface of the NCI-60 was profiled by high-throughput screening of a phage-displayed random peptide library and classified the cell lines according to the binding selectivity of 26,031 recovered tripeptide motifs. By analyzing selected cell-homing peptide motifs and their NCI-60 recognition patterns, the inventors established that some of these motifs (a) are similar to domains of human proteins known as ligands for tumor cell receptors and (b) segregate among the NCI-60 in a pattern correlating with expression profiles of the corresponding receptors. The inventors biochemically validated some of the motifs as mimic peptides of native ligands for the epidermal growth factor receptor. The results indicate that ligand-directed profiling of tumor cell lines can select functional peptides from combinatorial libraries based on the expression of tumor cell surface molecules, which in turn could be exploited as "druggable" receptors in specific types of cancer (Kolonin et al., 2006).
[0032] The National Cancer Institute panel of human cancer cell lines from different histologic origins and grades (NCI-60) has been extensively used to screen compounds for anticancer activity (Monks et al., 1991; Weinstein et al., 1997). The NCI-60 includes carcinomas of several origins (kidney, breast, colon, lung, prostate, and ovarian), tumors of the central nervous system, malignant melanomas, leukemias, and lymphomas. Gene expression determined by high-throughput microarrays has been used to survey the variation in abundance of thousands of distinct transcripts in the NCI-60; such data provided functional insights about the corresponding gene products in tumor cell transformation (Weinstein et al., 1997; Scherf et al., 2000; Nishizuka et al., 2003). This information-intensive genomic approach has yielded candidate diagnostic tumor markers to be validated at the protein level in prospective studies (Nishizuka et al., 2003). Moreover, systematic proteomic studies based on two-dimensional PAGE (Myers et al., 1997) and protein microarrays (Nishizuka et al., 2003) have also been implemented. Finally, in parallel with the NCI-60 transcriptome and proteome initiatives, pharmacologic sensitivity of the cells to >105 different chemical compounds has been registered (Monks et al., 1991; Weinstein et al., 1997). Indeed, for some genes, correlation of expression data to drug sensitivity profiles has uncovered the mechanistic basis for the drug activity (Scherf et al., 2000; Zaharevitz et al., 2002; Blower et al., 2002; Rabow et al., 2002; Wallqvist et al., 2002; Szakacs et al., 2004). Thus, conventional genomic and proteomic approaches have identified several potential tumor markers and drug targets. However, despite such advances, correlation between drug activity and gene expression profiles has not as yet been established for most of the compounds tested (Wallqvist et al., 2002; Brown, 1997; Walloyist et al., 2003). This suggests the likely existence of unknown factors and the need to develop alternative methodology to discover "druggable" molecular targets.
[0033] Over the past few years, it has been proposed that (a) characterization of molecular diversity at the tumor cell surface level (represented primarily by membrane-associated proteins that are often modified by lipids and carbohydrates) is required for the development of ligand-directed anticancer therapies, and that (Zaharevitz et al., 2002) peptides binding to surface receptors preferentially expressed on tumor cells may be used to ligand-direct therapeutics to sites of disease with potential for increased therapeutic windows (Arap et al., 1998; Kolonin et al., 2001). It has become increasingly clear that selective cell surface features can be mapped by screening libraries of peptides (Kolonin et al., 2001; Pasqualini and Ruoslahti, 1996; Giordano et al., 2001; Arap et al., 2002). In fact, combinatorial peptide libraries displayed from pIII protein of an M13-derived phage have now been successfully screened on intact cells and in vivo (Arap et al., 1998; Kolonin et al., 2001; Pasqualini and Ruoslahti, 1996). Peptide ligands selected from unbiased screens without any predetermined notions about the nature of the cellular receptor repertoire have been used for the subsequent identification of the corresponding target cell surface receptors (Giordano et al., 2001; Arap et al., 2002; Pasqualini et al., 2000; Kolonin et al., 2002; Kolonin et al., 2004; Pasqualini et al., 2001). In addition, novel techniques, such as the biopanning and rapid analysis of selective interactive ligands (BRASIL), have enabled high-throughput phage library screening on cells (Giordano et al., 2001). Here, the BRASIL method is used to systematically screen combinatorial libraries on tumor cells of the NCI-60 panel. Results of this feasibility study suggest that tumor cells can be grouped by profiles of their peptide ligands directed to differentially expressed cell surface receptors. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be developed as broad tumor targets. Integration of ligand-directed surface profiling with other approaches related to the NCI-60 may uncover functional ligand-receptor pairs for the targeted drug delivery.
I. CELL TARGETING MOLECULES
[0034] Modified cell targeting molecules of the present invention may be produced by chemical synthetic methods, by chemical linkage between the two moieties or in some cases by fusion of a second polypeptide coding sequence to the targeting moiety. It is contemplated that modified cell targeting molecules of the invention may be used as therapeutics and/or as imaging agents to target specific classes of cells.
[0035] As mentioned above, in certain aspects of the invention, a modified cell targeting moiety may comprise a second polypeptide wherein the two polypeptides together comprise a fusion protein. For example, in certain aspects the second polypeptide may be a therapeutic or cytotoxic (e.g., a toxin) polypeptide as exemplified below. A fusion of two polypeptide coding sequences can be achieved by methods well known in the art of molecular biology. It is preferred that a fusion polynucleotide contain only the AUG translation initiation codon at the 5' end of the first coding sequence without the initiation codon of the second coding sequence to avoid the production of two separate encoded products. In addition, a leader sequence may be placed at the 5' end of the polynucleotide in order to target the expressed product to a specific site or compartment within a host cell to facilitate secretion or subsequent purification after gene expression. The two coding sequences can be fused directly without any linker or by using a flexible polylinker.
A. Cell Targeting Moieties
[0036] Cell targeting moities as provided here may, in some aspects, comprise peptides or polypeptides that exhibit binding to a specific class of cells. For example, in some cases the cell targeting moiety is selected from one of the polypeptide sequences provided in Table 3. The skilled artisan will understand that such sequences may comprise additional amino acids or other covalent modifications. For instance, in preferred embodiments a polypeptide sequence from Table 3 is provided a cyclic polypeptide. Thus, in some specific examples, an amino acid sequence from Table 3 is flanked by cysteine residues that may form a disulfide bond thereby providing a cyclic polypeptide. Thus, in some aspects the invention provides compositions and methods for targeting any of the classes of cells that bind to the peptides and polypeptides provided herein (e.g., as indicated in Table 3) such as leukemia cells, lung cancer cells, colon cancer cells, CNS cancer cells, melanoma cells, ovarian cancer cells, prostate cancer cells, renal cancer cells or breast cancer cells.
B. Therapeutic Moieties
[0037] As mentioned above in certain aspects, a therapeutic moiety may be a toxin such as radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, cytotoxins (cytotoxic agents), or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. "Toxin" also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi, or other radioisotopes such as, for example, 103Pd, 133Xe, 131I, 68Ge, 57Co, 65Zn, 85Sr, 32P, 35S, 90Y, 153Sm, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn, 90Yttrium, 117Tin, 186Rhenium, 166Holmium, and 188Rhenium; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. Furthermore, a therapeutic moiety may be a pro-apoptotic protein such as a BCL2 family member, a caspase or a granzyme.
II. CANCER THERAPIES
[0038] A variety of conventional cancer therapies are currently used in the treatment of cancer. Thus, in some aspects of the invention there are provided methods for classifying cancer cells such as cells that are sensitive or resistant to an anticancer therapy. Some examples of conventional cancer therapies discussed below. It is contemplated that methods according to the invention may be used to identify cells that are sensitive or resistant to any particular cancer treatment. Furthermore, some aspects of the invention concern compositions and methods for cell targeted anticancer therapy. Thus, it is contemplated that any anticancer method known to those in the art (as exemplified below) may be used in combination or conjunction with compositions and methods provided herein.
A. Chemotherapy
[0039] Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments. Combination chemotherapies include, for example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.
B. Radiotherapy
[0040] Other factors that cause DNA damage and have been used extensively include what are commonly known as γ-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
[0041] The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic construct and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.
C. Immunotherapy
[0042] Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
[0043] Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with gene therapy. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155.
III. EXAMPLES
Example 1
Combinatorial Library Screening on Cells
[0044] All the NCI-60 cell lines (1), except MDA-N (unavailable), were grown in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and 5 mmol/L L-glutamine. A phage display random peptide library based on the vector fUSE5 displaying the insert CX7C (SEQ ID NO:1) was screened by using BRASIL as described (Giordano et al., 2001). Exponentially growing cells were harvested with 0.5 mmol/L EDTA, 0.4 g/L KCl, 8 g/L NaCl, and 1 g/L dextrose, washed once with phosphate buffer saline (PBS), and resuspended in RPMI containing 1% bovine serum albumin (BSA) and 1 mmol/L HEPES. Cells (˜106) were incubated for 2 hours on ice with 109 transduction units (T.U.) of CX7C phage in 200-μL suspension, transferred to the top of a nonmiscible organic lower phase (dibutyl phtalate/cyclohexane, 9:1), and centrifuged at 10,000×g for 10 minutes. The phage-bound cell pellet was incubated with 200 μL of K91 bacterial culture, and the bound phages were amplified and used in the following round. To prevent preferential isolation of peptides containing the RGD motif, which is selected on tissue-cultured cells due to expression of cell adhesion molecules binding to vitronectin, library screening was done in the presence of 1 mg/mL of the synthetic peptide RGD-4C (AnaSpec, San Diego, Calif.) in each round. After three rounds of selection, phage peptide-encoding inserts were sequenced as described (Pasqualini and Ruoslahti, 1996; Arap et al., 2002; Pasqualini et al., 2001).
Example 2
Hierarchical Cluster Analysis of Peptide Motif/Cell Line Association
[0045] The inventors created an interactive sequence management database of all peptide sequences isolated in the screen. Calculation of tripeptide motif frequencies in CX7C peptides (in both directions) was done by using a character pattern recognition program based on SAS (version 8.1.2, SAS Institute, Cary, N.C.) and Perl (version 5.6.1) as described (Arap et al., 2002). To identify the most closely related tripeptides and cell lines, clustered image maps (CIM) were generated by using online software CIMminer available at discover.nci.nih.gov/tools.jsp. Data were centered (mean subtracted and divided by SD) on both cell lines and tripeptide motifs; correlation coefficient metric with average linkage algorithm was used as distance measurement. The tripeptide motif frequencies across the NCI-60 cell lines formed a two-dimensional data matrix that was used to correlate motif enrichment with groups of cell lines. To evaluate whether CIMMiner algorithm is appropriate for clustering analysis of peptide frequency data, a simulation test was devised assuming that the frequencies of tripeptide motifs in a given data set follow an independent Poisson distribution. The inventors simulated a random 3,280×59 data matrix of the dimension identical to that of tripeptide motif frequency data matrix (corresponding to the set of 3,280 tripeptides and 59 cell lines). These simulated data were centered the same way as the experimental data by transforming to mean of 0, variance of 1. For CIM in FIG. 1, tripeptides selected on all but one cell line of common origin (Arap et al., 2002) were used. Specificity of five tripeptides selectively overrepresented or underrepresented in lung tumor cell binding peptides for the 11 boxed cell lines (against the other 48 cell lines) was evaluated by using the R Package, version 2.0.0 (www.r-project.org) by performing two-sample t test (one tailed), as well as using Wilcoxon rank sum test (one tailed) and Fisher exact test (one tailed) as described (Arap et al., 2002).
Example 3
Identification of Candidate Targeted Receptors
[0046] To identify lead receptors targeted by tripeptide motifs, the Molecular Target Database (found on the world wide web at dtp.nci.nih.gov) was screened to identify proteins, expression levels of which in individual cell lines of the NCI-60 correlated with frequencies of individual tripeptides from FIG. 1 in the corresponding cell lines. The inventors used the COMPARE software (found on the world wide web at dtp.nci.nih.gov/docs/compare/compare.html) to calculate pairwise Pearson correlations between tripeptide frequencies in cell lines and the protein expression patterns in the database. Minimum Pearson correlation coefficient of 0.2 served as cutoff for the selection of lead receptors, as it provided a reasonable number of candidate molecular targets for which NCI-60 expression profiles and tripeptide frequency distribution profiles correlated. To initially restrict the candidate targets analyzed to broad-specificity receptors, only putative cell surface molecules (Table 1) were included, expression of which in the NCI-60 was found to correlate with the frequency profile of at least 25% of the tripeptides.
Example 4
Protein Database Screening for Peptide Motif Similarity
[0047] To identify natural prototype ligands of candidate receptors that are mimicked by selected peptides, the inventors screened all 7-mer peptides selected in the screen by using online ClustalW software (www.ebi.ac.uk/clustalw/) to identify extended (four or longer amino acids) motifs shared between multiple peptides containing the broad-specificity tripeptides (FIG. 1). Nonredundant databases of human proteins were searched by the BLAST software (www.ncbi.nlm.nih.gov/BLAST/) for proteins containing the cell-targeting 4-mers under the condition that at least the tripeptide part of the motif is identical to the part of the BLAST match.
Example 5
Validation of Epidermal Growth Factor Receptor as One of the Peptide Targets
[0048] To isolate peptides binding to epidermal growth factor receptor (EGFR), phage clones selected on SKOV3 in rounds 2 and 3 of the screening were individually amplified and pooled, and 109 transduction units of the mixed phage were incubated overnight at 4° C. with 10 μg of purified human EGFR (Sigma, St. Louis, Mo.), or BSA control immobilized on plastic. Unbound phages were extensively washed off with PBS, and then the bound phages were recovered by infecting host K91 Escherichia coli directly on the plate, and tetracycline-resistant clones were selected, quantified, and sequenced. To identify EGFR ligand-matching motifs among phage-displayed SKOV3-binding peptides, custom-designed Perl 5.8.1-based software was used to run peptide sequences against biological EGFR ligand sequences. Each 7-mer peptide sequence was aligned in each orientation against the EGFR ligand sequences from the NH2 to COOH terminus in one-amino-acid shifts. The peptide/protein similarity scores for each residue were calculated based on a BLOSUM62 matrix modified to identify peptide matches of at least three amino acids in any position being identical and one being similar to the corresponding amino acid positions in the EGFR ligands (FIG. 2A).
Example 6
Isolation of Peptides Binding to Surface of the NCI-60 Cancer Cells
[0049] As an initial attempt to profile cell surface of the tumor cell panel, a large (2×108 unique sequences) cyclic random peptide library was screened with the basic structure CX7C (C, cysteine; X any residue) on every cell line of the NCI-60. Phage selection was done in the excess of a competing Arg-Gly-Asp (RGD) synthetic integrin-binding peptide (Arap et al., 1009) to minimize the recovery of RGD-containing peptides. This strategy was designed to facilitate the recovery of ligands binding to nonintegrin families of cell surface receptors because RGD tends to become dominant in the screening due to the high levels of integrin expression in adherent cells (unpublished observation). Preferential cell binding of specific cell-targeting peptides results in enrichment, defined by the increased recovery frequency of these peptide motifs in each subsequent round of the screen (Kolonin et al., 2001; Pasqualini et al., 2001). Thus, the inventors set out to profile the expression of nonintegrin cell surface molecules among the cell lines of the NCI-60 according to the differential selection of motifs enriched in the screen.
Example 7
Hierarchical Cluster Analysis of Peptides Binding to the NCI-60 Cells
[0050] To analyze the spectrum of the peptides resulting from the screening and compare those among different cell lines of the panel, a combinatorial statistical approach was adopted based on the premise that three residue motifs (tripeptides) provide a sufficient structure for protein-peptide interactions in the context of phage display (Arap et al., 2002). For each NCI-60 cell line, CX7C peptide-encoding DNA inserts from 96 phage clones recovered after three rounds of selection were sequenced. A computer-assisted survey of all tripeptides within the library-derived sequences selected on each cell line by analyzing a database of 26,031 tripeptides contained within the 5,270 CX7C-encoded 7-mer peptides isolated (an average of eighty-nine 7-mer peptide sequences analyzed per each NCI-60 cell line) was performed. Thus, each cell line was assigned a unique set of tripeptides that was identified during the selection for cell surface binders, and the frequencies of each motif among all peptides for a given cell line were calculated.
[0051] To classify cell lines according to their association with particular motifs, which might provide inference on the targeted surface molecules, a hierarchical clustering analysis of the 3,280 nonredundant tripeptides was done based on the frequency of association with the NCI-60 cell lines. For the construction of a CIM, the inventors adapted a hierarchical clustering algorithm and a pseudo-color visualization matrix initially designed to address differential gene expression among the cells of the panel (Scherf et al., 2000; Zaharevitz et al., 2002; Blower et al., 2002; Rabow et al., 2002). CIMMiner (Weinstein et al., 1997) was used for inference of the variation in peptide binding specificity across the cell lines by comparing relative frequencies of tripeptides found in 7-mer peptides binding to each cell. Clustering of peptide motifs with similar cell selectivity revealed that the peptide distribution of the combinatorial library within the NCI-60 set was nonrandom. Computer simulations of the permutated data set show that the observed pattern could not be generated by random chance, thus indicating that the discontinuous tripeptide frequency data is applicable for cluster analysis.
[0052] The selective spectra of peptide motifs interacting with the clustered cell lines suggest the existence of shared targeted surface receptor(s) expressed in these lines. In this study, the inventors chose to focus on putative peptide-targeted receptors with broad cell line specificity, which would be more informative for an initial peptide binding/receptor expression correlation analysis. the inventors therefore excluded from the data set motifs selected only on a single or few cell lines. Instead, the inventors focused on 38 tripeptides that showed a semiubiquitous distribution among the NCI-60 lines (FIG. 1). A CIM constructed according to the isolation frequency of these broader-specificity tripeptides from each cell line revealed several apparent clusters of cell lines that displayed distinct profiles of association with certain classes of peptide motifs. For example, the majority of lung cancer-derived cell lines segregated as a separate group, suggesting that some of the receptors targeted may be conserved among cell lines derived from a common origin (FIG. 1). Thus, although the analysis was severely restricted by limiting it to semiubiquitous tripeptides, clustering of some of them (predominantly with cell lines derived from the same tumor type) is consistent with their relative tissue specificity. To evaluate individual motifs for selectivity, a distinct cluster of five tripeptides associated with lung tumor-derived cell lines (FIG. 1, boxed) were identified. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t test). Consistently, the GGS motif was isolated for the clustered lines significantly (P<0.05) more frequently than for the other NCI-60 cell lines.
[0053] Notably, the distribution of cell lines in the dendrogram (FIG. 1) was partially consistent with the reported association of cells derived from tumors with common tissue origin (Scherf et al., 2000; Nishizuka et al., 2003). This suggests that some of the receptors, such as the one presumably recognized by the lung tumor-specific tripeptide GGS (FIG. 1), may be up-regulated only in certain cancer origins. However, the tumor cell phylogeny was recapitulated only to an extent; the majority of the observed clusters contained cell lines derived from unrelated tumor types (FIG. 1). The limited grouping of lines derived from tumors of common origin is perhaps not surprising: the relationship between different cell lines in the study is based on peptide binding to putative cell surface molecules, many of which may be tumor induced rather than characteristic of the tissue of origin. If so, the analysis of broad-specificity motif distribution may be well suitable for identification of specific surface molecules that are generally up-regulated by tumors and thus may constitute broad drug targets against cancer.
Example 8
Identification of Candidate Receptor Targets for Peptide Motifs
[0054] The inventors proceeded to identify the targets for the 38 broad-specificity tripeptides, most of which presumably bind to receptors expressed by multiple NCI-60 cell lines. The NCI Molecular Targets Database that contains detailed information on the expression and activity of 1,218 human proteins measured by nonarray methods was used (Holbeck, 2004). By using the COMPARE algorithm (Zaharevitz et al., 2002), the inventors correlated the selectivity profiles of the 38 tripeptide motifs with the expression profiles of the characterized molecular targets. It was observed that several of the qualifying proteins, expression of which correlated with enrichment profiles of certain motifs, represented tyrosine kinase receptors, such as those for ligands belonging to families of EGFs, fibroblast growth factors (FGF), nerve growth factors (NGF), and ephrins (Table 1). When transferred to molecular target correlation data, the order of the 38-tripeptide motif set in the dendrogram (FIG. 1) revealed clusters of tripeptides for which cell line association profile correlated with expression profiles of EGF, FGF, NGF, or ephrin receptors (Table 1).
[0055] The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR, and ephrin receptor families (Table 1), are often up-regulated in many types of cancer (Vogelstein and Kinzler, 2004). To determine if the cell-binding peptides may target these tyrosine kinases, the inventors employed the notion that receptor-binding peptide motifs often mimic natural ligands for these receptors (Giordano et al., 2001; Arap et al., 2002; Kolonin et al., 2002). Thus, the selected motifs mimic ligands for the candidate tyrosine kinases were tested by determining whether tripeptides listed in Table 1 are embedded into longer peptides that may be responsible for cell surface binding. The inventors analyzed the CX7C (SEQ ID NO:1) phage inserts containing the 38 tripeptides by using the ClustalW software and compiled extended motifs containing the tripeptides shared among multiple peptides selected during the screen (data not shown). To identify candidate prototype human ligands, epitopes of which could be mimicked, each of the ClustalW-extended motifs were screened against the nonredundant database of human proteins by using the BLAST software (National Center for Biotechnology Information). As a result of this analysis, the inventors found the motifs containing 34 of 38 tripeptides (89%) to be identical or very similar to segments of proven or putative ligands for the tyrosine kinase receptors listed (Table 1).
Example 9
Validation of EGFR as a Targeted Receptor
[0056] To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGFR is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Table 1). Of these tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKOV3 and OVCAR4 (data not shown). Because EGFR is well known to be associated with ovarian cancer (Vogelstein and Kinzler, 2004), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sublibrary (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After two rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different 7-mer peptides (FIG. 2A) that contained 17 of 22 SKOV3-selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression (Table 1). Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sublibrary to immobilized BSA control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the 7-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands (Vogelstein and Kinzler, 2004). These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS), were found highly similar to fragments of EGF, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin (FIG. 2A). Similarity search using the same algorithm on the same twelve 7-mers did not reveal any matches to two other EGFR ligands, transforming growth factor-α and β-cellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 1: ephrin A, NGF-β, and FGF6 (data not shown). Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, whereas others may bind to different tyrosine kinases, possibly including those from TRK, ephrin, or FGF receptor families.
[0057] Expression profiles of the candidate receptor targets for peptides identified in the screen illustrate the concept that in cancer, at least some tumor-associated cell surface molecules seem up-regulated regardless of cancer tissue origin. As such, this is the case for the EGFR and other tyrosine kinases possibly targeted by peptide ligands selected on the NCI-60 cell panel. This may also be the case for many other receptors with a role in tumorigenesis, expression profiles of which may not correlate with the overall proteomic profile of the original tumor tissue. In fact, these observations may account for the relatively limited success in correlating drug toxicity profiles with the genomic and/or proteomic profiles of the NCI-60 panel (Walloyist et al., 2003). On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines (FIG. 1), seem to be at least partially specific for the progenitor cancer type.
[0058] The candidate ligand-receptor leads identified in this study can be characterized further for the development of targeted agents selective for tumors. Moreover, the peptides identified by the approach described here may map receptor interaction domains of biological (native) ligands. Similarity of peptides to the corresponding receptor-binding ligands has already been used for validation of the IL-11Rα receptor as a target of an interleukin-11 mimic peptide homing to blood vessels in the prostate (Arap et al., 2002; Zurita et al., 2004). The inventors and others have modeled the usage of peptides homing to receptors expressed by tumors (Pasqualini et al., 2000) or non-malignant tissues (Kolonin et al., 2002; Kolonin et al., 2004) for directing the delivery of cytotoxics, proapoptotic peptides, metalloprotease inhibitors, cytokines, fluorophores, and genes (Arap et al., 1998; Kolonin et al., 2001). Thus, the approach provides a straightforward way to identify drug-accessible tumor cell surface receptors and to discover peptide ligands that can serve as mimetic prototype drugs. Unlike genomic or proteomic-based approaches that rely on differential expression levels of transcripts or protein products, this discovery platform directly addresses functional protein-protein interactions at the level of physical binding. In contrast to protein array systems, it is possible to select binding peptides even if the ligand-receptor interaction is mediated by conformational (rather than linear) epitopes. Ligand-directed screening of combinatorial libraries on tumor cell surfaces can lead to improved selection of functionally relevant peptides that can be developed for targeting "druggable" molecular targets.
##STR00001##
TABLE-US-00001 TABLE 1 Candidate ligand-receptor interactions mimicked* RLS ErbB2, ErbB4 FGF2, 4 EGF-TM7 RGV RGS ErbB4 FGF2 EphA2, A3, A4, A8, B1 EGF-TM7, FGF-12b, FGF-5, NGF-beta RAV ErbB2 MEGF7, NGF-beta. NTF 6 alpha RAS TRKA FGF-20, NRG-3 GAG EGFR FGF1, 2, 3 MEGF4, FGF6, NGF-beta AVS EGFR, ErbB2, FGF1 TRKB, C EphA2, A3, A4, A7, TRK1 ErbB4 B1, B2, B3, B5 LLS Amphlregulin LLR TRKA EphA4 LRV EGFR, ErbB2, FGF3 TRKA, B, C EphA2, A3, A7 FGF-12b, Eph-B3 ErbB4 LRS ErbB3 MEGF4, MEGF5, MEGFS, NRG-3, NGF-beta RVS EGFR, ErbB2, FGF1, 2 TRKB EphA7 MEGF10, amphiregulin ErbB4 RSS FGF3 TRKA EphAS EGF-TM7, FGF-S, NRG-3 AGS EGFR TRKA MEGF6, brain NGF AGR MEGF2, MEGF4, FGF6, NTF-5, NTF-6 AGL EGFR, ErbB2, FGF1, 3 EphAS, A6, A8 MEGF12 ErbB3 AGG EphA5 HB-EGF, Ephr-B3 GVR EGFR, ErbB2, FGF1, 2 TRKB EphA7 MEGF4, MEGF6, MEGF8, FGF-5, bFGF, ErbB4 brain NGF GVL FGF1, 2 EphA2, A3, A5, A6, B3 NGF2, Ephrin-B3, GAV MEGFS, MEGF6, NGF-beta GLV ErbB4 FGF4 EphA5 ESF-TM7, betaceilulin, NTF 3, Eph-B3, GLR ErbB4 MEGF5, EGFL5, FGF-12b, FGF-16, NRG-3 LVS FGF1, 4 EphA5, A6 EGFL5, FGF23, GDNF, Eph-B3 ARG ErbB2 FGF2, 4 TRKA EphAI FGF-12b, FGF23, NGF-beta, GDNF, NTF 6 ASL FGF1, 2 TRKC EGF-TM7, FGFR1 AAV TRKB EphA2, A3, A4, A7, • B3, B5 AAS FGF1, 2 TRKC • GGS EphA5 Eph-B3, Eph A4 GGR EGFR ErbB2 FGF2 EGF-TM7, HB-EGF, FGF23, Ephrin-B3 GLG ErbB2, ErbB3 FGF2, 3, 4 EphA1, A6 heparin binding growth factor 8 GGL ErbB2 HB-EGF, MEGF5, EGFL5, NRG-3 GSS EGFR, ErbB2 FGF3 TRKA, C EphA5 MEGFS GSG EGFR EphA5 GSV EGFR, ErbB2, FGF4 TRKB EphA7, B2 MEGF5, NRG-3, Ephrin-B3 ErbB4 GRV EGFR MEGFS, EGF-TM7, FGF23, NTF5 GRL EGFR ErbB2 EphAS, B1, B2, B4 betacellulin, EGFL5, NGF2, NTF5, EphB3, EphA4 GPS EGFR, ErbB2, FGF3 TRKB EpnA2, A3, A4, A7, MEGFS, EGFL5, EGF-like EMR3, SPGF ERB4 B2, B5 GVS EGFR FGF4 TRKA MEGF-1, MEGF5, NRG-3, NTF-6, NTF-5 *NOTE: Candidate peptide motif receptors are the human cell surface proteins (identified by COMPARE) expressed in profiles correlating with the selectivity of the corresponding tripeptides. Candidate peptide-mimicked receptor ligands are human proteins (identified by automated BLAST) that contained the corresponding tripeptides. Tripeptides in the column are ordered as in FIG. 1. Receptors of the same family and their corresponding candidate biological ligands identified based on tripeptide similarity are coded by the same color [EGFR, blue; FGFR, green; TRK receptor (NGFR), purple; ephrin receptor, red]. Tripeptides that both have a selectivity correlating with EGFR family receptor expression and are found within EGFR ligands (boldface). Tripeptides that were confirmed to reside within EGFR-binding SKOV3-slected peptides (FIG. 2; blue).
Example 10
Molecular Fingerprinting of Cancer Cell Lines
[0059] Proteomics can be defined as the systematic analysis of the proteins in biological samples that aims to document the overall distribution of proteins in tumor cells or tumor-associated cells, identify and characterize individual proteins of interest and to elucidate their relationships and functional roles. Ultimately, high-throughput profiling of protein expression will lead to the "proteome", a protein-based fingerprint, for each tissue in humans and other species. As technologies related to proteomics advance, new approaches for systematic molecular analysis of cancer at the protein level are surfacing. However, methods for systematic protein expression profiling may also easily overlook potential targets for intervention. These methods often do not take anatomical context into account. Therefore, for the generation of molecular map of accessible receptors that can be used for targeting therapeutics, information derived from conventional protein profiling approaches should be enhanced by integration with data from functional screenings ex vivo and in vivo. Studies by the inventors and others have advanced the concept of cancer proteomics: the molecular phenotyping of tumor cells and cells forming blood vessels at the protein-protein interaction level. Exploiting the molecular diversity of cell surface receptors expressed in cancer will eventually result in a ligand-receptor functional map for targeted delivery.
[0060] A major goal in drug development has long been to generate targeted therapies. This approach would improve drug therapeutic indexes by limiting the systemic exposure of other tissues to untoward or toxic effects. Thus, the promise for the identification of selectively expressed tumor-associated receptors and the ligands that home to these receptors is translation of this knowledge into the development of targeted therapeutics. Generally, coupling of homing peptides yields targeted compounds that are more effective and less toxic than the parental compound. So far, peptides selected by homing to tumor vasculature have been used as carriers to guide the delivery of cytotoxic drugs, pro-apoptotic peptides, metalloprotease inhibitors, cytokines, fluorofores, and genes in transgenic and xenograft mouse models of human disease.
[0061] Recognition of molecular diversity in human cancer is essential for the development of targeted therapies. The methods developed have two main applications. First, they may identify ligands targeting human cancer. Second, the determination of molecular profiles of biomarkers in specific types of tumors may enable identification of differentially expressed cancer markers. Thus, the approach may lead to construction of a molecular profile of human tumors. Early identification of targets, optimized regimens tailored to molecular profile of individual cancer patients, combined with the identification of new vascular addresses may result in revisiting or salvaging of drug candidates that are ineffective or too toxic. Ultimately, it may be possible to guide imaging or therapeutic compounds to tumor targets in cancer patients.
[0062] By fingerprinting lung cancer cells the inventors have confirmed the expression of a previously characterized molecular target, EGFR, in multiple cancer origins, which demonstrates the power of the approach. Recently, the inventors used this approach to identify a new cancer origin-selective molecular target, Ephrin A5 receptor, which the inventors have preliminary validated in the context of human lung cancer cell lines and tissues.
Example 11
Motifs Targeting NCI-60 Cells in Correlation with EGFR Expression Pattern are Found within Peptides Similar to Domains of Biological EGFR Ligands and Bind to EGFR
[0063] To show that the approach taken can lead to actual targetable tumor cell surface proteins, the inventors chose to test if the EGF receptor (EGFR) is bound by any of the tripeptide motifs distributed in the panel in a profile correlating with EGFR expression. Consistently, 24 out of 38 tripeptides surveyed displayed NCI-60 cell line association pattern consistent with that of EGFR expression (Kolonin et al., 2001). Of these, tripeptides, 22 were isolated in the screens on ovarian cancer cell lines SKOV3 and OVCAR4 (data not shown). Since EGFR is well known to be associated with ovarian cancer (Vogelstein, 2004; Maihle and Lafky, 2002), the inventors deemed these cell lines to be likely expressers of targetable EGFR, which would account for the selection of EGFR ligand-mimicking motifs. To validate EGFR binding by the selected motifs, the SKOV3-binding phage sub-library (pooled clones recovered in rounds 2 and 3) were screened against immobilized human EGFR. After 2 rounds of selection, phage displaying the EGFR-binding peptides were analyzed: the majority were comprised by different seven-mer peptides (FIG. 3A) that contained 17 out of 22 SKOV3-selected tripeptide motifs distributed in the panel in a profile correlating with EGFR expression.
[0064] Phage displaying these peptides had specific affinity to EGFR, as determined by subjecting the same sub-library to immobilized bovine serum albumin (BSA) control binding (FIG. 2B). Remarkably, computer-assisted analysis of sequences (FIG. 2A) revealed that 12 of the seven-mer EGFR-binding peptides contained amino acid motifs similar to those present in some of the biological EGFR ligands. These peptides, containing eight of the candidate tripeptides (RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS) were found highly similar to fragments of EGF, Amphiregulin, heparin-binding EGF-like growth factor, and Epiregulin (FIG. 2A). Similarity search using the same algorithm on the same 12 seven-mers did not reveal any matches to two other EGFR ligands, TGF-α and betacellulin, or randomly chosen control ligands of tyrosine kinase receptors from the three other candidate families listed in Table 2 (Kolonin et al. 2001): Ephrin A, NGF-β, and FGF6. Taken together, these data suggest that at least some of the peptides selected on the NCI-60 cells target EGFR, while others may bind to different tyrosine kinases, possibly including those from TRK, Ephrin, or FGF receptor families.
[0065] A phage-displayed combinatorial library was systematically screened for peptides capable of targeting the cell lines in the NCI-60 panel. By statistical analysis of peptide motif sequences, each NCI-60 cell line was assigned a unique set of peptide motifs that were isolated during the selection for cell surface binders. It was shown that tumor cells can be grouped by profiles of their phage display-derived peptide ligands directed to differentially expressed cell surface receptors.
[0066] An approach for peptide-targeted receptor identification was designed. Profiles of peptide motif preference for specific lines of the NCI-60 were correlated with expression profiles of known breast cancer-related targets. Some of the peptide motifs were found within proteins known to bind the receptors that had NCI-60 expression profiles matching cell line recognition profiles of the peptides, and that are implicated in cancer.
[0067] Candidate targeted cell surface molecules were identified, which included a number of tyrosine kinase receptors. As a proof of principle, EGFR, a receptor known to be upregulated in various cancers, was validated as a target of tripeptides RVS, AGS, AGL, GVR, GGR, GGL, GSV, and GVS, which were The results described uncover a previously overlooked phenomenon. The data support the notion that many tumor cell surface-exposed receptors are expressed irrespective of tumor origin, thus suggesting they could be explored as broad tumor targets.
Example 12
Ephrin A5 Receptor as a Lung Cancer Cell Surface Marker
[0068] The peptide distribution-correlating tyrosine kinase receptors, belonging to EGFR, FGFR, NGFR and Ephrin receptor families are often up-regulated in many types of cancer. On the other hand, some of the receptors, such as EphA5 presumably targeted by GGS tripeptide and its derivatives predominantly selective for lung tumor-derived cell lines appear to be at least partially specific for the progenitor cancer type. Since this approach clearly allowed identification of cell surface receptors ubiquitously upregulated in various cancers, the inventors took a step further to attempt identification of cancer type-specific receptors.
[0069] Having chosen lung cancer for the initial procedure establishment, the inventors identified a distinct cluster of five tripeptides associated with lung tumor-derived cell lines. The inventors compared tripeptide frequencies for the 11 cell lines within this cluster with their frequencies for the rest of NCI-60 lines by using statistical tests (Fisher exact, Wilcoxon rank-sum, and t-test). Consistently, the inventors observed that motif GGS was isolated for the clustered lines significantly (P<0.05) more frequently than for the other NCI-60 cell lines (Table 2).
TABLE-US-00002 TABLE 2 Association of specific tripeptides with lung cancer-derived cell lines: P value Mean motif count P value Wilcoxon P value (±SEM) inside vs. t-test, rank-sum Fisher exact Motif outside cluster 1-sided test, 1-sided test, 1-sided GGS 2.2 (±0.5) vs. 1.2 (±0.2) 0.0422 0.0407 0.0043 GGR 1.3 (±0.3) vs. 1.5 (±0.2) 0.6991 0.6466 0.6739 GLG 0.7 (±0.4) vs. 0.7 (±0.2) 0.5375 0.6888 0.5150 GGL 1.2 (±0.2) vs. 1.3 (±0.2) 0.6457 0.4174 0.5485 GSS 2.2 (±0.4) vs. 1.1 (±0.2) 0.0422 0.0026 0.0008
[0070] To determine statistical significance of association or dissociation between exemplary tripeptides and cell lines, normalized frequencies of five tripeptides predominantly associated (GGS, GGR, GLG, and GGL) or dissociated (GSS) with the cluster containing the majority of lung tumor-derived cell lines (FIG. 1, boxed) were compared for cell lines inside the cluster and outside the cluster. Selective association of tripeptide GGS with the clustered cell lines was found significant according to t-test, Fisher exact test and Wilcoxon rank-sum test (all tests one-tailed).
[0071] Based on the automated BLAST analysis (Table 2) the inventors identified proteins of the ephrin family candidate prototypes of the GGS-containing peptides: ephrins -B3 and A4 contain the GGS, consistent with a functional mimickry. Ephrins (A and B) and their receptors (EphA and EphB) represent a large class of cell-cell communication molecules with well-defined developmental functions. Their role in healthy adult tissues and in human disease is still largely unknown, although diverse roles in carcinogenesis have been postulated and a number of Eph receptors have been found overexpressed by various cancers (Hafner et al., 2004). Based on the COMPARE analysis of GGS distribution within NCI-60 (Kolonin et al., 2001, Table 2), the receptor expressed in the corresponding pattern is EphA5. The EphA5 expression (FIG. 4 has been explored using cDNA microarray analysis and is reported at the DTP server (dtp.nci.nih.gov/mtweb/servlet/moltidsearch?moltid=MT894), however, no studies of EphA5 function in cancer have been published. Intriguingly EphA5 is not expressed in normal lung and normally is only thought to have brain-specific functions.
Example 13
Validation of Ephrin-Mimic Peptides in Lung Cancer
[0072] To validate phage containing the motif GGS as a ligand of Eph receptors, the inventors tested phage binding to the EphA5 immobilized receptor. The inventors started testing eight peptides (CAGLSGGTC (SEQ ID NO:2133), CSGIGSGGC (SEQ ID NO:2134), CSSGGVLGC (SEQ ID NO:2135), CSWGSGGSC (SEQ ID NO:2136), CTLVLGGSC (SEQ ID NO:2137), CRFESSGGC (SEQ ID NO:2138), CHVSGGSGC (SEQ ID NO:2139), CTGGSLGAC (SEQ ID NO:2140)) containing the enriched motif GGS, all of them displayed by phage clones obtained from the screening on different cell lines known to express the EphA5 receptor (FIG. 3A). From this first round of selection, 5 clones (CAGLSGGTC (SEQ ID NO:2133), CSGIGSGGC (SEQ ID NO:2134), CSSGGVLGC (SEQ ID NO:2135), CRFESSGGC (SEQ ID NO:2138) and CSWGSGGSC (SEQ ID NO:2136) showed good binding to the receptor relative to the control (BSA) and were further analyzed by their ability to specifically bind to EphA5 but not to the control EphA4 receptor (FIG. 3B). Phage displaying the peptide sequences CSGIGSGGC (SEQ ID NO:2134) and CRFESSGGC (SEQ ID NO:2138) showed binding specificity and were chosen for characterization. The inventors investigated the binding of the selected phage to the lung cancer cells Hop92 and H460. These cells are known to express EphA5 receptor on its surface, as confirmed by immunofluorescence analysis (FIG. 5). The ovarian cancer cell line OVCAR-3, negative for EphA5 expression, was used as control.
[0073] Next, the inventors used the BRASIL method (biopanning and rapid analysis of selective interactive ligands) to analyze binding of selected phage to lung cancer cells. The inventors observed specific binding of phage displaying the sequences CSGIGSGGC and CRFESSGGC to Hop92 and H460, confirming the data obtained from the screening on the immobilized EphA5 receptor (FIG. 6).
[0074] Finally, by using banked sections or patient tissues from the MD Anderson Cancer Center, the inventors showed that EphA5 protein is overexpressed by human lung adenocarcinoma epithelium.
[0075] Immunohistochemistry (polyclonal anti-prohibitin antibody) on formalin-fixed paraffin sections of human non-small cell lung cancer (NSLC) or normal prostate with EphA5 or EphA4-specific antibodies. Immunostaining demonstrates selective EphA5 upregulation of EphA5 protein expression in NSLC lung adenocarcinoma epithelium, but not stroma, as compared with the control prostate tissue.
[0076] Taken together, these data suggest that the two selected phage displaying the motif GGS are ligands of EphA5 receptor. Upregulation of EphA5 in gliomas has been reported, without any functional connections, and, up to date, there has been no reports of investigation of this tyrosine kinase receptor in lung cancer. Therefore, EphA5 protein overexpression in lung cancer cells (FIG. 4) in light of candidate ephrin mimics (GGS peptides) targeting these cells provides an original evidence for EphA5 being a lung cancer marker and has potential functional implications.
[0077] It is contemplated by the inventors that the cancer-associated motifs identified here can be used for the development of approaches for targeted imaging or therapy of breast tumors in patients. Their receptors, including EGFR, EphA5, and other cell surface molecules, can be further explored for their oncogenic properties and the potential to serve as universal or origin/grade-selective targets of cancer.
Example 14
Cell Internalization of Ephrin-Mimic Peptides
[0078] The ability of ephrin-mimic peptides to mediate cell internaization was assessed. The A549 cell line was used as a representative human lung cancer-derived cells expressing the EphA5 receptor on the cell surface. Each phage clone or control insertless phage was incubated with cells for 4 h at 37° C. Both CSGIGSGGC (SEQ ID NO:2) and CRFESSGGC (SEQ ID NO:3)-phage were internalized into A549 cells while only background fluorescence was obtained when nontargeted control phage was used (see FIG. 8).
Example 15
Activation of Cells by Ephrin-Mimic Peptide
[0079] Activation of the EphA5 receptor by the peptides CSGIGSGGC (SEQ ID NO: 2) and CRFESSGGC (SEQ ID NO:3) lead to proliferation and/or survival of lung cancer cells. In the absence of sera, this peptides increased lung cancer cells proliferation by 4-fold (FIG. 9A-B). This effect was confirmed in two different human cell lines, which express the EphA5 receptor.
TABLE-US-00003 TABLE 3 Peptides and Motifs Associated with NCI-60 cell lines. Peptide Motif w/Seq ID: No. Cell Line RLS LRLSSIP (6) CCRF-CEM Leukemia RGV ARGVLLM (7) CCRF-CEM Leukemia RGS RGSHLVP (8) CCRF-CEM Leukemia DVETRGS (9) CCRF-CEM Leukemia RAV SRAVIDM (10) CCRF-CEM Leukemia RAS CCRF-CEM Leukemia GAG CCRF-CEM Leukemia AVS CCRF-CEM Leukemia LLS GLLSLXL (11) CCRF-CEM Leukemia TSLLSFR (12) CCRF-CEM Leukemia LLR CCRF-CEM Leukemia LRV CCRF-CEM Leukemia LRS CCRF-CEM Leukemia RVS RRVSLVA (13) CCRF-CEM Leukemia SRFRVSI (14) CCRF-CEM Leukemia RSS CCRF-CEM Leukemia AGS AGSLSVF (15) CCRF-CEM Leukemia AGR AGRICEG (16) CCRF-CEM Leukemia QVAGRER (17) CCRF-CEM Leukemia VEYAAGR (18) CCRF-CEM Leukemia AGL YNRSAGL (19) CCRF-CEM Leukemia AGG AVLVAGG (20) CCRF-CEM Leukemia LAGGVPG (21) CCRF-CEM Leukemia GVR DWWAGVR (22) CCRF-CEM Leukemia EPDGVRS (23) CCRF-CEM Leukemia EQLSGVR (24) CCRF-CEM Leukemia GVL GVLARVT (25) CCRF-CEM Leukemia ARGVLLM (26) CCRF-CEM Leukemia GAV GGAVLVA (27) CCRF-CEM Leukemia RERGAVQ (28) CCRF-CEM Leukemia GLV RALGLVS (29) CCRF-CEM Leukemia GLR SLGLRNQ (30) CCRF-CEM Leukemia LVS RALGLVS (31) CCRF-CEM Leukemia GAYRLVS (32) CCRF-CEM Leukemia ARG FDARGGL (33) CCRF-CEM Leukemia MFARGWE (34) CCRF-CEM Leukemia ARGVLLM (35) CCRF-CEM Leukemia ASL CCRF-CEM Leukemia AAV CCRF-CEM Leukemia AAS CCRF-CEM Leukemia GGS GGGSDGV (36) CCRF-CEM Leukemia GGR LGGRADF (37) CCRF-CEM Leukemia CCRF-CEM Leukemia GLG CCRF-CEM Leukemia GGL EVGGGLT (38) CCRF-CEM Leukemia FDARGGL (39) CCRF-CEM Leukemia GSS CCRF-CEM Leukemia GSG CCRF-CEM Leukemia GSV CCRF-CEM Leukemia GRV TGRVVRR (40) CCRF-CEM Leukemia GRL CCRF-CEM Leukemia GPS MGMSGPS (41) CCRF-CEM Leukemia GVS CCRF-CEM Leukemia RLS HL-60-Leukemia RGV AVRGVAR (42) HL-60-Leukemia DRGVPGL (43) HL-60-Leukemia RGS LSFSRGS (44) HL-60-Leukemia RGSVRVL (45) HL-60-Leukemia PVRGSVD (46) HL-60-Leukemia QVMMRGS (47) HL-60-Leukemia NGRGSGW (48) HL-60-Leukemia RAV RAVGRVA (49) HL-60-Leukemia RAS RASCALT (50) HL-60-Leukemia GAG ADIGAGG (51) HL-60-Leukemia FMGAGFA (52) HL-60-Leukemia AVS AGVFAVS (53) HL-60-Leukemia LLS HL-60-Leukemia LLR VMLLRPE (54) HL-60-Leukemia LLRGLEL (55) HL-60-Leukemia LPLLRGI (56) HL-60-Leukemia LRV DPRGLRV (57) HL-60-Leukemia LRS HL-60-Leukemia RVS LVRVSGR (58) HL-60-Leukemia SGSRVSL (59) HL-60-Leukemia RSS HL-60-Leukemia AGS AGSIALR (60) HL-60-Leukemia AGR MLASAGR (61) HL-60-Leukemia AGL HL-60-Leukemia AGG ADIGAGG (62) HL-60-Leukemia FAGGSTD (63) HL-60-Leukemia GVR HL-60-Leukemia GVL HL-60-Leukemia GAV TGFGAVG (64) HL-60-Leukemia HL-60-Leukemia GLV HL-60-Leukemia GLR FGLRNSR (65) HL-60-Leukemia DPRGLRV (66) HL-60-Leukemia LVS LVSSGSK (67) HL-60-Leukemia LVSSSEP (68) HL-60-Leukemia ARG HL-60-Leukemia ASL HL-60-Leukemia AAV AAVWAAD (69) HL-60-Leukemia AAS HL-60-Leukemia GGS FAGGSTD (70) HL-60-Leukemia GGR HL-60-Leukemia GLG HL-60-Leukemia GGL TFGKGGL (71) HL-60-Leukemia GSS KSGSSVL (72) HL-60-Leukemia HL-60-Leukemia GSG WGSGRGN (73) HL-60-Leukemia GSV RGSVRVL (74) HL-60-Leukemia PVRGSVD (75) HL-60-Leukemia TEGSVTV (76) HL-60-Leukemia GRV RAVGRVA (77) HL-60-Leukemia DVSGRVP (78) HL-60-Leukemia LGQCGRV (79) HL-60-Leukemia GRL GRLRLTD (80) HL-60-Leukemia LELGRLL (81) HL-60-Leukemia IGRLLPL (82) HL-60-Leukemia SDENGRL (83) HL-60-Leukemia GPS HL-60-Leukemia GVS HL-60-Leukemia RLS K-562-Leukemia RGV ELHPRGV (84) K-562-Leukemia FDRGVEA (85) K-562-Leukemia RGS EAVSRGS (86) K-562-Leukemia WTKRGSV (87) K-562-Leukemia RAV K-562-Leukemia RAS ERASQTA (88) K-562-Leukemia GAG K-562-Leukemia AVS EAVSRGS (89) K-562-Leukemia LLS AATLLSF (90) K-562-Leukemia LLSASLV (91) K-562-Leukemia RRHGLLS (92) K-562-Leukemia LLR RYSTLLR (93) K-562-Leukemia LRV FTLRVDK (94) K-562-Leukemia LRS K-562-Leukemia RVS SHRVSDS (95) K-562-Leukemia K-562-Leukemia RSS NRSSAKF (96) K-562-Leukemia LRRSSFS (97) K-562-Leukemia AGS AIRAGSD (98) K-562-Leukemia VLFSAGS (99) K-562-Leukemia AGR K-562-Leukemia AGL K-562-Leukemia AGG K-562-Leukemia GVR K-562-Leukemia GVL GVLHSIA (100) K-562-Leukemia GAV RQTTGAV (101) K-562-Leukemia GLV CQGLVLQ (102) K-562-Leukemia GLR PPPWGLR (103) K-562-Leukemia LVS K-562-Leukemia ARG SNARGPR (104) K-562-Leukemia
ASL LLSASLV (105) K-562-Leukemia AAV AAVFVRS (106) K-562-Leukemia AAS K-562-Leukemia GGS FFGGSRA (107) K-562-Leukemia GGSQCDT (108) K-562-Leukemia VWGVGGS (109) K-562-Leukemia GGR FAWGGRG (110) K-562-Leukemia GLG GLGIMGP (111) K-562-Leukemia GGL K-562-Leukemia GSS SSGSSNG (112) K-562-Leukemia GSG K-562-Leukemia GSV WTKRGSV (113) K-562-Leukemia GRV K-562-Leukemia GRL K-562-Leukemia GPS K-562-Leukemia GVS GVSTGFT (114) K-562-Leukemia RLS Molt-4-Leukemia RGV CHARGVT (115) Molt-4-Leukemia RGS WGRGSVA (116) Molt-4-Leukemia RAV Molt-4-Leukemia RAS Molt-4-Leukemia GAG LRSGAGS (117) Molt-4-Leukemia AVS RAAVSAI (118) Molt-4-Leukemia AVSGRGW (119) Molt-4-Leukemia LLS LLSFLGR (120) Molt-4-Leukemia LLR Molt-4-Leukemia LRV Molt-4-Leukemia LRS GFYWLRS (121) Molt-4-Leukemia RVS RGARVSA (122) Molt-4-Leukemia RSS GGRSSHP (123) Molt-4-Leukemia RSSIAPS (124) Molt-4-Leukemia AGS LAGSGSH (125) Molt-4-Leukemia LRSGAGS (126) Molt-4-Leukemia AGR ASVRAGR (127) Molt-4-Leukemia AGL Molt-4-Leukemia AGG Molt-4-Leukemia GVR IGVRGFF (128) Molt-4-Leukemia GVL ANGVLEL (129) Molt-4-Leukemia Molt-4-Leukemia GAV WFGAVGL (130) Molt-4-Leukemia GLV GLVRGTA (131) Molt-4-Leukemia GLVRGTA Molt-4-Leukemia EGLVSVV (132) Molt-4-Leukemia GLR DLGLRPV (133) Molt-4-Leukemia LVS ALVSRRG (134) Molt-4-Leukemia EVLVSGD (135) Molt-4-Leukemia EGLVSVV (136) Molt-4-Leukemia ARG CHARGVT (137) Molt-4-Leukemia ASL Molt-4-Leukemia AAV RAAVSAI (138) Molt-4-Leukemia AAS Molt-4-Leukemia GGS HRGGSQS (139) Molt-4-Leukemia GGR GGRSSHP (140) Molt-4-Leukemia SQSGGRH (141) Molt-4-Leukemia GLG ARAIGLG (142) Molt-4-Leukemia GGL STEGGGL (143) Molt-4-Leukemia GSS Molt-4-Leukemia GSG LAGSGSH (144) Molt-4-Leukemia GSV DGSVLVE (145) Molt-4-Leukemia WGRGSVA (146) Molt-4-Leukemia GRV ATGRVLG (147) Molt-4-Leukemia ATGRVLG (148) Molt-4-Leukemia FFGRVGI (149) Molt-4-Leukemia RIGRVWA (150) Molt-4-Leukemia GRL RGRLEVP (151) Molt-4-Leukemia GPS Molt-4-Leukemia GVS Molt-4-Leukemia RLS RRLSYRD (152) RPMI-8226-Leukemia SRLSYRG (153) RPMI-8226-Leukemia RGV FSSKRGV (154) RPMI-8226-Leukemia RGS RGSAQNF (155) RPMI-8226-Leukemia LRSGRGS (156) RPMI-8226-Leukemia LRSGRGS RPMI-8226-Leukemia LRSGRGS RPMI-8226-Leukemia YRGSSGK (157) RPMI-8226-Leukemia RAV RPMI-8226-Leukemia RAS FWISRAS (158) RPMI-8226-Leukemia GAG GAGSISD (159) RPMI-8226-Leukemia RAMGGAG (160) RPMI-8226-Leukemia AVS RPMI-8226-Leukemia LLS LLSTSIR (161) RPMI-8226-Leukemia LLR LLLRSGG (162) RPMI-8226-Leukemia LLRSAAP (163) RPMI-8226-Leukemia LRV RPMI-8226-Leukemia LRS LLLRSGG (164) RPMI-8226-Leukemia GRYSLRS (165) RPMI-8226-Leukemia LRSGRGS (166) RPMI-8226-Leukemia LRYDLRS (167) RPMI-8226-Leukemia LRYNLRS (168) RPMI-8226-Leukemia LLRSAAP (169) RPMI-8226-Leukemia SKYRLRS (170) RPMI-8226-Leukemia RVS VHRVSGG (171) RPMI-8226-Leukemia RSS RPMI-8226-Leukemia AGS GAGSISD (172) RPMI-8226-Leukemia AGR FAGRVPS (173) RPMI-8226-Leukemia AGL AGLSGSQ (174) RPMI-8226-Leukemia TDLAGLH (175) RPMI-8226-Leukemia AGG LAAGGEL (176) RPMI-8226-Leukemia GAGGMAR (177) RPMI-8226-Leukemia RAAGGSR (178) RPMI-8226-Leukemia GVR LYGVRYG (179) RPMI-8226-Leukemia PRYGVRA (180) RPMI-8226-Leukemia GVL RPMI-8226-Leukemia GAV GAVDGSR (181) RPMI-8226-Leukemia GLV ADFFGLV (182) RPMI-8226-Leukemia GLR KYYGLRR (183) RPMI-8226-Leukemia SRYGLRR (184) RPMI-8226-Leukemia LVS RPMI-8226-Leukemia ARG RPMI-8226-Leukemia ASL RPMI-8226-Leukemia AAV RPMI-8226-Leukemia AAS PAASRLL (185) RPMI-8226-Leukemia RLRAASY (186) RPMI-8226-Leukemia RPMI-8226-Leukemia GGS GGSRLLL (187) RPMI-8226-Leukemia RAAGGSR (188) RPMI-8226-Leukemia GGSVRHV (189) RPMI-8226-Leukemia GGR GGRSWVN (190) RPMI-8226-Leukemia GLG GLGNRPT (191) RPMI-8226-Leukemia HGLGSGT (192) RPMI-8226-Leukemia GGL RPMI-8226-Leukemia GSS GSSLHLL (193) RPMI-8226-Leukemia YRGSSGK (194) RPMI-8226-Leukemia GSG EGSGVDC (195) RPMI-8226-Leukemia HGLGSGT (196) RPMI-8226-Leukemia GSV SGSVNRG (197) RPMI-8226-Leukemia GGSVRHV (198) RPMI-8226-Leukemia GRV FAGRVPS (199) RPMI-8226-Leukemia GRL AMRPGRL (200) RPMI-8226-Leukemia GRLYYYR (201) RPMI-8226-Leukemia GPS PAFGPSR (202) RPMI-8226-Leukemia GVS HSGVSHG (203) RPMI-8226-Leukemia RLS VYYRLSA (204) SR Leukemia RGV SR Leukemia RGS GRGSFES (205) SR Leukemia RRGSSRN (206) SR Leukemia RAV HSRAVAP (207) SR Leukemia RAS RASFRAG (208) SR Leukemia LMGRASG (209) SR Leukemia WRASAFT (210) SR Leukemia GAG GAGRTVM (211) SR Leukemia AVS PLAVSMV (212) SR Leukemia LLS SR Leukemia LLR FLLRSSF (213) SR Leukemia WRLLRRQ (214) SR Leukemia LRS FLLRSSF (215) SR Leukemia LRSRLGF (216) SR Leukemia RVS GRRVSLV (217) SR Leukemia RSS FLLRSSF (218) SR Leukemia NRSSGRR (219) SR Leukemia
VLGMRSS (220) SR Leukemia THRNRSS (221) SR Leukemia AGS LAGSTRR (222) SR Leukemia AGR AGRTGVG (223) SR Leukemia EFAVAGR (224) SR Leukemia GAGRTVM (225) SR Leukemia REEFAGR (226) SR Leukemia AGL SR Leukemia AGG AGGPTKY (227) SR Leukemia FHVAGGS (228) SR Leukemia WSAGGPH (229) SR Leukemia GVR SR Leukemia GVL SR Leukemia GAV RGAVAFE (230) SR Leukemia SGGAVHF (231) SR Leukemia GAVRARL (232) SR Leukemia GLV GLVRGFP (233) SR Leukemia GAHGLVR (234) SR Leukemia SSRMGLV (235) SR Leukemia YVGLVVS (236) SR Leukemia GLR GLRKAGF (237) SR Leukemia AVDGLRL (238) SR Leukemia FGLRSRL (239) SR Leukemia LVS SR Leukemia ARG SR Leukemia ERARGYP (240) SR Leukemia GSARGML (241) SR Leukemia ASL ASLRYYV (242) SR Leukemia NAASLPS (243) SR Leukemia WLDASLM (244) SR Leukemia AAV SR Leukemia AAS NAASLPS (245) SR Leukemia GGS FHVAGGS (246) SR Leukemia GEHLGGS (247) SR Leukemia GGR SR Leukemia GLG SR Leukemia GGL SGGLHEG (248) SR Leukemia LRV SR Leukemia RLS SRLSYRS (249) A549-Lung RGV GGLRGVR (250) A549-Lung VAWRGVS (251) A549-Lung SVEGRGV (252) A549-Lung RGS FWRGSVP (253) A549-Lung RAV A549-Lung RAS EFTRRAS (254) A549-Lung WGWRASS (255) A549-Lung GAG A549-Lung AVS A549-Lung LLS A549-Lung LLR A549-Lung LRV A549-Lung LRS RFYHLRS (256) A549-Lung SRYSLRS (257) A549-Lung RVS A549-Lung RSS RRSSKQA (258) A549-Lung DWGRSSF (259) A549-Lung RFTRSSG (260) A549-Lung VFQRSSG (261) A549-Lung AGS AGSQSWE (262) A549-Lung AGR A549-Lung AGL A549-Lung AGG EHPAGGM (263) A549-Lung GVR GVRTAGP (264) A549-Lung GGLRGVR (265) A549-Lung LYGGVRY (266) A549-Lung GVL PVGGVLL (267) A549-Lung GAV GAVVKPI (268) A549-Lung SVGAVGG (269) A549-Lung GLV GLVSVEA (270) A549-Lung GLR GGLRGVR (271) A549-Lung LVS DIALVSP (272) A549-Lung GLVSVEA (273) A549-Lung ARG A549-Lung ASL A549-Lung AAV A549-Lung AAS ARNAASP (274) A549-Lung GGS AEGGSGH (275) A549-Lung GGSFSGL (276) A549-Lung GGR VTGGRVD (277) A549-Lung GLG A549-Lung GGL GGLRGVR (278) A549-Lung A549-Lung GSS GSSWVVD (279) A549-Lung GSSRTFR (280) A549-Lung GSSRQFV (281) A549-Lung WVGSSKF (282) A549-Lung GSG AEGGSGH (283) A549-Lung EVIGSGI (284) A549-Lung GSV FWRGSVP (285) A549-Lung VGSVSVN (286) A549-Lung GRV VTGGRVD (287) A549-Lung GRVTVAV (288) A549-Lung GRL RVGRLGG (289) A549-Lung GPS NYMGPSA (290) A549-Lung GWHGPSH (291) A549-Lung GVS GGVSPVD (292) A549-Lung GVSKVRA (293) A549-Lung GGVAGVS (294) A549-Lung VAWRGVS (295) A549-Lung RLS VIGSRLS (296) EKVX-Lung RGV HLRGRGV (297) EKVX-Lung RGS EVRSRGS (298) EKVX-Lung RGSRLPA (299) EKVX-Lung RAV DVRAVSS (300) EKVX-Lung RAS EKVX-Lung GAG EKVX-Lung AVS DVRAVSS (301) EKVX-Lung LLS EKVX-Lung LLR EKVX-Lung LRV EKVX-Lung LRS APLRSGR (302) EKVX-Lung SLRSGIV (303) EKVX-Lung RVS EKVX-Lung RSS DGGRRSS (304) EKVX-Lung AGS QAGSFLR (305) EKVX-Lung DAGSDRR (306) EKVX-Lung AGR AGRRFGG (307) EKVX-Lung AGL AGLSGGT (308) EKVX-Lung AGG AGGGPPA (309) EKVX-Lung AGGGPPA (310) EKVX-Lung FFPAGGP (311) EKVX-Lung PRAGGRW (312) EKVX-Lung GVR DVPGVRF (313) EKVX-Lung GVL FGVLFRS (314) EKVX-Lung SRYGVLV (315) EKVX-Lung GAV EKVX-Lung GLV LRGGLVS (316) EKVX-Lung GLR KSGLRPA (317) EKVX-Lung LVS ALVSFSV (318) EKVX-Lung LRGGLVS (319) EKVX-Lung ARG HKLARGR (320) EKVX-Lung ASL ASLPPRA (321) EKVX-Lung AAV EKVX-Lung AAS EKVX-Lung GGS TGGSLGA (322) EKVX-Lung GGGSWLI (323) EKVX-Lung GGR DGGRRSS (324) EKVX-Lung SVLGGRL (325) EKVX-Lung PRAGGRW (326) EKVX-Lung GLG YWFIGLG (327) EKVX-Lung GGL GGLSVDL (328) EKVX-Lung LRGGLVS (329) EKVX-Lung GSS SGVGSSL (330) EKVX-Lung GSG GSGILDL (331) EKVX-Lung GSV SLGSVGS (332) EKVX-Lung GRV EKVX-Lung GRL VGRGRLH (333) EKVX-Lung SVLGGRL (334) EKVX-Lung MSAFGRL (335) EKVX-Lung GPS EKVX-Lung GVS SGVSGLS (336) EKVX-Lung RLS Hop-62-Lung RGV GDSRRGV (337) Hop-62-Lung GKALRGV (338) Hop-62-Lung
RGS PKAGRGS (339) Hop-62-Lung RAV FDRAVAN (340) Hop-62-Lung LLRRAVF (341) Hop-62-Lung RAS FRASSEV (342) Hop-62-Lung PDRASDG (343) Hop-62-Lung FRASLQY (344) Hop-62-Lung GAG Hop-62-Lung AVS Hop-62-Lung LLS Hop-62-Lung LLR HVGLLRA (345) Hop-62-Lung QVLLRSF (346) Hop-62-Lung LLRRAVF (347) Hop-62-Lung LRV FLRVGEL (348) Hop-62-Lung LRS QVLLRSF (349) Hop-62-Lung RVS RRVSCDL (350) Hop-62-Lung RSS RSSGLGF (351) Hop-62-Lung SSGPRSS (352) Hop-62-Lung YSQRSSL (353) Hop-62-Lung Hop-62-Lung AGS Hop-62-Lung AGR DAGRTID (354) Hop-62-Lung AAGREFR (355) Hop-62-Lung PKAGRGS (356) Hop-62-Lung VRAAGRV (357) Hop-62-Lung Hop-62-Lung AGL Hop-62-Lung AGG HGYRAGG (358) Hop-62-Lung WGATAGG (359) Hop-62-Lung YYAGGLK (360) Hop-62-Lung GVR LEGVRLF (361) Hop-62-Lung GVRPFPR (362) Hop-62-Lung GVL GTFGVLG (363) Hop-62-Lung VWAGVLL (364) Hop-62-Lung GAV GAVLFRV (365) Hop-62-Lung GLV GLVGFTG (366) Hop-62-Lung GLVSAFY (367) Hop-62-Lung GLR ARAMGLR (368) Hop-62-Lung LVS GLVSAFY (369) Hop-62-Lung SWRPLVS (370) Hop-62-Lung ARG Hop-62-Lung ASL FRASLQY (371) Hop-62-Lung AAV HSESAAV (372) Hop-62-Lung LFAVAAV (373) Hop-62-Lung AAS VAASESH (374) Hop-62-Lung GGS Hop-62-Lung GGR HPSMGGR (375) Hop-62-Lung GLG GLGVSGV (376) Hop-62-Lung KRESGLG (377) Hop-62-Lung RSSGLGF (378) Hop-62-Lung VGLGHWP (379) Hop-62-Lung GGL YYAGGLK (380) Hop-62-Lung GSS NYGSSFH (381) Hop-62-Lung FGLGSSR (382) Hop-62-Lung SSRPGSS (383) Hop-62-Lung GSG Hop-62-Lung GSV VGSVGLG (384) Hop-62-Lung GRV VRAAGRV (385) Hop-62-Lung GRL HNGRLEV (386) Hop-62-Lung VGRLAKG (387) Hop-62-Lung GPS VMGGPSL (388) Hop-62-Lung GVS GLGVSGV (389) Hop-62-Lung SGVSVEG (390) Hop-62-Lung RLS GESGRLS (391) Hop-92-Lung RGV GSGRGVA (392) Hop-92-Lung RGVVSAK (393) Hop-92-Lung RGVVSGV (394) Hop-92-Lung RGS AVGRGSG (395) Hop-92-Lung SLRGSEG (396) Hop-92-Lung PATRGSV (397) Hop-92-Lung RAV SLTRAVR (398) Hop-92-Lung VARAVPC (399) Hop-92-Lung RAS EGARASD (400) Hop-92-Lung GAG Hop-92-Lung AVS MGSAVSL (401) Hop-92-Lung LLS Hop-92-Lung LLR GGALLRG (402) Hop-92-Lung LRV Hop-92-Lung LRS Hop-92-Lung RVS PNRRVSA (403) Hop-92-Lung QDRVSRS (404) Hop-92-Lung RSS SERSSLG (405) Hop-92-Lung LVRSSGL (406) Hop-92-Lung AGS Hop-92-Lung AGR Hop-92-Lung AGL INWAGLS (407) Hop-92-Lung WAGLSPS (408) Hop-92-Lung AGG GRLLAGG (409) Hop-92-Lung GVR Hop-92-Lung GVL Hop-92-Lung GAV Hop-92-Lung GLV SYGLVLP (410) Hop-92-Lung SGGLVLT (411) Hop-92-Lung HAAHGLV (412) Hop-92-Lung GLR GLRTRQV (413) Hop-92-Lung LVS LVSGYNG (414) Hop-92-Lung ARG AGIARGG (415) Hop-92-Lung ASL Hop-92-Lung AAV Hop-92-Lung AAS Hop-92-Lung GGS HVSGGSG (416) Hop-92-Lung GGSSEFR (417) Hop-92-Lung GGSGIGS (418) Hop-92-Lung SWGSGGS (419) Hop-92-Lung TLVLGGS (420) Hop-92-Lung GGR AVRGGRP (421) Hop-92-Lung GGRAIGA (422) Hop-92-Lung GLG Hop-92-Lung GGL SGGLVLT (423) Hop-92-Lung GSS RTGSSDL (424) Hop-92-Lung LGSSRVL (425) Hop-92-Lung GGSSEFR (426) Hop-92-Lung GSG AVGRGSG (427) Hop-92-Lung HVSGGSG (428) Hop-92-Lung SGIGSGG (429) Hop-92-Lung SWGSGGS (430) Hop-92-Lung WVGSGSP (431) Hop-92-Lung GSV GSGGSVH (432) Hop-92-Lung GNYGSVL (433) Hop-92-Lung VGSVVGR (434) Hop-92-Lung PATRGSV (435) Hop-92-Lung GRV PRGGRVA (436) Hop-92-Lung GRVHLMP (437) Hop-92-Lung GRL GESGRLS (438) Hop-92-Lung GRLLAGG (439) Hop-92-Lung GRLWWHT (440) Hop-92-Lung GRLWSRV (441) Hop-92-Lung GPS AGPSAWL (442) Hop-92-Lung GVS SGVSRGQ (443) Hop-92-Lung RLS H226-Lung RGV RGVSLKG (444) H226-Lung RGS H226-Lung RAV QMQGRAV (445) H226-Lung RAS H226-Lung GAG H226-Lung AVS H226-Lung LLS H226-Lung LLR H226-Lung LRV H226-Lung LRS RGLRSVN (446) H226-Lung RVS H226-Lung RSS RSSLGLP (447) H226-Lung AGS LEAGSQL (448) H226-Lung AGR H226-Lung AGL H226-Lung AGG AGGQSER (449) H226-Lung GVR H226-Lung GVL GGVLYLE (450) H226-Lung GAV H226-Lung GLV H226-Lung GLR RGLRSVN (451) H226-Lung LVS H226-Lung ARG VARGQMQ (452) H226-Lung
ASL H226-Lung AAV H226-Lung AAS H226-Lung GGS GGSRNRW (453) H226-Lung GGR GGGRSGV (454) H226-Lung GLG GLGGWVA (455) H226-Lung GGL AVWGGLG (456) H226-Lung GGLSECV (457) H226-Lung GSS H226-Lung GSG H226-Lung GSV AKLGSVY (458) H226-Lung GRV QGRVNVK (459) H226-Lung GRL GRLWGFW (460) H226-Lung GPS H226-Lung GVS RGVSLKG (461) H226-Lung GSLGVSL (462) H226-Lung RLS LLRLSLA (463) H23-Lung RGV H23-Lung RGS RRGSGGL (464) H23-Lung VRGSVRA (465) H23-Lung RAV H23-Lung RAS H23-Lung GAG H23-Lung AVS H23-Lung LLS H23-Lung LLR LLRLSLA (466) H23-Lung LRV PLRVDNL (467) H23-Lung LRVGIGY (468) H23-Lung QGYALRV (469) H23-Lung LRS PLRSFDS (470) H23-Lung RVS ARVSGRV (471) H23-Lung RSS PFPARSS (472) H23-Lung AGS AGSPLAK (473) H23-Lung FVDIAGS (474) H23-Lung AGR SYFRAGR (475) H23-Lung AGL AGLGHEG (476) H23-Lung AGG AGGSLGS (477) H23-Lung GVR YGIGVRL (478) H23-Lung GVL RANGVLV (479) H23-Lung GAV H23-Lung GLV H23-Lung GLR H23-Lung LVS H23-Lung ARG H23-Lung ASL LASLGVG (480) H23-Lung AAV RAAVGAR (481) H23-Lung AAS H23-Lung GGS GCDGGSA (482) H23-Lung GGSGELG (483) H23-Lung LGGSGRR (484) H23-Lung AGGSLGS (485) H23-Lung GGR IGGREIT (486) H23-Lung GLG GEHGLGA (487) H23-Lung GGL RRGSGGL (488) H23-Lung GSS RSGSSVY (489) H23-Lung GSG GLEGSGG (490) H23-Lung LGGSGRR (491) H23-Lung GSV TTGSVIV (492) H23-Lung VRGSVRA (493) H23-Lung GRV HGRVHRL (494) H23-Lung ARVSGRV (495) H23-Lung GRL H23-Lung GPS H23-Lung GVS SGHGVSA (496) H23-Lung RLS AVWRLSH (497) H322-Lung RGV RGVFYGK (498) H322-Lung RGVGWAK (499) H322-Lung RGS SRGSTAG (500) H322-Lung RAV H322-Lung RAS H322-Lung GAG SEDEGAG (501) H322-Lung STSLGAG (502) H322-Lung AVS H322-Lung LLS H322-Lung LLR DLLRYLA (503) H322-Lung LRV LRVRYAV (504) H322-Lung LRS LRSSGAT (505) H322-Lung LSMLRSA (506) H322-Lung RVS REAERVS (507) H322-Lung RSS LRSSGAT (508) H322-Lung AGS TAGSSRL (509) H322-Lung AGR AAGRAGC (510) H322-Lung AGL GAGLSTS (511) H322-Lung AGG H322-Lung GVR PSVGVRA (512) H322-Lung GVL H322-Lung GAV VGAVYFL (513) H322-Lung GLV H322-Lung GLR LGLRAFV (514) H322-Lung LVS TELVSWS (515) H322-Lung ARG CGARGAA (516) H322-Lung ASL H322-Lung AAV H322-Lung AAS H322-Lung GGS GGSRAAE (517) H322-Lung VNLGGSW (518) H322-Lung GGR LIGPGGR (519) H322-Lung GLG H322-Lung GGL LGGLSPH (520) H322-Lung WSGGLNV (521) H322-Lung GSS TAGSSRL (522) H322-Lung SDVSGSS (523) H322-Lung WGSSTVR (524) H322-Lung GSG H322-Lung GSV NLADGSV (525) H322-Lung SSGSVDS (526) H322-Lung GRV GRVPGFE (527) H322-Lung GRVVGEA (528) H322-Lung GRL H322-Lung GPS SRFGPSV (529) H322-Lung GVS ARVGVSP (530) H322-Lung RLS H460-Lung RGV PGKRGVQ (531) H460-Lung RGVASRS (532) H460-Lung RGS ERGSPSR (533) H460-Lung RAV LIRAVSA (534) H460-Lung RAVEMGT (535) H460-Lung RAS H460-Lung GAG WGAGFWM (536) H460-Lung AVS LIRAVSA (537) H460-Lung LLS H460-Lung LLR H460-Lung LRV H460-Lung LRS DRYMLRS (538) H460-Lung RVS H460-Lung RSS PRSSYNE (539) H460-Lung PRSSLVV (540) H460-Lung AGS H460-Lung AGR H460-Lung AGL RRFWAGL (541) H460-Lung AGG PVHSAGG (542) H460-Lung GVR H460-Lung GVL FGGSGVL (543) H460-Lung SSGGVLG (544) H460-Lung GAV H460-Lung GLV GLVGGSS (545) H460-Lung LSSGLVS (546) H460-Lung GLR H460-Lung LVS LSSGLVS (547) H460-Lung WFSWLVS (548) H460-Lung
ARG H460-Lung ASL GASLTGD (549) H460-Lung WSSTASL (550) H460-Lung AAV H460-Lung AAS H460-Lung GGS FGGSGVL (551) H460-Lung GLVGGSS (552) H460-Lung GGR H460-Lung GLG H460-Lung GGL GGLSPHR (553) H460-Lung GSS GLVGGSS (554) H460-Lung SVLGSSL (555) H460-Lung GSG FGGSGVL (556) H460-Lung GSV H460-Lung GRV DVRGRVW (557) H460-Lung AEPRGRV (558) H460-Lung GRL H460-Lung GPS SIGPSTN (559) H460-Lung GVS GVSIRQL (560) H460-Lung RLS H522-Lung RGV H522-Lung RGS H522-Lung RAV H522-Lung RAS H522-Lung GAG H522-Lung AVS AVSKRLP (561) H522-Lung RLAVSGY (562) H522-Lung H522-Lung LLS H522-Lung LLR H522-Lung LRV H522-Lung LRS RREGLRS (563) H522-Lung SRYWLRS (564) H522-Lung H522-Lung RVS H522-Lung RSS H522-Lung AGS H522-Lung AGR AVYRAGR (565) H522-Lung H522-Lung AGL H522-Lung AGG H522-Lung GVR H522-Lung GVL H522-Lung GAV H522-Lung GLV H522-Lung GLR RHFGLRE (566) H522-Lung RREGLRS (567) H522-Lung H522-Lung LVS H522-Lung ARG H522-Lung ASL GQGAASL (568) H522-Lung AAV H522-Lung AAS GQGAASL (569) H522-Lung H522-Lung GGS H522-Lung GGR H522-Lung GLG H522-Lung GGL H522-Lung GSS H522-Lung GSG H522-Lung GSV YGSVALR (570) H522-Lung H522-Lung GRV H522-Lung GRL H522-Lung GPS H522-Lung GVS H522-Lung RLS COLO-205-Colon RGV ARRGVLG (571) COLO-205-Colon LRIARGV (572) COLO-205-Colon RGS YRGSMVG (573) COLO-205-Colon GLRGSVW (574) COLO-205-Colon RAV GPFRAVP (575) COLO-205-Colon RAS COLO-205-Colon GAG COLO-205-Colon AVS COLO-205-Colon LLS COLO-205-Colon LLR COLO-205-Colon LRV COLO-205-Colon LRS AHYTLRS (576) COLO-205-Colon SELRSIR (577) COLO-205-Colon SVYALRS (578) COLO-205-Colon RVS COLO-205-Colon RSS COLO-205-Colon AGS COLO-205-Colon AGR COLO-205-Colon AGL COLO-205-Colon AGG COLO-205-Colon GVR COLO-205-Colon GVL ARRGVLG (579) COLO-205-Colon GAV PGAVLTV (580) COLO-205-Colon GLV GLVGRRA (581) COLO-205-Colon GLVRCVL (582) COLO-205-Colon YDGLVSG (583) COLO-205-Colon GLVTAPL (584) COLO-205-Colon RGLVRVV (585) COLO-205-Colon GLR GLRGSVW (586) COLO-205-Colon NSFGLRY (587) COLO-205-Colon LVS YDGLVSG (588) COLO-205-Colon ARG AARGLEA (589) COLO-205-Colon DNDGARG (590) COLO-205-Colon LRIARGV (591) COLO-205-Colon ASL COLO-205-Colon AAV MSNLAAV (592) COLO-205-Colon AAS COLO-205-Colon GGS COLO-205-Colon GGR COLO-205-Colon GLG COLO-205-Colon GGL COLO-205-Colon GSS YSGSSDF (593) COLO-205-Colon GSG COLO-205-Colon GSV GSVLGDY (594) COLO-205-Colon GLRGSVW (595) COLO-205-Colon GRV DLDGRVV (596) COLO-205-Colon GRL WVSGRLG (597) COLO-205-Colon GPS GPSSMTF (598) COLO-205-Colon GVS DGVSSDY (599) COLO-205-Colon FTSGVSW (600) COLO-205-Colon RLS HCC-2998-Colon RGV HCC-2998-Colon RGS HCC-2998-Colon RAV HCC-2998-Colon RAS VLTRAST (601) HCC-2998-Colon LRASLLW (602) HCC-2998-Colon GAG HCC-2998-Colon AVS HCC-2998-Colon LLS WLLSARL (603) HCC-2998-Colon LLR LLRPGTV (604) HCC-2998-Colon LRV HCC-2998-Colon LRS HCC-2998-Colon RVS HCC-2998-Colon RSS HCC-2998-Colon AGS HCC-2998-Colon AGR HCC-2998-Colon AGL HCC-2998-Colon AGG AAGGLLV (605) HCC-2998-Colon GVR HCC-2998-Colon GVL HCC-2998-Colon GAV HCC-2998-Colon GLV HCC-2998-Colon
GLR HCC-2998-Colon LVS HCC-2998-Colon ARG HCC-2998-Colon ASL LRASLLW (606) HCC-2998-Colon AAV HCC-2998-Colon AAS HCC-2998-Colon GGS HCC-2998-Colon GGR HCC-2998-Colon GLG LWGLGWL (607) HCC-2998-Colon RRSGLGD (608) HCC-2998-Colon WWGLGWL (609) HCC-2998-Colon GGL AAGGLLV (610) HCC-2998-Colon GSS HCC-2998-Colon GSG HCC-2998-Colon GSV HCC-2998-Colon GRV HCC-2998-Colon GRL HCC-2998-Colon GPS HCC-2998-Colon GVS HCC-2998-Colon RLS HCT-116 Colon RGV GLRGVVK (611) HCT-116 Colon RGS AVEGRGS (612) HCT-116 Colon NAVRGSA (613) HCT-116 Colon RAV HCT-116 Colon RAS HCT-116 Colon GAG HCT-116 Colon AVS HCT-116 Colon LLS HCT-116 Colon LLR LLRSSLG (614) HCT-116 Colon MYLRLLR (615) HCT-116 Colon LRV HCT-116 Colon LRS LLRSSLG (616) HCT-116 Colon DEGLRSR (617) HCT-116 Colon RVS YWQHRVS (618) HCT-116 Colon RSS ARSSHRA (619) HCT-116 Colon LLRSSLG (620) HCT-116 Colon AGS HCT-116 Colon AGR AGRSCNL (621) HCT-116 Colon AGRPRAT (622) HCT-116 Colon AGL HCT-116 Colon AGG HCT-116 Colon GVR GGVRIAA (623) HCT-116 Colon GVRYLRT (624) HCT-116 Colon GVL HCT-116 Colon GAV HCT-116 Colon GLV PLAVGLV (625) HCT-116 Colon GLR GLRGVVK (626) HCT-ll6 Colon DEGLRSR (627) HCT-116 Colon LVS QLVSGSL (628) HCT-116 Colon ARG HCT-116 Colon ASL GWSASLG (629) HCT-116 Colon AAV IAAVWRS (630) HCT-116 Colon AAS HCT-116 Colon GGS GGSSLDA (631) HCT-116 Colon LGGSRDL (632) HCT-116 Colon GGR LIGGRNA (633) HCT-116 Colon GLG HCT-116 Colon GGL LDRSGGL (634) HCT-116 Colon GSS GGSSLDA (635) HCT-116 Colon GSSYSGP (636) HCT-116 Colon GSG TVGSGCL (637) HCT-116 Colon GSV LSGSVLQ (638) HCT-116 Colon GRV ASGRVAN (639) HCT-116 Colon GRL KVVGRLG (640) HCT-116 Colon GRLVWGL (641) HCT-116 Colon NEFLGRL (642) HCT-116 Colon GPS LCDAGPS (643) HCT-116 Colon GVS FRAGVSH (644) HCT-116 Colon RLS AGDSRLS (645) HCT-15 Colon RGV HCT-15 Colon RGS HCT-15 Colon RAV DWRRRAV (646) HCT-15 Colon RAS WTERASA (647) HCT-15 Colon GAG HCT-15 Colon AVS HCT-15 Colon LLS RLLSAFG (648) HCT-15 Colon LLR GFASLLR (649) HCT-15 Colon LRV GALRVPW (650) HCT-15 Colon GALRVPW HCT-15 Colon GALRVPW HCT-15 Colon LRS SLRSDGA (651) HCT-15 Colon DTLRSQW (652) HCT-15 Colon LRSVGSW (653) HCT-15 Colon RVS HCT-15 Colon RSS ISPRSSG (654) HCT-15 Colon WRVRSSG (655) HCT-15 Colon AGS HCT-15 Colon AGR AAGRIRP (656) HCT-15 Colon RAAGRVG (657) HCT-15 Colon AGL AGLQHAV (658) HCT-15 Colon AGG AGGWWVG (659) HCT-15 Colon GVR GVRGAAR (660) HCT-15 Colon GVL GVLPVVT (661) HCT-15 Colon GVLPVVT HCT-15 Colon GAV HCT-15 Colon GLV GLVSSLP (662) HCT-15 Colon SRHGLVR (663) HCT-15 Colon SDRGLVV (664) HCT-15 Colon SDRGLVV (665) HCT-15 Colon GLR HCT-15 Colon LVS GLVSSLP (666) HCT-15 Colon LVSVWSR (667) HCT-15 Colon ARG GSWARGY (668) HCT-15 Colon ASL GFASLLR (669) HCT-15 Colon AAV HAAVMSL (670) HCT-15 Colon AAS HCT-15 Colon GGS HCT-15 Colon GGR DGGRRTD (671) HCT-15 Colon GRPLGGR (672) HCT-15 Colon GRVTGGR (673) HCT-15 Colon GLG HCT-15 Colon GGL RGGLPRG (674) HCT-15 Colon YGQYGGL (675) HCT-15 Colon GSS GSSRPSI (676) HCT-15 Colon PGSSFVG (677) HCT-15 Colon GSSRVRW (678) HCT-15 Colon GSG HCT-15 Colon GSV HCT-15 Colon GRV RAAGRVG (679) HCT-15 Colon GRVTGGR (680) HCT-15 Colon YVRIGRV (681) HCT-15 Colon GRL MITRGRL (682) HCT-15 Colon GPS HCT-15 Colon GVS SVVGVST (683) HCT-15 Colon WSGVSRL (684) HCT-15 Colon RLS RRLSYFH (685) HT-29 Colon PRLSWVL (686) HT-29 Colon RLSALTD (687) HT-29 Colon RGV GRGVGTD (688) HT-29 Colon LKVRGVL (689) HT-29 Colon SSTRGVY (690) HT-29 Colon QVRRGVV (691) HT-29 Colon GRGVTIW (692) HT-29 Colon RGS RGSVASA (693) HT-29 Colon HFIRGSV (694) HT-29 Colon RGSWAGV (695) HT-29 Colon VRGSRWR (696) HT-29 Colon RAV LERAVRT (697) HT-29 Colon RAS GYSRASD (698) HT-29 Colon SRASGHG (699) HT-29 Colon GHYRASV (700) HT-29 Colon DWVCRAS (701) HT-29 Colon GAG GAGRGTP (702) HT-29 Colon LSLAGAG (703) HT-29 Colon AVS ASAVSGR (704) HT-29 Colon FSGDAVS (705) HT-29 Colon LLS LKLLSVP (706) HT-29 Colon LLR HT-29 Colon
LRV GTLRVGS (707) HT-29 Colon LRS EHYRLRS (708) HT-29 Colon LRSWLLF (709) HT-29 Colon RRPGLRS (710) HT-29 Colon SKYNLRS (711) HT-29 Colon WQVALRS (712) HT-29 Colon LRSDPRS (713) HT-29 Colon VPLRSSA (714) HT-29 Colon RVS HT-29 Colon RSS GRSSGME (715) HT-29 Colon VPLRSSA (716) HT-29 Colon AGS AGSGFPF (717) HT-29 Colon AGR GAGRGTP (718) HT-29 Colon AGRIASK (719) HT-29 Colon AGL WGVAGLG (720) HT-29 Colon LAGLVSG (721) HT-29 Colon AGG DAGGMDL (722) HT-29 Colon AGGRWNL (723) HT-29 Colon GVR GCGGVRD (724) HT-29 Colon SGVRLTG (725) HT-29 Colon GVL LKVRGVL (726) HT-29 Colon GAV GLGAVGW (727) HT-29 Colon PGAVPGA (728) HT-29 Colon RIGAVWY (729) HT-29 Colon GLV FSGLVVA (730) HT-29 Colon PGGLVPG (731) HT-29 Colon LAGLVSG (732) HT-29 Colon LGLVSTT (733) HT-29 Colon GLR GLRLGVT (734) HT-29 Colon RRPGLRS (735) HT-29 Colon LVS LAGLVSG (736) HT-29 Colon LGLVSTT (737) HT-29 Colon RQLVSPA (738) HT-29 Colon ARG LRARGGH (739) HT-29 Colon ASL ELWASLG (740) HT-29 Colon DTLASLR (741) HT-29 Colon VVASLPH (742) HT-29 Colon AAV HT-29 Colon AAS VLRAASR (743) HT-29 Colon AASGSYY (744) HT-29 Colon GGS GGSALFG (745) HT-29 Colon GRGGSGY (746) HT-29 Colon GGR YGSGGRG (747) HT-29 Colon GTLGGRV (748) HT-29 Colon AGGRWNL (749) HT-29 Colon HGGRARL (750) HT-29 Colon RGGRSPS (751) HT-29 Colon RKPGGGR (752) HT-29 Colon EGGRTHW (753) HT-29 Colon GLG GEVGLGV (754) HT-29 Colon GLGAVGW (755) HT-29 Colon GGL PGGLVPG (756) HT-29 Colon VRGGLTG (757) HT-29 Colon RQKCGGL (758) HT-29 Colon RYGVGGL (759) HT-29 Colon GSS EMGSSRG (760) HT-29 Colon GSG AGSGFPF (761) HT-29 Colon GRGGSGY (762) HT-29 Colon GSV GSVSAGA (763) HT-29 Colon RGSVASA (764) HT-29 Colon DLGSVQH (765) HT-29 Colon HFIRGSV (766) HT-29 Colon GSVLGAL (767) HT-29 Colon GRV GTLGGRV (768) HT-29 Colon LGRVHVW (769) HT-29 Colon LVGRVKL (770) HT-29 Colon RWRSGRV (771) HT-29 Colon GRL RNPGRLA (772) HT-29 Colon PRGRLFD (773) HT-29 Colon GRLAVVA (774) HT-29 Colon LAQGRLA (775) HT-29 Colon GGMNGRL (776) HT-29 Colon GPS RSTLGPS (777) HT-29 Colon GVS GVSALSL (778) HT-29 Colon GGR KM-12C Colon RLS SRLSYYA (779) KM-12C Colon SRLSYYA KM-12C Colon RGV ARGVSAP (780) KM-12C Colon GRGVLAF (781) KM-12C Colon RGS MRGSGRN (782) KM-12C Colon RAV RDGRAVR (783) KM-12C Colon GRAVWMV (784) KM-12C Colon RAS KM-12C Colon GAG KM-12C Colon AVS KM-12C Colon LLS KM-12C Colon LLR KM-12C Colon LRV LRVPGGP (785) KM-12C Colon LRS AYYSLRS (786) KM-12C Colon AYYSLRS KM-12C Colon VLRSALQ (787) KM-12C Colon VYYALRS (788) KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon VYYALRS KM-12C Colon RVS RYRVSVY (789) KM-12C Colon RSS KM-12C Colon AGS KM-12C Colon AGR KM-12C Colon AGL KM-12C Colon AGG AGGIWIR (790) KM-12C Colon GVR WQVSGVR (791) KM-12C Colon GVL GRGVLAF (792) KM-12C Colon GAV KM-12C Colon GLV KM-12C Colon GLR KM-12C Colon LVS HAELVSL (793) KM-12C Colon ARG ARGVSAP (794) KM-12C Colon RVARGDR (795) KM-12C Colon VMWVARG (796) KM-12C Colon ASL KM-12C Colon AAV AAVTVVR (797) KM-12C Colon AAS KM-12C Colon GGS KM-12C Colon GLG KM-12C Colon GGL TREGGLD (798) KM-12C Colon LGGGGLL (799) KM-12C Colon GSS KM-12C Colon GSG GSGHSFA (800) KM-12C Colon MRGSGRN (801) KM-12C Colon GSV RVGSVQW (802) KM-12C Colon EGTSGSV (803) KM-12C Colon GRV GRVPTVV (804) KM-12C Colon KM-12C Colon GRL ADGRLRY (805) KM-12C Colon GPS KM-12C Colon GVS ARGVSAP (806) KM-12C Colon RLS SW620-Colon RGV RGVKLGD (807) SW620-Colon RGS LRGSYVL (808) SW620-Colon RRGSLMF (809) SW620-Colon RGSVGPS (810) SW620-Colon RAV SW620-Colon RAS SRASDVT (811) SW620-Colon GAG SW620-Colon AVS SW620-Colon LLS AAKTLLS (812) SW620-Colon LLR SW620-Colon LRV SW620-Colon LRS RSYPLRS (813) SW620-Colon RVS YLGRRVS (814) SW620-Colon RSS RSSPVWT (815) SW620-Colon AGS DLRRAGS (816) SW620-Colon AGR SW620-Colon AGL GVAGLRW (817) SW620-Colon AGG RIDAGGG (818) SW620-Colon GVAGGAT (819) SW620-Colon GVR SW620-Colon GVL SW620-Colon GAV TAGGAVG (820) SW620-Colon WRLGAVG (821) SW620-Colon GLV SGLVAMV (822) SW620-Colon GLR VGLRDWG (823) SW620-Colon GVAGLRW (824) SW620-Colon LVS SW620-Colon ARG ARGIVRV (825) SW620-Colon ASL ASLHHRR (826) SW620-Colon
AAV SW620-Colon AAS GAAASGY (827) SW620-Colon GGS SW620-Colon GGR SW620-Colon GLG LAIRGLG (828) SW620-Colon GGL GGLSNVV (829) SW620-Colon PPGGLKW (830) SW620-Colon GSS SW620-Colon GSG SW620-Colon GSV EGSVDAH (831) SW620-Colon RGSVGPS (832) SW620-Colon GRV SW620-Colon GRL LVYSGRL (833) SW620-Colon VEEGRLR (834) SW620-Colon GPS RGSVGPS (835) SW620-Colon GVS SPGVSGR (836) SW620-Colon RGV RVGRGVL (837) SF-268 CNS RGS SF-268 CNS RAV WIWRAVS (838) SF-268 CNS RAS SF-268 CNS GAG VTDGAGQ (839) SF-268 CNS AVS LGTAVSS (840) SF-268 CNS WIWRAVS (841) SF-268 CNS DTPSAVS (842) SF-268 CNS LLS GLLSAGI (843) SF-268 CNS LLR YLLRALG (844) SF-268 CNS LRV SF-268 CNS LRS LRSGSLG (845) SF-268 CNS PLRSVWS (846) SF-268 CNS RVS SF-268 CNS RSS ARSSIVR (847) SF-268 CNS AGS SF-268 CNS AGR SF-268 CNS AGL SF-268 CNS AGG AGGRLGL (848) SF-268 CNS AGGWRGR (849) SF-268 CNS GVR LVGRGVR (850) SF-268 CNS GVL DVVGVLK (851) SF-268 CNS RVGRGVL (852) SF-268 CNS GAV GAVTGYP (853) SF-268 CNS GLV WGLVRHA (854) SF-268 CNS GLR LGLRGGA (855) SF-268 CNS LVS SF-268 CNS ARG SF-268 CNS ASL IGASLLG (856) SF-268 CNS AAV AAVETGV (857) SF-268 CNS AAS SF-268 CNS GGS GLGGGGS (858) SF-268 CNS GGR EVLWGGR (859) SF-268 CNS AGGRLGL (860) SF-268 CNS GGRSKKV (861) SF-268 CNS GLG GLGGGGS (862) SF-268 CNS GGL SGGGGLG (863) SF-268 CNS GAYGGLL (864) SF-268 CNS GGLSRSN (865) SF-268 CNS GSS FGSSNRS (866) SF-268 CNS GSG SF-268 CNS GSV GSVSDRF (867) SF-268 CNS GRV SF-268 CNS GRL AGGRLGL (868) SF-268 CNS GPS WFKGPSV (869) SF-268 CNS GVS SF-268 CNS RLS SF-295 CNS RGV LSERRGV (870) SF-295 CNS ARGVAEY (871) SF-295 CNS SF-295 CNS RGS FDRGSLT (872) SF-295 CNS SF-295 CNS RAV SF-295 CNS RAS GRLRASL (873) SF-295 CNS SF-295 CNS GAG RDGRGAG (874) SF-295 CNS SF-295 CNS AVS GAVSVLA (875) SF-295 CNS TRGDAVS (876) SF-295 CNS SF-295 CNS LLS LLSPRGT (877) SF-295 CNS SF-295 CNS LLR LLRSHGV (878) SF-295 CNS SF-295 CNS LRV PLRVLKR (879) SF-295 CNS GRLRLRV (880) SF-295 CNS SF-295 CNS LRS LLRSHGV (881) SF-295 CNS VLRSGEL (882) SF-295 CNS VLRSIPS (883) SF-295 CNS VLRSIPS SF-295 CNS SF-295 CNS RVS GSMHRVS (884) SF-295 CNS YSIMRVS (885) SF-295 CNS SF-295 CNS RSS SF-295 CNS AGS RAGSRVQ (886) SF-295 CNS SF-295 CNS AGR RRDAGRM (887) SF-295 CNS GAGRGDR (888) SF-295 CNS SF-295 CNS AGL RWAGLVA (889) SF-295 CNS SF-295 CNS AGG QTLSAGG (890) SF-295 CNS LAGGWGS (891) SF-295 CNS SF-295 CNS GVR RHGVRSK (892) SF-295 CNS SF-295 CNS GVL SF-295 CNS GAV GAVSVLA (893) SF-295 CNS SF-295 CNS GLV RWAGLVA (894) SF-295 CNS SF-295 CNS GLR GRGLRTD (895) SF-295 CNS TLGGLRT (896) SF-295 CNS SF-295 CNS LVS ALVSVAG (897) SF-295 CNS SF-295 CNS ARG ARGVAEY (898) SF-295 CNS SF-295 CNS ASL GGASLTQ (899) SF-295 CNS GRLRASL (900) SF-295 CNS SNHTASL (901) SF-295 CNS SF-295 CNS AAV YADGAAV (902) SF-295 CNS SF-295 CNS AAS SF-295 CNS GGS SF-295 CNS GGR SF-295 CNS GLG LGGLGIH (903) SF-295 CNS SF-295 CNS GGL GGFTGGL (904) SF-295 CNS HIGLGGL (905) SF-295 CNS TRLGGLT (906) SF-295 CNS SF-295 CNS GSS SF-295 CNS GSG SF-295 CNS GSV VMPGSVV (907) SF-295 CNS SF-295 CNS GRV SF-295 CNS GRL GRLRASL (908) SF-295 CNS GRLYLGI (909) SF-295 CNS GRLRLRV (910) SF-295 CNS SF-295 CNS SF-295 CNS GPS SHCGPSN (911) SF-295 CNS SHCGPSN SF-295 CNS SF-295 CNS GVS SF-295 CNS RLS VRLSGRA (912) SNB-19 CNS RLSTFAG (913) SNB-19 CNS RGV SNB-19 CNS RGS ARGSLRV (914) SNB-19 CNS FSPRGSV (915) SNB-19 CNS RAV GGRLRAV (916) SNB-19 CNS RAS SNB-19 CNS GAG SNB-19 CNS AVS VLSAVSS (917) SNB-19 CNS LLS SNB-19 CNS
LLR SNB-19 CNS LRV ARGSLRV (918) SNB-19 CNS LRS LRSYAWS (919) SNB-19 CNS RVS KGRVSAG (920) SNB-19 CNS RSS SNB-19 CNS AGS SNB-19 CNS AGR SNB-19 CNS AGL AGLTIGI (921) SNB-19 CNS AGG AWRHAGG (922) SNB-19 CNS WARAGGF (923) SNB-19 CNS GVR SNB-19 CNS GVL MGVLTAE (924) SNB-19 CNS FAGYGVL (925) SNB-19 CNS GAV RIFHGAV (926) SNB-19 CNS GLV EGLVVFE (927) SNB-19 CNS GLR REVPGLR (928) SNB-19 CNS LVS LVSVNGA (929) SNB-19 CNS HSLVSQP (930) SNB-19 CNS ARG ARGSLRV (931) SNB-19 CNS ASL SSVASLV (932) SNB-19 CNS AAV AAVWQMK (933) SNB-19 CNS QRAAVIV (934) SNB-19 CNS AAS SNB-19 CNS GGS PGGSDAA (935) SNB-19 CNS GGR GGRLRAV (936) SNB-19 CNS GLG SNB-19 CNS GGL LPCGGLA (937) SNB-19 CNS GSS GSSHDAL (938) SNB-19 CNS TQYYGSS (939) SNB-19 CNS GSG SNB-19 CNS GSV FSPRGSV (940) SNB-19 CNS GRV KGRVSAG (941) SNB-19 CNS QGRVNVK (942) SNB-19 CNS GRL GGRLRAV (943) SNB-19 CNS YDGRLAR (944) SNB-19 CNS GPS SNB-19 CNS GVS SNB-19 CNS RLS SNB-75 CNS RGV PQGRGVK (945) SNB-75 CNS RGS MVLRGSY (946) SNB-75 CNS RAV GGWARAV (947) SNB-75 CNS VRAVCLM (948) SNB-75 CNS RAS TRASRRG (949) SNB-75 CNS GAG LGAGEGD (950) SNB-75 CNS AVS IGAVSGW (951) SNB-75 CNS LLS LLSRRVG (952) SNB-75 CNS LELLSVV (953) SNB-75 CNS RLLSEGY (954) SNB-75 CNS LLR QLPGLLR (955) SNB-75 CNS YGESLLR (956) SNB-75 CNS LRV LRVYGEG (957) SNB-75 CNS LRS SNB-75 CNS RVS YRVSSGS (958) SNB-75 CNS RSS RSSSSTR (959) SNB-75 CNS AGS WAGSNYS (960) SNB-75 CNS AGR CAGRARR (961) SNB-75 CNS AGL IAGLAVV (962) SNB-75 CNS DGEGAGL (963) SNB-75 CNS AGG ALAGGGL (964) SNB-75 CNS GVR GVRRSLL (965) SNB-75 CNS GVL ADWGVLE (966) SNB-75 CNS GAV IGAVSGW (967) SNB-75 CNS GLV ASGLVVT (968) SNB-75 CNS GLR IGLRGEN (969) SNB-75 CNS LVS SNB-75 CNS ARG RRARGAC (970) SNB-75 CNS ASL YAASLMG (971) SNB-75 CNS AAV LTAAVMV (972) SNB-75 CNS AAS YAASLMG (973) SNB-75 CNS GGS RARTGGS (974) SNB-75 CNS VSGDGGS (975) SNB-75 CNS GGR FGGRSLS (976) SNB-75 CNS SLGGRTF (977) SNB-75 CNS GLG ARRGLGL (978) SNB-75 CNS GGL ALAGGGL (979) SNB-75 CNS FRALGGL (980) SNB-75 CNS FTRGGLS (981) SNB-75 CNS GSS SGSSVRY (982) SNB-75 CNS GSG SNB-75 CNS GSV WGSVAGI (983) SNB-75 CNS SGGDGSV (984) SNB-75 CNS GRV SNB-75 CNS GRL NEGRLGI (985) SNB-75 CNS YSGRLVM (986) SNB-75 CNS GPS DGPSGCS (987) SNB-75 CNS GVS SNB-75 CNS RLS U251 CNS RGV U251 CNS RGS RGSRTGP (988) U251 CNS RAV U251 CNS RAS U251 CNS GAG U251 CNS AVS U251 CNS LLS U251 CNS LLR U251 CNS LRV U251 CNS LRS U251 CNS RVS U251 CNS RSS U251 CNS AGS U251 CNS AGR U251 CNS AGL U251 CNS AGG U251 CNS GVR U251 CNS GVL U251 CNS GAV U251 CNS GLV U251 CNS GLR U251 CNS LVS U251 CNS ARG U251 CNS ASL U251 CNS AAV U251 CNS AAS U251 CNS GGS U251 CNS GGR U251 CNS GLG U251 CNS GGL U251 CNS GSS GSSACGA (989) U251 CNS GSG U251 CNS GSV U251 CNS GRV U251 CNS GRL U251 CNS GPS U251 CNS GVS U251 CNS RLS VRLSGRA (990) SF-539 CNS RLSTFAG (991) SF-539 CNS RGV SF-539 CNS RGS ARGSLRV (992) SF-539 CNS FSPRGSV (993) SF-539 CNS RAV GGRLRAV (994) SF-539 CNS RAS SF-539 CNS GAG SF-539 CNS AVS VLSAVSS (995) SF-539 CNS LLS SF-539 CNS LLR SF-539 CNS
LRV ARGSLRV (996) SF-539 CNS LRS LRSYAWS (997) SF-539 CNS RVS KGRVSAG (998) SF-539 CNS RSS SF-539 CNS AGS SF-539 CNS AGR SF-539 CNS AGL AGLTIGI (999) SF-539 CNS AGG AWRHAGG (1000) SF-539 CNS WARAGGF (1001) SF-539 CNS GVR SF-539 CNS GVL MGVLTAE (1002) SF-539 CNS FAGYGVL (1003) SF-539 CNS GAV RIFHGAV (1004) SF-539 CNS GLV EGLVVFE (1005) SF-539 CNS GLR REVPGLR (1006) SF-539 CNS LVS LVSVNGA (1007) SF-539 CNS HSLVSQP (1008) SF-539 CNS ARG ARGSLRV (1009) SF-539 CNS ASL SSVASLV (1010) SF-539 CNS AAV AAVWQMK (1011) SF-539 CNS QRAAVIV (1012) SF-539 CNS AAS SF-539 CNS GGS SF-539 CNS GGR GGRLRAV (1013) SF-539 CNS GLG SF-539 CNS GGL LPCGGLA (1014) SF-539 CNS GSS GSSHDAL (1015) SF-539 CNS TQYYGSS (1016) SF-539 CNS GSG SF-539 CNS GSV FSPRGSV (1017) SF-539 CNS GRV KGRVSAG (1018) SF-539 CNS QGRVNVK (1019) SF-539 CNS GRL GGRLRAV (1020) SF-539 CNS YDGRLAR (1021) SF-539 CNS GPS SF-539 CNS GVS SF-539 CNS RLS SRLSYWQ (1022) LOX-IMVI Melanoma RGV FVGSRGV (1023) LOX-IMVI Melanoma SVDRGVI (1024) LOX-IMVI Melanoma RGS GRGSGGF (1025) LOX-IMVI Melanoma RAV LOX-IMVI Melanoma RAS LOX-IMVI Melanoma GAG IFGAGLR (1026) LOX-IMVI Melanoma AVS GWVAVSC (1027) LOX-IMVI Melanoma LLS LLSGVIL (1028) LOX-IMVI Melanoma GSTLLSR (1029) LOX-IMVI Melanoma LLR LOX-IMVI Melanoma LRV LOX-IMVI Melanoma LRS QWYSLRS (1030) LOX-IMVI Melanoma RVS TWIGRVS (1031) LOX-IMVI Melanoma RSS LOX-IMVI Melanoma AGS SVVLAGS (1032) LOX-IMVI Melanoma AGR LOX-IMVI Melanoma AGL IFGAGLR (1033) LOX-IMVI Melanoma AGG SAGGWCA (1034) LOX-IMVI Melanoma GVR RDGVRVG (1035) LOX-IMVI Melanoma VSRIGVR (1036) LOX-IMVI Melanoma GVRSMPV (1037) LOX-IMVI Melanoma GVL GGVLGSD (1038) LOX-IMVI Melanoma WGVLQLE (1039) LOX-IMVI Melanoma GAV HGGPGAV (1040) LOX-IMVI Melanoma GLV DSGLVGG (1041) LOX-IMVI Melanoma GLR IFGAGLR (1042) LOX-IMVI Melanoma RMGFGLR (1043) LOX-IMVI Melanoma LVS LOX-IMVI Melanoma ARG LOX-IMVI Melanoma ASL LOX-IMVI Melanoma AAV WLDAAVK (1044) LOX-IMVI Melanoma AAS IAASYRG (1045) LOX-IMVI Melanoma GGS ATIPGGS (1046) LOX-IMVI Melanoma DGGSLVV (1047) LOX-IMVI Melanoma FGGSGRG (1048) LOX-IMVI Melanoma GGR SPTGGRR (1049) LOX-IMVI Melanoma TWSTGGR (1050) LOX-IMVI Melanoma GLG LOX-IMVI Melanoma GGL SRSCGGL (1051) LOX-IMVI Melanoma GSS LOX-IMVI Melanoma GSG CPGSGII (1052) LOX-IMVI Melanoma FGGSGRG (1053) LOX-IMVI Melanoma GSV SGSVVQR (1054) LOX-IMVI Melanoma GRV TWIGRVS (1055) LOX-IMVI Melanoma GRL LOX-IMVI Melanoma GPS GPSWATV (1056) LOX-IMVI Melanoma GVS LOX-IMVI Melanoma RLS MALME-3M Melanoma RGV MALME-3M Melanoma RGS ARRGSGL (1057) MALME-3M Melanoma RAV RAVGYNA (1058) MALME-3M Melanoma LRAVEFL (1059) MALME-3M Melanoma RAS MALME-3M Melanoma GAG MALME-3M Melanoma AVS MALME-3M Melanoma LLS FEDLLSL (1060) MALME-3M Melanoma RWLSLLS (1061) MALME-3M Melanoma LLR MALME-3M Melanoma LRV HAPGLRV (1062) MALME-3M Melanoma LRS LRSSMML (1063) MALME-3M Melanoma RPKLRSV (1064) MALME-3M Melanoma RVS SRVSFHE (1065) MALME-3M Melanoma RSS LRSSMML (1066) MALME-3M Melanoma SSGGRSS (1067) MALME-3M Melanoma AGS MALME-3M Melanoma AGR VAGRVGI (1068) MALME-3M Melanoma AGL AGLALTV (1069) MALME-3M Melanoma AGG MALME-3M Melanoma GVR IGVRGAV (1070) MALME-3M Melanoma GVL LVRDGVL (1071) MALME-3M Melanoma GAV IGVRGAV (1072) MALME-3M Melanoma GLV HGLVTHN (1073) MALME-3M Melanoma GLR HAPGLRV (1074) MALME-3M Melanoma LVS MALME-3M Melanoma ARG VSSTARG (1075) MALME-3M Melanoma ASL MALME-3M Melanoma AAV RAAVIHT (1076) MALME-3M Melanoma AAS AASTRSL (1077) MALME-3M Melanoma GGS GWGGGSA (1078) MALME-3M Melanoma SSRGGSS (1079) MALME-3M Melanoma GGR SSGGRSS (1080) MALME-3M Melanoma GLG MALME-3M Melanoma GGL MALME-3M Melanoma GSS SSRGGSS (1081) MALME-3M Melanoma GSG ARRGSGL (1082) MALME-3M Melanoma GSV MALME-3M Melanoma GRV VAGRVGI (1083) MALME-3M Melanoma GRL EGRLMLA (1084) MALME-3M Melanoma GPS MALME-3M Melanoma GVS MALME-3M Melanoma RLS RLSSAPS (1085) M14 Melanoma RRLSYHS (1086) M14 Melanoma FLHMRLS (1087) M14 Melanoma RGV LARGVPP (1088) M14 Melanoma RGS LSRGSVA (1089) M14 Melanoma VWLRGST (1090) M14 Melanoma RAV M14 Melanoma RAS RGGQRAS (1091) M14 Melanoma GAG M14 Melanoma AVS AVSGRSL (1092) M14 Melanoma LLS GLLSSFS (1093) M14 Melanoma
LLR RMGLLRQ (1094) M14 Melanoma LRV M14 Melanoma LRS RLHYLRS (1095) M14 Melanoma GGYWLRS (1096) M14 Melanoma RVS M14 Melanoma RSS NRSSHCG (1097) M14 Melanoma QRSSDLT (1098) M14 Melanoma AGS M14 Melanoma AGR AAGRSRI (1099) M14 Melanoma AGL M14 Melanoma AGG GRAGGNG (1100) M14 Melanoma GVR ANASGVR (1101) M14 Melanoma GVL WAHGVLS (1102) M14 Melanoma GAV M14 Melanoma GLV M14 Melanoma GLR SLYGLRW (1103) M14 Melanoma LVS M14 Melanoma ARG GNGGARG (1104) M14 Melanoma LARGVPP (1105) M14 Melanoma NWDARGR (1106) M14 Melanoma ASL ASLPVLD (1107) M14 Melanoma PPGASLY (1108) M14 Melanoma AAV AAVGGRV (1109) M14 Melanoma AAS AASSWAV (1110) M14 Melanoma GGS AFKTGGS (1111) M14 Melanoma GGR FEGGRSG (1112) M14 Melanoma RTWGGRM (1113) M14 Melanoma SARQGGR (lll4) M14 Melanoma AAVGGRV (1115) M14 Melanoma GLG M14 Melanoma GGL M14 Melanoma GSS ARHGSSV (1116) M14 Melanoma SNFYGSS (1117) M14 Melanoma GSG GSGQLIP (1118) M14 Melanoma GSV LSRGSVA (1119) M14 Melanoma GRV AEYGRVL (1120) M14 Melanoma RGRVLLP (1121) M14 Melanoma AAVGGRV (1122) M14 Melanoma GRL RGRLALL (1123) M14 Melanoma SGPGRLP (1124) M14 Melanoma TSGRLWV (1125) M14 Melanoma GPS M14 Melanoma GVS MVYSGVS (1126) M14 Melanoma RLS WRLSREG (1127) SK-MEL-2 Melanoma LLRRLSW (1128) SK-MEL-2 Melanoma RGV AARGVMV (1129) SK-MEL-2 Melanoma RGS ALARGSG (1130) SK-MEL-2 Melanoma NLRGSRS (1131) SK-MEL-2 Melanoma RAV RAVWRAS (1132) SK-MEL-2 Melanoma RAS RAVWRAS SK-MEL-2 Melanoma GAG GAGSFSS (1133) SK-MEL-2 Melanoma AVS SK-MEL-2 Melanoma LLS LLSSRRC (1134) SK-MEL-2 Melanoma LLSLDPG (1135) SK-MEL-2 Melanoma SSLLSSL (1136) SK-MEL-2 Melanoma LLR LLRPAHG (1137) SK-MEL-2 Melanoma LLRRLSW (1138) SK-MEL-2 Melanoma LRV SK-MEL-2 Melanoma LRS CMLRSAT (1139) SK-MEL-2 Melanoma SKAVLRS (1140) SK-MEL-2 Melanoma RVS SRVSNPS (1141) SK-MEL-2 Melanoma RSS CRRSSLL (1142) SK-MEL-2 Melanoma AGS GAGSFSS (1143) SK-MEL-2 Melanoma AGR SAAGRTF (1144) SK-MEL-2 Melanoma PAGRMLS (1145) SK-MEL-2 Melanoma AGL IAMAGLR (1146) SK-MEL-2 Melanoma AGG AGGFRFI (1147) SK-MEL-2 Melanoma GVR SGVRPVI (1148) SK-MEL-2 Melanoma GVL GVLSDRS (1149) SK-MEL-2 Melanoma GAV GAVTSAD (1150) SK-MEL-2 Melanoma GAVTSAD (1151) SK-MEL-2 Melanoma GAVNTPA (1152) SK-MEL-2 Melanoma GLV GGLVKRL (1153) SK-MEL-2 Melanoma EVASGLV (1154) SK-MEL-2 Melanoma GLR IAMAGLR (1155) SK-MEL-2 Melanoma GTHSGLR (1156) SK-MEL-2 Melanoma LVS LVSTSNR (1157) SK-MEL-2 Melanoma FSLVSFV (1158) SK-MEL-2 Melanoma ALVSSHV (1159) SK-MEL-2 Melanoma ARG AARGVMV (1160) SK-MEL-2 Melanoma ALARGSG (1161) SK-MEL-2 Melanoma ASL SK-MEL-2 Melanoma AAV LRYWAAV (1162) SK-MEL-2 Melanoma AAS FTRGAAS (1163) SK-MEL-2 Melanoma EWHAASG (1164) SK-MEL-2 Melanoma GGS FGGSMAP (1165) SK-MEL-2 Melanoma GGSLKWV (1166) SK-MEL-2 Melanoma GGR RGLQGGR (1167) SK-MEL-2 Melanoma TCGGRSY (1168) SK-MEL-2 Melanoma GLG GEALGLG (1169) SK-MEL-2 Melanoma PRGLGVG (1170) SK-MEL-2 Melanoma VGLGNSA (1171) SK-MEL-2 Melanoma GGL GGLVKRL (1172) SK-MEL-2 Melanoma GSS SK-MEL-2 Melanoma GSG GSGRALA (1173) SK-MEL-2 Melanoma GSV SK-MEL-2 Melanoma GRV SK-MEL-2 Melanoma GRL SRSGRLN (1174) SK-MEL-2 Melanoma GPS SK-MEL-2 Melanoma GVS SAGVSDS (1175) SK-MEL-2 Melanoma RLS PRLSDKS (1176) SK-MEL-28 Melanoma RGV GRGDRGV (1177) SK-MEL-28 Melanoma RGVSGRL (1178) SK-MEL-28 Melanoma RGS INRGSRE (1179) SK-MEL-28 Melanoma LRGSRQF (1180) SK-MEL-28 Melanoma LRGSVGR (1181) SK-MEL-28 Melanoma RAV GLWYRAV (1182) SK-MEL-28 Melanoma RVRAVLG (1183) SK-MEL-28 Melanoma RAVLELW (1184) SK-MEL-28 Melanoma RAS LVRASNG (1185) SK-MEL-28 Melanoma GAG SK-MEL-28 Melanoma AVS SK-MEL-28 Melanoma LLS SK-MEL-28 Melanoma LLR ASGTLLR (1186) SK-MEL-28 Melanoma LRV SK-MEL-28 Melanoma LRS SK-MEL-28 Melanoma RVS GSGVRVS (1187) SK-MEL-28 Melanoma RSS VGSTRSS (1188) SK-MEL-28 Melanoma AGS RAGSRYI (1189) SK-MEL-28 Melanoma AGR SK-MEL-28 Melanoma AGL SK-MEL-28 Melanoma AGG SK-MEL-28 Melanoma GVR VGVRFSR (1190) SK-MEL-28 Melanoma GSGVRVS (1191) SK-MEL-28 Melanoma GVL IGVLASA (1192) SK-MEL-28 Melanoma GAV SK-MEL-28 Melanoma GLV GLVARVR (1193) SK-MEL-28 Melanoma GLR SK-MEL-28 Melanoma LVS SK-MEL-28 Melanoma ARG SK-MEL-28 Melanoma ASL SK-MEL-28 Melanoma AAV SK-MEL-28 Melanoma AAS SK-MEL-28 Melanoma GGS LLGIGGS (1194) SK-MEL-28 Melanoma QLGGSFR (1195) SK-MEL-28 Melanoma GGR LFRWGGR (1196) SK-MEL-28 Melanoma GLG SK-MEL-28 Melanoma GGL RFSGGLQ (1197) SK-MEL-28 Melanoma GSS VGSSHGL (1198) SK-MEL-28 Melanoma GSG SVRVGSG (1199) SK-MEL-28 Melanoma GSV GVNGSVS (1200) SK-MEL-28 Melanoma LRGSVGR (1201) SK-MEL-28 Melanoma GRV HVKNGRV (1202) SK-MEL-28 Melanoma GRL FQRSGRL (1203) SK-MEL-28 Melanoma HGRLAFG (1204) SK-MEL-28 Melanoma RGVSGRL (1205) SK-MEL-28 Melanoma GPS SK-MEL-28 Melanoma
GVS RGVSGRL (1206) SK-MEL-28 Melanoma RLS SK-MEL-5 Melanoma RGV FGIGRGV (1207) SK-MEL-5 Melanoma RGS SK-MEL-5 Melanoma RAV SK-MEL-5 Melanoma RAS SK-MEL-5 Melanoma GAG SK-MEL-5 Melanoma AVS GVVQAVS (1208) SK-MEL-5 Melanoma LSAVSVK (1209) SK-MEL-5 Melanoma LLS LYLLSSA (1210) SK-MEL-5 Melanoma LIGGLLS (1211) SK-MEL-5 Melanoma LLR LLRRGIG (1212) SK-MEL-5 Melanoma LRV SK-MEL-5 Melanoma LRS FLRSLSL (1213) SK-MEL-5 Melanoma RVS VRVSGLT (1214) SK-MEL-5 Melanoma RSS SK-MEL-5 Melanoma AGS AGSVDLV (1215) SK-MEL-5 Melanoma AGR GFVAGRT (1216) SK-MEL-5 Melanoma AGL SK-MEL-5 Melanoma AGG SK-MEL-5 Melanoma GVR SK-MEL-5 Melanoma GVL SK-MEL-5 Melanoma GAV TRGAVFG (1217) SK-MEL-5 Melanoma GLV IYGGLVI (1218) SK-MEL-5 Melanoma GLR PTGEGLR (1219) SK-MEL-5 Melanoma LVS SK-MEL-5 Melanoma ARG SK-MEL-5 Melanoma ASL KVSVASL (1220) SK-MEL-5 Melanoma RYSMASL (1221) SK-MEL-5 Melanoma AAV SK-MEL-5 Melanoma AAS ANAASSP (1222) SK-MEL-5 Melanoma GGS PGGSRHA (1223) SK-MEL-5 Melanoma GGSPGVW (1224) SK-MEL-5 Melanoma GGR SK-MEL-5 Melanoma GLG SK-MEL-5 Melanoma GGL IYGGLVI (1225) SK-MEL-5 Melanoma LIGGLLS (1226) SK-MEL-5 Melanoma GSS SK-MEL-5 Melanoma GSG ACGSGLD (1227) SK-MEL-5 Melanoma GSV AGSVDLV (1228) SK-MEL-5 Melanoma TLGSVRV (1229) SK-MEL-5 Melanoma GRV HVRGRVA (1230) SK-MEL-5 Melanoma IDLGRVN (1231) SK-MEL-5 Melanoma GRL GRLDAFG (1232) SK-MEL-5 Melanoma GPS WVGPSGG (1233) SK-MEL-5 Melanoma GVS SK-MEL-5 Melanoma GSS UACC 257 Melanoma RLS DLRLSFP (1234) UACC 257 Melanoma SARLSHV (1235) UACC 257 Melanoma RGV VMDRGVA (1236) UACC 257 Melanoma RGS RGSLLWA (1237) UACC 257 Melanoma RGSPLTK (1238) UACC 257 Melanoma RAV UACC 257 Melanoma RAS RASIGIE (1239) UACC 257 Melanoma VHSLRAS (1240) UACC 257 Melanoma GAG UACC 257 Melanoma AVS UACC 257 Melanoma LLS AWLLSGR (1241) UACC 257 Melanoma LLR UACC 257 Melanoma LRV UACC 257 Melanoma LRS LWLRSRE (1242) UACC 257 Melanoma RVS VTRIRVS (1243) UACC 257 Melanoma RSS NSQRSSV (1244) UACC 257 Melanoma AGS AATRAGS (1245) UACC 257 Melanoma AGR UACC 257 Melanoma AGL UACC 257 Melanoma AGG UACC 257 Melanoma GVR TDGVRAF (1246) UACC 257 Melanoma GVL FAASGVL (1247) UACC 257 Melanoma GVLEGRR (1248) UACC 257 Melanoma GAV EADPGAV (1249) UACC 257 Melanoma DGAVILH (1250) UACC 257 Melanoma RDGAVNL (1251) UACC 257 Melanoma GLV UACC 257 Melanoma GLR GLRPHGA (1252) UACC 257 Melanoma TSRGLRL (1253) UACC 257 Melanoma LVS RMLVSSF (1254) UACC 257 Melanoma ARG DVIARGW (1255) UACC 257 Melanoma UACC 257 Melanoma ASL UACC 257 Melanoma AAV TLTAAVF (1256) UACC 257 Melanoma GWLNAAV (1257) UACC 257 Melanoma AAS FAASGVL (1258) UACC 257 Melanoma GGS GGSKGSA (1259) UACC 257 Melanoma AVALGGS (1260) UACC 257 Melanoma GGR HGGRYRH (1261) UACC 257 Melanoma SGVGGRY (1262) UACC 257 Melanoma GLG UACC 257 Melanoma GGL SGGLAVA (1263) UACC 257 Melanoma GSG UACC 257 Melanoma GSV UACC 257 Melanoma GRV UACC 257 Melanoma GRL GRLAKSI (1264) UACC 257 Melanoma GPS AGPSRGP (1265) UACC 257 Melanoma UACC 257 Melanoma GVS UACC 257 Melanoma RLS GLMRLSH (1266) UACC62 Melanoma VRVGRLS (1267) UACC62 Melanoma TGRLSAA (1268) UACC62 Melanoma RGV SLRGVRV (1269) UACC62 Melanoma DNCERGV (1270) UACC62 Melanoma TTQLRGV (1271) UACC62 Melanoma RGS GVIGRGS (1272) UACC62 Melanoma LAGMRGS (1273) UACC62 Melanoma RAV VRPRAVL (1274) UACC62 Melanoma PPRAVTN (1275) UACC62 Melanoma RAS WRARASP (1276) UACC62 Melanoma GAG UACC62 Melanoma AVS UACC62 Melanoma LLS FGRLLSP (1277) UACC62 Melanoma LLR PSLLRGF (1278) UACC62 Melanoma LRV RDLRVHL (1279) UACC62 Melanoma LRVSNPR (1280) UACC62 Melanoma LRVDQLY (1281) UACC62 Melanoma LRS HRLRSMS (1282) UACC62 Melanoma RVS LRVSNPR (1283) UACC62 Melanoma RSS UACC62 Melanoma AGS PGFMAGS (1284) UACC62 Melanoma AGR AGRGISQ (1285) UACC62 Melanoma RAGRDAP (1286) UACC62 Melanoma RAGRGFE (1287) UACC62 Melanoma AGL UACC62 Melanoma AGG HQAGGVT (1288) UACC62 Melanoma GVR SLRGVRV (1289) UACC62 Melanoma GVL DWVGVLM (1290) UACC62 Melanoma GTLGVLS (1291) UACC62 Melanoma GVLLWRP (1292) UACC62 Melanoma GAV UACC62 Melanoma GLV UACC62 Melanoma GLR GLREAHV (1293) UACC62 Melanoma LVS UACC62 Melanoma ARG AARGELR (1294) UACC62 Melanoma ASL AASLRGT (1295) UACC62 Melanoma AAV PVGAAVA (1296) UACC62 Melanoma AAS AASLRGT (1297) UACC62 Melanoma GGS UACC62 Melanoma GGR UACC62 Melanoma GLG UACC62 Melanoma GGL UACC62 Melanoma GSS UACC62 Melanoma GSG SNPGSGS (1298) UACC62 Melanoma
GSV UACC62 Melanoma GRV GRVRETP (1299) UACC62 Melanoma UACC62 Melanoma GRL FGRLLSP (1300) UACC62 Melanoma VRVGRLS (1301) UACC62 Melanoma TGRLSAA (1302) UACC62 Melanoma VGRLQTT (1303) UACC62 Melanoma GPS DGPSCVI (1304) UACC62 Melanoma UACC62 Melanoma GVS UACC62 Melanoma RLS IGROV1 Ovarian RGV IGROV1 Ovarian RGS IGROV1 Ovarian RAV RFSSRAV (1305) IGROV1 Ovarian RAS HAGSRAS (1306) IGROV1 Ovarian GAG GAGLGVS (1307) IGROV1 Ovarian LLGAGTP (1308) IGROV1 Ovarian AVS IGROV1 Ovarian LLS LLSILKA (1309) IGROV1 Ovarian GLLSGGT (1310) IGROV1 Ovarian LLR IGROV1 Ovarian LRV LSVLRVL (1311) IGROV1 Ovarian LRS SRYTLRS (1312) IGROV1 Ovarian RVS IGROV1 Ovarian RSS LFHTRSS (1313) IGROV1 Ovarian VARSSFR (1314) IGROV1 Ovarian AGS CTAGSVS (1315) IGROV1 Ovarian RAAGSAG (1316) IGROV1 Ovarian HAGSRAS (1317) IGROV1 Ovarian AGR IGROV1 Ovarian AGL GAGLGVS (1318) IGROV1 Ovarian PTGAGLL (1319) IGROV1 Ovarian ASYAGLV (2) IGROV1 Ovarian (1320) AGG AGGFGVL (1321) IGROV1 Ovarian NMAGGQE (1322) IGROV1 Ovarian LRAGGSY (1323) IGROV1 Ovarian YLAGGKA (1324) IGROV1 Ovarian GVR PYYNGVR (1325) IGROV1 Ovarian GVL AGGFGVL (1326) IGROV1 Ovarian LIGGVLH (1327) IGROV1 Ovarian GAV IGROV1 Ovarian GLV DGLVPVA (1328) IGROV1 Ovarian GLVASMP (1329) IGROV1 Ovarian ASYAGLV (2) IGROV1 Ovarian (1330) GLR IGROV1 Ovarian LVS LVRLVSL (1331) IGROV1 Ovarian ARG IGROV1 Ovarian ASL VLASLSG (1332) IGROV1 Ovarian AAV IGROV1 Ovarian AAS IGROV1 Ovarian GGS GSITGGS (1333) IGROV1 Ovarian LRAGGSY (1334) IGROV1 Ovarian TGGSLLG (1335) IGROV1 Ovarian DEGGSRW (1336) IGROV1 Ovarian GGR IGROV1 Ovarian GLG GAGLGVS (1337) IGROV1 Ovarian GGL IGROV1 Ovarian GSS WGSSAVK (1338) IGROV1 Ovarian QGSSNSV (1339) IGROV1 Ovarian GSG IGROV1 Ovarian GSV CTAGSVS (1340) IGROV1 Ovarian SVTGSVG (1341) IGROV1 Ovarian GRV SPGRVAD (1342) IGROV1 Ovarian GRL IGROV1 Ovarian GPS DAVRGPS (1343) IGROV1 Ovarian GVS GAGLGVS (1344) IGROV1 Ovarian GVSGTVS (1345) IGROV1 Ovarian SGVSISC (1346) IGROV1 Ovarian RLS RRLSYHS (65) OVCAR-3 Ovarian (1347) RGV OVCAR-3 Ovarian RGS OVCAR-3 Ovarian RAV OVCAR-3 Ovarian RAS OVCAR-3 Ovarian GAG OVCAR-3 Ovarian AVS OVCAR-3 Ovarian LLS OVCAR-3 Ovarian LLR OVCAR-3 Ovarian LRV OVCAR-3 Ovarian LRS RREGLRS (10) OVCAR-3 Ovarian (1348) RVS ERVSAAV (1349) OVCAR-3 Ovarian RSS OVCAR-3 Ovarian AGS AGSMMEF (1350) OVCAR-3 Ovarian AGR OVCAR-3 Ovarian AGL OVCAR-3 Ovarian AGG OVCAR-3 Ovarian GVR OVCAR-3 Ovarian GVL RHGPGVL (1351) OVCAR-3 Ovarian GAV OVCAR-3 Ovarian GLV OVCAR-3 Ovarian GLR GLRRDNG (1352) OVCAR-3 Ovarian RREGLRS (10) OVCAR-3 Ovarian (1353) LVS OVCAR-3 Ovarian ARG OVCAR-3 Ovarian ASL OVCAR-3 Ovarian AAV ERVSAAV (1354) OVCAR-3 Ovarian AAS VAASVRE (1355) OVCAR-3 Ovarian GGS OVCAR-3 Ovarian GGR OVCAR-3 Ovarian GLG OVCAR-3 Ovarian GGL OVCAR-3 Ovarian GSS OVCAR-3 Ovarian GSG OVCAR-3 Ovarian GSV PWYDGSV (1356) OVCAR-3 Ovarian GRV GRVTLES (1357) OVCAR-3 Ovarian GRL OVCAR-3 Ovarian GPS OVCAR-3 Ovarian GVS OVCAR-3 Ovarian RLS GRLSRAP (1358) OVCAR-4 Ovarian SRLSYCN (1359) OVCAR-4 Ovarian RGV OVCAR-4 Ovarian RGS QARGSWL (1360) OVCAR-4 Ovarian FVPRGSY (1361) OVCAR-4 Ovarian RAV AALLRAV (1362) OVCAR-4 Ovarian RAS LAGRASE (1363) OVCAR-4 Ovarian GAG AAGAGWR (1364) OVCAR-4 Ovarian ADLGAGW (1365) OVCAR-4 Ovarian ADLGAGW (1366) OVCAR-4 Ovarian GGAGRGA (1367) OVCAR-4 Ovarian AVS DVWVAVS (1368) OVCAR-4 Ovarian LLS OVCAR-4 Ovarian LLR AALLRAV (1369) OVCAR-4 Ovarian LRV NLRVGAE (1370) OVCAR-4 Ovarian LRS NCYSLRS (1371) OVCAR-4 Ovarian RVS LAGSRVS (1372) OVCAR-4 Ovarian RSS OVCAR-4 Ovarian AGS SGPAGSF (1373) OVCAR-4 Ovarian LAGSRVS (1374) OVCAR-4 Ovarian AGR GGAGRGA (1375) OVCAR-4 Ovarian LAGRASE (1376) OVCAR-4 Ovarian VAGRLQM (1377) OVCAR-4 Ovarian AGL WGAGLDA (1378) OVCAR-4 Ovarian WGAGLDA (1379) OVCAR-4 Ovarian AGG AGRGAGG (1380) OVCAR-4 Ovarian GVR EAGVRLN (1381) OVCAR-4 Ovarian GVL OVCAR-4 Ovarian GAV MQLRGAV (1382) OVCAR-4 Ovarian GLV GGPGLVM (1383) OVCAR-4 Ovarian QGLVRGG (1384) OVCAR-4 Ovarian GLR PGLRGPA (1385) OVCAR-4 Ovarian PGLRGPA (1386) OVCAR-4 Ovarian LVS GRMLVSG (1387) OVCAR-4 Ovarian ARG ESARGAL (1388) OVCAR-4 Ovarian
QARGSWL (1389) OVCAR-4 Ovarian ASL OVCAR-4 Ovarian AAV OVCAR-4 Ovarian AAS OVCAR-4 Ovarian GGS GGGSGGG (1390) OVCAR-4 Ovarian NNVGGSS (1391) OVCAR-4 Ovarian GGR GGRVLGQ (1392) OVCAR-4 Ovarian GGRVRGG (1393) OVCAR-4 Ovarian GGRVRGG (1394) OVCAR-4 Ovarian WYGGRGN (1395) OVCAR-4 Ovarian GLG CVGLGCH (1396) OVCAR-4 Ovarian GGL OVCAR-4 Ovarian GSS NNVGGSS (1397) OVCAR-4 Ovarian GSG FMTYGSG (1398) OVCAR-4 Ovarian GGGSGGG (1399) OVCAR-4 Ovarian WDQGSGY (1400) OVCAR-4 Ovarian GSV GSVLMRG (1401) OVCAR-4 Ovarian GRV GGRVLGQ (1402) OVCAR-4 Ovarian GGRVRGG (1403) OVCAR-4 Ovarian GGRVRGG (1404) OVCAR-4 Ovarian YMYHGRV (1405) OVCAR-4 Ovarian GRL GRLSRAP (1406) OVCAR-4 Ovarian VAGRLQM (1407) OVCAR-4 Ovarian APGRLGP (1408) OVCAR-4 Ovarian APGRLGP (1409) OVCAR-4 Ovarian GPS RDLAGPS (1410) OVCAR-4 Ovarian GVS OVCAR-4 Ovarian RLS RLSGAGD (1411) OVCAR-5 Ovarian RGV LQRGVAR (1412) OVCAR-5 Ovarian RGS OVCAR-5 Ovarian RAV RAVGRQL (1413) OVCAR-5 Ovarian SRAVIRL (1414) OVCAR-5 Ovarian RAS VRASSKR (1415) OVCAR-5 Ovarian GAG DGAGSLR (1416) OVCAR-5 Ovarian SVSGAGS (1417) OVCAR-5 Ovarian AVS OVCAR-5 Ovarian LLS TTLLSRQ (1418) OVCAR-5 Ovarian VAELLSM (1419) OVCAR-5 Ovarian LLR OVCAR-5 Ovarian LRV LPGRLRV (1420) OVCAR-5 Ovarian LRS LKAGLRS (1421) OVCAR-5 Ovarian RVS HRVSESV (1422) OVCAR-5 Ovarian RSS YYGERSS (1423) OVCAR-5 Ovarian AGS DGAGSLR (1424) OVCAR-5 Ovarian SVSGAGS (1425) OVCAR-5 Ovarian AGSVYSV (1426) OVCAR-5 Ovarian AGR OVCAR-5 Ovarian AGL SAGLLPS (1427) OVCAR-5 Ovarian LKAGLRS (1428) OVCAR-5 Ovarian AGG RRAGGSV (1429) OVCAR-5 Ovarian GVR SWAGVRF (1430) OVCAR-5 Ovarian GVL OVCAR-5 Ovarian GAV IYPGAVL (1431) OVCAR-5 Ovarian GLV OVCAR-5 Ovarian GLR LKAGLRS (1432) OVCAR-5 Ovarian LVS SLVSPRT (1433) OVCAR-5 Ovarian ARG OVCAR-5 Ovarian ASL OVCAR-5 Ovarian AAV HAAVEPS (1434) OVCAR-5 Ovarian TAAAVLL (1435) OVCAR-5 Ovarian AAS OVCAR-5 Ovarian GGS FHFGGSG (1436) OVCAR-5 Ovarian GEGGSGG (1437) OVCAR-5 Ovarian RRAGGSV (1438) OVCAR-5 Ovarian GGR ALPGGGR (1439) OVCAR-5 Ovarian YVGGRLR (1440) OVCAR-5 Ovarian GLG GKGMGLG (1441) OVCAR-5 Ovarian SLGLGGL (1442) OVCAR-5 Ovarian GGL DGGLNDC (1443) OVCAR-5 Ovarian LGGLGLS (1444) OVCAR-5 Ovarian GSS OVCAR-5 Ovarian GSG FHFGGSG (1445) OVCAR-5 Ovarian GEGGSGG (1446) OVCAR-5 Ovarian GSV RRAGGSV (1447) OVCAR-5 Ovarian SGAGSVS (1448) OVCAR-5 Ovarian AGSVYSV (1449) OVCAR-5 Ovarian GRV GRVTWRS (1450) OVCAR-5 Ovarian GRL LPGRLRV (1451) OVCAR-5 Ovarian YVGGRLR (1452) OVCAR-5 Ovarian GPS GPSSAVE (1453) OVCAR-5 Ovarian GVS OVCAR-5 Ovarian RLS RRLSYRE (28) OVCAR-8 Ovarian (1454) RGV OVCAR-8 Ovarian RGS OVCAR-8 Ovarian RAV HTRAVSE (1455) OVCAR-8 Ovarian NVSRAVG (1456) OVCAR-8 Ovarian RAS PRHRASQ (1457) OVCAR-8 Ovarian GAG LGAGMIA (1458) OVCAR-8 Ovarian AVS AVSLVVL (1459) OVCAR-8 Ovarian HTRAVSE (1460) OVCAR-8 Ovarian LLS OVCAR-8 Ovarian LLR OVCAR-8 Ovarian LRV ELGLRVP (1461) OVCAR-8 Ovarian LRS OVCAR-8 Ovarian RVS OVCAR-8 Ovarian RSS GRSSVSD (1462) OVCAR-8 Ovarian AGS YAGSGQL (2) OVCAR-8 Ovarian (1463) AGR AGRFGAR (1464) OVCAR-8 Ovarian AGL AIMGAGL (1465) OVCAR-8 Ovarian AGG OVCAR-8 Ovarian GVR THVGGVR (1466) OVCAR-8 Ovarian GVL GVLTRGN (1467) OVCAR-8 Ovarian GAV OVCAR-8 Ovarian GLV OVCAR-8 Ovarian GLR ELGLRVP (1468) OVCAR-8 Ovarian GLGLRLG (1469) OVCAR-8 Ovarian LVS IDLVSPG (1470) OVCAR-8 Ovarian ARG OVCAR-8 Ovarian ASL OVCAR-8 Ovarian AAV OVCAR-8 Ovarian AAS OVCAR-8 Ovarian GGS GGSTVPQ (1471) OVCAR-8 Ovarian GGR OVCAR-8 Ovarian GLG GLGLRLG (1472) OVCAR-8 Ovarian GGL TATGGLL (1473) OVCAR-8 Ovarian GSS GSNGSSH (3) OVCAR-8 Ovarian (1474) GSG LQGSGAY (2) OVCAR-8 Ovarian (1475) LQHLGSG (1476) OVCAR-8 Ovarian GSV OVCAR-8 Ovarian GRV OVCAR-8 Ovarian GRL OVCAR-8 Ovarian GPS GPSVLDI (1477) OVCAR-8 Ovarian GVS GATGVSS (1478) OVCAR-8 Ovarian RLS TRLSFRH (1479) SK-OV-3-3 Ovarian RGV FLRGVEL (1480) SK-OV-3-3 Ovarian RGS NSVRGSR (1481) SK-OV-3-3 Ovarian RAV NRAVLSA (1482) SK-OV-3-3 Ovarian RAS LIGRASM (1483) SK-OV-3-3 Ovarian GAG RVGAGAF (1484) SK-OV-3-3 Ovarian AVS WISAVSK (1485) SK-OV-3-3 Ovarian SAVSESP (1486) SK-OV-3-3 Ovarian LLS SK-OV-3-3 Ovarian LLR SK-OV-3-3 Ovarian LRV RVGTLRV(4) SK-OV-3-3 Ovarian (1487) LRS SK-OV-3-3 Ovarian RVS RVSGDGK (1488) SK-OV-3-3 Ovarian RSGRVSN (1489) SK-OV-3-3 Ovarian RVSNEAL (1490) SK-OV-3-3 Ovarian RVSSDPI (1491) SK-OV-3-3 Ovarian RSS VRSSGVL (1492) SK-OV-3-3 Ovarian AGS SGWFAGS (1493) SK-OV-3-3 Ovarian
AGR SK-OV-3-3 Ovarian AGL AGLGLLD (1494) SK-OV-3-3 Ovarian SAAGLAR (1495) SK-OV-3-3 Ovarian AGG SK-OV-3-3 Ovarian GVR FAGAGVR (1496) SK-OV-3-3 Ovarian VRLTGVR (4) SK-OV-3-3 Ovarian (1497) GVL VRSSGVL (1498) SK-OV-3-3 Ovarian GAV RPWGAVA (1499) SK-OV-3-3 Ovarian GLV PVSDGLV (1500) SK-OV-3-3 Ovarian GLR NKGGLRQ (1501) SK-OV-3-3 Ovarian LVS GGFLLVS (1502) SK-OV-3-3 Ovarian LVPLVSG (1503) SK-OV-3-3 Ovarian ARG ARGGESA (1504) SK-OV-3-3 Ovarian MSARGIL (1505) SK-OV-3-3 Ovarian ASL ASLVARN (1506) SK-OV-3-3 Ovarian AAV RVEAAVP (1507) SK-OV-3-3 Ovarian AAS RALGAAS (1508) SK-OV-3-3 Ovarian GGS SK-OV-3-3 Ovarian GGR ASEGGRA (1509) SK-OV-3-3 Ovarian IGGRWVV (1510) SK-OV-3-3 Ovarian GLG AGLGLLD (1511) SK-OV-3-3 Ovarian GGL LGGLSER (1512) SK-OV-3-3 Ovarian NKGGLRQ (1513) SK-OV-3-3 Ovarian GSS LVGSSRV (1514) SK-OV-3-3 Ovarian YTGSSPS (1515) SK-OV-3-3 Ovarian GSG SK-OV-3-3 Ovarian GSV GSVLPVL (1516) SK-OV-3-3 Ovarian KGDGSVR (1517) SK-OV-3-3 Ovarian GSVSHRR (1518) SK-OV-3-3 Ovarian RLWGSVV (1519) SK-OV-3-3 Ovarian GRV MQGRVIV (1520) SK-OV-3-3 Ovarian RSGRVSN (1521) SK-OV-3-3 Ovarian GRL LEVGRLF (1522) SK-OV-3-3 Ovarian GPS SQFGPSF (3) SK-OV-3-3 Ovarian (1523) GVS ATLDGVS (1524) SK-OV-3-3 Ovarian RLS RLSWTVL (1525) PC3 Prostate RGV LRFRRGV (1526) PC3 Prostate RGS ARGRGSQ (1527) PC3 Prostate VLRGSTP (1528) PC3 Prostate RAV PC3 Prostate RAS ARLRASR (1529) PC3 Prostate GAG RIGAGHR (1530) PC3 Prostate AVS PC3 Prostate LLS WLLSSEI (1531) PC3 Prostate LLR PC3 Prostate LRV GGLRVGG (1532) PC3 Prostate GLRVYEP (1533) PC3 Prostate LRS YLRSAGM (1534) PC3 Prostate RVS RVSRAGG (1535) PC3 Prostate RSS PC3 Prostate AGS PC3 Prostate AGR AGRPGGY (1536) PC3 Prostate AGL YGALAGL (1537) PC3 Prostate AGG RVSRAGG (1538) PC3 Prostate SHTAGGG (1539) PC3 Prostate AGGVRDL (1540) PC3 Prostate RPAGGRT (1541) PC3 Prostate GVR GGVRLGG (1542) PC3 Prostate AGGVRDL (1543) PC3 Prostate GVL GVLGCDG (1544) PC3 Prostate GAV CGAVAEW (1545) PC3 Prostate GLV GDCGLVG (1546) PC3 Prostate GLR GGLRVGG (1547) PC3 Prostate GLRVYEP (1548) PC3 Prostate LVS PC3 Prostate ARG ARGRGSQ (1549) PC3 Prostate ASL PC3 Prostate AAV PC3 Prostate AAS PC3 Prostate GGS PC3 Prostate GGR GGRELKA (1550) PC3 Prostate GGGRRAL (1551) PC3 Prostate RPAGGRT (1552) PC3 Prostate GLG PC3 Prostate GGL GGLKVWR (1553) PC3 Prostate GGLRVGG (1554) PC3 Prostate GGLPVQM (1555) PC3 Prostate RQDGGLY (1556) PC3 Prostate GSS YATLGSS (1557) PC3 Prostate GSG SGSGCVF (1558) PC3 Prostate VSGSGTA (1559) PC3 Prostate GSV VGSVKAS (1560) PC3 Prostate ATGSGSV (1561) PC3 Prostate GRV PC3 Prostate GRL PTSGRLV (1562) PC3 Prostate GPS LACRGPS (1563) PC3 Prostate RGPSQVL (1564) PC3 Prostate GVS PC3 Prostate RLS TLGRLSS (1565) DU-145 Prostate RGV AGDRGVA (1566) DU-145 Prostate RGS DU-145 Prostate RAV LPRRAVF (1567) DU-145 Prostate RAS RASCVWR (6) DU-145 Prostate (1568) FSKMRAS (1569) DU-145 Prostate GAG DYVGAGT (1570) DU-145 Prostate AVS DU-145 Prostate LLS DU-145 Prostate LLR ARLLRGG (1571) DU-145 Prostate LLRSVGY (1572) DU-145 Prostate LRV DU-145 Prostate LRS HLRSGFS (1573) DU-145 Prostate LLRSVGY (1574) DU-145 Prostate RVS DU-145 Prostate RSS DU-145 Prostate AGS DU-145 Prostate AGR AGRPDGV (1575) DU-145 Prostate AGL DENRAGL (1576) DU-145 Prostate AGG AWAGGDM (1577) DU-145 Prostate LNAGGSG (1578) DU-145 Prostate GVR DU-145 Prostate GVL DU-145 Prostate GAV NMGAVGS (1579) DU-145 Prostate PIGAVMN (1580) DU-145 Prostate GLV LTGGLVF (1581) DU-145 Prostate CGEGLVV (1582) DU-145 Prostate GLR SDLGLRR (1583) DU-145 Prostate LVS HADVLVS (1584) DU-145 Prostate ARG FSNARGY (1585) DU-145 Prostate ASL DU-145 Prostate AAV AAVWWAA (1586) DU-145 Prostate AAS DU-145 Prostate GGS LNAGGSG (1587) DU-145 Prostate GGSAWWG (1588) DU-145 Prostate VYGWGGS (1589) DU-145 Prostate GGR GGRLLRA (1590) DU-145 Prostate LGGRTIS (1591) DU-145 Prostate GLG YLGLGGL (1592) DU-145 Prostate GGL SITRGGL (1593) DU-145 Prostate LTGGLVF (1594) DU-145 Prostate LGGLGLY (1595) DU-145 Prostate GSS GSSELSR (1596) DU-145 Prostate GSG GSGGANL (1597) DU-145 Prostate VDGSGDD (1598) DU-145 Prostate GSV RSLGSVG (1599) DU-145 Prostate GRV GRVKPGA (1600) DU-145 Prostate GRL GGRLLRA (1601) DU-145 Prostate GRLWYVA (1602) DU-145 Prostate TLGRLSS (1603) DU-145 Prostate GPS DU-145 Prostate GVS GVSGLSR (1604) DU-145 Prostate YGVSRLL (1605) DU-145 Prostate RLS SRLSYRA (1606) 786-0 Renal RGV IHRGVWG (1607) 786-0 Renal RGS YFRARGS (1608) 786-0 Renal
RAV 786-0 Renal RAS 786-0 Renal GAG GAGRFPH (1609) 786-0 Renal SGAGAAF (1610) 786-0 Renal VDVGGAG (1611) 786-0 Renal AVS ASAGAVS (1612) 786-0 Renal LLS 786-0 Renal LLR 786-0 Renal LRV 786-0 Renal LRS ARYSLRS (1613) 786-0 Renal RLRSYVA (1614) 786-0 Renal SRKGLRS (1615) 786-0 Renal RVS SVTGRVS (1616) 786-0 Renal RSS 786-0 Renal AGS AGSAFWA (1617) 786-0 Renal DQQEAGS (1618) 786-0 Renal FAAGAGS (1619) 786-0 Renal AGR GAGRFPH (1620) 786-0 Renal AGL 786-0 Renal AGG GAGGVDV (1621) 786-0 Renal GVR 786-0 Renal GVL 786-0 Renal GAV ASAGAVS (1622) 786-0 Renal GLV RRDGLVE (1623) 786-0 Renal GLR SRKGLRS (1624) 786-0 Renal LVS GDATLVS (1625) 786-0 Renal GDATLVS (1626) 786-0 Renal ARG YFRARGS (1627) 786-0 Renal ASL 786-0 Renal AAV 786-0 Renal AAS 786-0 Renal GGS 786-0 Renal GGR 786-0 Renal GLG DRGLGMS (1628) 786-0 Renal GGL 786-0 Renal GSS 786-0 Renal GSG GSGYFIT (1629) 786-0 Renal GSV 786-0 Renal GRV SVTGRVS (1630) 786-0 Renal GRL 786-0 Renal GPS VGPSVHL (1631) 786-0 Renal GVS 786-0 Renal RLS A498 Renal RGV EGVRGVF (1632) A498 Renal GDRGVRG (1633) A498 Renal MRGVARK (1634) A498 Renal RGS A498 Renal RAV KRAVGRM (1635) A498 Renal RAS DRASSWA (1636) A498 Renal GAG LQGAGIH (1637) A498 Renal AVS A498 Renal LLS A498 Renal LLR WLLRGFG (1638) A498 Renal LRV A498 Renal LRS ASPPLRS (1639) A498 Renal RVS RVSSETF (1640) A498 Renal RSS A498 Renal AGS ARAGSTF (1641) A498 Renal AGR TFAGRSL (1642) A498 Renal AGL A498 Renal AGG YAAGGST (1643) A498 Renal GVR EGVRGVF (1644) A498 Renal GDRGVRG (1645) A498 Renal GVL PGVLREP (1646) A498 Renal GAV A498 Renal GLV A498 Renal GLR GLRDGVE (1647) A498 Renal LVS A498 Renal ARG FPARGED (1648) A498 Renal ASL MLGSASL (1649) A498 Renal AAV A498 Renal AAS A498 Renal GGS HGGSNDR (1650) A498 Renal YAAGGST (1651) A498 Renal GGR QGGRSGV (1652) A498 Renal WTVGGRV (1653) A498 Renal GLG A498 Renal GGL A498 Renal GSS VKGSSMR (1654) A498 Renal GSG A498 Renal GSV A498 Renal GRV FVGRVGE (1655) A498 Renal GRVGRDG (1656) A498 Renal SVSRGRV (1657) A498 Renal WTVGGRV (1658) A498 Renal GRL GFGRLLW (1659) A498 Renal GPS AAYWGPS (1660) A498 Renal GVS MDGVSTE (1661) A498 Renal VYWWGVS (1662) A498 Renal RLS RLSMASR (1663) ACHN Renal GRLSFGV (1664) ACHN Renal RGV GLSRGVL (1665) ACHN Renal RGS LRGSHVA (1666) ACHN Renal NMGRGSL (1667) ACHN Renal SVVRRGS (1668) ACHN Renal RAV ACHN Renal RAS ACHN Renal GAG VMGAGVQ (1669) ACHN Renal AVS ACHN Renal LLS ACHN Renal LLR PLLRQQL (1670) ACHN Renal LRV SNGLRVV (1671) ACHN Renal LRS LRSMAVM (1672) ACHN Renal VDLRSAF (1673) ACHN Renal RVS FRVSLGY (1674) ACHN Renal RSS RSSYAPP (1675) ACHN Renal AGS FPGSAGS (1676) ACHN Renal AGR FAGRAPR (1677) ACHN Renal AGL ACHN Renal AGG FIAGGVG (1678) ACHN Renal LIHAGGQ (1679) ACHN Renal RAGGGAP (1680) ACHN Renal TWHAGGI (1681) ACHN Renal GVR GVRSITL (1682) ACHN Renal GVL GLSRGVL (1683) ACHN Renal GAV RVVGAVL (1684) ACHN Renal GLV ACHN Renal GLR FGLRMSN (1685) ACHN Renal LGLRGWT (1686) ACHN Renal AFFMGLR (1687) ACHN Renal SNGLRVV (1688) ACHN Renal LVS ACHN Renal ARG ARGTMTG (1689) ACHN Renal RPARGAF (1690) ACHN Renal ASL ASLPMLH (1691) ACHN Renal AAV ACHN Renal AAS ACHN Renal GGS GGSVEGQ (1692) ACHN Renal GGR LGGRQES (1693) ACHN Renal NGGRVLS (1694) ACHN Renal GLG ACHN Renal GGL PIGGLFG (1695) ACHN Renal AECCGGL (1696) ACHN Renal SEQRGGL (1697) ACHN Renal GSS DRFGSSA (1698) ACHN Renal GSG GHGSGSR (1699) ACHN Renal GSV GGSVEGQ (1700) ACHN Renal GSVVSSW (1701) ACHN Renal GRV NGGRVLS (1702) ACHN Renal GRL GRLMPGG (1703) ACHN Renal TWGRLGL (1704) ACHN Renal AVHSGRL (1705) ACHN Renal GRLSFGV (1706) ACHN Renal
GPS PQGPSSV (1707) ACHN Renal GVS ACHN Renal RLS AGWRLSQ (1708) CAIK-1 Renal RGV CAIK-1 Renal RGS RVDRGSL (1709) CAIK-1 Renal RAV RAVCEWD (1710) CAIK-1 Renal RAVERVA (1711) CAIK-1 Renal RAS AVFRASR (1712) CAIK-1 Renal GAG GAGSSVW (1713) CAIK-1 Renal GAGSSVW (1714) CAIK-1 Renal AVS CAIK-1 Renal LLS CAIK-1 Renal LLR WLLRSWS (1715) CAIK-1 Renal LRV RKEALRV (1716) CAIK-1 Renal RLRVSVR (1717) CAIK-1 Renal LRS LRPGLRS (1718) CAIK-1 Renal QRYHLRS (13) CAIK-1 Renal (1719) WLLRSWS (1720) CAIK-1 Renal RVS GRERVSH (2) CAIK-1 Renal (1721) RVSVRLR (1722) CAIK-1 Renal RSS CAIK-1 Renal AGS GAGSSVW (1723) CAIK-1 Renal GAGSSVW (1724) CAIK-1 Renal AGR CAIK-1 Renal AGL AGLWPWN (1725) CAIK-1 Renal AGG CAIK-1 Renal GVR GVRGGGD (1726) CAIK-1 Renal GVL CAIK-1 Renal GAV CAIK-1 Renal GLV GLVRRVV (1727) CAIK-1 Renal GLR LRPGLRS (1728) CAIK-1 Renal LVS CAIK-1 Renal ARG CAIK-1 Renal ASL CAIK-1 Renal AAV CAIK-1 Renal AAS WAHAASY (1729) CAIK-1 Renal GGS CAIK-1 Renal GGR DGGGRVG (1730) CAIK-1 Renal VGVMGGR (1731) CAIK-1 Renal VYGGRSE (1732) CAIK-1 Renal GLG TICLGLG (1733) CAIK-1 Renal GGL CAIK-1 Renal GSS GAGSSVW (1734) CAIK-1 Renal GAGSSVW (1735) CAIK-1 Renal GSG CAIK-1 Renal GSV DHVSGSV (1736) CAIK-1 Renal GRV DGGGRVG (1737) CAIK-1 Renal GRL GEGRLCG (1738) CAIK-1 Renal GVAIGRL (1739) CAIK-1 Renal GPS CAIK-1 Renal GVS FGVSQVH (1740) CAIK-1 Renal GGVSRMR (1741) CAIK-1 Renal GGL RXF393 Renal RLS GRIRLSF (1742) RXF393 Renal RGV RGVNYRS (1743) RXF393 Renal TEGTRGV (1744) RXF393 Renal RGS GYARGSG (1745) RXF393 Renal GVWLRGS (1746) RXF393 Renal RAV AARAVWG (1747) RXF393 Renal RAS RASYYGV (1748) RXF393 Renal GAG GAGVEYF (1749) RXF393 Renal AVS RXF393 Renal LLS LLLLSGS (1750) RXF393 Renal VLLSAGL (1751) RXF393 Renal LLR TGLLRLY (1752) RXF393 Renal LRV RXF393 Renal LRS LRSSLVS (1753) RXF393 Renal RVS RXF393 Renal RSS LRSSLVS (1754) RXF393 Renal PRSSGPM (1755) RXF393 Renal AGS RXF393 Renal AGR TAGRLEV (1756) RXF393 Renal AGL AGLEDLG (1757) RXF393 Renal MPAGLGV (1758) RXF393 Renal VLLSAGL (1759) RXF393 Renal AGG RXF393 Renal GVR GVRWNWS (1760) RXF393 Renal TRDGVRW (1761) RXF393 Renal GVL RXF393 Renal GAV RXF393 Renal GLV RAHGLVC (1762) RXF393 Renal GLR LGSSGLR (1763) RXF393 Renal LVS LLVSLSS (1764) RXF393 Renal LRSSLVS (1765) RXF393 Renal LVSTRWA (1766) RXF393 Renal LVSYSAV (1767) RXF393 Renal ARG GYARGSG (1768) RXF393 Renal ASL LGASLLV (1769) RXF393 Renal AAV GTGAAVF (1770) RXF393 Renal AAVGTAL (1771) RXF393 Renal AAS VSAASSV (1772) RXF393 Renal GGS RGGSPPV (1773) RXF393 Renal GGR VPPSGGR (1774) RXF393 Renal GLG GLGSCAP (1775) RXF393 Renal MPAGLGV (1776) RXF393 Renal GSS MPGSSRP (1777) RXF393 Renal GSSLSRP (1778) RXF393 Renal RLGSSGL (1779) RXF393 Renal GSG GYARGSG (1780) RXF393 Renal GSV RXF393 Renal GRV RXF393 Renal GRL SGRLWVG (1781) RXF393 Renal TAGRLEV (1782) RXF393 Renal GPS GPSFDAK (1783) RXF393 Renal GVS ACTGVSR (1784) RXF393 Renal RLS SN12C Renal RGV LGMGRGV (1785) SN12C Renal RGS MLGRGSV (1786) SN12C Renal RAV SN12C Renal RAS PRASSTG (1787) SN12C Renal RASCFWD (1788) SN12C Renal RASCFWD (1789) SN12C Renal GAG SN12C Renal AVS SN12C Renal LLS FLLLSHR (1790) SN12C Renal LLSVTSX (1791) SN12C Renal LLR PLLREVG (1792) SN12C Renal LRV LRVGHAG (1793) SN12C Renal NELRVCR (1794) SN12C Renal LRS MRYELRS (1795) SN12C Renal RVS RVSVWWA (1796) SN12C Renal FAQRRVS (1797) SN12C Renal RSS SHHRSSI (1798) SN12C Renal AGS CMAGSQD (1799) SN12C Renal RYGTAGS (1800) SN12C Renal SAGSHPA (1801) SN12C Renal PNSAGSV (1802) SN12C Renal AGR KMRIAGR (1803) SN12C Renal MERVAGR (1804) SN12C Renal AGL WAGLSRP (1805) SN12C Renal AGG SN12C Renal GVR GAHGVRL (1806) SN12C Renal RVPTGVR (1807) SN12C Renal GVL SN12C Renal GAV RGAVREM (1808) SN12C Renal GLV SN12C Renal GLR FDPGGLR (1809) SN12C Renal LVS ILSDLVS (1810) SN12C Renal ARG LLNPARG (1811) SN12C Renal ASL SN12C Renal AAV WWAAVPG (1812) SN12C Renal AAS KAASTED (1813) SN12C Renal SYMGAAS (1814) SN12C Renal
GGS GGSIDCC (1815) SN12C Renal GPGGSKR (1816) SN12C Renal AFGGGSM (1817) SN12C Renal GGR PEGGRRP (1818) SN12C Renal GLG SN12C Renal GGL GGLEQDG (1819) SN12C Renal FDPGGLR (1820) SN12C Renal GSS LFGSSVS (1821) SN12C Renal WDGSSVS (1822) SN12C Renal GSG SN12C Renal GSV PNSAGSV (1823) SN12C Renal MLGRGSV (1824) SN12C Renal GRV SN12C Renal GRL TRRGRLD (1825) SN12C Renal GPS SN12C Renal GVS GVSISDG (1826) SN12C Renal GVSIYDL (1827) SN12C Renal RLS ARLSLEL (1828) TK-10 Renal RLRLSSW (1829) TK-10 Renal RRLSSIA (1830) TK-10 Renal SRLSYRT (1831) TK-10 Renal RGV TK-10 Renal RGS ARGSWRE (1832) TK-10 Renal RAV VRLRAVF (1833) TK-10 Renal RAS RASRIGL (1834) TK-10 Renal GAG GAGTSEG (1835) TK-10 Renal AVS TK-10 Renal LLS LLSTVWV (1836) TK-10 Renal ELRRLLS (1837) TK-10 Renal LLR LLRGLRP (1838) TK-10 Renal SLLRRLE (1839) TK-10 Renal LRV LRVSRGL (1840) TK-10 Renal TLGLRVP (1841) TK-10 Renal FVARLRV (1842) TK-10 Renal LRS GVYWLRS (1843) TK-10 Renal SFWWLRS (1844) TK-10 Renal TRYSLRS (1845) TK-10 Renal RVS LRVSRGL (1846) TK-10 Renal RSS RSSSGSG (1847) TK-10 Renal TRSSLTH (1848) TK-10 Renal TGRSSFW (1849) TK-10 Renal AGS TK-10 Renal AGR NAGRGAS (1850) TK-10 Renal AGL HAGLLVV (1851) TK-10 Renal AGG TK-10 Renal GVR HTYGVRF (1852) TK-10 Renal GVL TK-10 Renal GAV GAVRSVM (1853) TK-10 Renal VLVEGAV (1854) TK-10 Renal GLV TK-10 Renal GLR LLRGLRP (1855) TK-10 Renal TLGLRVP (1856) TK-10 Renal LVS TK-10 Renal ARG ARGSWRE (1857) TK-10 Renal ASL TK-10 Renal AAV GLWAAVL (1858) TK-10 Renal AAS GWTMAAS (1859) TK-10 Renal GGS LYMGGSH (1860) TK-10 Renal GGR GVGGRQS (1861) TK-10 Renal GLG RRGLGDA (1862) TK-10 Renal GGL TGGLHWY (1863) TK-10 Renal GSS GSGSSSR (1864) TK-10 Renal GSSTLQW (1865) TK-10 Renal GSG RSSSGSG (1866) TK-10 Renal GSV DELGSVQ (1867) TK-10 Renal GRV TK-10 Renal GRL GRLRPFS (1868) TK-10 Renal PRLGRLL (1869) TK-10 Renal GPS TK-10 Renal GVS VGVSQEW (1870) TK-10 Renal DGVSPLW (1871) TK-10 Renal RLS UO31 Renal RGV UO31 Renal RGS PRGSLFA (1872) UO31 Renal VIVRGSL (1873) UO31 Renal RAV GDRAVGL (1874) UO31 Renal VHKRAVL (1875) UO31 Renal RAS UO31 Renal GAG GGAGSRR (1876) UO31 Renal AVS UO31 Renal LLS RLETLLS (1877) UO31 Renal LLR LLRAGVR (1878) UO31 Renal LRV PAILRVR (1879) UO31 Renal GDLRVSV (1880) UO31 Renal LRS UO31 Renal RVS GDLRVSV (1881) UO31 Renal RSS UO31 Renal AGS GGAGSRR (1882) UO31 Renal AGSVTEQ (1883) UO31 Renal SSSLAGS (1884) UO31 Renal AGR RSWNAGR (1885) UO31 Renal AGL AGLPHRF (1886) UO31 Renal RNSRAGL (1887) UO31 Renal AGG RRSGAGG (1888) UO31 Renal AGGPSSY (1889) UO31 Renal GVR TGVRNSP (1890) UO31 Renal LLRAGVR (1891) UO31 Renal GVL UO31 Renal GAV UO31 Renal GLV UO31 Renal GLR UO31 Renal LVS ALVSTIL (1892) UO31 Renal ARG ARGRDEG (1893) UO31 Renal ASL ASLSVVI (1894) UO31 Renal AAV UO31 Renal AAS UO31 Renal GGS GGSRGYR (1895) UO31 Renal YWGGSVP (1896) UO31 Renal GGR GGRPVER (1897) UO31 Renal GGRSQEG (1898) UO31 Renal PGGGRGR (1899) UO31 Renal GLG UO31 Renal GGL UO31 Renal GSS FSLGSSP (1900) UO31 Renal GSG UO31 Renal GSV GSVFGTP (1901) UO31 Renal AGSVTEQ (1902) UO31 Renal YWGGSVP (1903) UO31 Renal GRV LSGRVIV (1904) UO31 Renal LSTPGRV (1905) UO31 Renal GRL UO31 Renal GPS AGGPSSY (1906) UO31 Renal UO31 Renal GVS UO31 Renal RLS MCF-7 Breast RGV MCF-7 Breast RGS RVMRGSL (1907) MCF-7 Breast RAV MCF-7 Breast RAS RASCVWA (1908) MCF-7 Breast GAG MCF-7 Breast AVS MCF-7 Breast LLS QLLSQVY (1909) MCF-7 Breast LLR MCF-7 Breast LRV MCF-7 Breast LRS ERYYLRS (1910) MCF-7 Breast GLVKLRS (1911) MCF-7 Breast RVS MCF-7 Breast RSS MCF-7 Breast AGS GRLAAGS (1912) MCF-7 Breast AGR MCF-7 Breast AGL MCF-7 Breast AGG MCF-7 Breast GVR MCF-7 Breast GVL MCF-7 Breast
GAV MCF-7 Breast GLV GLVKLRS (1913) MCF-7 Breast GLR MCF-7 Breast LVS LWFELVS (1914) MCF-7 Breast ARG MCF-7 Breast ASL MCF-7 Breast AAV MCF-7 Breast AAS IGAASWF (1915) MCF-7 Breast GGS MCF-7 Breast GGR GGRRGTS (1916) MCF-7 Breast RDLGGRW (1917) MCF-7 Breast GLG MCF-7 Breast GGL WRGGLDR (1918) MCF-7 Breast GSS GRWTGSS (1919) MCF-7 Breast SYWVGSS (1920) MCF-7 Breast GSG MCF-7 Breast GSV MCF-7 Breast GRV MCF-7 Breast GRL GRLAAGS (1921) MCF-7 Breast GPS MCF-7 Breast GVS AKAGVSR (1922) MCF-7 Breast RLS LRLSGHD (1923) NCI/ADR-RES Breast RGV RGVGAKA (1924) NCI/ADR-RES Breast LRGVYVA (1925) NCI/ADR-RES Breast RGS NCI/ADR-RES Breast RAV NCI/ADR-RES Breast RAS NCI/ADR-RES Breast GAG NCI/ADR-RES Breast AVS GTPAVSY (1926) NCI/ADR-RES Breast LLS FLLSRSA (1927) NCI/ADR-RES Breast AGLLSDV (1928) NCI/ADR-RES Breast LLR NCI/ADR-RES Breast LRV LRVGXPG (1929) NCI/ADR-RES Breast LRS NCI/ADR-RES Breast RVS RVSGSPV (1930) NCI/ADR-RES Breast RSS RSSIDVG (1931) NCI/ADR-RES Breast AGS NCI/ADR-RES Breast AGR AGRRLRD (1932) NCI/ADR-RES Breast AGL WRLAGLG (1933) NCI/ADR-RES Breast PTVSAGL (1934) NCI/ADR-RES Breast AGLLSDV (1935) NCI/ADR-RES Breast AGG NCI/ADR-RES Breast GVR NCI/ADR-RES Breast GVL TLGVLVT (1936) NCI/ADR-RES Breast GAV NCI/ADR-RES Breast GLV NCI/ADR-RES Breast GLR NCI/ADR-RES Breast LVS GDRRLVS (1937) NCI/ADR-RES Breast LMLVSGK (1938) NCI/ADR-RES Breast ARG DVHARGD (1939) NCI/ADR-RES Breast ASL NCI/ADR-RES Breast AAV NCI/ADR-RES Breast AAS NCI/ADR-RES Breast GGS REGGSDT (1940) NCI/ADR-RES Breast GGR GGRRVVV (1941) NCI/ADR-RES Breast NVGGGRF (1942) NCI/ADR-RES Breast GLG GLGALRW (1943) NCI/ADR-RES Breast LGLSGLG (1944) NCI/ADR-RES Breast RGLGRPV (1945) NCI/ADR-RES Breast GGL NCI/ADR-RES Breast GSS GSSGLLA (1946) NCI/ADR-RES Breast LGSSSHI (1947) NCI/ADR-RES Breast GSG IGSGVGV (1948) NCI/ADR-RES Breast GSV KGSVLML (1949) NCI/ADR-RES Breast VPSGSVR (1950) NCI/ADR-RES Breast GRV NCI/ADR-RES Breast GRL GYLGRLP (1951) NCI/ADR-RES Breast AVYVGRL (1952) NCI/ADR-RES Breast GPS NCI/ADR-RES Breast GVS NCI/ADR-RES Breast RLS LGGRLSL (1953) MDA-MB-231 Breast RGV RGVGKTK (1954) MDA-MB-231 Breast LGGARGV (1955) MDA-MB-231 Breast HAWDRGV (1956) MDA-MB-231 Breast DWGSRGV (1957) MDA-MB-231 Breast RGS PYRRGSC (1958) MDA-MB-231 Breast ALNRGSR (3) MDA-MB-231 Breast (1959) RAV MDA-MB-231 Breast RAS MDA-MB-231 Breast GAG TFRGAGV (1960) MDA-MB-231 Breast AVS MDA-MB-231 Breast LLS LLSAARF (1961) MDA-MB-231 Breast LLR MDA-MB-231 Breast LRV MDA-MB-231 Breast LRS MRPGLRS (1962) MDA-MB-231 Breast RVS PRVSALV (1963) MDA-MB-231 Breast VRVSLNS (1964) MDA-MB-231 Breast RSS GRSSAGP (1965) MDA-MB-231 Breast AGS LHAGSSV (1966) MDA-MB-231 Breast VVMIAGS (1967) MDA-MB-231 Breast AGR DTPAGRL (1968) MDA-MB-231 Breast VGAGRFT (1969) MDA-MB-231 Breast AGL MDA-MB-231 Breast AGG AGGTDRT (1970) MDA-MB-231 Breast FISAGGW (1971) MDA-MB-231 Breast TIPAGGG (1972) MDA-MB-231 Breast VGRAGGL (1973) MDA-MB-231 Breast GVR MDA-MB-231 Breast GVL MDA-MB-231 Breast GAV MDA-MB-231 Breast GLV NPGLVWN (1974) MDA-MB-231 Breast LGLVHWV (1975) MDA-MB-231 Breast GLR MRPGLRS (1976) MDA-MB-231 Breast LVS MDA-MB-231 Breast ARG ARGNVRF (1977) MDA-MB-231 Breast LGGARGV (1978) MDA-MB-231 Breast ASL FRAASLL (1979) MDA-MB-231 Breast AAV MDA-MB-231 Breast AAS AASVGVA (1980) MDA-MB-231 Breast FRAASLL (1981) MDA-MB-231 Breast GGS PVFRGGS (1982) MDA-MB-231 Breast SGGSVGF (1983) MDA-MB-231 Breast VRANGGS (1984) MDA-MB-231 Breast GGR FHIWGGR (1985) MDA-MB-231 Breast LGGRLSL (1986) MDA-MB-231 Breast SGGRFVP (1987) MDA-MB-231 Breast GLG MDA-MB-231 Breast GGL GGGLPVD (1988) MDA-MB-231 Breast LSLRGGL (1989) MDA-MB-231 Breast VGRAGGL (1990) MDA-MB-231 Breast GSS ANGSSKK (1991) MDA-MB-231 Breast DFTLGSS (1992) MDA-MB-231 Breast LHAGSSV (1993) MDA-MB-231 Breast GSG MDA-MB-231 Breast GSV NSGSVVS (1994) MDA-MB-231 Breast SGGSVGF (1995) MDA-MB-231 Breast WSISGSV (1996) MDA-MB-231 Breast GRV MDA-MB-231 Breast GRL DTPAGRL (1997) MDA-MB-231 Breast LGGRLSL (1998) MDA-MB-231 Breast GPS MDA-MB-231 Breast GVS AVGVSAA (1999) MDA-MB-231 Breast SGVSNPG (2000) MDA-MB-231 Breast FGVSGGS (2001) MDA-MB-231 Breast ESATGVS (2002) MDA-MB-231 Breast AAIVGVS (2003) MDA-MB-231 Breast RLS MDA-MB-435-Breast RGV MDA-MB-435-Breast RGS LRSGRGS (2004) MDA-MB-435-Breast LRSGRGS (2005) MDA-MB-435-Breast RGRGSTL (2006) MDA-MB-435-Breast RGSPAAA (2007) MDA-MB-435-Breast SRGSYGS (2008) MDA-MB-435-Breast MDA-MB-435-Breast RAV MDA-MB-435-Breast RAS MDA-MB-435-Breast GAG GVGGGAG (2009) MDA-MB-435-Breast MDA-MB-435-Breast AVS MDA-MB-435-Breast
LLS MDA-MB-435-Breast LLR MDA-MB-435-Breast LRV MDA-MB-435-Breast LRS LRSGRGS (49) MDA-MB-435-Breast (2010) RVS MDA-MB-435-Breast RSS MDA-MB-435-Breast AGS MDA-MB-435-Breast AGR MDA-MB-435-Breast AGL MDA-MB-435-Breast AGG AGGGGYH (2011) MDA-MB-435-Breast GAGGGVG (2012) MDA-MB-435-Breast YRALAGG (2) MDA-MB-435-Breast (2013) MDA-MB-435-Breast GVR MDA-MB-435-Breast GVL MDA-MB-435-Breast GAV MDA-MB-435-Breast GLV MDA-MB-435-Breast GLR MDA-MB-435-Breast LVS MDA-MB-435-Breast ARG MDA-MB-435-Breast ASL LYVDASL (2014) MDA-MB-435-Breast AAV MDA-MB-435-Breast AAS MDA-MB-435-Breast GGS MDA-MB-435-Breast GGR MDA-MB-435-Breast GLG MDA-MB-435-Breast GGL MDA-MB-435-Breast GSS MDA-MB-435-Breast GSG GEGSGSA (2015) MDA-MB-435-Breast GSV MDA-MB-435-Breast GRV MDA-MB-435-Breast GRL MDA-MB-435-Breast GPS MDA-MB-435-Breast GVS MDA-MB-435-Breast RLS BT-549 Breast RGV RVRGVLD (2016) BT-549 Breast SMRGVLS (2017) BT-549 Breast EAGPRGV (2018) BT-549 Breast RGS CRGSIGA (2019) BT-549 Breast PLQRGSG (2020) BT-549 Breast RGSRWSS (2021) BT-549 Breast RGSYVER (2022) BT-549 Breast RAV TYCDRAV (2023) BT-549 Breast RAS LGVRASP (2024) BT-549 Breast WRASPGM (2025) BT-549 Breast PRASDIL (2026) BT-549 Breast GAG RVGAGWP (2027) BT-549 Breast AVS BT-549 Breast LLS LLSRAQA (2028) BT-549 Breast LLR BT-549 Breast LRV SALRVGL (2029) BT-549 Breast VGLRVRF (2030) BT-549 Breast LRS YGLRSLV (2031) BT-549 Breast RVS TRVSGSG (2032) BT-549 Breast RSS VRRSSKF (2033) BT-549 Breast AGS BT-549 Breast AGR BT-549 Breast AGL TFAGLAQ (2034) BT-549 Breast AGG BT-549 Breast GVR LGVRASP (2035) BT-549 Breast LGVRLAS (2036) BT-549 Breast PWGAGVR (2037) BT-549 Breast GVL GVLTIGA (2038) BT-549 Breast RVRGVLD (2039) BT-549 Breast IGWGVLG (2040) BT-549 Breast SMRGVLS (2041) BT-549 Breast GAV GAVLTSC (2042) BT-549 Breast GLV GLVSTLI (2043) BT-549 Breast GLVGWGI (2044) BT-549 Breast GLR VGLRCSV (2045) BT-549 Breast VGLRVRF (2046) BT-549 Breast YGLRSLV (2047) BT-549 Breast LVS GLVSTLI (2048) BT-549 Breast ARG PRGMARG (2049) BT-549 Breast ASL BT-549 Breast AAV BT-549 Breast AAS BT-549 Breast GGS RGGSDEA (2050) BT-549 Breast GGR AEDSGGR (2051) BT-549 Breast GGRCGAE (2052) BT-549 Breast GLG BT-549 Breast GGL GGLMPRY (2053) BT-549 Breast GSS GSSVSLG (2054) BT-549 Breast GSG GSGRQLP (2055) BT-549 Breast RKGSGTA (2056) BT-549 Breast TRVSGSG (2057) BT-549 Breast GSV GSGSVRT (2058) BT-549 Breast GRV DDGRVHR (2059) BT-549 Breast DLVGRVR (2060) BT-549 Breast GRL WGRLEST (2061) BT-549 Breast GPS MGPSARW (2062) BT-549 Breast GVS ISGVSDD (2063) BT-549 Breast RLS GHSERLS (2064) T-47D Breast RGV ERGVFVY (2065) T-47D Breast TRGVIGG (2066) T-47D Breast RGS RGSFGLG (2067) T-47D Breast RAV PFHRRAV (2068) T-47D Breast RAS T-47D Breast GAG VGIGAGG (2) T-47D Breast (2069) AVS AVSLAWQ (2070) T-47D Breast FPAVSTE (2071) T-47D Breast LLS T-47D Breast LLR T-47D Breast LRV T-47D Breast LRS SGARLRS (2072) T-47D Breast RVS T-47D Breast RSS SHRSSTG (2073) T-47D Breast AGS SRLRAGS (2074) T-47D Breast AGR SFAGRIL (2075) T-47D Breast AGL T-47D Breast AGG RVAAGGL (2076) T-47D Breast VGIGAGG (2077) T-47D Breast VGIGAGG (2078) T-47D Breast GVR T-47D Breast GVL T-47D Breast GAV QKPGAVG (2079) T-47D Breast LGYYGAV (2080) T-47D Breast GLV LPLGLVS (2081) T-47D Breast LGLVFTR (2082) T-47D Breast GLR T-47D Breast LVS LPLGLVS (2083) T-47D Breast NSKPLVS (2084) T-47D Breast ARG TNRFARG (2085) T-47D Breast ASL LASLARP (2086) T-47D Breast AAV LGGAAVR (2087) T-47D Breast AAS AASPHPG (2088) T-47D Breast GGS LSKGGSE (2089) T-47D Breast GGR T-47D Breast GLG GLGRSVN (2090) T-47D Breast PGLGYAL (2091) T-47D Breast RGSFGLG (2092) T-47D Breast GGL GRDWGGL (2093) T-47D Breast RVAAGGL (2094) T-47D Breast GSS TVGSSLG (2095) T-47D Breast GSG T-47D Breast GSV T-47D Breast GRV GRVDPVD (2096) T-47D Breast GRL SLYRGRL (2097) T-47D Breast GPS T-47D Breast GVS VALGVSS (2098) T-47D Breast
RLS VSVTRLS (2099) HS 578 T Breast RGV HS 578 T Breast RGS AGATRGS (2100) HS 578 T Breast RRGSVAE (2101) HS 578 T Breast FRFVRGS (2102) HS 578 T Breast TRGSGAG (2103) HS 578 T Breast RAV GARAVAP (2104) HS 578 T Breast RAS HS 578 T Breast GAG TRGSGAG (2105) HS 578 T Breast AVS EAVSGRR (2106) HS 578 T Breast LLS HS 578 T Breast LLR HS 578 T Breast LRV HS 578 T Breast LRS HS 578 T Breast RVS PVRRVSS (2107) HS 578 T Breast IRVSAVV (2108) HS 578 T Breast RSS HVRSSYA (2109) HS 578 T Breast RVRSSLA (2110) HS 578 T Breast AGS TAAGSSF (2111) HS 578 T Breast GAGSGRT (2112) HS 578 T Breast PAVAGST (2113) HS 578 T Breast AGR AGRHLDA (2114) HS 578 T Breast DRQLAGR (2115) HS 578 T Breast AGL HS 578 T Breast AGG HS 578 T Breast GVR LGVREVG (2116) HS 578 T Breast VAVGVRS (2117) HS 578 T Breast GVL SFGVLSG (2118) HS 578 T Breast GAV TSGAVAP (2119) HS 578 T Breast GLV HS 578 T Breast GLR GLREVQD (2120) HS 578 T Breast LVS SLVSERA (2121) HS 578 T Breast SVHLVSG (2122) HS 578 T Breast ARG TQVEARG (2123) HS 578 T Breast ASL HS 578 T Breast AAV HS 578 T Breast AAS HS 578 T Breast GGS HS 578 T Breast GGR GGRPTVT (2124) HS 578 T Breast VVGGRRT (2125) HS 578 T Breast GLG HS 578 T Breast GGL GVGGLSS (2126) HS 578 T Breast GSS TAAGSSF (2127) HS 578 T Breast GSG TRGSGAG (2128) HS 578 T Breast GSV RRGSVAE (2129) HS 578 T Breast GSVLHVS (2130) HS 578 T Breast GRV SGRVFRF (2131) HS 578 T Breast GRL HS 578 T Breast GPS HS 578 T Breast GVS WSATGVS (2132) HS 578 T Breast
REFERENCES
[0080] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
[0081] Arap et al., Nature Med. 8, 121-127, 2002.
[0082] Arap et al., Science, 279:377-80, 1998.
[0083] Blower et al., Pharmacogenomics J., 2:259-271, 2002.
[0084] Brown, Oncol. Res., 1997; 9:213-5, 1997.
[0085] Giordano et al., Nat. Med., 7:1249-1253, 2001.
[0086] Hafner et al., Clin. Chem., 50:490-499, 2004.
[0087] Holbeck, Eur. J. Cancer, 40:785-793, 2004.
[0088] Kolonin et al., Cancer Res., 66(1):1-7, 2006.
[0089] Kolonin et al., Curr. Opin. Chem. Biol., 5:308-13, 2001.
[0090] Kolonin et al., Nat. Med., 6:625-632, 2004.
[0091] Kolonin et al., Proc. Natl. Acad. Sci. USA, 99:13055-13060, 2002.
[0092] Maihle and Lafky, Trends Cell Biol., 12:160-161, 2002.
[0093] Monks et al., J. Natl. Cancer Inst., 1991; 83:757-66, 1991.
[0094] Myers et al., Electrophoresis, 18:647-653, 1997.
[0095] Nishizuka et al., Proc. Natl. Acad. Sci. USA, 100:14229-14234, 2003.
[0096] Pasqualini and Ruoslahti, Nature, 380:364-366, 1996.
[0097] Pasqualini et al., Cancer Res., 60:722-727, 2000.
[0098] Pasqualini et al., In: Phage Display, A Laboratory Manual, Barbas et al. (Eds.), NY, Cold Spring Harbor Laboratory Press, 22:1-24, 2001.
[0099] Rabow et al., J. Med. Chem., 45:818-40, 2002.
[0100] Scherf et al., Nat. Genet., 24:236-244, 2000.
[0101] Szakacs et al., Cancer Cell, 6:129-37, 2004.
[0102] Vogelstein and Kinzler, Nat. Med., 10:789-799, 2004.
[0103] Walloyist et al., Bioinformatics, 19:2212-24, 2003.
[0104] Wallqvist et al., Mol. Cancer Ther., 1:311-20, 2002.
[0105] Weinstein et al., Science, 275:343-349, 1997.
[0106] Zaharevitz et al., J. Mol. Graph. Model, 30:297-303, 2002.
[0107] Zurita et al., Cancer Res., 2004:64:435-9, 2004.
Sequence CWU
1
1
214019PRTArtificial SequenceSynthetic peptide 1Cys Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Cys 1 5 29PRTArtificial
SequenceArtificial peptide 2Cys Ser Gly Ile Gly Ser Gly Gly Cys 1
5 39PRTArtificial SequenceArtificial peptide 3Cys
Arg Phe Glu Ser Ser Gly Gly Cys 1 5
47PRTArtificial SequenceArtificial peptide 4Ser Gly Ile Gly Ser Gly Gly 1
5 57PRTArtificial SequenceArtificial peptide 5Arg
Phe Glu Ser Ser Gly Gly 1 5 67PRTArtificial
SequenceArtificial peptide 6Leu Arg Leu Ser Ser Ile Pro 1 5
77PRTArtificial SequenceArtificial peptide 7Ala Arg Gly Val Leu
Leu Met 1 5 87PRTArtificial SequenceArtificial
peptide 8Arg Gly Ser His Leu Val Pro 1 5
97PRTArtificial SequenceArtificial peptide 9Asp Val Glu Thr Arg Gly Ser 1
5 107PRTArtificial SequenceArtificial peptide
10Ser Arg Ala Val Ile Asp Met 1 5
117PRTArtificial SequenceArtificial peptide 11Gly Leu Leu Ser Leu Xaa Leu
1 5 127PRTArtificial SequenceArtificial peptide
12Thr Ser Leu Leu Ser Phe Arg 1 5
137PRTArtificial SequenceArtificial peptide 13Arg Arg Val Ser Leu Val Ala
1 5 147PRTArtificial SequenceArtificial peptide
14Ser Arg Phe Arg Val Ser Ile 1 5
157PRTArtificial SequenceArtificial peptide 15Ala Gly Ser Leu Ser Val Phe
1 5 167PRTArtificial SequenceArtificial peptide
16Ala Gly Arg Ile Cys Glu Gly 1 5
177PRTArtificial SequenceArtificial peptide 17Gln Val Ala Gly Arg Glu Arg
1 5 187PRTArtificial SequenceArtificial peptide
18Val Glu Tyr Ala Ala Gly Arg 1 5
197PRTArtificial SequenceArtificial peptide 19Tyr Asn Arg Ser Ala Gly Leu
1 5 207PRTArtificial SequenceArtificial peptide
20Ala Val Leu Val Ala Gly Gly 1 5
217PRTArtificial SequenceArtificial peptide 21Leu Ala Gly Gly Val Pro Gly
1 5 227PRTArtificial SequenceArtificial peptide
22Asp Trp Trp Ala Gly Val Arg 1 5
237PRTArtificial SequenceArtificial peptide 23Glu Pro Asp Gly Val Arg Ser
1 5 247PRTArtificial SequenceArtificial peptide
24Glu Gln Leu Ser Gly Val Arg 1 5
257PRTArtificial SequenceArtificial peptide 25Gly Val Leu Ala Arg Val Thr
1 5 267PRTArtificial SequenceArtificial peptide
26Ala Arg Gly Val Leu Leu Met 1 5
277PRTArtificial SequenceArtificial peptide 27Gly Gly Ala Val Leu Val Ala
1 5 287PRTArtificial SequenceArtificial peptide
28Arg Glu Arg Gly Ala Val Gln 1 5
297PRTArtificial SequenceArtificial peptide 29Arg Ala Leu Gly Leu Val Ser
1 5 307PRTArtificial SequenceArtificial peptide
30Ser Leu Gly Leu Arg Asn Gln 1 5
317PRTArtificial SequenceArtificial peptide 31Arg Ala Leu Gly Leu Val Ser
1 5 327PRTArtificial SequenceArtificial peptide
32Gly Ala Tyr Arg Leu Val Ser 1 5
337PRTArtificial SequenceArtificial peptide 33Phe Asp Ala Arg Gly Gly Leu
1 5 347PRTArtificial SequenceArtificial peptide
34Met Phe Ala Arg Gly Trp Glu 1 5
357PRTArtificial SequenceArtificial peptide 35Ala Arg Gly Val Leu Leu Met
1 5 367PRTArtificial SequenceArtificial peptide
36Gly Gly Gly Ser Asp Gly Val 1 5
377PRTArtificial SequenceArtificial peptide 37Leu Gly Gly Arg Ala Asp Phe
1 5 387PRTArtificial SequenceArtificial peptide
38Glu Val Gly Gly Gly Leu Thr 1 5
397PRTArtificial SequenceArtificial peptide 39Phe Asp Ala Arg Gly Gly Leu
1 5 407PRTArtificial SequenceArtificial peptide
40Thr Gly Arg Val Val Arg Arg 1 5
417PRTArtificial SequenceArtificial peptide 41Met Gly Met Ser Gly Pro Ser
1 5 427PRTArtificial SequenceArtificial peptide
42Ala Val Arg Gly Val Ala Arg 1 5
437PRTArtificial SequenceArtificial peptide 43Asp Arg Gly Val Pro Gly Leu
1 5 447PRTArtificial SequenceArtificial peptide
44Leu Ser Phe Ser Arg Gly Ser 1 5
457PRTArtificial SequenceArtificial peptide 45Arg Gly Ser Val Arg Val Leu
1 5 467PRTArtificial SequenceArtificial peptide
46Pro Val Arg Gly Ser Val Asp 1 5
477PRTArtificial SequenceArtificial peptide 47Gln Val Met Met Arg Gly Ser
1 5 487PRTArtificial SequenceArtificial peptide
48Asn Gly Arg Gly Ser Gly Trp 1 5
497PRTArtificial SequenceArtificial peptide 49Arg Ala Val Gly Arg Val Ala
1 5 507PRTArtificial SequenceArtificial peptide
50Arg Ala Ser Cys Ala Leu Thr 1 5
517PRTArtificial SequenceArtificial peptide 51Ala Asp Ile Gly Ala Gly Gly
1 5 527PRTArtificial SequenceArtificial peptide
52Phe Met Gly Ala Gly Phe Ala 1 5
537PRTArtificial SequenceArtificial peptide 53Ala Gly Val Phe Ala Val Ser
1 5 547PRTArtificial SequenceArtificial peptide
54Val Met Leu Leu Arg Pro Glu 1 5
557PRTArtificial SequenceArtificial peptide 55Leu Leu Arg Gly Leu Glu Leu
1 5 567PRTArtificial SequenceArtificial peptide
56Leu Pro Leu Leu Arg Gly Ile 1 5
577PRTArtificial SequenceArtificial peptide 57Asp Pro Arg Gly Leu Arg Val
1 5 587PRTArtificial SequenceArtificial peptide
58Leu Val Arg Val Ser Gly Arg 1 5
597PRTArtificial SequenceArtificial peptide 59Ser Gly Ser Arg Val Ser Leu
1 5 607PRTArtificial SequenceArtificial peptide
60Ala Gly Ser Ile Ala Leu Arg 1 5
617PRTArtificial SequenceArtificial peptide 61Met Leu Ala Ser Ala Gly Arg
1 5 627PRTArtificial SequenceArtificial peptide
62Ala Asp Ile Gly Ala Gly Gly 1 5
637PRTArtificial SequenceArtificial peptide 63Phe Ala Gly Gly Ser Thr Asp
1 5 647PRTArtificial SequenceArtificial peptide
64Thr Gly Phe Gly Ala Val Gly 1 5
657PRTArtificial SequenceArtificial peptide 65Phe Gly Leu Arg Asn Ser Arg
1 5 667PRTArtificial SequenceArtificial peptide
66Asp Pro Arg Gly Leu Arg Val 1 5
677PRTArtificial SequenceArtificial peptide 67Leu Val Ser Ser Gly Ser Lys
1 5 687PRTArtificial SequenceArtificial peptide
68Leu Val Ser Ser Ser Glu Pro 1 5
697PRTArtificial SequenceArtificial peptide 69Ala Ala Val Trp Ala Ala Asp
1 5 707PRTArtificial SequenceArtificial peptide
70Phe Ala Gly Gly Ser Thr Asp 1 5
717PRTArtificial SequenceArtificial peptide 71Thr Phe Gly Lys Gly Gly Leu
1 5 727PRTArtificial SequenceArtificial peptide
72Lys Ser Gly Ser Ser Val Leu 1 5
737PRTArtificial SequenceArtificial peptide 73Trp Gly Ser Gly Arg Gly Asn
1 5 747PRTArtificial SequenceArtificial peptide
74Arg Gly Ser Val Arg Val Leu 1 5
757PRTArtificial SequenceArtificial peptide 75Pro Val Arg Gly Ser Val Asp
1 5 767PRTArtificial SequenceArtificial peptide
76Thr Glu Gly Ser Val Thr Val 1 5
777PRTArtificial SequenceArtificial peptide 77Arg Ala Val Gly Arg Val Ala
1 5 787PRTArtificial SequenceArtificial peptide
78Asp Val Ser Gly Arg Val Pro 1 5
797PRTArtificial SequenceArtificial peptide 79Leu Gly Gln Cys Gly Arg Val
1 5 807PRTArtificial SequenceArtificial peptide
80Gly Arg Leu Arg Leu Thr Asp 1 5
817PRTArtificial SequenceArtificial peptide 81Leu Glu Leu Gly Arg Leu Leu
1 5 827PRTArtificial SequenceArtificial peptide
82Ile Gly Arg Leu Leu Pro Leu 1 5
837PRTArtificial SequenceArtificial peptide 83Ser Asp Glu Asn Gly Arg Leu
1 5 847PRTArtificial SequenceArtificial peptide
84Glu Leu His Pro Arg Gly Val 1 5
857PRTArtificial SequenceArtificial peptide 85Phe Asp Arg Gly Val Glu Ala
1 5 867PRTArtificial SequenceArtificial peptide
86Glu Ala Val Ser Arg Gly Ser 1 5
877PRTArtificial SequenceArtificial peptide 87Trp Thr Lys Arg Gly Ser Val
1 5 887PRTArtificial SequenceArtificial peptide
88Glu Arg Ala Ser Gln Thr Ala 1 5
897PRTArtificial SequenceArtificial peptide 89Glu Ala Val Ser Arg Gly Ser
1 5 907PRTArtificial SequenceArtificial peptide
90Ala Ala Thr Leu Leu Ser Phe 1 5
917PRTArtificial SequenceArtificial peptide 91Leu Leu Ser Ala Ser Leu Val
1 5 927PRTArtificial SequenceArtificial peptide
92Arg Arg His Gly Leu Leu Ser 1 5
937PRTArtificial SequenceSynthetic peptide 93Arg Tyr Ser Thr Leu Leu Arg
1 5 947PRTArtificial SequenceSynthetic peptide
94Phe Thr Leu Arg Val Asp Lys 1 5
957PRTArtificial SequenceSynthetic peptide 95Ser His Arg Val Ser Asp Ser
1 5 967PRTArtificial SequenceSynthetic peptide
96Asn Arg Ser Ser Ala Lys Phe 1 5
977PRTArtificial SequenceSynthetic peptide 97Leu Arg Arg Ser Ser Phe Ser
1 5 987PRTArtificial SequenceSynthetic peptide
98Ala Ile Arg Ala Gly Ser Asp 1 5
997PRTArtificial SequenceSynthetic peptide 99Val Leu Phe Ser Ala Gly Ser
1 5 1007PRTArtificial SequenceSynthetic peptide
100Gly Val Leu His Ser Ile Ala 1 5
1017PRTArtificial SequenceSynthetic peptide 101Arg Gln Thr Thr Gly Ala
Val 1 5 1027PRTArtificial SequenceSynthetic
peptide 102Cys Gln Gly Leu Val Leu Gln 1 5
1037PRTArtificial SequenceSynthetic peptide 103Pro Pro Pro Trp Gly Leu
Arg 1 5 1047PRTArtificial SequenceSynthetic
peptide 104Ser Asn Ala Arg Gly Pro Arg 1 5
1057PRTArtificial SequenceSynthetic peptide 105Leu Leu Ser Ala Ser Leu
Val 1 5 1067PRTArtificial SequenceSynthetic
peptide 106Ala Ala Val Phe Val Arg Ser 1 5
1077PRTArtificial SequenceSynthetic peptide 107Phe Phe Gly Gly Ser Arg
Ala 1 5 1087PRTArtificial SequenceSynthetic
peptide 108Gly Gly Ser Gln Cys Asp Thr 1 5
1097PRTArtificial SequenceSynthetic peptide 109Val Trp Gly Val Gly Gly
Ser 1 5 1107PRTArtificial SequenceSynthetic
peptide 110Phe Ala Trp Gly Gly Arg Gly 1 5
1117PRTArtificial SequenceSynthetic peptide 111Gly Leu Gly Ile Met Gly
Pro 1 5 1127PRTArtificial SequenceSynthetic
peptide 112Ser Ser Gly Ser Ser Asn Gly 1 5
1137PRTArtificial SequenceSynthetic peptide 113Trp Thr Lys Arg Gly Ser
Val 1 5 1147PRTArtificial SequenceSynthetic
peptide 114Gly Val Ser Thr Gly Phe Thr 1 5
1157PRTArtificial SequenceSynthetic peptide 115Cys His Ala Arg Gly Val
Thr 1 5 1167PRTArtificial SequenceSynthetic
peptide 116Trp Gly Arg Gly Ser Val Ala 1 5
1177PRTArtificial SequenceSynthetic peptide 117Leu Arg Ser Gly Ala Gly
Ser 1 5 1187PRTArtificial SequenceSynthetic
peptide 118Arg Ala Ala Val Ser Ala Ile 1 5
1197PRTArtificial SequenceSynthetic peptide 119Ala Val Ser Gly Arg Gly
Trp 1 5 1207PRTArtificial SequenceSynthetic
peptide 120Leu Leu Ser Phe Leu Gly Arg 1 5
1217PRTArtificial SequenceSynthetic peptide 121Gly Phe Tyr Trp Leu Arg
Ser 1 5 1227PRTArtificial SequenceSynthetic
peptide 122Arg Gly Ala Arg Val Ser Ala 1 5
1237PRTArtificial SequenceSynthetic peptide 123Gly Gly Arg Ser Ser His
Pro 1 5 1247PRTArtificial SequenceSynthetic
peptide 124Arg Ser Ser Ile Ala Pro Ser 1 5
1257PRTArtificial SequenceSynthetic peptide 125Leu Ala Gly Ser Gly Ser
His 1 5 1267PRTArtificial SequenceSynthetic
peptide 126Leu Arg Ser Gly Ala Gly Ser 1 5
1277PRTArtificial SequenceSynthetic peptide 127Ala Ser Val Arg Ala Gly
Arg 1 5 1287PRTArtificial SequenceSynthetic
peptide 128Ile Gly Val Arg Gly Phe Phe 1 5
1297PRTArtificial SequenceSynthetic peptide 129Ala Asn Gly Val Leu Glu
Leu 1 5 1307PRTArtificial SequenceSynthetic
peptide 130Trp Phe Gly Ala Val Gly Leu 1 5
1317PRTArtificial SequenceSynthetic peptide 131Gly Leu Val Arg Gly Thr
Ala 1 5 1327PRTArtificial SequenceSynthetic
peptide 132Glu Gly Leu Val Ser Val Val 1 5
1337PRTArtificial SequenceSynthetic peptide 133Asp Leu Gly Leu Arg Pro
Val 1 5 1347PRTArtificial SequenceSynthetic
peptide 134Ala Leu Val Ser Arg Arg Gly 1 5
1357PRTArtificial SequenceSynthetic peptide 135Glu Val Leu Val Ser Gly
Asp 1 5 1367PRTArtificial SequenceSynthetic
peptide 136Glu Gly Leu Val Ser Val Val 1 5
1377PRTArtificial SequenceSynthetic peptide 137Cys His Ala Arg Gly Val
Thr 1 5 1387PRTArtificial SequenceSynthetic
peptide 138Arg Ala Ala Val Ser Ala Ile 1 5
1397PRTArtificial SequenceSynthetic peptide 139His Arg Gly Gly Ser Gln
Ser 1 5 1407PRTArtificial SequenceSynthetic
peptide 140Gly Gly Arg Ser Ser His Pro 1 5
1417PRTArtificial SequenceSynthetic peptide 141Ser Gln Ser Gly Gly Arg
His 1 5 1427PRTArtificial SequenceSynthetic
peptide 142Ala Arg Ala Ile Gly Leu Gly 1 5
1437PRTArtificial SequenceSynthetic peptide 143Ser Thr Glu Gly Gly Gly
Leu 1 5 1447PRTArtificial SequenceSynthetic
peptide 144Leu Ala Gly Ser Gly Ser His 1 5
1457PRTArtificial SequenceSynthetic peptide 145Asp Gly Ser Val Leu Val
Glu 1 5 1467PRTArtificial SequenceSynthetic
peptide 146Trp Gly Arg Gly Ser Val Ala 1 5
1477PRTArtificial SequenceSynthetic peptide 147Ala Thr Gly Arg Val Leu
Gly 1 5 1487PRTArtificial SequenceSynthetic
peptide 148Ala Thr Gly Arg Val Leu Gly 1 5
1497PRTArtificial SequenceSynthetic peptide 149Phe Phe Gly Arg Val Gly
Ile 1 5 1507PRTArtificial SequenceSynthetic
peptide 150Arg Ile Gly Arg Val Trp Ala 1 5
1517PRTArtificial SequenceSynthetic peptide 151Arg Gly Arg Leu Glu Val
Pro 1 5 1527PRTArtificial SequenceSynthetic
peptide 152Arg Arg Leu Ser Tyr Arg Asp 1 5
1537PRTArtificial SequenceSynthetic peptide 153Ser Arg Leu Ser Tyr Arg
Gly 1 5 1547PRTArtificial SequenceSynthetic
peptide 154Phe Ser Ser Lys Arg Gly Val 1 5
1557PRTArtificial SequenceSynthetic peptide 155Arg Gly Ser Ala Gln Asn
Phe 1 5 1567PRTArtificial SequenceSynthetic
peptide 156Leu Arg Ser Gly Arg Gly Ser 1 5
1577PRTArtificial SequenceSynthetic peptide 157Tyr Arg Gly Ser Ser Gly
Lys 1 5 1587PRTArtificial SequenceSynthetic
peptide 158Phe Trp Ile Ser Arg Ala Ser 1 5
1597PRTArtificial SequenceSynthetic peptide 159Gly Ala Gly Ser Ile Ser
Asp 1 5 1607PRTArtificial SequenceSynthetic
peptide 160Arg Ala Met Gly Gly Ala Gly 1 5
1617PRTArtificial SequenceSynthetic peptide 161Leu Leu Ser Thr Ser Ile
Arg 1 5 1627PRTArtificial SequenceSynthetic
peptide 162Leu Leu Leu Arg Ser Gly Gly 1 5
1637PRTArtificial SequenceSynthetic peptide 163Leu Leu Arg Ser Ala Ala
Pro 1 5 1647PRTArtificial SequenceSynthetic
peptide 164Leu Leu Leu Arg Ser Gly Gly 1 5
1657PRTArtificial SequenceSynthetic peptide 165Gly Arg Tyr Ser Leu Arg
Ser 1 5 1667PRTArtificial SequenceSynthetic
peptide 166Leu Arg Ser Gly Arg Gly Ser 1 5
1677PRTArtificial SequenceSynthetic peptide 167Leu Arg Tyr Asp Leu Arg
Ser 1 5 1687PRTArtificial SequenceSynthetic
peptide 168Leu Arg Tyr Asn Leu Arg Ser 1 5
1697PRTArtificial SequenceSynthetic peptide 169Leu Leu Arg Ser Ala Ala
Pro 1 5 1707PRTArtificial SequenceSynthetic
peptide 170Ser Lys Tyr Arg Leu Arg Ser 1 5
1717PRTArtificial SequenceSynthetic peptide 171Val His Arg Val Ser Gly
Gly 1 5 1727PRTArtificial SequenceSynthetic
peptide 172Gly Ala Gly Ser Ile Ser Asp 1 5
1737PRTArtificial SequenceSynthetic peptide 173Phe Ala Gly Arg Val Pro
Ser 1 5 1747PRTArtificial SequenceSynthetic
peptide 174Ala Gly Leu Ser Gly Ser Gln 1 5
1757PRTArtificial SequenceSynthetic peptide 175Thr Asp Leu Ala Gly Leu
His 1 5 1767PRTArtificial SequenceSynthetic
peptide 176Leu Ala Ala Gly Gly Glu Leu 1 5
1777PRTArtificial SequenceSynthetic peptide 177Gly Ala Gly Gly Met Ala
Arg 1 5 1787PRTArtificial SequenceSynthetic
peptide 178Arg Ala Ala Gly Gly Ser Arg 1 5
1797PRTArtificial SequenceSynthetic peptide 179Leu Tyr Gly Val Arg Tyr
Gly 1 5 1807PRTArtificial SequenceSynthetic
peptide 180Pro Arg Tyr Gly Val Arg Ala 1 5
1817PRTArtificial SequenceSynthetic peptide 181Gly Ala Val Asp Gly Ser
Arg 1 5 1827PRTArtificial SequenceSynthetic
peptide 182Ala Asp Phe Phe Gly Leu Val 1 5
1837PRTArtificial SequenceSynthetic peptide 183Lys Tyr Tyr Gly Leu Arg
Arg 1 5 1847PRTArtificial SequenceSynthetic
peptide 184Ser Arg Tyr Gly Leu Arg Arg 1 5
1857PRTArtificial SequenceSynthetic peptide 185Pro Ala Ala Ser Arg Leu
Leu 1 5 1867PRTArtificial SequenceSynthetic
peptide 186Arg Leu Arg Ala Ala Ser Tyr 1 5
1877PRTArtificial SequenceSynthetic peptide 187Gly Gly Ser Arg Leu Leu
Leu 1 5 1887PRTArtificial SequenceSynthetic
peptide 188Arg Ala Ala Gly Gly Ser Arg 1 5
1897PRTArtificial SequenceSynthetic peptide 189Gly Gly Ser Val Arg His
Val 1 5 1907PRTArtificial SequenceSynthetic
peptide 190Gly Gly Arg Ser Trp Val Asn 1 5
1917PRTArtificial SequenceSynthetic peptide 191Gly Leu Gly Asn Arg Pro
Thr 1 5 1927PRTArtificial SequenceSynthetic
peptide 192His Gly Leu Gly Ser Gly Thr 1 5
1937PRTArtificial SequenceSynthetic peptide 193Gly Ser Ser Leu His Leu
Leu 1 5 1947PRTArtificial SequenceSynthetic
peptide 194Tyr Arg Gly Ser Ser Gly Lys 1 5
1957PRTArtificial SequenceSynthetic peptide 195Glu Gly Ser Gly Val Asp
Cys 1 5 1967PRTArtificial SequenceSynthetic
peptide 196His Gly Leu Gly Ser Gly Thr 1 5
1977PRTArtificial SequenceSynthetic peptide 197Ser Gly Ser Val Asn Arg
Gly 1 5 1987PRTArtificial SequenceSynthetic
peptide 198Gly Gly Ser Val Arg His Val 1 5
1997PRTArtificial SequenceSynthetic peptide 199Phe Ala Gly Arg Val Pro
Ser 1 5 2007PRTArtificial SequenceSynthetic
peptide 200Ala Met Arg Pro Gly Arg Leu 1 5
2017PRTArtificial SequenceSynthetic peptide 201Gly Arg Leu Tyr Tyr Tyr
Arg 1 5 2027PRTArtificial SequenceSynthetic
peptide 202Pro Ala Phe Gly Pro Ser Arg 1 5
2037PRTArtificial SequenceSynthetic peptide 203His Ser Gly Val Ser His
Gly 1 5 2047PRTArtificial SequenceSynthetic
peptide 204Val Tyr Tyr Arg Leu Ser Ala 1 5
2057PRTArtificial SequenceSynthetic peptide 205Gly Arg Gly Ser Phe Glu
Ser 1 5 2067PRTArtificial SequenceSynthetic
peptide 206Arg Arg Gly Ser Ser Arg Asn 1 5
2077PRTArtificial SequenceSynthetic peptide 207His Ser Arg Ala Val Ala
Pro 1 5 2087PRTArtificial SequenceSynthetic
peptide 208Arg Ala Ser Phe Arg Ala Gly 1 5
2097PRTArtificial SequenceSynthetic peptide 209Leu Met Gly Arg Ala Ser
Gly 1 5 2107PRTArtificial SequenceSynthetic
peptide 210Trp Arg Ala Ser Ala Phe Thr 1 5
2117PRTArtificial SequenceSynthetic peptide 211Gly Ala Gly Arg Thr Val
Met 1 5 2127PRTArtificial SequenceSynthetic
peptide 212Pro Leu Ala Val Ser Met Val 1 5
2137PRTArtificial SequenceSynthetic peptide 213Phe Leu Leu Arg Ser Ser
Phe 1 5 2147PRTArtificial SequenceSynthetic
peptide 214Trp Arg Leu Leu Arg Arg Gln 1 5
2157PRTArtificial SequenceSynthetic peptide 215Phe Leu Leu Arg Ser Ser
Phe 1 5 2167PRTArtificial SequenceSynthetic
peptide 216Leu Arg Ser Arg Leu Gly Phe 1 5
2177PRTArtificial SequenceSynthetic peptide 217Gly Arg Arg Val Ser Leu
Val 1 5 2187PRTArtificial SequenceSynthetic
peptide 218Phe Leu Leu Arg Ser Ser Phe 1 5
2197PRTArtificial SequenceSynthetic peptide 219Asn Arg Ser Ser Gly Arg
Arg 1 5 2207PRTArtificial SequenceSynthetic
peptide 220Val Leu Gly Met Arg Ser Ser 1 5
2217PRTArtificial SequenceSynthetic peptide 221Thr His Arg Asn Arg Ser
Ser 1 5 2227PRTArtificial SequenceSynthetic
peptide 222Leu Ala Gly Ser Thr Arg Arg 1 5
2237PRTArtificial SequenceSynthetic peptide 223Ala Gly Arg Thr Gly Val
Gly 1 5 2247PRTArtificial SequenceSynthetic
peptide 224Glu Phe Ala Val Ala Gly Arg 1 5
2257PRTArtificial SequenceSynthetic peptide 225Gly Ala Gly Arg Thr Val
Met 1 5 2267PRTArtificial SequenceSynthetic
peptide 226Arg Glu Glu Phe Ala Gly Arg 1 5
2277PRTArtificial SequenceSynthetic peptide 227Ala Gly Gly Pro Thr Lys
Tyr 1 5 2287PRTArtificial SequenceSynthetic
peptide 228Phe His Val Ala Gly Gly Ser 1 5
2297PRTArtificial SequenceSynthetic peptide 229Trp Ser Ala Gly Gly Pro
His 1 5 2307PRTArtificial SequenceSynthetic
peptide 230Arg Gly Ala Val Ala Phe Glu 1 5
2317PRTArtificial SequenceSynthetic peptide 231Ser Gly Gly Ala Val His
Phe 1 5 2327PRTArtificial SequenceSynthetic
peptide 232Gly Ala Val Arg Ala Arg Leu 1 5
2337PRTArtificial SequenceSynthetic peptide 233Gly Leu Val Arg Gly Phe
Pro 1 5 2347PRTArtificial SequenceSynthetic
peptide 234Gly Ala His Gly Leu Val Arg 1 5
2357PRTArtificial SequenceSynthetic peptide 235Ser Ser Arg Met Gly Leu
Val 1 5 2367PRTArtificial SequenceSynthetic
peptide 236Tyr Val Gly Leu Val Val Ser 1 5
2377PRTArtificial SequenceSynthetic peptide 237Gly Leu Arg Lys Ala Gly
Phe 1 5 2387PRTArtificial SequenceSynthetic
peptide 238Ala Val Asp Gly Leu Arg Leu 1 5
2397PRTArtificial SequenceSynthetic peptide 239Phe Gly Leu Arg Ser Arg
Leu 1 5 2407PRTArtificial SequenceSynthetic
peptide 240Glu Arg Ala Arg Gly Tyr Pro 1 5
2417PRTArtificial SequenceSynthetic peptide 241Gly Ser Ala Arg Gly Met
Leu 1 5 2427PRTArtificial SequenceSynthetic
peptide 242Ala Ser Leu Arg Tyr Tyr Val 1 5
2437PRTArtificial SequenceSynthetic peptide 243Asn Ala Ala Ser Leu Pro
Ser 1 5 2447PRTArtificial SequenceSynthetic
peptide 244Trp Leu Asp Ala Ser Leu Met 1 5
2457PRTArtificial SequenceSynthetic peptide 245Asn Ala Ala Ser Leu Pro
Ser 1 5 2467PRTArtificial SequenceSynthetic
peptide 246Phe His Val Ala Gly Gly Ser 1 5
2477PRTArtificial SequenceSynthetic peptide 247Gly Glu His Leu Gly Gly
Ser 1 5 2487PRTArtificial SequenceSynthetic
peptide 248Ser Gly Gly Leu His Glu Gly 1 5
2497PRTArtificial SequenceSynthetic peptide 249Ser Arg Leu Ser Tyr Arg
Ser 1 5 2507PRTArtificial SequenceSynthetic
peptide 250Gly Gly Leu Arg Gly Val Arg 1 5
2517PRTArtificial SequenceSynthetic peptide 251Val Ala Trp Arg Gly Val
Ser 1 5 2527PRTArtificial SequenceSynthetic
peptide 252Ser Val Glu Gly Arg Gly Val 1 5
2537PRTArtificial SequenceSynthetic peptide 253Phe Trp Arg Gly Ser Val
Pro 1 5 2547PRTArtificial SequenceSynthetic
peptide 254Glu Phe Thr Arg Arg Ala Ser 1 5
2557PRTArtificial SequenceSynthetic peptide 255Trp Gly Trp Arg Ala Ser
Ser 1 5 2567PRTArtificial SequenceSynthetic
peptide 256Arg Phe Tyr His Leu Arg Ser 1 5
2577PRTArtificial SequenceSynthetic peptide 257Ser Arg Tyr Ser Leu Arg
Ser 1 5 2587PRTArtificial SequenceSynthetic
peptide 258Arg Arg Ser Ser Lys Gln Ala 1 5
2597PRTArtificial SequenceSynthetic peptide 259Asp Trp Gly Arg Ser Ser
Phe 1 5 2607PRTArtificial SequenceSynthetic
peptide 260Arg Phe Thr Arg Ser Ser Gly 1 5
2617PRTArtificial SequenceSynthetic peptide 261Val Phe Gln Arg Ser Ser
Gly 1 5 2627PRTArtificial SequenceSynthetic
peptide 262Ala Gly Ser Gln Ser Trp Glu 1 5
2637PRTArtificial SequenceSynthetic peptide 263Glu His Pro Ala Gly Gly
Met 1 5 2647PRTArtificial SequenceSynthetic
peptide 264Gly Val Arg Thr Ala Gly Pro 1 5
2657PRTArtificial SequenceSynthetic peptide 265Gly Gly Leu Arg Gly Val
Arg 1 5 2667PRTArtificial SequenceSynthetic
peptide 266Leu Tyr Gly Gly Val Arg Tyr 1 5
2677PRTArtificial SequenceSynthetic peptide 267Pro Val Gly Gly Val Leu
Leu 1 5 2687PRTArtificial SequenceSynthetic
peptide 268Gly Ala Val Val Lys Pro Ile 1 5
2697PRTArtificial SequenceSynthetic peptide 269Ser Val Gly Ala Val Gly
Gly 1 5 2707PRTArtificial SequenceSynthetic
peptide 270Gly Leu Val Ser Val Glu Ala 1 5
2717PRTArtificial SequenceSynthetic peptide 271Gly Gly Leu Arg Gly Val
Arg 1 5 2727PRTArtificial SequenceSynthetic
peptide 272Asp Ile Ala Leu Val Ser Pro 1 5
2737PRTArtificial SequenceSynthetic peptide 273Gly Leu Val Ser Val Glu
Ala 1 5 2747PRTArtificial SequenceSynthetic
peptide 274Ala Arg Asn Ala Ala Ser Pro 1 5
2757PRTArtificial SequenceSynthetic peptide 275Ala Glu Gly Gly Ser Gly
His 1 5 2767PRTArtificial SequenceSynthetic
peptide 276Gly Gly Ser Phe Ser Gly Leu 1 5
2777PRTArtificial SequenceSynthetic peptide 277Val Thr Gly Gly Arg Val
Asp 1 5 2787PRTArtificial SequenceSynthetic
peptide 278Gly Gly Leu Arg Gly Val Arg 1 5
2797PRTArtificial SequenceSynthetic peptide 279Gly Ser Ser Trp Val Val
Asp 1 5 2807PRTArtificial SequenceSynthetic
peptide 280Gly Ser Ser Arg Thr Phe Arg 1 5
2817PRTArtificial SequenceSynthetic peptide 281Gly Ser Ser Arg Gln Phe
Val 1 5 2827PRTArtificial SequenceSynthetic
peptide 282Trp Val Gly Ser Ser Lys Phe 1 5
2837PRTArtificial SequenceSynthetic peptide 283Ala Glu Gly Gly Ser Gly
His 1 5 2847PRTArtificial SequenceSynthetic
peptide 284Glu Val Ile Gly Ser Gly Ile 1 5
2857PRTArtificial SequenceSynthetic peptide 285Phe Trp Arg Gly Ser Val
Pro 1 5 2867PRTArtificial SequenceSynthetic
peptide 286Val Gly Ser Val Ser Val Asn 1 5
2877PRTArtificial SequenceSynthetic peptide 287Val Thr Gly Gly Arg Val
Asp 1 5 2887PRTArtificial SequenceSynthetic
peptide 288Gly Arg Val Thr Val Ala Val 1 5
2897PRTArtificial SequenceSynthetic peptide 289Arg Val Gly Arg Leu Gly
Gly 1 5 2907PRTArtificial SequenceSynthetic
peptide 290Asn Tyr Met Gly Pro Ser Ala 1 5
2917PRTArtificial SequenceSynthetic peptide 291Gly Trp His Gly Pro Ser
His 1 5 2927PRTArtificial SequenceSynthetic
peptide 292Gly Gly Val Ser Pro Val Asp 1 5
2937PRTArtificial SequenceSynthetic peptide 293Gly Val Ser Lys Val Arg
Ala 1 5 2947PRTArtificial SequenceSynthetic
peptide 294Gly Gly Val Ala Gly Val Ser 1 5
2957PRTArtificial SequenceSynthetic peptide 295Val Ala Trp Arg Gly Val
Ser 1 5 2967PRTArtificial SequenceSynthetic
peptide 296Val Ile Gly Ser Arg Leu Ser 1 5
2977PRTArtificial SequenceSynthetic peptide 297His Leu Arg Gly Arg Gly
Val 1 5 2987PRTArtificial SequenceSynthetic
peptide 298Glu Val Arg Ser Arg Gly Ser 1 5
2997PRTArtificial SequenceSynthetic peptide 299Arg Gly Ser Arg Leu Pro
Ala 1 5 3007PRTArtificial SequenceSynthetic
peptide 300Asp Val Arg Ala Val Ser Ser 1 5
3017PRTArtificial SequenceSynthetic peptide 301Asp Val Arg Ala Val Ser
Ser 1 5 3027PRTArtificial SequenceSynthetic
peptide 302Ala Pro Leu Arg Ser Gly Arg 1 5
3037PRTArtificial SequenceSynthetic peptide 303Ser Leu Arg Ser Gly Ile
Val 1 5 3047PRTArtificial SequenceSynthetic
peptide 304Asp Gly Gly Arg Arg Ser Ser 1 5
3057PRTArtificial SequenceSynthetic peptide 305Gln Ala Gly Ser Phe Leu
Arg 1 5 3067PRTArtificial SequenceSynthetic
peptide 306Asp Ala Gly Ser Asp Arg Arg 1 5
3077PRTArtificial SequenceSynthetic peptide 307Ala Gly Arg Arg Phe Gly
Gly 1 5 3087PRTArtificial SequenceSynthetic
peptide 308Ala Gly Leu Ser Gly Gly Thr 1 5
3097PRTArtificial SequenceSynthetic peptide 309Ala Gly Gly Gly Pro Pro
Ala 1 5 3107PRTArtificial SequenceSynthetic
peptide 310Ala Gly Gly Gly Pro Pro Ala 1 5
3117PRTArtificial SequenceSynthetic peptide 311Phe Phe Pro Ala Gly Gly
Pro 1 5 3127PRTArtificial SequenceSynthetic
peptide 312Pro Arg Ala Gly Gly Arg Trp 1 5
3137PRTArtificial SequenceSynthetic peptide 313Asp Val Pro Gly Val Arg
Phe 1 5 3147PRTArtificial SequenceSynthetic
peptide 314Phe Gly Val Leu Phe Arg Ser 1 5
3157PRTArtificial SequenceSynthetic peptide 315Ser Arg Tyr Gly Val Leu
Val 1 5 3167PRTArtificial SequenceSynthetic
peptide 316Leu Arg Gly Gly Leu Val Ser 1 5
3177PRTArtificial SequenceSynthetic peptide 317Lys Ser Gly Leu Arg Pro
Ala 1 5 3187PRTArtificial SequenceSynthetic
peptide 318Ala Leu Val Ser Phe Ser Val 1 5
3197PRTArtificial SequenceSynthetic peptide 319Leu Arg Gly Gly Leu Val
Ser 1 5 3207PRTArtificial SequenceSynthetic
peptide 320His Lys Leu Ala Arg Gly Arg 1 5
3217PRTArtificial SequenceSynthetic peptide 321Ala Ser Leu Pro Pro Arg
Ala 1 5 3227PRTArtificial SequenceSynthetic
peptide 322Thr Gly Gly Ser Leu Gly Ala 1 5
3237PRTArtificial SequenceSynthetic peptide 323Gly Gly Gly Ser Trp Leu
Ile 1 5 3247PRTArtificial SequenceSynthetic
peptide 324Asp Gly Gly Arg Arg Ser Ser 1 5
3257PRTArtificial SequenceSynthetic peptide 325Ser Val Leu Gly Gly Arg
Leu 1 5 3267PRTArtificial SequenceSynthetic
peptide 326Pro Arg Ala Gly Gly Arg Trp 1 5
3277PRTArtificial SequenceSynthetic peptide 327Tyr Trp Phe Ile Gly Leu
Gly 1 5 3287PRTArtificial SequenceSynthetic
peptide 328Gly Gly Leu Ser Val Asp Leu 1 5
3297PRTArtificial SequenceSynthetic peptide 329Leu Arg Gly Gly Leu Val
Ser 1 5 3307PRTArtificial SequenceSynthetic
peptide 330Ser Gly Val Gly Ser Ser Leu 1 5
3317PRTArtificial SequenceSynthetic peptide 331Gly Ser Gly Ile Leu Asp
Leu 1 5 3327PRTArtificial SequenceSynthetic
peptide 332Ser Leu Gly Ser Val Gly Ser 1 5
3337PRTArtificial SequenceSynthetic peptide 333Val Gly Arg Gly Arg Leu
His 1 5 3347PRTArtificial SequenceSynthetic
peptide 334Ser Val Leu Gly Gly Arg Leu 1 5
3357PRTArtificial SequenceSynthetic peptide 335Met Ser Ala Phe Gly Arg
Leu 1 5 3367PRTArtificial SequenceSynthetic
peptide 336Ser Gly Val Ser Gly Leu Ser 1 5
3377PRTArtificial SequenceSynthetic peptide 337Gly Asp Ser Arg Arg Gly
Val 1 5 3387PRTArtificial SequenceSynthetic
peptide 338Gly Lys Ala Leu Arg Gly Val 1 5
3397PRTArtificial SequenceSynthetic peptide 339Pro Lys Ala Gly Arg Gly
Ser 1 5 3407PRTArtificial SequenceSynthetic
peptide 340Phe Asp Arg Ala Val Ala Asn 1 5
3417PRTArtificial SequenceSynthetic peptide 341Leu Leu Arg Arg Ala Val
Phe 1 5 3427PRTArtificial SequenceSynthetic
peptide 342Phe Arg Ala Ser Ser Glu Val 1 5
3437PRTArtificial SequenceSynthetic peptide 343Pro Asp Arg Ala Ser Asp
Gly 1 5 3447PRTArtificial SequenceSynthetic
peptide 344Phe Arg Ala Ser Leu Gln Tyr 1 5
3457PRTArtificial SequenceSynthetic peptide 345His Val Gly Leu Leu Arg
Ala 1 5 3467PRTArtificial SequenceSynthetic
peptide 346Gln Val Leu Leu Arg Ser Phe 1 5
3477PRTArtificial SequenceSynthetic peptide 347Leu Leu Arg Arg Ala Val
Phe 1 5 3487PRTArtificial SequenceSynthetic
peptide 348Phe Leu Arg Val Gly Glu Leu 1 5
3497PRTArtificial SequenceSynthetic peptide 349Gln Val Leu Leu Arg Ser
Phe 1 5 3507PRTArtificial SequenceSynthetic
peptide 350Arg Arg Val Ser Cys Asp Leu 1 5
3517PRTArtificial SequenceSynthetic peptide 351Arg Ser Ser Gly Leu Gly
Phe 1 5 3527PRTArtificial SequenceSynthetic
peptide 352Ser Ser Gly Pro Arg Ser Ser 1 5
3537PRTArtificial SequenceSynthetic peptide 353Tyr Ser Gln Arg Ser Ser
Leu 1 5 3547PRTArtificial SequenceSynthetic
peptide 354Asp Ala Gly Arg Thr Ile Asp 1 5
3557PRTArtificial SequenceSynthetic peptide 355Ala Ala Gly Arg Glu Phe
Arg 1 5 3567PRTArtificial SequenceSynthetic
peptide 356Pro Lys Ala Gly Arg Gly Ser 1 5
3577PRTArtificial SequenceSynthetic peptide 357Val Arg Ala Ala Gly Arg
Val 1 5 3587PRTArtificial SequenceSynthetic
peptide 358His Gly Tyr Arg Ala Gly Gly 1 5
3597PRTArtificial SequenceSynthetic peptide 359Trp Gly Ala Thr Ala Gly
Gly 1 5 3607PRTArtificial SequenceSynthetic
peptide 360Tyr Tyr Ala Gly Gly Leu Lys 1 5
3617PRTArtificial SequenceSynthetic peptide 361Leu Glu Gly Val Arg Leu
Phe 1 5 3627PRTArtificial SequenceSynthetic
peptide 362Gly Thr Phe Gly Val Leu Gly 1 5
3637PRTArtificial SequenceSynthetic peptide 363Gly Thr Phe Gly Val Leu
Gly 1 5 3647PRTArtificial SequenceSynthetic
peptide 364Val Trp Ala Gly Val Leu Leu 1 5
3657PRTArtificial SequenceSynthetic peptide 365Gly Ala Val Leu Phe Arg
Val 1 5 3667PRTArtificial SequenceSynthetic
peptide 366Gly Leu Val Gly Phe Thr Gly 1 5
3677PRTArtificial SequenceSynthetic peptide 367Gly Leu Val Ser Ala Phe
Tyr 1 5 3687PRTArtificial SequenceSynthetic
peptide 368Ala Arg Ala Met Gly Leu Arg 1 5
3697PRTArtificial SequenceSynthetic peptide 369Gly Leu Val Ser Ala Phe
Tyr 1 5 3707PRTArtificial SequenceSynthetic
peptide 370Ser Trp Arg Pro Leu Val Ser 1 5
3717PRTArtificial SequenceSynthetic peptide 371Phe Arg Ala Ser Leu Gln
Tyr 1 5 3727PRTArtificial SequenceSynthetic
peptide 372His Ser Glu Ser Ala Ala Val 1 5
3737PRTArtificial SequenceSynthetic peptide 373Leu Phe Ala Val Ala Ala
Val 1 5 3747PRTArtificial SequenceSynthetic
peptide 374Val Ala Ala Ser Glu Ser His 1 5
3757PRTArtificial SequenceSynthetic peptide 375His Pro Ser Met Gly Gly
Arg 1 5 3767PRTArtificial SequenceSynthetic
peptide 376Gly Leu Gly Val Ser Gly Val 1 5
3777PRTArtificial SequenceSynthetic peptide 377Lys Arg Glu Ser Gly Leu
Gly 1 5 3787PRTArtificial SequenceSynthetic
peptide 378Arg Ser Ser Gly Leu Gly Phe 1 5
3797PRTArtificial SequenceSynthetic peptide 379Val Gly Leu Gly His Trp
Pro 1 5 3807PRTArtificial SequenceSynthetic
peptide 380Tyr Tyr Ala Gly Gly Leu Lys 1 5
3817PRTArtificial SequenceSynthetic peptide 381Asn Tyr Gly Ser Ser Phe
His 1 5 3827PRTArtificial SequenceSynthetic
peptide 382Phe Gly Leu Gly Ser Ser Arg 1 5
3837PRTArtificial SequenceSynthetic peptide 383Ser Ser Arg Pro Gly Ser
Ser 1 5 3847PRTArtificial SequenceSynthetic
peptide 384Val Gly Ser Val Gly Leu Gly 1 5
3857PRTArtificial SequenceSynthetic peptide 385Val Arg Ala Ala Gly Arg
Val 1 5 3867PRTArtificial SequenceSynthetic
peptide 386His Asn Gly Arg Leu Glu Val 1 5
3877PRTArtificial SequenceSynthetic peptide 387Val Gly Arg Leu Ala Lys
Gly 1 5 3887PRTArtificial SequenceSynthetic
peptide 388Val Met Gly Gly Pro Ser Leu 1 5
3897PRTArtificial SequenceSynthetic peptide 389Gly Leu Gly Val Ser Gly
Val 1 5 3907PRTArtificial SequenceSynthetic
peptide 390Ser Gly Val Ser Val Glu Gly 1 5
3917PRTArtificial SequenceSynthetic peptide 391Gly Glu Ser Gly Arg Leu
Ser 1 5 3927PRTArtificial SequenceSynthetic
peptide 392Gly Ser Gly Arg Gly Val Ala 1 5
3937PRTArtificial SequenceSynthetic peptide 393Arg Gly Val Val Ser Ala
Lys 1 5 3947PRTArtificial SequenceSynthetic
peptide 394Arg Gly Val Val Ser Gly Val 1 5
3957PRTArtificial SequenceSynthetic peptide 395Ala Val Gly Arg Gly Ser
Gly 1 5 3967PRTArtificial SequenceSynthetic
peptide 396Ser Leu Arg Gly Ser Glu Gly 1 5
3977PRTArtificial SequenceSynthetic peptide 397Pro Ala Thr Arg Gly Ser
Val 1 5 3987PRTArtificial SequenceSynthetic
peptide 398Ser Leu Thr Arg Ala Val Arg 1 5
3997PRTArtificial SequenceSynthetic peptide 399Val Ala Arg Ala Val Pro
Cys 1 5 4007PRTArtificial SequenceSynthetic
peptide 400Glu Gly Ala Arg Ala Ser Asp 1 5
4017PRTArtificial SequenceSynthetic peptide 401Met Gly Ser Ala Val Ser
Leu 1 5 4027PRTArtificial SequenceSynthetic
peptide 402Gly Gly Ala Leu Leu Arg Gly 1 5
4037PRTArtificial SequenceSynthetic peptide 403Pro Asn Arg Arg Val Ser
Ala 1 5 4047PRTArtificial SequenceSynthetic
peptide 404Gln Asp Arg Val Ser Arg Ser 1 5
4057PRTArtificial SequenceSynthetic peptide 405Ser Glu Arg Ser Ser Leu
Gly 1 5 4067PRTArtificial SequenceSynthetic
peptide 406Leu Val Arg Ser Ser Gly Leu 1 5
4077PRTArtificial SequenceSynthetic peptide 407Ile Asn Trp Ala Gly Leu
Ser 1 5 4087PRTArtificial SequenceSynthetic
peptide 408Trp Ala Gly Leu Ser Pro Ser 1 5
4097PRTArtificial SequenceSynthetic peptide 409Gly Arg Leu Leu Ala Gly
Gly 1 5 4107PRTArtificial SequenceSynthetic
peptide 410Ser Tyr Gly Leu Val Leu Pro 1 5
4117PRTArtificial SequenceSynthetic peptide 411Ser Gly Gly Leu Val Leu
Thr 1 5 4127PRTArtificial SequenceSynthetic
peptide 412His Ala Ala His Gly Leu Val 1 5
4137PRTArtificial SequenceSynthetic peptide 413Gly Leu Arg Thr Arg Gln
Val 1 5 4147PRTArtificial SequenceSynthetic
peptide 414Leu Val Ser Gly Tyr Asn Gly 1 5
4157PRTArtificial SequenceSynthetic peptide 415Ala Gly Ile Ala Arg Gly
Gly 1 5 4167PRTArtificial SequenceSynthetic
peptide 416His Val Ser Gly Gly Ser Gly 1 5
4177PRTArtificial SequenceSynthetic peptide 417Gly Gly Ser Ser Glu Phe
Arg 1 5 4187PRTArtificial SequenceSynthetic
peptide 418Gly Gly Ser Gly Ile Gly Ser 1 5
4197PRTArtificial SequenceSynthetic peptide 419Ser Trp Gly Ser Gly Gly
Ser 1 5 4207PRTArtificial SequenceSynthetic
peptide 420Thr Leu Val Leu Gly Gly Ser 1 5
4217PRTArtificial SequenceSynthetic peptide 421Ala Val Arg Gly Gly Arg
Pro 1 5 4227PRTArtificial SequenceSynthetic
peptide 422Gly Gly Arg Ala Ile Gly Ala 1 5
4237PRTArtificial SequenceSynthetic peptide 423Ser Gly Gly Leu Val Leu
Thr 1 5 4247PRTArtificial SequenceSynthetic
peptide 424Arg Thr Gly Ser Ser Asp Leu 1 5
4257PRTArtificial SequenceSynthetic peptide 425Leu Gly Ser Ser Arg Val
Leu 1 5 4267PRTArtificial SequenceSynthetic
peptide 426Gly Gly Ser Ser Glu Phe Arg 1 5
4277PRTArtificial SequenceSynthetic peptide 427Ala Val Gly Arg Gly Ser
Gly 1 5 4287PRTArtificial SequenceSynthetic
peptide 428His Val Ser Gly Gly Ser Gly 1 5
4297PRTArtificial SequenceSynthetic peptide 429Ser Gly Ile Gly Ser Gly
Gly 1 5 4307PRTArtificial SequenceSynthetic
peptide 430Ser Trp Gly Ser Gly Gly Ser 1 5
4317PRTArtificial SequenceSynthetic peptide 431Trp Val Gly Ser Gly Ser
Pro 1 5 4327PRTArtificial SequenceSynthetic
peptide 432Gly Ser Gly Gly Ser Val His 1 5
4337PRTArtificial SequenceSynthetic peptide 433Gly Asn Tyr Gly Ser Val
Leu 1 5 4347PRTArtificial SequenceSynthetic
peptide 434Val Gly Ser Val Val Gly Arg 1 5
4357PRTArtificial SequenceSynthetic peptide 435Pro Ala Thr Arg Gly Ser
Val 1 5 4367PRTArtificial SequenceSynthetic
peptide 436Pro Arg Gly Gly Arg Val Ala 1 5
4377PRTArtificial SequenceSynthetic peptide 437Gly Arg Val His Leu Met
Pro 1 5 4387PRTArtificial SequenceSynthetic
peptide 438Gly Glu Ser Gly Arg Leu Ser 1 5
4397PRTArtificial SequenceSynthetic peptide 439Gly Arg Leu Leu Ala Gly
Gly 1 5 4407PRTArtificial SequenceSynthetic
peptide 440Gly Arg Leu Trp Trp His Thr 1 5
4417PRTArtificial SequenceSynthetic peptide 441Gly Arg Leu Trp Ser Arg
Val 1 5 4427PRTArtificial SequenceSynthetic
peptide 442Ala Gly Pro Ser Ala Trp Leu 1 5
4437PRTArtificial SequenceSynthetic peptide 443Ser Gly Val Ser Arg Gly
Gln 1 5 4447PRTArtificial SequenceSynthetic
peptide 444Arg Gly Val Ser Leu Lys Gly 1 5
4457PRTArtificial SequenceSynthetic peptide 445Gln Met Gln Gly Arg Ala
Val 1 5 4467PRTArtificial SequenceSynthetic
peptide 446Arg Gly Leu Arg Ser Val Asn 1 5
4477PRTArtificial SequenceSynthetic peptide 447Arg Ser Ser Leu Gly Leu
Pro 1 5 4487PRTArtificial SequenceSynthetic
peptide 448Leu Glu Ala Gly Ser Gln Leu 1 5
4497PRTArtificial SequenceSynthetic peptide 449Ala Gly Gly Gln Ser Glu
Arg 1 5 4507PRTArtificial SequenceSynthetic
peptide 450Gly Gly Val Leu Tyr Leu Glu 1 5
4517PRTArtificial SequenceSynthetic peptide 451Arg Gly Leu Arg Ser Val
Asn 1 5 4527PRTArtificial SequenceSynthetic
peptide 452Val Ala Arg Gly Gln Met Gln 1 5
4537PRTArtificial SequenceSynthetic peptide 453Gly Gly Ser Arg Asn Arg
Trp 1 5 4547PRTArtificial SequenceSynthetic
peptide 454Gly Gly Gly Arg Ser Gly Val 1 5
4557PRTArtificial SequenceSynthetic peptide 455Gly Leu Gly Gly Trp Val
Ala 1 5 4567PRTArtificial SequenceSynthetic
peptide 456Ala Val Trp Gly Gly Leu Gly 1 5
4577PRTArtificial SequenceSynthetic peptide 457Gly Gly Leu Ser Glu Cys
Val 1 5 4587PRTArtificial SequenceSynthetic
peptide 458Ala Lys Leu Gly Ser Val Tyr 1 5
4597PRTArtificial SequenceSynthetic peptide 459Gln Gly Arg Val Asn Val
Lys 1 5 4607PRTArtificial SequenceSynthetic
peptide 460Gly Arg Leu Trp Gly Phe Trp 1 5
4617PRTArtificial SequenceSynthetic peptide 461Arg Gly Val Ser Leu Lys
Gly 1 5 4627PRTArtificial SequenceSynthetic
peptide 462Gly Ser Leu Gly Val Ser Leu 1 5
4637PRTArtificial SequenceSynthetic peptide 463Leu Leu Arg Leu Ser Leu
Ala 1 5 4647PRTArtificial SequenceSynthetic
peptide 464Arg Arg Gly Ser Gly Gly Leu 1 5
4657PRTArtificial SequenceSynthetic peptide 465Val Arg Gly Ser Val Arg
Ala 1 5 4667PRTArtificial SequenceSynthetic
peptide 466Leu Leu Arg Leu Ser Leu Ala 1 5
4677PRTArtificial SequenceSynthetic peptide 467Pro Leu Arg Val Asp Asn
Leu 1 5 4687PRTArtificial SequenceSynthetic
peptide 468Leu Arg Val Gly Ile Gly Tyr 1 5
4697PRTArtificial SequenceSynthetic peptide 469Gln Gly Tyr Ala Leu Arg
Val 1 5 4707PRTArtificial SequenceSynthetic
peptide 470Pro Leu Arg Ser Phe Asp Ser 1 5
4717PRTArtificial SequenceSynthetic peptide 471Ala Arg Val Ser Gly Arg
Val 1 5 4727PRTArtificial SequenceSynthetic
peptide 472Pro Phe Pro Ala Arg Ser Ser 1 5
4737PRTArtificial SequenceSynthetic peptide 473Ala Gly Ser Pro Leu Ala
Lys 1 5 4747PRTArtificial SequenceSynthetic
peptide 474Phe Val Asp Ile Ala Gly Ser 1 5
4757PRTArtificial SequenceSynthetic peptide 475Ser Tyr Phe Arg Ala Gly
Arg 1 5 4767PRTArtificial SequenceSynthetic
peptide 476Ala Gly Leu Gly His Glu Gly 1 5
4777PRTArtificial SequenceSynthetic peptide 477Ala Gly Gly Ser Leu Gly
Ser 1 5 4787PRTArtificial SequenceSynthetic
peptide 478Tyr Gly Ile Gly Val Arg Leu 1 5
4797PRTArtificial SequenceSynthetic peptide 479Arg Ala Asn Gly Val Leu
Val 1 5 4807PRTArtificial SequenceSynthetic
peptide 480Leu Ala Ser Leu Gly Val Gly 1 5
4817PRTArtificial SequenceSynthetic peptide 481Arg Ala Ala Val Gly Ala
Arg 1 5 4827PRTArtificial SequenceSynthetic
peptide 482Gly Cys Asp Gly Gly Ser Ala 1 5
4837PRTArtificial SequenceSynthetic peptide 483Gly Gly Ser Gly Glu Leu
Gly 1 5 4847PRTArtificial SequenceSynthetic
peptide 484Leu Gly Gly Ser Gly Arg Arg 1 5
4857PRTArtificial SequenceSynthetic peptide 485Ala Gly Gly Ser Leu Gly
Ser 1 5 4867PRTArtificial SequenceSynthetic
peptide 486Ile Gly Gly Arg Glu Ile Thr 1 5
4877PRTArtificial SequenceSynthetic peptide 487Gly Glu His Gly Leu Gly
Ala 1 5 4887PRTArtificial SequenceSynthetic
peptide 488Arg Arg Gly Ser Gly Gly Leu 1 5
4897PRTArtificial SequenceSynthetic peptide 489Arg Ser Gly Ser Ser Val
Tyr 1 5 4907PRTArtificial SequenceSynthetic
peptide 490Gly Leu Glu Gly Ser Gly Gly 1 5
4917PRTArtificial SequenceSynthetic peptide 491Leu Gly Gly Ser Gly Arg
Arg 1 5 4927PRTArtificial SequenceSynthetic
peptide 492Thr Thr Gly Ser Val Ile Val 1 5
4937PRTArtificial SequenceSynthetic peptide 493Val Arg Gly Ser Val Arg
Ala 1 5 4947PRTArtificial SequenceSynthetic
peptide 494His Gly Arg Val His Arg Leu 1 5
4957PRTArtificial SequenceSynthetic peptide 495Ala Arg Val Ser Gly Arg
Val 1 5 4967PRTArtificial SequenceSynthetic
peptide 496Ser Gly His Gly Val Ser Ala 1 5
4977PRTArtificial SequenceSynthetic peptide 497Ala Val Trp Arg Leu Ser
His 1 5 4987PRTArtificial SequenceSynthetic
peptide 498Arg Gly Val Phe Tyr Gly Lys 1 5
4997PRTArtificial SequenceSynthetic peptide 499Arg Gly Val Gly Trp Ala
Lys 1 5 5007PRTArtificial SequenceSynthetic
peptide 500Ser Arg Gly Ser Thr Ala Gly 1 5
5017PRTArtificial SequenceSynthetic peptide 501Ser Glu Asp Glu Gly Ala
Gly 1 5 5027PRTArtificial SequenceSynthetic
peptide 502Ser Thr Ser Leu Gly Ala Gly 1 5
5037PRTArtificial SequenceSynthetic peptide 503Asp Leu Leu Arg Tyr Leu
Ala 1 5 5047PRTArtificial SequenceSynthetic
peptide 504Leu Arg Val Arg Tyr Ala Val 1 5
5057PRTArtificial SequenceSynthetic peptide 505Leu Arg Ser Ser Gly Ala
Thr 1 5 5067PRTArtificial SequenceSynthetic
peptide 506Leu Ser Met Leu Arg Ser Ala 1 5
5077PRTArtificial SequenceSynthetic peptide 507Arg Glu Ala Glu Arg Val
Ser 1 5 5087PRTArtificial SequenceSynthetic
peptide 508Leu Arg Ser Ser Gly Ala Thr 1 5
5097PRTArtificial SequenceSynthetic peptide 509Thr Ala Gly Ser Ser Arg
Leu 1 5 5107PRTArtificial SequenceSynthetic
peptide 510Ala Ala Gly Arg Ala Gly Cys 1 5
5117PRTArtificial SequenceSynthetic peptide 511Gly Ala Gly Leu Ser Thr
Ser 1 5 5127PRTArtificial SequenceSynthetic
peptide 512Pro Ser Val Gly Val Arg Ala 1 5
5137PRTArtificial SequenceSynthetic peptide 513Val Gly Ala Val Tyr Phe
Leu 1 5 5147PRTArtificial SequenceSynthetic
peptide 514Leu Gly Leu Arg Ala Phe Val 1 5
5157PRTArtificial SequenceSynthetic peptide 515Thr Glu Leu Val Ser Trp
Ser 1 5 5167PRTArtificial SequenceSynthetic
peptide 516Cys Gly Ala Arg Gly Ala Ala 1 5
5177PRTArtificial SequenceSynthetic peptide 517Gly Gly Ser Arg Ala Ala
Glu 1 5 5187PRTArtificial SequenceSynthetic
peptide 518Val Asn Leu Gly Gly Ser Trp 1 5
5197PRTArtificial SequenceSynthetic peptide 519Leu Ile Gly Pro Gly Gly
Arg 1 5 5207PRTArtificial SequenceSynthetic
peptide 520Leu Gly Gly Leu Ser Pro His 1 5
5217PRTArtificial SequenceSynthetic peptide 521Trp Ser Gly Gly Leu Asn
Val 1 5 5227PRTArtificial SequenceSynthetic
peptide 522Thr Ala Gly Ser Ser Arg Leu 1 5
5237PRTArtificial SequenceSynthetic peptide 523Ser Asp Val Ser Gly Ser
Ser 1 5 5247PRTArtificial SequenceSynthetic
peptide 524Trp Gly Ser Ser Thr Val Arg 1 5
5257PRTArtificial SequenceSynthetic peptide 525Asn Leu Ala Asp Gly Ser
Val 1 5 5267PRTArtificial SequenceSynthetic
peptide 526Ser Ser Gly Ser Val Asp Ser 1 5
5277PRTArtificial SequenceSynthetic peptide 527Gly Arg Val Pro Gly Phe
Glu 1 5 5287PRTArtificial SequenceSynthetic
peptide 528Gly Arg Val Val Gly Glu Ala 1 5
5297PRTArtificial SequenceSynthetic peptide 529Ser Arg Phe Gly Pro Ser
Val 1 5 5307PRTArtificial SequenceSynthetic
peptide 530Ala Arg Val Gly Val Ser Pro 1 5
5317PRTArtificial SequenceSynthetic peptide 531Pro Gly Lys Arg Gly Val
Gln 1 5 5327PRTArtificial SequenceSynthetic
peptide 532Arg Gly Val Ala Ser Arg Ser 1 5
5337PRTArtificial SequenceSynthetic peptide 533Glu Arg Gly Ser Pro Ser
Arg 1 5 5347PRTArtificial SequenceSynthetic
peptide 534Leu Ile Arg Ala Val Ser Ala 1 5
5357PRTArtificial SequenceSynthetic peptide 535Arg Ala Val Glu Met Gly
Thr 1 5 5367PRTArtificial SequenceSynthetic
peptide 536Trp Gly Ala Gly Phe Trp Met 1 5
5377PRTArtificial SequenceSynthetic peptide 537Leu Ile Arg Ala Val Ser
Ala 1 5 5387PRTArtificial SequenceSynthetic
peptide 538Asp Arg Tyr Met Leu Arg Ser 1 5
5397PRTArtificial SequenceSynthetic peptide 539Pro Arg Ser Ser Tyr Asn
Glu 1 5 5407PRTArtificial SequenceSynthetic
peptide 540Pro Arg Ser Ser Leu Val Val 1 5
5417PRTArtificial SequenceSynthetic peptide 541Arg Arg Phe Trp Ala Gly
Leu 1 5 5427PRTArtificial SequenceSynthetic
peptide 542Pro Val His Ser Ala Gly Gly 1 5
5437PRTArtificial SequenceSynthetic peptide 543Phe Gly Gly Ser Gly Val
Leu 1 5 5447PRTArtificial SequenceSynthetic
peptide 544Ser Ser Gly Gly Val Leu Gly 1 5
5457PRTArtificial SequenceSynthetic peptide 545Gly Leu Val Gly Gly Ser
Ser 1 5 5467PRTArtificial SequenceSynthetic
peptide 546Leu Ser Ser Gly Leu Val Ser 1 5
5477PRTArtificial SequenceSynthetic peptide 547Leu Ser Ser Gly Leu Val
Ser 1 5 5487PRTArtificial SequenceSynthetic
peptide 548Trp Phe Ser Trp Leu Val Ser 1 5
5497PRTArtificial SequenceSynthetic peptide 549Gly Ala Ser Leu Thr Gly
Asp 1 5 5507PRTArtificial SequenceSynthetic
peptide 550Trp Ser Ser Thr Ala Ser Leu 1 5
5517PRTArtificial SequenceSynthetic peptide 551Phe Gly Gly Ser Gly Val
Leu 1 5 5527PRTArtificial SequenceSynthetic
peptide 552Gly Leu Val Gly Gly Ser Ser 1 5
5537PRTArtificial SequenceSynthetic peptide 553Gly Gly Leu Ser Pro His
Arg 1 5 5547PRTArtificial SequenceSynthetic
peptide 554Gly Leu Val Gly Gly Ser Ser 1 5
5557PRTArtificial SequenceSynthetic peptide 555Ser Val Leu Gly Ser Ser
Leu 1 5 5567PRTArtificial SequenceSynthetic
peptide 556Phe Gly Gly Ser Gly Val Leu 1 5
5577PRTArtificial SequenceSynthetic peptide 557Asp Val Arg Gly Arg Val
Trp 1 5 5587PRTArtificial SequenceSynthetic
peptide 558Ala Glu Pro Arg Gly Arg Val 1 5
5597PRTArtificial SequenceSynthetic peptide 559Ser Ile Gly Pro Ser Thr
Asn 1 5 5607PRTArtificial SequenceSynthetic
peptide 560Gly Val Ser Ile Arg Gln Leu 1 5
5617PRTArtificial SequenceSynthetic peptide 561Ala Val Ser Lys Arg Leu
Pro 1 5 5627PRTArtificial SequenceSynthetic
peptide 562Arg Leu Ala Val Ser Gly Tyr 1 5
5637PRTArtificial SequenceSynthetic peptide 563Arg Arg Glu Gly Leu Arg
Ser 1 5 5647PRTArtificial SequenceSynthetic
peptide 564Ser Arg Tyr Trp Leu Arg Ser 1 5
5657PRTArtificial SequenceSynthetic peptide 565Ala Val Tyr Arg Ala Gly
Arg 1 5 5667PRTArtificial SequenceSynthetic
peptide 566Arg His Phe Gly Leu Arg Glu 1 5
5677PRTArtificial SequenceSynthetic peptide 567Arg Arg Glu Gly Leu Arg
Ser 1 5 5687PRTArtificial SequenceSynthetic
peptide 568Gly Gln Gly Ala Ala Ser Leu 1 5
5697PRTArtificial SequenceSynthetic peptide 569Gly Gln Gly Ala Ala Ser
Leu 1 5 5707PRTArtificial SequenceSynthetic
peptide 570Tyr Gly Ser Val Ala Leu Arg 1 5
5717PRTArtificial SequenceSynthetic peptide 571Ala Arg Arg Gly Val Leu
Gly 1 5 5727PRTArtificial SequenceSynthetic
peptide 572Leu Arg Ile Ala Arg Gly Val 1 5
5737PRTArtificial SequenceSynthetic peptide 573Tyr Arg Gly Ser Met Val
Gly 1 5 5747PRTArtificial SequenceSynthetic
peptide 574Gly Leu Arg Gly Ser Val Trp 1 5
5757PRTArtificial SequenceSynthetic peptide 575Gly Pro Phe Arg Ala Val
Pro 1 5 5767PRTArtificial SequenceSynthetic
peptide 576Ala His Tyr Thr Leu Arg Ser 1 5
5777PRTArtificial SequenceSynthetic peptide 577Ser Glu Leu Arg Ser Ile
Arg 1 5 5787PRTArtificial SequenceSynthetic
peptide 578Ser Val Tyr Ala Leu Arg Ser 1 5
5797PRTArtificial SequenceSynthetic peptide 579Ala Arg Arg Gly Val Leu
Gly 1 5 5807PRTArtificial SequenceSynthetic
peptide 580Pro Gly Ala Val Leu Thr Val 1 5
5817PRTArtificial SequenceSynthetic peptide 581Gly Leu Val Gly Arg Arg
Ala 1 5 5827PRTArtificial SequenceSynthetic
peptide 582Gly Leu Val Arg Cys Val Leu 1 5
5837PRTArtificial SequenceSynthetic peptide 583Tyr Asp Gly Leu Val Ser
Gly 1 5 5847PRTArtificial SequenceSynthetic
peptide 584Gly Leu Val Thr Ala Pro Leu 1 5
5857PRTArtificial SequenceSynthetic peptide 585Arg Gly Leu Val Arg Val
Val 1 5 5867PRTArtificial SequenceSynthetic
peptide 586Gly Leu Arg Gly Ser Val Trp 1 5
5877PRTArtificial SequenceSynthetic peptide 587Asn Ser Phe Gly Leu Arg
Tyr 1 5 5887PRTArtificial SequenceSynthetic
peptide 588Tyr Asp Gly Leu Val Ser Gly 1 5
5897PRTArtificial SequenceSynthetic peptide 589Ala Ala Arg Gly Leu Glu
Ala 1 5 5907PRTArtificial SequenceSynthetic
peptide 590Asp Asn Asp Gly Ala Arg Gly 1 5
5917PRTArtificial SequenceSynthetic peptide 591Leu Arg Ile Ala Arg Gly
Val 1 5 5927PRTArtificial SequenceSynthetic
peptide 592Met Ser Asn Leu Ala Ala Val 1 5
5937PRTArtificial SequenceSynthetic peptide 593Tyr Ser Gly Ser Ser Asp
Phe 1 5 5947PRTArtificial SequenceSynthetic
peptide 594Gly Ser Val Leu Gly Asp Tyr 1 5
5957PRTArtificial SequenceSynthetic peptide 595Gly Leu Arg Gly Ser Val
Trp 1 5 5967PRTArtificial SequenceSynthetic
peptide 596Asp Leu Asp Gly Arg Val Val 1 5
5977PRTArtificial SequenceSynthetic peptide 597Trp Val Ser Gly Arg Leu
Gly 1 5 5987PRTArtificial SequenceSynthetic
peptide 598Gly Pro Ser Ser Met Thr Phe 1 5
5997PRTArtificial SequenceSynthetic peptide 599Asp Gly Val Ser Ser Asp
Tyr 1 5 6007PRTArtificial SequenceSynthetic
peptide 600Phe Thr Ser Gly Val Ser Trp 1 5
6017PRTArtificial SequenceSynthetic peptide 601Val Leu Thr Arg Ala Ser
Thr 1 5 6027PRTArtificial SequenceSynthetic
peptide 602Leu Arg Ala Ser Leu Leu Trp 1 5
6037PRTArtificial SequenceSynthetic peptide 603Trp Leu Leu Ser Ala Arg
Leu 1 5 6047PRTArtificial SequenceSynthetic
peptide 604Leu Leu Arg Pro Gly Thr Val 1 5
6057PRTArtificial SequenceSynthetic peptide 605Ala Ala Gly Gly Leu Leu
Val 1 5 6067PRTArtificial SequenceSynthetic
peptide 606Leu Arg Ala Ser Leu Leu Trp 1 5
6077PRTArtificial SequenceSynthetic peptide 607Leu Trp Gly Leu Gly Trp
Leu 1 5 6087PRTArtificial SequenceSynthetic
peptide 608Arg Arg Ser Gly Leu Gly Asp 1 5
6097PRTArtificial SequenceSynthetic peptide 609Trp Trp Gly Leu Gly Trp
Leu 1 5 6107PRTArtificial SequenceSynthetic
peptide 610Ala Ala Gly Gly Leu Leu Val 1 5
6117PRTArtificial SequenceSynthetic peptide 611Gly Leu Arg Gly Val Val
Lys 1 5 6127PRTArtificial SequenceSynthetic
peptide 612Ala Val Glu Gly Arg Gly Ser 1 5
6137PRTArtificial SequenceSynthetic peptide 613Asn Ala Val Arg Gly Ser
Ala 1 5 6147PRTArtificial SequenceSynthetic
peptide 614Leu Leu Arg Ser Ser Leu Gly 1 5
6157PRTArtificial SequenceSynthetic peptide 615Met Tyr Leu Arg Leu Leu
Arg 1 5 6167PRTArtificial SequenceSynthetic
peptide 616Leu Leu Arg Ser Ser Leu Gly 1 5
6177PRTArtificial SequenceSynthetic peptide 617Asp Glu Gly Leu Arg Ser
Arg 1 5 6187PRTArtificial SequenceSynthetic
peptide 618Tyr Trp Gln His Arg Val Ser 1 5
6197PRTArtificial SequenceSynthetic peptide 619Ala Arg Ser Ser His Arg
Ala 1 5 6207PRTArtificial SequenceSynthetic
peptide 620Leu Leu Arg Ser Ser Leu Gly 1 5
6217PRTArtificial SequenceSynthetic peptide 621Ala Gly Arg Ser Cys Asn
Leu 1 5 6227PRTArtificial SequenceSynthetic
peptide 622Ala Gly Arg Pro Arg Ala Thr 1 5
6237PRTArtificial SequenceSynthetic peptide 623Gly Gly Val Arg Ile Ala
Ala 1 5 6247PRTArtificial SequenceSynthetic
peptide 624Gly Val Arg Tyr Leu Arg Thr 1 5
6257PRTArtificial SequenceSynthetic peptide 625Pro Leu Ala Val Gly Leu
Val 1 5 6267PRTArtificial SequenceSynthetic
peptide 626Gly Leu Arg Gly Val Val Lys 1 5
6277PRTArtificial SequenceSynthetic peptide 627Asp Glu Gly Leu Arg Ser
Arg 1 5 6287PRTArtificial SequenceSynthetic
peptide 628Gln Leu Val Ser Gly Ser Leu 1 5
6297PRTArtificial SequenceSynthetic peptide 629Gly Trp Ser Ala Ser Leu
Gly 1 5 6307PRTArtificial SequenceSynthetic
peptide 630Ile Ala Ala Val Trp Arg Ser 1 5
6317PRTArtificial SequenceSynthetic peptide 631Gly Gly Ser Ser Leu Asp
Ala 1 5 6327PRTArtificial SequenceSynthetic
peptide 632Leu Gly Gly Ser Arg Asp Leu 1 5
6337PRTArtificial SequenceSynthetic peptide 633Leu Ile Gly Gly Arg Asn
Ala 1 5 6347PRTArtificial SequenceSynthetic
peptide 634Leu Asp Arg Ser Gly Gly Leu 1 5
6357PRTArtificial SequenceSynthetic peptide 635Gly Gly Ser Ser Leu Asp
Ala 1 5 6367PRTArtificial SequenceSynthetic
peptide 636Gly Ser Ser Tyr Ser Gly Pro 1 5
6377PRTArtificial SequenceSynthetic peptide 637Thr Val Gly Ser Gly Cys
Leu 1 5 6387PRTArtificial SequenceSynthetic
peptide 638Leu Ser Gly Ser Val Leu Gln 1 5
6397PRTArtificial SequenceSynthetic peptide 639Ala Ser Gly Arg Val Ala
Asn 1 5 6407PRTArtificial SequenceSynthetic
peptide 640Lys Val Val Gly Arg Leu Gly 1 5
6417PRTArtificial SequenceSynthetic peptide 641Gly Arg Leu Val Trp Gly
Leu 1 5 6427PRTArtificial SequenceSynthetic
peptide 642Asn Glu Phe Leu Gly Arg Leu 1 5
6437PRTArtificial SequenceSynthetic peptide 643Leu Cys Asp Ala Gly Pro
Ser 1 5 6447PRTArtificial SequenceSynthetic
peptide 644Phe Arg Ala Gly Val Ser His 1 5
6457PRTArtificial SequenceSynthetic peptide 645Ala Gly Asp Ser Arg Leu
Ser 1 5 6467PRTArtificial SequenceSynthetic
peptide 646Asp Trp Arg Arg Arg Ala Val 1 5
6477PRTArtificial SequenceSynthetic peptide 647Trp Thr Glu Arg Ala Ser
Ala 1 5 6487PRTArtificial SequenceSynthetic
peptide 648Arg Leu Leu Ser Ala Phe Gly 1 5
6497PRTArtificial SequenceSynthetic peptide 649Gly Phe Ala Ser Leu Leu
Arg 1 5 6507PRTArtificial SequenceSynthetic
peptide 650Gly Ala Leu Arg Val Pro Trp 1 5
6517PRTArtificial SequenceSynthetic peptide 651Ser Leu Arg Ser Asp Gly
Ala 1 5 6527PRTArtificial SequenceSynthetic
peptide 652Asp Thr Leu Arg Ser Gln Trp 1 5
6537PRTArtificial SequenceSynthetic peptide 653Leu Arg Ser Val Gly Ser
Trp 1 5 6547PRTArtificial SequenceSynthetic
peptide 654Ile Ser Pro Arg Ser Ser Gly 1 5
6557PRTArtificial SequenceSynthetic peptide 655Trp Arg Val Arg Ser Ser
Gly 1 5 6567PRTArtificial SequenceSynthetic
peptide 656Ala Ala Gly Arg Ile Arg Pro 1 5
6577PRTArtificial SequenceSynthetic peptide 657Arg Ala Ala Gly Arg Val
Gly 1 5 6587PRTArtificial SequenceSynthetic
peptide 658Ala Gly Leu Gln His Ala Val 1 5
6597PRTArtificial SequenceSynthetic peptide 659Ala Gly Gly Trp Trp Val
Gly 1 5 6607PRTArtificial SequenceSynthetic
peptide 660Gly Val Arg Gly Ala Ala Arg 1 5
6617PRTArtificial SequenceSynthetic peptide 661Gly Val Leu Pro Val Val
Thr 1 5 6627PRTArtificial SequenceSynthetic
peptide 662Gly Leu Val Ser Ser Leu Pro 1 5
6637PRTArtificial SequenceSynthetic peptide 663Ser Arg His Gly Leu Val
Arg 1 5 6647PRTArtificial SequenceSynthetic
peptide 664Ser Asp Arg Gly Leu Val Val 1 5
6657PRTArtificial SequenceSynthetic peptide 665Ser Asp Arg Gly Leu Val
Val 1 5 6667PRTArtificial SequenceSynthetic
peptide 666Gly Leu Val Ser Ser Leu Pro 1 5
6677PRTArtificial SequenceSynthetic peptide 667Leu Val Ser Val Trp Ser
Arg 1 5 6687PRTArtificial SequenceSynthetic
peptide 668Gly Ser Trp Ala Arg Gly Tyr 1 5
6697PRTArtificial SequenceSynthetic peptide 669Gly Phe Ala Ser Leu Leu
Arg 1 5 6707PRTArtificial SequenceSynthetic
peptide 670His Ala Ala Val Met Ser Leu 1 5
6717PRTArtificial SequenceSynthetic peptide 671Asp Gly Gly Arg Arg Thr
Asp 1 5 6727PRTArtificial SequenceSynthetic
peptide 672Gly Arg Pro Leu Gly Gly Arg 1 5
6737PRTArtificial SequenceSynthetic peptide 673Gly Arg Val Thr Gly Gly
Arg 1 5 6747PRTArtificial SequenceSynthetic
peptide 674Arg Gly Gly Leu Pro Arg Gly 1 5
6757PRTArtificial SequenceSynthetic peptide 675Tyr Gly Gln Tyr Gly Gly
Leu 1 5 6767PRTArtificial SequenceSynthetic
peptide 676Gly Ser Ser Arg Pro Ser Ile 1 5
6777PRTArtificial SequenceSynthetic peptide 677Pro Gly Ser Ser Phe Val
Gly 1 5 6787PRTArtificial SequenceSynthetic
peptide 678Gly Ser Ser Arg Val Arg Trp 1 5
6797PRTArtificial SequenceSynthetic peptide 679Arg Ala Ala Gly Arg Val
Gly 1 5 6807PRTArtificial SequenceSynthetic
peptide 680Gly Arg Val Thr Gly Gly Arg 1 5
6817PRTArtificial SequenceSynthetic peptide 681Tyr Val Arg Ile Gly Arg
Val 1 5 6827PRTArtificial SequenceSynthetic
peptide 682Met Ile Thr Arg Gly Arg Leu 1 5
6837PRTArtificial SequenceSynthetic peptide 683Ser Val Val Gly Val Ser
Thr 1 5 6847PRTArtificial SequenceSynthetic
peptide 684Trp Ser Gly Val Ser Arg Leu 1 5
6857PRTArtificial SequenceSynthetic peptide 685Arg Arg Leu Ser Tyr Phe
His 1 5 6867PRTArtificial SequenceSynthetic
peptide 686Pro Arg Leu Ser Trp Val Leu 1 5
6877PRTArtificial SequenceSynthetic peptide 687Arg Leu Ser Ala Leu Thr
Asp 1 5 6887PRTArtificial SequenceSynthetic
peptide 688Gly Arg Gly Val Gly Thr Asp 1 5
6897PRTArtificial SequenceSynthetic peptide 689Leu Lys Val Arg Gly Val
Leu 1 5 6907PRTArtificial SequenceSynthetic
peptide 690Ser Ser Thr Arg Gly Val Tyr 1 5
6917PRTArtificial SequenceSynthetic peptide 691Gln Val Arg Arg Gly Val
Val 1 5 6927PRTArtificial SequenceSynthetic
peptide 692Gly Arg Gly Val Thr Ile Trp 1 5
6937PRTArtificial SequenceSynthetic peptide 693Arg Gly Ser Val Ala Ser
Ala 1 5 6947PRTArtificial SequenceSynthetic
peptide 694His Phe Ile Arg Gly Ser Val 1 5
6957PRTArtificial SequenceSynthetic peptide 695Arg Gly Ser Trp Ala Gly
Val 1 5 6967PRTArtificial SequenceSynthetic
peptide 696Val Arg Gly Ser Arg Trp Arg 1 5
6977PRTArtificial SequenceSynthetic peptide 697Leu Glu Arg Ala Val Arg
Thr 1 5 6987PRTArtificial SequenceSynthetic
peptide 698Gly Tyr Ser Arg Ala Ser Asp 1 5
6997PRTArtificial SequenceSynthetic peptide 699Ser Arg Ala Ser Gly His
Gly 1 5 7007PRTArtificial SequenceSynthetic
peptide 700Gly His Tyr Arg Ala Ser Val 1 5
7017PRTArtificial SequenceSynthetic peptide 701Asp Trp Val Cys Arg Ala
Ser 1 5 7027PRTArtificial SequenceSynthetic
peptide 702Gly Ala Gly Arg Gly Thr Pro 1 5
7037PRTArtificial SequenceSynthetic peptide 703Leu Ser Leu Ala Gly Ala
Gly 1 5 7047PRTArtificial SequenceSynthetic
peptide 704Ala Ser Ala Val Ser Gly Arg 1 5
7057PRTArtificial SequenceSynthetic peptide 705Phe Ser Gly Asp Ala Val
Ser 1 5 7067PRTArtificial SequenceSynthetic
peptide 706Leu Lys Leu Leu Ser Val Pro 1 5
7077PRTArtificial SequenceSynthetic peptide 707Gly Thr Leu Arg Val Gly
Ser 1 5 7087PRTArtificial SequenceSynthetic
peptide 708Glu His Tyr Arg Leu Arg Ser 1 5
7097PRTArtificial SequenceSynthetic peptide 709Leu Arg Ser Trp Leu Leu
Phe 1 5 7107PRTArtificial SequenceSynthetic
peptide 710Arg Arg Pro Gly Leu Arg Ser 1 5
7117PRTArtificial SequenceSynthetic peptide 711Ser Lys Tyr Asn Leu Arg
Ser 1 5 7127PRTArtificial SequenceSynthetic
peptide 712Trp Gln Val Ala Leu Arg Ser 1 5
7137PRTArtificial SequenceSynthetic peptide 713Leu Arg Ser Asp Pro Arg
Ser 1 5 7147PRTArtificial SequenceSynthetic
peptide 714Val Pro Leu Arg Ser Ser Ala 1 5
7157PRTArtificial SequenceSynthetic peptide 715Gly Arg Ser Ser Gly Met
Glu 1 5 7167PRTArtificial SequenceSynthetic
peptide 716Val Pro Leu Arg Ser Ser Ala 1 5
7177PRTArtificial SequenceSynthetic peptide 717Ala Gly Ser Gly Phe Pro
Phe 1 5 7187PRTArtificial SequenceSynthetic
peptide 718Gly Ala Gly Arg Gly Thr Pro 1 5
7197PRTArtificial SequenceSynthetic peptide 719Ala Gly Arg Ile Ala Ser
Lys 1 5 7207PRTArtificial SequenceSynthetic
peptide 720Trp Gly Val Ala Gly Leu Gly 1 5
7217PRTArtificial SequenceSynthetic peptide 721Leu Ala Gly Leu Val Ser
Gly 1 5 7227PRTArtificial SequenceSynthetic
peptide 722Asp Ala Gly Gly Met Asp Leu 1 5
7237PRTArtificial SequenceSynthetic peptide 723Ala Gly Gly Arg Trp Asn
Leu 1 5 7247PRTArtificial SequenceSynthetic
peptide 724Gly Cys Gly Gly Val Arg Asp 1 5
7257PRTArtificial SequenceSynthetic peptide 725Ser Gly Val Arg Leu Thr
Gly 1 5 7267PRTArtificial SequenceSynthetic
peptide 726Leu Lys Val Arg Gly Val Leu 1 5
7277PRTArtificial SequenceSynthetic peptide 727Gly Leu Gly Ala Val Gly
Trp 1 5 7287PRTArtificial SequenceSynthetic
peptide 728Pro Gly Ala Val Pro Gly Ala 1 5
7297PRTArtificial SequenceSynthetic peptide 729Arg Ile Gly Ala Val Trp
Tyr 1 5 7307PRTArtificial SequenceSynthetic
peptide 730Phe Ser Gly Leu Val Val Ala 1 5
7317PRTArtificial SequenceSynthetic peptide 731Pro Gly Gly Leu Val Pro
Gly 1 5 7327PRTArtificial SequenceSynthetic
peptide 732Leu Ala Gly Leu Val Ser Gly 1 5
7337PRTArtificial SequenceSynthetic peptide 733Leu Gly Leu Val Ser Thr
Thr 1 5 7347PRTArtificial SequenceSynthetic
peptide 734Gly Leu Arg Leu Gly Val Thr 1 5
7357PRTArtificial SequenceSynthetic peptide 735Arg Arg Pro Gly Leu Arg
Ser 1 5 7367PRTArtificial SequenceSynthetic
peptide 736Leu Ala Gly Leu Val Ser Gly 1 5
7377PRTArtificial SequenceSynthetic peptide 737Leu Gly Leu Val Ser Thr
Thr 1 5 7387PRTArtificial SequenceSynthetic
peptide 738Arg Gln Leu Val Ser Pro Ala 1 5
7397PRTArtificial SequenceSynthetic peptide 739Leu Arg Ala Arg Gly Gly
His 1 5 7407PRTArtificial SequenceSynthetic
peptide 740Glu Leu Trp Ala Ser Leu Gly 1 5
7417PRTArtificial SequenceSynthetic peptide 741Asp Thr Leu Ala Ser Leu
Arg 1 5 7427PRTArtificial SequenceSynthetic
peptide 742Val Val Ala Ser Leu Pro His 1 5
7437PRTArtificial SequenceSynthetic peptide 743Val Leu Arg Ala Ala Ser
Arg 1 5 7447PRTArtificial SequenceSynthetic
peptide 744Ala Ala Ser Gly Ser Tyr Tyr 1 5
7457PRTArtificial SequenceSynthetic peptide 745Gly Gly Ser Ala Leu Phe
Gly 1 5 7467PRTArtificial SequenceSynthetic
peptide 746Gly Arg Gly Gly Ser Gly Tyr 1 5
7477PRTArtificial SequenceSynthetic peptide 747Tyr Gly Ser Gly Gly Arg
Gly 1 5 7487PRTArtificial SequenceSynthetic
peptide 748Gly Thr Leu Gly Gly Arg Val 1 5
7497PRTArtificial SequenceSynthetic peptide 749Ala Gly Gly Arg Trp Asn
Leu 1 5 7507PRTArtificial SequenceSynthetic
peptide 750His Gly Gly Arg Ala Arg Leu 1 5
7517PRTArtificial SequenceSynthetic peptide 751Arg Gly Gly Arg Ser Pro
Ser 1 5 7527PRTArtificial SequenceSynthetic
peptide 752Arg Lys Pro Gly Gly Gly Arg 1 5
7537PRTArtificial SequenceSynthetic peptide 753Glu Gly Gly Arg Thr His
Trp 1 5 7547PRTArtificial SequenceSynthetic
peptide 754Gly Glu Val Gly Leu Gly Val 1 5
7557PRTArtificial SequenceSynthetic peptide 755Gly Leu Gly Ala Val Gly
Trp 1 5 7567PRTArtificial SequenceSynthetic
peptide 756Pro Gly Gly Leu Val Pro Gly 1 5
7577PRTArtificial SequenceSynthetic peptide 757Val Arg Gly Gly Leu Thr
Gly 1 5 7587PRTArtificial SequenceSynthetic
peptide 758Arg Gln Lys Cys Gly Gly Leu 1 5
7597PRTArtificial SequenceSynthetic peptide 759Arg Tyr Gly Val Gly Gly
Leu 1 5 7607PRTArtificial SequenceSynthetic
peptide 760Glu Met Gly Ser Ser Arg Gly 1 5
7617PRTArtificial SequenceSynthetic peptide 761Ala Gly Ser Gly Phe Pro
Phe 1 5 7627PRTArtificial SequenceSynthetic
peptide 762Gly Arg Gly Gly Ser Gly Tyr 1 5
7637PRTArtificial SequenceSynthetic peptide 763Gly Ser Val Ser Ala Gly
Ala 1 5 7647PRTArtificial SequenceSynthetic
peptide 764Arg Gly Ser Val Ala Ser Ala 1 5
7657PRTArtificial SequenceSynthetic peptide 765Asp Leu Gly Ser Val Gln
His 1 5 7667PRTArtificial SequenceSynthetic
peptide 766His Phe Ile Arg Gly Ser Val 1 5
7677PRTArtificial SequenceSynthetic peptide 767Gly Ser Val Leu Gly Ala
Leu 1 5 7687PRTArtificial SequenceSynthetic
peptide 768Gly Thr Leu Gly Gly Arg Val 1 5
7697PRTArtificial SequenceSynthetic peptide 769Leu Gly Arg Val His Val
Trp 1 5 7707PRTArtificial SequenceSynthetic
peptide 770Leu Val Gly Arg Val Lys Leu 1 5
7717PRTArtificial SequenceSynthetic peptide 771Arg Trp Arg Ser Gly Arg
Val 1 5 7727PRTArtificial SequenceSynthetic
peptide 772Arg Asn Pro Gly Arg Leu Ala 1 5
7737PRTArtificial SequenceSynthetic peptide 773Pro Arg Gly Arg Leu Phe
Asp 1 5 7747PRTArtificial SequenceSynthetic
peptide 774Gly Arg Leu Ala Val Val Ala 1 5
7757PRTArtificial SequenceSynthetic peptide 775Leu Ala Gln Gly Arg Leu
Ala 1 5 7767PRTArtificial SequenceSynthetic
peptide 776Gly Gly Met Asn Gly Arg Leu 1 5
7777PRTArtificial SequenceSynthetic peptide 777Arg Ser Thr Leu Gly Pro
Ser 1 5 7787PRTArtificial SequenceSynthetic
peptide 778Gly Val Ser Ala Leu Ser Leu 1 5
7797PRTArtificial SequenceSynthetic peptide 779Ser Arg Leu Ser Tyr Tyr
Ala 1 5 7807PRTArtificial SequenceSynthetic
peptide 780Ala Arg Gly Val Ser Ala Pro 1 5
7817PRTArtificial SequenceSynthetic peptide 781Gly Arg Gly Val Leu Ala
Phe 1 5 7827PRTArtificial SequenceSynthetic
peptide 782Met Arg Gly Ser Gly Arg Asn 1 5
7837PRTArtificial SequenceSynthetic peptide 783Arg Asp Gly Arg Ala Val
Arg 1 5 7847PRTArtificial SequenceSynthetic
peptide 784Gly Arg Ala Val Trp Met Val 1 5
7857PRTArtificial SequenceSynthetic peptide 785Leu Arg Val Pro Gly Gly
Pro 1 5 7867PRTArtificial SequenceSynthetic
peptide 786Ala Tyr Tyr Ser Leu Arg Ser 1 5
7877PRTArtificial SequenceSynthetic peptide 787Val Leu Arg Ser Ala Leu
Gln 1 5 7887PRTArtificial SequenceSynthetic
peptide 788Val Tyr Tyr Ala Leu Arg Ser 1 5
7897PRTArtificial SequenceSynthetic peptide 789Arg Tyr Arg Val Ser Val
Tyr 1 5 7907PRTArtificial SequenceSynthetic
peptide 790Ala Gly Gly Ile Trp Ile Arg 1 5
7917PRTArtificial SequenceSynthetic peptide 791Trp Gln Val Ser Gly Val
Arg 1 5 7927PRTArtificial SequenceSynthetic
peptide 792Gly Arg Gly Val Leu Ala Phe 1 5
7937PRTArtificial SequenceSynthetic peptide 793His Ala Glu Leu Val Ser
Leu 1 5 7947PRTArtificial SequenceSynthetic
peptide 794Ala Arg Gly Val Ser Ala Pro 1 5
7957PRTArtificial SequenceSynthetic peptide 795Arg Val Ala Arg Gly Asp
Arg 1 5 7967PRTArtificial SequenceSynthetic
peptide 796Val Met Trp Val Ala Arg Gly 1 5
7977PRTArtificial SequenceSynthetic peptide 797Ala Ala Val Thr Val Val
Arg 1 5 7987PRTArtificial SequenceSynthetic
peptide 798Thr Arg Glu Gly Gly Leu Asp 1 5
7997PRTArtificial SequenceSynthetic peptide 799Leu Gly Gly Gly Gly Leu
Leu 1 5 8007PRTArtificial SequenceSynthetic
peptide 800Gly Ser Gly His Ser Phe Ala 1 5
8017PRTArtificial SequenceSynthetic peptide 801Met Arg Gly Ser Gly Arg
Asn 1 5 8027PRTArtificial SequenceSynthetic
peptide 802Arg Val Gly Ser Val Gln Trp 1 5
8037PRTArtificial SequenceSynthetic peptide 803Glu Gly Thr Ser Gly Ser
Val 1 5 8047PRTArtificial SequenceSynthetic
peptide 804Gly Arg Val Pro Thr Val Val 1 5
8057PRTArtificial SequenceSynthetic peptide 805Ala Asp Gly Arg Leu Arg
Tyr 1 5 8067PRTArtificial SequenceSynthetic
peptide 806Ala Arg Gly Val Ser Ala Pro 1 5
8077PRTArtificial SequenceSynthetic peptide 807Arg Gly Val Lys Leu Gly
Asp 1 5 8087PRTArtificial SequenceSynthetic
peptide 808Leu Arg Gly Ser Tyr Val Leu 1 5
8097PRTArtificial SequenceSynthetic peptide 809Arg Arg Gly Ser Leu Met
Phe 1 5 8107PRTArtificial SequenceSynthetic
peptide 810Arg Gly Ser Val Gly Pro Ser 1 5
8117PRTArtificial SequenceSynthetic peptide 811Ser Arg Ala Ser Asp Val
Thr 1 5 8127PRTArtificial SequenceSynthetic
peptide 812Ala Ala Lys Thr Leu Leu Ser 1 5
8137PRTArtificial SequenceSynthetic peptide 813Arg Ser Tyr Pro Leu Arg
Ser 1 5 8147PRTArtificial SequenceSynthetic
peptide 814Tyr Leu Gly Arg Arg Val Ser 1 5
8157PRTArtificial SequenceSynthetic peptide 815Arg Ser Ser Pro Val Trp
Thr 1 5 8167PRTArtificial SequenceSynthetic
peptide 816Asp Leu Arg Arg Ala Gly Ser 1 5
8177PRTArtificial SequenceSynthetic peptide 817Gly Val Ala Gly Leu Arg
Trp 1 5 8187PRTArtificial SequenceSynthetic
peptide 818Arg Ile Asp Ala Gly Gly Gly 1 5
8197PRTArtificial SequenceSynthetic peptide 819Gly Val Ala Gly Gly Ala
Thr 1 5 8207PRTArtificial SequenceSynthetic
peptide 820Thr Ala Gly Gly Ala Val Gly 1 5
8217PRTArtificial SequenceSynthetic peptide 821Trp Arg Leu Gly Ala Val
Gly 1 5 8227PRTArtificial SequenceSynthetic
peptide 822Ser Gly Leu Val Ala Met Val 1 5
8237PRTArtificial SequenceSynthetic peptide 823Val Gly Leu Arg Asp Trp
Gly 1 5 8247PRTArtificial SequenceSynthetic
peptide 824Gly Val Ala Gly Leu Arg Trp 1 5
8257PRTArtificial SequenceSynthetic peptide 825Ala Arg Gly Ile Val Arg
Val 1 5 8267PRTArtificial SequenceSynthetic
peptide 826Ala Ser Leu His His Arg Arg 1 5
8277PRTArtificial SequenceSynthetic peptide 827Gly Ala Ala Ala Ser Gly
Tyr 1 5 8287PRTArtificial SequenceSynthetic
peptide 828Leu Ala Ile Arg Gly Leu Gly 1 5
8297PRTArtificial SequenceSynthetic peptide 829Gly Gly Leu Ser Asn Val
Val 1 5 8307PRTArtificial SequenceSynthetic
peptide 830Pro Pro Gly Gly Leu Lys Trp 1 5
8317PRTArtificial SequenceSynthetic peptide 831Glu Gly Ser Val Asp Ala
His 1 5 8327PRTArtificial SequenceSynthetic
peptide 832Arg Gly Ser Val Gly Pro Ser 1 5
8337PRTArtificial SequenceSynthetic peptide 833Leu Val Tyr Ser Gly Arg
Leu 1 5 8347PRTArtificial SequenceSynthetic
peptide 834Val Glu Glu Gly Arg Leu Arg 1 5
8357PRTArtificial SequenceSynthetic peptide 835Arg Gly Ser Val Gly Pro
Ser 1 5 8367PRTArtificial SequenceSynthetic
peptide 836Ser Pro Gly Val Ser Gly Arg 1 5
8377PRTArtificial SequenceSynthetic peptide 837Arg Val Gly Arg Gly Val
Leu 1 5 8387PRTArtificial SequenceSynthetic
peptide 838Trp Ile Trp Arg Ala Val Ser 1 5
8397PRTArtificial SequenceSynthetic peptide 839Val Thr Asp Gly Ala Gly
Gln 1 5 8407PRTArtificial SequenceSynthetic
peptide 840Leu Gly Thr Ala Val Ser Ser 1 5
8417PRTArtificial SequenceSynthetic peptide 841Trp Ile Trp Arg Ala Val
Ser 1 5 8427PRTArtificial SequenceSynthetic
peptide 842Asp Thr Pro Ser Ala Val Ser 1 5
8437PRTArtificial SequenceSynthetic peptide 843Gly Leu Leu Ser Ala Gly
Ile 1 5 8447PRTArtificial SequenceSynthetic
peptide 844Tyr Leu Leu Arg Ala Leu Gly 1 5
8457PRTArtificial SequenceSynthetic peptide 845Leu Arg Ser Gly Ser Leu
Gly 1 5 8467PRTArtificial SequenceSynthetic
peptide 846Pro Leu Arg Ser Val Trp Ser 1 5
8477PRTArtificial SequenceSynthetic peptide 847Ala Arg Ser Ser Ile Val
Arg 1 5 8487PRTArtificial SequenceSynthetic
peptide 848Ala Gly Gly Arg Leu Gly Leu 1 5
8497PRTArtificial SequenceSynthetic peptide 849Ala Gly Gly Trp Arg Gly
Arg 1 5 8507PRTArtificial SequenceSynthetic
peptide 850Leu Val Gly Arg Gly Val Arg 1 5
8517PRTArtificial SequenceSynthetic peptide 851Asp Val Val Gly Val Leu
Lys 1 5 8527PRTArtificial SequenceSynthetic
peptide 852Arg Val Gly Arg Gly Val Leu 1 5
8537PRTArtificial SequenceSynthetic peptide 853Gly Ala Val Thr Gly Tyr
Pro 1 5 8547PRTArtificial SequenceSynthetic
peptide 854Trp Gly Leu Val Arg His Ala 1 5
8557PRTArtificial SequenceSynthetic peptide 855Leu Gly Leu Arg Gly Gly
Ala 1 5 8567PRTArtificial SequenceSynthetic
peptide 856Ile Gly Ala Ser Leu Leu Gly 1 5
8577PRTArtificial SequenceSynthetic peptide 857Ala Ala Val Glu Thr Gly
Val 1 5 8587PRTArtificial SequenceSynthetic
peptide 858Gly Leu Gly Gly Gly Gly Ser 1 5
8597PRTArtificial SequenceSynthetic peptide 859Glu Val Leu Trp Gly Gly
Arg 1 5 8607PRTArtificial SequenceSynthetic
peptide 860Ala Gly Gly Arg Leu Gly Leu 1 5
8617PRTArtificial SequenceSynthetic peptide 861Gly Gly Arg Ser Lys Lys
Val 1 5 8627PRTArtificial SequenceSynthetic
peptide 862Gly Leu Gly Gly Gly Gly Ser 1 5
8637PRTArtificial SequenceSynthetic peptide 863Ser Gly Gly Gly Gly Leu
Gly 1 5 8647PRTArtificial SequenceSynthetic
peptide 864Gly Ala Tyr Gly Gly Leu Leu 1 5
8657PRTArtificial SequenceSynthetic peptide 865Gly Gly Leu Ser Arg Ser
Asn 1 5 8667PRTArtificial SequenceSynthetic
peptide 866Phe Gly Ser Ser Asn Arg Ser 1 5
8677PRTArtificial SequenceSynthetic peptide 867Gly Ser Val Ser Asp Arg
Phe 1 5 8687PRTArtificial SequenceSynthetic
peptide 868Ala Gly Gly Arg Leu Gly Leu 1 5
8697PRTArtificial SequenceSynthetic peptide 869Trp Phe Lys Gly Pro Ser
Val 1 5 8707PRTArtificial SequenceSynthetic
peptide 870Leu Ser Glu Arg Arg Gly Val 1 5
8717PRTArtificial SequenceSynthetic peptide 871Ala Arg Gly Val Ala Glu
Tyr 1 5 8727PRTArtificial SequenceSynthetic
peptide 872Phe Asp Arg Gly Ser Leu Thr 1 5
8737PRTArtificial SequenceSynthetic peptide 873Gly Arg Leu Arg Ala Ser
Leu 1 5 8747PRTArtificial SequenceSynthetic
peptide 874Arg Asp Gly Arg Gly Ala Gly 1 5
8757PRTArtificial SequenceSynthetic peptide 875Gly Ala Val Ser Val Leu
Ala 1 5 8767PRTArtificial SequenceSynthetic
peptide 876Thr Arg Gly Asp Ala Val Ser 1 5
8777PRTArtificial SequenceSynthetic peptide 877Leu Leu Ser Pro Arg Gly
Thr 1 5 8787PRTArtificial SequenceSynthetic
peptide 878Leu Leu Arg Ser His Gly Val 1 5
8797PRTArtificial SequenceSynthetic peptide 879Pro Leu Arg Val Leu Lys
Arg 1 5 8807PRTArtificial SequenceSynthetic
peptide 880Gly Arg Leu Arg Leu Arg Val 1 5
8817PRTArtificial SequenceSynthetic peptide 881Leu Leu Arg Ser His Gly
Val 1 5 8827PRTArtificial SequenceSynthetic
peptide 882Val Leu Arg Ser Gly Glu Leu 1 5
8837PRTArtificial SequenceSynthetic peptide 883Val Leu Arg Ser Ile Pro
Ser 1 5 8847PRTArtificial SequenceSynthetic
peptide 884Gly Ser Met His Arg Val Ser 1 5
8857PRTArtificial SequenceSynthetic peptide 885Tyr Ser Ile Met Arg Val
Ser 1 5 8867PRTArtificial SequenceSynthetic
peptide 886Arg Ala Gly Ser Arg Val Gln 1 5
8877PRTArtificial SequenceSynthetic peptide 887Arg Arg Asp Ala Gly Arg
Met 1 5 8887PRTArtificial SequenceSynthetic
peptide 888Gly Ala Gly Arg Gly Asp Arg 1 5
8897PRTArtificial SequenceSynthetic peptide 889Arg Trp Ala Gly Leu Val
Ala 1 5 8907PRTArtificial SequenceSynthetic
peptide 890Gln Thr Leu Ser Ala Gly Gly 1 5
8917PRTArtificial SequenceSynthetic peptide 891Leu Ala Gly Gly Trp Gly
Ser 1 5 8927PRTArtificial SequenceSynthetic
peptide 892Arg His Gly Val Arg Ser Lys 1 5
8937PRTArtificial SequenceSynthetic peptide 893Gly Ala Val Ser Val Leu
Ala 1 5 8947PRTArtificial SequenceSynthetic
peptide 894Arg Trp Ala Gly Leu Val Ala 1 5
8957PRTArtificial SequenceSynthetic peptide 895Gly Arg Gly Leu Arg Thr
Asp 1 5 8967PRTArtificial SequenceSynthetic
peptide 896Thr Leu Gly Gly Leu Arg Thr 1 5
8977PRTArtificial SequenceSynthetic peptide 897Ala Leu Val Ser Val Ala
Gly 1 5 8987PRTArtificial SequenceSynthetic
peptide 898Ala Arg Gly Val Ala Glu Tyr 1 5
8997PRTArtificial SequenceSynthetic peptide 899Gly Gly Ala Ser Leu Thr
Gln 1 5 9007PRTArtificial SequenceSynthetic
peptide 900Gly Arg Leu Arg Ala Ser Leu 1 5
9017PRTArtificial SequenceSynthetic peptide 901Ser Asn His Thr Ala Ser
Leu 1 5 9027PRTArtificial SequenceSynthetic
peptide 902Tyr Ala Asp Gly Ala Ala Val 1 5
9037PRTArtificial SequenceSynthetic peptide 903Leu Gly Gly Leu Gly Ile
His 1 5 9047PRTArtificial SequenceSynthetic
peptide 904Gly Gly Phe Thr Gly Gly Leu 1 5
9057PRTArtificial SequenceSynthetic peptide 905His Ile Gly Leu Gly Gly
Leu 1 5 9067PRTArtificial SequenceSynthetic
peptide 906Thr Arg Leu Gly Gly Leu Thr 1 5
9077PRTArtificial SequenceSynthetic peptide 907Val Met Pro Gly Ser Val
Val 1 5 9087PRTArtificial SequenceSynthetic
peptide 908Gly Arg Leu Arg Ala Ser Leu 1 5
9097PRTArtificial SequenceSynthetic peptide 909Gly Arg Leu Tyr Leu Gly
Ile 1 5 9107PRTArtificial SequenceSynthetic
peptide 910Gly Arg Leu Arg Leu Arg Val 1 5
9117PRTArtificial SequenceSynthetic peptide 911Ser His Cys Gly Pro Ser
Asn 1 5 9127PRTArtificial SequenceSynthetic
peptide 912Val Arg Leu Ser Gly Arg Ala 1 5
9137PRTArtificial SequenceSynthetic peptide 913Arg Leu Ser Thr Phe Ala
Gly 1 5 9147PRTArtificial SequenceSynthetic
peptide 914Ala Arg Gly Ser Leu Arg Val 1 5
9157PRTArtificial SequenceSynthetic peptide 915Phe Ser Pro Arg Gly Ser
Val 1 5 9167PRTArtificial SequenceSynthetic
peptide 916Gly Gly Arg Leu Arg Ala Val 1 5
9177PRTArtificial SequenceSynthetic peptide 917Val Leu Ser Ala Val Ser
Ser 1 5 9187PRTArtificial SequenceSynthetic
peptide 918Ala Arg Gly Ser Leu Arg Val 1 5
9197PRTArtificial SequenceSynthetic peptide 919Leu Arg Ser Tyr Ala Trp
Ser 1 5 9207PRTArtificial SequenceSynthetic
peptide 920Lys Gly Arg Val Ser Ala Gly 1 5
9217PRTArtificial SequenceSynthetic peptide 921Ala Gly Leu Thr Ile Gly
Ile 1 5 9227PRTArtificial SequenceSynthetic
peptide 922Ala Trp Arg His Ala Gly Gly 1 5
9237PRTArtificial SequenceSynthetic peptide 923Trp Ala Arg Ala Gly Gly
Phe 1 5 9247PRTArtificial SequenceSynthetic
peptide 924Met Gly Val Leu Thr Ala Glu 1 5
9257PRTArtificial SequenceSynthetic peptide 925Phe Ala Gly Tyr Gly Val
Leu 1 5 9267PRTArtificial SequenceSynthetic
peptide 926Arg Ile Phe His Gly Ala Val 1 5
9277PRTArtificial SequenceSynthetic peptide 927Glu Gly Leu Val Val Phe
Glu 1 5 9287PRTArtificial SequenceSynthetic
peptide 928Arg Glu Val Pro Gly Leu Arg 1 5
9297PRTArtificial SequenceSynthetic peptide 929Leu Val Ser Val Asn Gly
Ala 1 5 9307PRTArtificial SequenceSynthetic
peptide 930His Ser Leu Val Ser Gln Pro 1 5
9317PRTArtificial SequenceSynthetic peptide 931Ala Arg Gly Ser Leu Arg
Val 1 5 9327PRTArtificial SequenceSynthetic
peptide 932Ser Ser Val Ala Ser Leu Val 1 5
9337PRTArtificial SequenceSynthetic peptide 933Ala Ala Val Trp Gln Met
Lys 1 5 9347PRTArtificial SequenceSynthetic
peptide 934Gln Arg Ala Ala Val Ile Val 1 5
9357PRTArtificial SequenceSynthetic peptide 935Pro Gly Gly Ser Asp Ala
Ala 1 5 9367PRTArtificial SequenceSynthetic
peptide 936Gly Gly Arg Leu Arg Ala Val 1 5
9377PRTArtificial SequenceSynthetic peptide 937Leu Pro Cys Gly Gly Leu
Ala 1 5 9387PRTArtificial SequenceSynthetic
peptide 938Gly Ser Ser His Asp Ala Leu 1 5
9397PRTArtificial SequenceSynthetic peptide 939Thr Gln Tyr Tyr Gly Ser
Ser 1 5 9407PRTArtificial SequenceSynthetic
peptide 940Phe Ser Pro Arg Gly Ser Val 1 5
9417PRTArtificial SequenceSynthetic peptide 941Lys Gly Arg Val Ser Ala
Gly 1 5 9427PRTArtificial SequenceSynthetic
peptide 942Gln Gly Arg Val Asn Val Lys 1 5
9437PRTArtificial SequenceSynthetic peptide 943Gly Gly Arg Leu Arg Ala
Val 1 5 9447PRTArtificial SequenceSynthetic
peptide 944Tyr Asp Gly Arg Leu Ala Arg 1 5
9457PRTArtificial SequenceSynthetic peptide 945Pro Gln Gly Arg Gly Val
Lys 1 5 9467PRTArtificial SequenceSynthetic
peptide 946Met Val Leu Arg Gly Ser Tyr 1 5
9477PRTArtificial SequenceSynthetic peptide 947Gly Gly Trp Ala Arg Ala
Val 1 5 9487PRTArtificial SequenceSynthetic
peptide 948Val Arg Ala Val Cys Leu Met 1 5
9497PRTArtificial SequenceSynthetic peptide 949Thr Arg Ala Ser Arg Arg
Gly 1 5 9507PRTArtificial SequenceSynthetic
peptide 950Leu Gly Ala Gly Glu Gly Asp 1 5
9517PRTArtificial SequenceSynthetic peptide 951Ile Gly Ala Val Ser Gly
Trp 1 5 9527PRTArtificial SequenceSynthetic
peptide 952Leu Leu Ser Arg Arg Val Gly 1 5
9537PRTArtificial SequenceSynthetic peptide 953Leu Glu Leu Leu Ser Val
Val 1 5 9547PRTArtificial SequenceSynthetic
peptide 954Arg Leu Leu Ser Glu Gly Tyr 1 5
9557PRTArtificial SequenceSynthetic peptide 955Gln Leu Pro Gly Leu Leu
Arg 1 5 9567PRTArtificial SequenceSynthetic
peptide 956Tyr Gly Glu Ser Leu Leu Arg 1 5
9577PRTArtificial SequenceSynthetic peptide 957Leu Arg Val Tyr Gly Glu
Gly 1 5 9587PRTArtificial SequenceSynthetic
peptide 958Tyr Arg Val Ser Ser Gly Ser 1 5
9597PRTArtificial SequenceSynthetic peptide 959Arg Ser Ser Ser Ser Thr
Arg 1 5 9607PRTArtificial SequenceSynthetic
peptide 960Trp Ala Gly Ser Asn Tyr Ser 1 5
9617PRTArtificial SequenceSynthetic peptide 961Cys Ala Gly Arg Ala Arg
Arg 1 5 9627PRTArtificial SequenceSynthetic
peptide 962Ile Ala Gly Leu Ala Val Val 1 5
9637PRTArtificial SequenceSynthetic peptide 963Asp Gly Glu Gly Ala Gly
Leu 1 5 9647PRTArtificial SequenceSynthetic
peptide 964Ala Leu Ala Gly Gly Gly Leu 1 5
9657PRTArtificial SequenceSynthetic peptide 965Gly Val Arg Arg Ser Leu
Leu 1 5 9667PRTArtificial SequenceSynthetic
peptide 966Ala Asp Trp Gly Val Leu Glu 1 5
9677PRTArtificial SequenceSynthetic peptide 967Ile Gly Ala Val Ser Gly
Trp 1 5 9687PRTArtificial SequenceSynthetic
peptide 968Ala Ser Gly Leu Val Val Thr 1 5
9697PRTArtificial SequenceSynthetic peptide 969Ile Gly Leu Arg Gly Glu
Asn 1 5 9707PRTArtificial SequenceSynthetic
peptide 970Arg Arg Ala Arg Gly Ala Cys 1 5
9717PRTArtificial SequenceSynthetic peptide 971Tyr Ala Ala Ser Leu Met
Gly 1 5 9727PRTArtificial SequenceSynthetic
peptide 972Leu Thr Ala Ala Val Met Val 1 5
9737PRTArtificial SequenceSynthetic peptide 973Tyr Ala Ala Ser Leu Met
Gly 1 5 9747PRTArtificial SequenceSynthetic
peptide 974Arg Ala Arg Thr Gly Gly Ser 1 5
9757PRTArtificial SequenceSynthetic peptide 975Val Ser Gly Asp Gly Gly
Ser 1 5 9767PRTArtificial SequenceSynthetic
peptide 976Phe Gly Gly Arg Ser Leu Ser 1 5
9777PRTArtificial SequenceSynthetic peptide 977Ser Leu Gly Gly Arg Thr
Phe 1 5 9787PRTArtificial SequenceSynthetic
peptide 978Ala Arg Arg Gly Leu Gly Leu 1 5
9797PRTArtificial SequenceSynthetic peptide 979Ala Leu Ala Gly Gly Gly
Leu 1 5 9807PRTArtificial SequenceSynthetic
peptide 980Phe Arg Ala Leu Gly Gly Leu 1 5
9817PRTArtificial SequenceSynthetic peptide 981Phe Thr Arg Gly Gly Leu
Ser 1 5 9827PRTArtificial SequenceSynthetic
peptide 982Ser Gly Ser Ser Val Arg Tyr 1 5
9837PRTArtificial SequenceSynthetic peptide 983Trp Gly Ser Val Ala Gly
Ile 1 5 9847PRTArtificial SequenceSynthetic
peptide 984Ser Gly Gly Asp Gly Ser Val 1 5
9857PRTArtificial SequenceSynthetic peptide 985Asn Glu Gly Arg Leu Gly
Ile 1 5 9867PRTArtificial SequenceSynthetic
peptide 986Tyr Ser Gly Arg Leu Val Met 1 5
9877PRTArtificial SequenceSynthetic peptide 987Asp Gly Pro Ser Gly Cys
Ser 1 5 9887PRTArtificial SequenceSynthetic
peptide 988Arg Gly Ser Arg Thr Gly Pro 1 5
9897PRTArtificial SequenceSynthetic peptide 989Gly Ser Ser Ala Cys Gly
Ala 1 5 9907PRTArtificial SequenceSynthetic
peptide 990Val Arg Leu Ser Gly Arg Ala 1 5
9917PRTArtificial SequenceSynthetic peptide 991Arg Leu Ser Thr Phe Ala
Gly 1 5 9927PRTArtificial SequenceSynthetic
peptide 992Ala Arg Gly Ser Leu Arg Val 1 5
9937PRTArtificial SequenceSynthetic peptide 993Phe Ser Pro Arg Gly Ser
Val 1 5 9947PRTArtificial SequenceSynthetic
peptide 994Gly Gly Arg Leu Arg Ala Val 1 5
9957PRTArtificial SequenceSynthetic peptide 995Val Leu Ser Ala Val Ser
Ser 1 5 9967PRTArtificial SequenceSynthetic
peptide 996Ala Arg Gly Ser Leu Arg Val 1 5
9977PRTArtificial SequenceSynthetic peptide 997Leu Arg Ser Tyr Ala Trp
Ser 1 5 9987PRTArtificial SequenceSynthetic
peptide 998Lys Gly Arg Val Ser Ala Gly 1 5
9997PRTArtificial SequenceSynthetic peptide 999Ala Gly Leu Thr Ile Gly
Ile 1 5 10007PRTArtificial SequenceSynthetic
peptide 1000Ala Trp Arg His Ala Gly Gly 1 5
10017PRTArtificial SequenceSynthetic peptide 1001Trp Ala Arg Ala Gly Gly
Phe 1 5 10027PRTArtificial SequenceSynthetic
peptide 1002Met Gly Val Leu Thr Ala Glu 1 5
10037PRTArtificial SequenceSynthetic peptide 1003Phe Ala Gly Tyr Gly Val
Leu 1 5 10047PRTArtificial SequenceSynthetic
peptide 1004Arg Ile Phe His Gly Ala Val 1 5
10057PRTArtificial SequenceSynthetic peptide 1005Glu Gly Leu Val Val Phe
Glu 1 5 10067PRTArtificial SequenceSynthetic
peptide 1006Arg Glu Val Pro Gly Leu Arg 1 5
10077PRTArtificial SequenceSynthetic peptide 1007Leu Val Ser Val Asn Gly
Ala 1 5 10087PRTArtificial SequenceSynthetic
peptide 1008His Ser Leu Val Ser Gln Pro 1 5
10097PRTArtificial SequenceSynthetic peptide 1009Ala Arg Gly Ser Leu Arg
Val 1 5 10107PRTArtificial SequenceSynthetic
peptide 1010Ser Ser Val Ala Ser Leu Val 1 5
10117PRTArtificial SequenceSynthetic peptide 1011Ala Ala Val Trp Gln Met
Lys 1 5 10127PRTArtificial SequenceSynthetic
peptide 1012Gln Arg Ala Ala Val Ile Val 1 5
10137PRTArtificial SequenceSynthetic peptide 1013Gly Gly Arg Leu Arg Ala
Val 1 5 10147PRTArtificial SequenceSynthetic
peptide 1014Leu Pro Cys Gly Gly Leu Ala 1 5
10157PRTArtificial SequenceSynthetic peptide 1015Gly Ser Ser His Asp Ala
Leu 1 5 10167PRTArtificial SequenceSynthetic
peptide 1016Thr Gln Tyr Tyr Gly Ser Ser 1 5
10177PRTArtificial SequenceSynthetic peptide 1017Phe Ser Pro Arg Gly Ser
Val 1 5 10187PRTArtificial SequenceSynthetic
peptide 1018Lys Gly Arg Val Ser Ala Gly 1 5
10197PRTArtificial SequenceSynthetic peptide 1019Gln Gly Arg Val Asn Val
Lys 1 5 10207PRTArtificial SequenceSynthetic
peptide 1020Gly Gly Arg Leu Arg Ala Val 1 5
10217PRTArtificial SequenceSynthetic peptide 1021Tyr Asp Gly Arg Leu Ala
Arg 1 5 10227PRTArtificial SequenceSynthetic
peptide 1022Ser Arg Leu Ser Tyr Trp Gln 1 5
10237PRTArtificial SequenceSynthetic peptide 1023Phe Val Gly Ser Arg Gly
Val 1 5 10247PRTArtificial SequenceSynthetic
peptide 1024Ser Val Asp Arg Gly Val Ile 1 5
10257PRTArtificial SequenceSynthetic peptide 1025Gly Arg Gly Ser Gly Gly
Phe 1 5 10267PRTArtificial SequenceSynthetic
peptide 1026Ile Phe Gly Ala Gly Leu Arg 1 5
10277PRTArtificial SequenceSynthetic peptide 1027Gly Trp Val Ala Val Ser
Cys 1 5 10287PRTArtificial SequenceSynthetic
peptide 1028Leu Leu Ser Gly Val Ile Leu 1 5
10297PRTArtificial SequenceSynthetic peptide 1029Gly Ser Thr Leu Leu Ser
Arg 1 5 10307PRTArtificial SequenceSynthetic
peptide 1030Gln Trp Tyr Ser Leu Arg Ser 1 5
10317PRTArtificial SequenceSynthetic peptide 1031Thr Trp Ile Gly Arg Val
Ser 1 5 10327PRTArtificial SequenceSynthetic
peptide 1032Ser Val Val Leu Ala Gly Ser 1 5
10337PRTArtificial SequenceSynthetic peptide 1033Ile Phe Gly Ala Gly Leu
Arg 1 5 10347PRTArtificial SequenceSynthetic
peptide 1034Ser Ala Gly Gly Trp Cys Ala 1 5
10357PRTArtificial SequenceSynthetic peptide 1035Arg Asp Gly Val Arg Val
Gly 1 5 10367PRTArtificial SequenceSynthetic
peptide 1036Val Ser Arg Ile Gly Val Arg 1 5
10377PRTArtificial SequenceSynthetic peptide 1037Gly Val Arg Ser Met Pro
Val 1 5 10387PRTArtificial SequenceSynthetic
peptide 1038Gly Gly Val Leu Gly Ser Asp 1 5
10397PRTArtificial SequenceSynthetic peptide 1039Trp Gly Val Leu Gln Leu
Glu 1 5 10407PRTArtificial SequenceSynthetic
peptide 1040His Gly Gly Pro Gly Ala Val 1 5
10417PRTArtificial SequenceSynthetic peptide 1041Asp Ser Gly Leu Val Gly
Gly 1 5 10427PRTArtificial SequenceSynthetic
peptide 1042Ile Phe Gly Ala Gly Leu Arg 1 5
10437PRTArtificial SequenceSynthetic peptide 1043Arg Met Gly Phe Gly Leu
Arg 1 5 10447PRTArtificial SequenceSynthetic
peptide 1044Trp Leu Asp Ala Ala Val Lys 1 5
10457PRTArtificial SequenceSynthetic peptide 1045Ile Ala Ala Ser Tyr Arg
Gly 1 5 10467PRTArtificial SequenceSynthetic
peptide 1046Ala Thr Ile Pro Gly Gly Ser 1 5
10477PRTArtificial SequenceSynthetic peptide 1047Asp Gly Gly Ser Leu Val
Val 1 5 10487PRTArtificial SequenceSynthetic
peptide 1048Phe Gly Gly Ser Gly Arg Gly 1 5
10497PRTArtificial SequenceSynthetic peptide 1049Ser Pro Thr Gly Gly Arg
Arg 1 5 10507PRTArtificial SequenceSynthetic
peptide 1050Thr Trp Ser Thr Gly Gly Arg 1 5
10517PRTArtificial SequenceSynthetic peptide 1051Ser Arg Ser Cys Gly Gly
Leu 1 5 10527PRTArtificial SequenceSynthetic
peptide 1052Cys Pro Gly Ser Gly Ile Ile 1 5
10537PRTArtificial SequenceSynthetic peptide 1053Phe Gly Gly Ser Gly Arg
Gly 1 5 10547PRTArtificial SequenceSynthetic
peptide 1054Ser Gly Ser Val Val Gln Arg 1 5
10557PRTArtificial SequenceSynthetic peptide 1055Thr Trp Ile Gly Arg Val
Ser 1 5 10567PRTArtificial SequenceSynthetic
peptide 1056Gly Pro Ser Trp Ala Thr Val 1 5
10577PRTArtificial SequenceSynthetic peptide 1057Ala Arg Arg Gly Ser Gly
Leu 1 5 10587PRTArtificial SequenceSynthetic
peptide 1058Arg Ala Val Gly Tyr Asn Ala 1 5
10597PRTArtificial SequenceSynthetic peptide 1059Leu Arg Ala Val Glu Phe
Leu 1 5 10607PRTArtificial SequenceSynthetic
peptide 1060Phe Glu Asp Leu Leu Ser Leu 1 5
10617PRTArtificial SequenceSynthetic peptide 1061Arg Trp Leu Ser Leu Leu
Ser 1 5 10627PRTArtificial SequenceSynthetic
peptide 1062His Ala Pro Gly Leu Arg Val 1 5
10637PRTArtificial SequenceSynthetic peptide 1063Leu Arg Ser Ser Met Met
Leu 1 5 10647PRTArtificial SequenceSynthetic
peptide 1064Arg Pro Lys Leu Arg Ser Val 1 5
10657PRTArtificial SequenceSynthetic peptide 1065Ser Arg Val Ser Phe His
Glu 1 5 10667PRTArtificial SequenceSynthetic
peptide 1066Leu Arg Ser Ser Met Met Leu 1 5
10677PRTArtificial SequenceSynthetic peptide 1067Ser Ser Gly Gly Arg Ser
Ser 1 5 10687PRTArtificial SequenceSynthetic
peptide 1068Val Ala Gly Arg Val Gly Ile 1 5
10697PRTArtificial SequenceSynthetic peptide 1069Ala Gly Leu Ala Leu Thr
Val 1 5 10707PRTArtificial SequenceSynthetic
peptide 1070Ile Gly Val Arg Gly Ala Val 1 5
10717PRTArtificial SequenceSynthetic peptide 1071Leu Val Arg Asp Gly Val
Leu 1 5 10727PRTArtificial SequenceSynthetic
peptide 1072Ile Gly Val Arg Gly Ala Val 1 5
10737PRTArtificial SequenceSynthetic peptide 1073His Gly Leu Val Thr His
Asn 1 5 10747PRTArtificial SequenceSynthetic
peptide 1074His Ala Pro Gly Leu Arg Val 1 5
10757PRTArtificial SequenceSynthetic peptide 1075Val Ser Ser Thr Ala Arg
Gly 1 5 10767PRTArtificial SequenceSynthetic
peptide 1076Arg Ala Ala Val Ile His Thr 1 5
10777PRTArtificial SequenceSynthetic peptide 1077Ala Ala Ser Thr Arg Ser
Leu 1 5 10787PRTArtificial SequenceSynthetic
peptide 1078Gly Trp Gly Gly Gly Ser Ala 1 5
10797PRTArtificial SequenceSynthetic peptide 1079Ser Ser Arg Gly Gly Ser
Ser 1 5 10807PRTArtificial SequenceSynthetic
peptide 1080Ser Ser Gly Gly Arg Ser Ser 1 5
10817PRTArtificial SequenceSynthetic peptide 1081Ser Ser Arg Gly Gly Ser
Ser 1 5 10827PRTArtificial SequenceSynthetic
peptide 1082Ala Arg Arg Gly Ser Gly Leu 1 5
10837PRTArtificial SequenceSynthetic peptide 1083Val Ala Gly Arg Val Gly
Ile 1 5 10847PRTArtificial SequenceSynthetic
peptide 1084Glu Gly Arg Leu Met Leu Ala 1 5
10857PRTArtificial SequenceSynthetic peptide 1085Arg Leu Ser Ser Ala Pro
Ser 1 5 10867PRTArtificial SequenceSynthetic
peptide 1086Arg Arg Leu Ser Tyr His Ser 1 5
10877PRTArtificial SequenceSynthetic peptide 1087Phe Leu His Met Arg Leu
Ser 1 5 10887PRTArtificial SequenceSynthetic
peptide 1088Leu Ala Arg Gly Val Pro Pro 1 5
10897PRTArtificial SequenceSynthetic peptide 1089Leu Ser Arg Gly Ser Val
Ala 1 5 10907PRTArtificial SequenceSynthetic
peptide 1090Val Trp Leu Arg Gly Ser Thr 1 5
10917PRTArtificial SequenceSynthetic peptide 1091Arg Gly Gly Gln Arg Ala
Ser 1 5 10927PRTArtificial SequenceSynthetic
peptide 1092Ala Val Ser Gly Arg Ser Leu 1 5
10937PRTArtificial SequenceSynthetic peptide 1093Gly Leu Leu Ser Ser Phe
Ser 1 5 10947PRTArtificial SequenceSynthetic
peptide 1094Arg Met Gly Leu Leu Arg Gln 1 5
10957PRTArtificial SequenceSynthetic peptide 1095Arg Leu His Tyr Leu Arg
Ser 1 5 10967PRTArtificial SequenceSynthetic
peptide 1096Gly Gly Tyr Trp Leu Arg Ser 1 5
10977PRTArtificial SequenceSynthetic peptide 1097Asn Arg Ser Ser His Cys
Gly 1 5 10987PRTArtificial SequenceSynthetic
peptide 1098Gln Arg Ser Ser Asp Leu Thr 1 5
10997PRTArtificial SequenceSynthetic peptide 1099Ala Ala Gly Arg Ser Arg
Ile 1 5 11007PRTArtificial SequenceSynthetic
peptide 1100Gly Arg Ala Gly Gly Asn Gly 1 5
11017PRTArtificial SequenceSynthetic peptide 1101Ala Asn Ala Ser Gly Val
Arg 1 5 11027PRTArtificial SequenceSynthetic
peptide 1102Trp Ala His Gly Val Leu Ser 1 5
11037PRTArtificial SequenceSynthetic peptide 1103Ser Leu Tyr Gly Leu Arg
Trp 1 5 11047PRTArtificial SequenceSynthetic
peptide 1104Gly Asn Gly Gly Ala Arg Gly 1 5
11057PRTArtificial SequenceSynthetic peptide 1105Leu Ala Arg Gly Val Pro
Pro 1 5 11067PRTArtificial SequenceSynthetic
peptide 1106Asn Trp Asp Ala Arg Gly Arg 1 5
11077PRTArtificial SequenceSynthetic peptide 1107Ala Ser Leu Pro Val Leu
Asp 1 5 11087PRTArtificial SequenceSynthetic
peptide 1108Pro Pro Gly Ala Ser Leu Tyr 1 5
11097PRTArtificial SequenceSynthetic peptide 1109Ala Ala Val Gly Gly Arg
Val 1 5 11107PRTArtificial SequenceSynthetic
peptide 1110Ala Ala Ser Ser Trp Ala Val 1 5
11117PRTArtificial SequenceSynthetic peptide 1111Ala Phe Lys Thr Gly Gly
Ser 1 5 11127PRTArtificial SequenceSynthetic
peptide 1112Phe Glu Gly Gly Arg Ser Gly 1 5
11137PRTArtificial SequenceSynthetic peptide 1113Arg Thr Trp Gly Gly Arg
Met 1 5 11147PRTArtificial SequenceSynthetic
peptide 1114Ser Ala Arg Gln Gly Gly Arg 1 5
11157PRTArtificial SequenceSynthetic peptide 1115Ala Ala Val Gly Gly Arg
Val 1 5 11167PRTArtificial SequenceSynthetic
peptide 1116Ala Arg His Gly Ser Ser Val 1 5
11177PRTArtificial SequenceSynthetic peptide 1117Ser Asn Phe Tyr Gly Ser
Ser 1 5 11187PRTArtificial SequenceSynthetic
peptide 1118Gly Ser Gly Gln Leu Ile Pro 1 5
11197PRTArtificial SequenceSynthetic peptide 1119Leu Ser Arg Gly Ser Val
Ala 1 5 11207PRTArtificial SequenceSynthetic
peptide 1120Ala Glu Tyr Gly Arg Val Leu 1 5
11217PRTArtificial SequenceSynthetic peptide 1121Arg Gly Arg Val Leu Leu
Pro 1 5 11227PRTArtificial SequenceSynthetic
peptide 1122Ala Ala Val Gly Gly Arg Val 1 5
11237PRTArtificial SequenceSynthetic peptide 1123Arg Gly Arg Leu Ala Leu
Leu 1 5 11247PRTArtificial SequenceSynthetic
peptide 1124Ser Gly Pro Gly Arg Leu Pro 1 5
11257PRTArtificial SequenceSynthetic peptide 1125Thr Ser Gly Arg Leu Trp
Val 1 5 11267PRTArtificial SequenceSynthetic
peptide 1126Met Val Tyr Ser Gly Val Ser 1 5
11277PRTArtificial SequenceSynthetic peptide 1127Trp Arg Leu Ser Arg Glu
Gly 1 5 11287PRTArtificial SequenceSynthetic
peptide 1128Leu Leu Arg Arg Leu Ser Trp 1 5
11297PRTArtificial SequenceSynthetic peptide 1129Ala Ala Arg Gly Val Met
Val 1 5 11307PRTArtificial SequenceSynthetic
peptide 1130Ala Leu Ala Arg Gly Ser Gly 1 5
11317PRTArtificial SequenceSynthetic peptide 1131Asn Leu Arg Gly Ser Arg
Ser 1 5 11327PRTArtificial SequenceSynthetic
peptide 1132Arg Ala Val Trp Arg Ala Ser 1 5
11337PRTArtificial SequenceSynthetic peptide 1133Gly Ala Gly Ser Phe Ser
Ser 1 5 11347PRTArtificial SequenceSynthetic
peptide 1134Leu Leu Ser Ser Arg Arg Cys 1 5
11357PRTArtificial SequenceSynthetic peptide 1135Leu Leu Ser Leu Asp Pro
Gly 1 5 11367PRTArtificial SequenceSynthetic
peptide 1136Ser Ser Leu Leu Ser Ser Leu 1 5
11377PRTArtificial SequenceSynthetic peptide 1137Leu Leu Arg Pro Ala His
Gly 1 5 11387PRTArtificial SequenceSynthetic
peptide 1138Leu Leu Arg Arg Leu Ser Trp 1 5
11397PRTArtificial SequenceSynthetic peptide 1139Cys Met Leu Arg Ser Ala
Thr 1 5 11407PRTArtificial SequenceSynthetic
peptide 1140Ser Lys Ala Val Leu Arg Ser 1 5
11417PRTArtificial SequenceSynthetic peptide 1141Ser Arg Val Ser Asn Pro
Ser 1 5 11427PRTArtificial SequenceSynthetic
peptide 1142Cys Arg Arg Ser Ser Leu Leu 1 5
11437PRTArtificial SequenceSynthetic peptide 1143Gly Ala Gly Ser Phe Ser
Ser 1 5 11447PRTArtificial SequenceSynthetic
peptide 1144Ser Ala Ala Gly Arg Thr Phe 1 5
11457PRTArtificial SequenceSynthetic peptide 1145Pro Ala Gly Arg Met Leu
Ser 1 5 11467PRTArtificial SequenceSynthetic
peptide 1146Ile Ala Met Ala Gly Leu Arg 1 5
11477PRTArtificial SequenceSynthetic peptide 1147Ala Gly Gly Phe Arg Phe
Ile 1 5 11487PRTArtificial SequenceSynthetic
peptide 1148Ser Gly Val Arg Pro Val Ile 1 5
11497PRTArtificial SequenceSynthetic peptide 1149Gly Val Leu Ser Asp Arg
Ser 1 5 11507PRTArtificial SequenceSynthetic
peptide 1150Gly Ala Val Thr Ser Ala Asp 1 5
11517PRTArtificial SequenceSynthetic peptide 1151Gly Ala Val Thr Ser Ala
Asp 1 5 11527PRTArtificial SequenceSynthetic
peptide 1152Gly Ala Val Asn Thr Pro Ala 1 5
11537PRTArtificial SequenceSynthetic peptide 1153Gly Gly Leu Val Lys Arg
Leu 1 5 11547PRTArtificial SequenceSynthetic
peptide 1154Glu Val Ala Ser Gly Leu Val 1 5
11557PRTArtificial SequenceSynthetic peptide 1155Ile Ala Met Ala Gly Leu
Arg 1 5 11567PRTArtificial SequenceSynthetic
peptide 1156Gly Thr His Ser Gly Leu Arg 1 5
11577PRTArtificial SequenceSynthetic peptide 1157Leu Val Ser Thr Ser Asn
Arg 1 5 11587PRTArtificial SequenceSynthetic
peptide 1158Phe Ser Leu Val Ser Phe Val 1 5
11597PRTArtificial SequenceSynthetic peptide 1159Ala Leu Val Ser Ser His
Val 1 5 11607PRTArtificial SequenceSynthetic
peptide 1160Ala Ala Arg Gly Val Met Val 1 5
11617PRTArtificial SequenceSynthetic peptide 1161Ala Leu Ala Arg Gly Ser
Gly 1 5 11627PRTArtificial SequenceSynthetic
peptide 1162Leu Arg Tyr Trp Ala Ala Val 1 5
11637PRTArtificial SequenceSynthetic peptide 1163Phe Thr Arg Gly Ala Ala
Ser 1 5 11647PRTArtificial SequenceSynthetic
peptide 1164Glu Trp His Ala Ala Ser Gly 1 5
11657PRTArtificial SequenceSynthetic peptide 1165Phe Gly Gly Ser Met Ala
Pro 1 5 11667PRTArtificial SequenceSynthetic
peptide 1166Gly Gly Ser Leu Lys Trp Val 1 5
11677PRTArtificial SequenceSynthetic peptide 1167Arg Gly Leu Gln Gly Gly
Arg 1 5 11687PRTArtificial SequenceSynthetic
peptide 1168Thr Cys Gly Gly Arg Ser Tyr 1 5
11697PRTArtificial SequenceSynthetic peptide 1169Gly Glu Ala Leu Gly Leu
Gly 1 5 11707PRTArtificial SequenceSynthetic
peptide 1170Pro Arg Gly Leu Gly Val Gly 1 5
11717PRTArtificial SequenceSynthetic peptide 1171Val Gly Leu Gly Asn Ser
Ala 1 5 11727PRTArtificial SequenceSynthetic
peptide 1172Gly Gly Leu Val Lys Arg Leu 1 5
11737PRTArtificial SequenceSynthetic peptide 1173Gly Ser Gly Arg Ala Leu
Ala 1 5 11747PRTArtificial SequenceSynthetic
peptide 1174Ser Arg Ser Gly Arg Leu Asn 1 5
11757PRTArtificial SequenceSynthetic peptide 1175Ser Ala Gly Val Ser Asp
Ser 1 5 11767PRTArtificial SequenceSynthetic
peptide 1176Pro Arg Leu Ser Asp Lys Ser 1 5
11777PRTArtificial SequenceSynthetic peptide 1177Gly Arg Gly Asp Arg Gly
Val 1 5 11787PRTArtificial SequenceSynthetic
peptide 1178Arg Gly Val Ser Gly Arg Leu 1 5
11797PRTArtificial SequenceSynthetic peptide 1179Ile Asn Arg Gly Ser Arg
Glu 1 5 11807PRTArtificial SequenceSynthetic
peptide 1180Leu Arg Gly Ser Arg Gln Phe 1 5
11817PRTArtificial SequenceSynthetic peptide 1181Leu Arg Gly Ser Val Gly
Arg 1 5 11827PRTArtificial SequenceSynthetic
peptide 1182Gly Leu Trp Tyr Arg Ala Val 1 5
11837PRTArtificial SequenceSynthetic peptide 1183Arg Val Arg Ala Val Leu
Gly 1 5 11847PRTArtificial SequenceSynthetic
peptide 1184Arg Ala Val Leu Glu Leu Trp 1 5
11857PRTArtificial SequenceSynthetic peptide 1185Leu Val Arg Ala Ser Asn
Gly 1 5 11867PRTArtificial SequenceSynthetic
peptide 1186Ala Ser Gly Thr Leu Leu Arg 1 5
11877PRTArtificial SequenceSynthetic peptide 1187Gly Ser Gly Val Arg Val
Ser 1 5 11887PRTArtificial SequenceSynthetic
peptide 1188Val Gly Ser Thr Arg Ser Ser 1 5
11897PRTArtificial SequenceSynthetic peptide 1189Arg Ala Gly Ser Arg Tyr
Ile 1 5 11907PRTArtificial SequenceSynthetic
peptide 1190Val Gly Val Arg Phe Ser Arg 1 5
11917PRTArtificial SequenceSynthetic peptide 1191Gly Ser Gly Val Arg Val
Ser 1 5 11927PRTArtificial SequenceSynthetic
peptide 1192Ile Gly Val Leu Ala Ser Ala 1 5
11937PRTArtificial SequenceSynthetic peptide 1193Gly Leu Val Ala Arg Val
Arg 1 5 11947PRTArtificial SequenceSynthetic
peptide 1194Leu Leu Gly Ile Gly Gly Ser 1 5
11957PRTArtificial SequenceSynthetic peptide 1195Gln Leu Gly Gly Ser Phe
Arg 1 5 11967PRTArtificial SequenceSynthetic
peptide 1196Leu Phe Arg Trp Gly Gly Arg 1 5
11977PRTArtificial SequenceSynthetic peptide 1197Arg Phe Ser Gly Gly Leu
Gln 1 5 11987PRTArtificial SequenceSynthetic
peptide 1198Val Gly Ser Ser His Gly Leu 1 5
11997PRTArtificial SequenceSynthetic peptide 1199Ser Val Arg Val Gly Ser
Gly 1 5 12007PRTArtificial SequenceSynthetic
peptide 1200Gly Val Asn Gly Ser Val Ser 1 5
12017PRTArtificial SequenceSynthetic peptide 1201Leu Arg Gly Ser Val Gly
Arg 1 5 12027PRTArtificial SequenceSynthetic
peptide 1202His Val Lys Asn Gly Arg Val 1 5
12037PRTArtificial SequenceSynthetic peptide 1203Phe Gln Arg Ser Gly Arg
Leu 1 5 12047PRTArtificial SequenceSynthetic
peptide 1204His Gly Arg Leu Ala Phe Gly 1 5
12057PRTArtificial SequenceSynthetic peptide 1205Arg Gly Val Ser Gly Arg
Leu 1 5 12067PRTArtificial SequenceSynthetic
peptide 1206Arg Gly Val Ser Gly Arg Leu 1 5
12077PRTArtificial SequenceSynthetic peptide 1207Phe Gly Ile Gly Arg Gly
Val 1 5 12087PRTArtificial SequenceSynthetic
peptide 1208Gly Val Val Gln Ala Val Ser 1 5
12097PRTArtificial SequenceSynthetic peptide 1209Leu Ser Ala Val Ser Val
Lys 1 5 12107PRTArtificial SequenceSynthetic
peptide 1210Leu Tyr Leu Leu Ser Ser Ala 1 5
12117PRTArtificial SequenceSynthetic peptide 1211Leu Ile Gly Gly Leu Leu
Ser 1 5 12127PRTArtificial SequenceSynthetic
peptide 1212Leu Leu Arg Arg Gly Ile Gly 1 5
12137PRTArtificial SequenceSynthetic peptide 1213Phe Leu Arg Ser Leu Ser
Leu 1 5 12147PRTArtificial SequenceSynthetic
peptide 1214Val Arg Val Ser Gly Leu Thr 1 5
12157PRTArtificial SequenceSynthetic peptide 1215Ala Gly Ser Val Asp Leu
Val 1 5 12167PRTArtificial SequenceSynthetic
peptide 1216Gly Phe Val Ala Gly Arg Thr 1 5
12177PRTArtificial SequenceSynthetic peptide 1217Thr Arg Gly Ala Val Phe
Gly 1 5 12187PRTArtificial SequenceSynthetic
peptide 1218Ile Tyr Gly Gly Leu Val Ile 1 5
12197PRTArtificial SequenceSynthetic peptide 1219Pro Thr Gly Glu Gly Leu
Arg 1 5 12207PRTArtificial SequenceSynthetic
peptide 1220Lys Val Ser Val Ala Ser Leu 1 5
12217PRTArtificial SequenceSynthetic peptide 1221Arg Tyr Ser Met Ala Ser
Leu 1 5 12227PRTArtificial SequenceSynthetic
peptide 1222Ala Asn Ala Ala Ser Ser Pro 1 5
12237PRTArtificial SequenceSynthetic peptide 1223Pro Gly Gly Ser Arg His
Ala 1 5 12247PRTArtificial SequenceSynthetic
peptide 1224Gly Gly Ser Pro Gly Val Trp 1 5
12257PRTArtificial SequenceSynthetic peptide 1225Ile Tyr Gly Gly Leu Val
Ile 1 5 12267PRTArtificial SequenceSynthetic
peptide 1226Leu Ile Gly Gly Leu Leu Ser 1 5
12277PRTArtificial SequenceSynthetic peptide 1227Ala Cys Gly Ser Gly Leu
Asp 1 5 12287PRTArtificial SequenceSynthetic
peptide 1228Ala Gly Ser Val Asp Leu Val 1 5
12297PRTArtificial SequenceSynthetic peptide 1229Thr Leu Gly Ser Val Arg
Val 1 5 12307PRTArtificial SequenceSynthetic
peptide 1230His Val Arg Gly Arg Val Ala 1 5
12317PRTArtificial SequenceSynthetic peptide 1231Ile Asp Leu Gly Arg Val
Asn 1 5 12327PRTArtificial SequenceSynthetic
peptide 1232Gly Arg Leu Asp Ala Phe Gly 1 5
12337PRTArtificial SequenceSynthetic peptide 1233Trp Val Gly Pro Ser Gly
Gly 1 5 12347PRTArtificial SequenceSynthetic
peptide 1234Asp Leu Arg Leu Ser Phe Pro 1 5
12357PRTArtificial SequenceSynthetic peptide 1235Ser Ala Arg Leu Ser His
Val 1 5 12367PRTArtificial SequenceSynthetic
peptide 1236Val Met Asp Arg Gly Val Ala 1 5
12377PRTArtificial SequenceSynthetic peptide 1237Arg Gly Ser Leu Leu Trp
Ala 1 5 12387PRTArtificial SequenceSynthetic
peptide 1238Arg Gly Ser Pro Leu Thr Lys 1 5
12397PRTArtificial SequenceSynthetic peptide 1239Arg Ala Ser Ile Gly Ile
Glu 1 5 12407PRTArtificial SequenceSynthetic
peptide 1240Val His Ser Leu Arg Ala Ser 1 5
12417PRTArtificial SequenceSynthetic peptide 1241Ala Trp Leu Leu Ser Gly
Arg 1 5 12427PRTArtificial SequenceSynthetic
peptide 1242Leu Trp Leu Arg Ser Arg Glu 1 5
12437PRTArtificial SequenceSynthetic peptide 1243Val Thr Arg Ile Arg Val
Ser 1 5 12447PRTArtificial SequenceSynthetic
peptide 1244Asn Ser Gln Arg Ser Ser Val 1 5
12457PRTArtificial SequenceSynthetic peptide 1245Ala Ala Thr Arg Ala Gly
Ser 1 5 12467PRTArtificial SequenceSynthetic
peptide 1246Thr Asp Gly Val Arg Ala Phe 1 5
12477PRTArtificial SequenceSynthetic peptide 1247Phe Ala Ala Ser Gly Val
Leu 1 5 12487PRTArtificial SequenceSynthetic
peptide 1248Gly Val Leu Glu Gly Arg Arg 1 5
12497PRTArtificial SequenceSynthetic peptide 1249Glu Ala Asp Pro Gly Ala
Val 1 5 12507PRTArtificial SequenceSynthetic
peptide 1250Asp Gly Ala Val Ile Leu His 1 5
12517PRTArtificial SequenceSynthetic peptide 1251Arg Asp Gly Ala Val Asn
Leu 1 5 12527PRTArtificial SequenceSynthetic
peptide 1252Gly Leu Arg Pro His Gly Ala 1 5
12537PRTArtificial SequenceSynthetic peptide 1253Thr Ser Arg Gly Leu Arg
Leu 1 5 12547PRTArtificial SequenceSynthetic
peptide 1254Arg Met Leu Val Ser Ser Phe 1 5
12557PRTArtificial SequenceSynthetic peptide 1255Asp Val Ile Ala Arg Gly
Trp 1 5 12567PRTArtificial SequenceSynthetic
peptide 1256Thr Leu Thr Ala Ala Val Phe 1 5
12577PRTArtificial SequenceSynthetic peptide 1257Gly Trp Leu Asn Ala Ala
Val 1 5 12587PRTArtificial SequenceSynthetic
peptide 1258Phe Ala Ala Ser Gly Val Leu 1 5
12597PRTArtificial SequenceSynthetic peptide 1259Gly Gly Ser Lys Gly Ser
Ala 1 5 12607PRTArtificial SequenceSynthetic
peptide 1260Ala Val Ala Leu Gly Gly Ser 1 5
12617PRTArtificial SequenceSynthetic peptide 1261His Gly Gly Arg Tyr Arg
His 1 5 12627PRTArtificial SequenceSynthetic
peptide 1262Ser Gly Val Gly Gly Arg Tyr 1 5
12637PRTArtificial SequenceSynthetic peptide 1263Ser Gly Gly Leu Ala Val
Ala 1 5 12647PRTArtificial SequenceSynthetic
peptide 1264Gly Arg Leu Ala Lys Ser Ile 1 5
12657PRTArtificial SequenceSynthetic peptide 1265Ala Gly Pro Ser Arg Gly
Pro 1 5 12667PRTArtificial SequenceSynthetic
peptide 1266Gly Leu Met Arg Leu Ser His 1 5
12677PRTArtificial SequenceSynthetic peptide 1267Val Arg Val Gly Arg Leu
Ser 1 5 12687PRTArtificial SequenceSynthetic
peptide 1268Thr Gly Arg Leu Ser Ala Ala 1 5
12697PRTArtificial SequenceSynthetic peptide 1269Ser Leu Arg Gly Val Arg
Val 1 5 12707PRTArtificial SequenceSynthetic
peptide 1270Asp Asn Cys Glu Arg Gly Val 1 5
12717PRTArtificial SequenceSynthetic peptide 1271Thr Thr Gln Leu Arg Gly
Val 1 5 12727PRTArtificial SequenceSynthetic
peptide 1272Gly Val Ile Gly Arg Gly Ser 1 5
12737PRTArtificial SequenceSynthetic peptide 1273Leu Ala Gly Met Arg Gly
Ser 1 5 12747PRTArtificial SequenceSynthetic
peptide 1274Val Arg Pro Arg Ala Val Leu 1 5
12757PRTArtificial SequenceSynthetic peptide 1275Pro Pro Arg Ala Val Thr
Asn 1 5 12767PRTArtificial SequenceSynthetic
peptide 1276Trp Arg Ala Arg Ala Ser Pro 1 5
12777PRTArtificial SequenceSynthetic peptide 1277Phe Gly Arg Leu Leu Ser
Pro 1 5 12787PRTArtificial SequenceSynthetic
peptide 1278Pro Ser Leu Leu Arg Gly Phe 1 5
12797PRTArtificial SequenceSynthetic peptide 1279Arg Asp Leu Arg Val His
Leu 1 5 12807PRTArtificial SequenceSynthetic
peptide 1280Leu Arg Val Ser Asn Pro Arg 1 5
12817PRTArtificial SequenceSynthetic peptide 1281Leu Arg Val Asp Gln Leu
Tyr 1 5 12827PRTArtificial SequenceSynthetic
peptide 1282His Arg Leu Arg Ser Met Ser 1 5
12837PRTArtificial SequenceSynthetic peptide 1283Leu Arg Val Ser Asn Pro
Arg 1 5 12847PRTArtificial SequenceSynthetic
peptide 1284Pro Gly Phe Met Ala Gly Ser 1 5
12857PRTArtificial SequenceSynthetic peptide 1285Ala Gly Arg Gly Ile Ser
Gln 1 5 12867PRTArtificial SequenceSynthetic
peptide 1286Arg Ala Gly Arg Asp Ala Pro 1 5
12877PRTArtificial SequenceSynthetic peptide 1287Arg Ala Gly Arg Gly Phe
Glu 1 5 12887PRTArtificial SequenceSynthetic
peptide 1288His Gln Ala Gly Gly Val Thr 1 5
12897PRTArtificial SequenceSynthetic peptide 1289Ser Leu Arg Gly Val Arg
Val 1 5 12907PRTArtificial SequenceSynthetic
peptide 1290Asp Trp Val Gly Val Leu Met 1 5
12917PRTArtificial SequenceSynthetic peptide 1291Gly Thr Leu Gly Val Leu
Ser 1 5 12927PRTArtificial SequenceSynthetic
peptide 1292Gly Val Leu Leu Trp Arg Pro 1 5
12937PRTArtificial SequenceSynthetic peptide 1293Gly Leu Arg Glu Ala His
Val 1 5 12947PRTArtificial SequenceSynthetic
peptide 1294Ala Ala Arg Gly Glu Leu Arg 1 5
12957PRTArtificial SequenceSynthetic peptide 1295Ala Ala Ser Leu Arg Gly
Thr 1 5 12967PRTArtificial SequenceSynthetic
peptide 1296Pro Val Gly Ala Ala Val Ala 1 5
12977PRTArtificial SequenceSynthetic peptide 1297Ala Ala Ser Leu Arg Gly
Thr 1 5 12987PRTArtificial SequenceSynthetic
peptide 1298Ser Asn Pro Gly Ser Gly Ser 1 5
12997PRTArtificial SequenceSynthetic peptide 1299Gly Arg Val Arg Glu Thr
Pro 1 5 13007PRTArtificial SequenceSynthetic
peptide 1300Phe Gly Arg Leu Leu Ser Pro 1 5
13017PRTArtificial SequenceSynthetic peptide 1301Val Arg Val Gly Arg Leu
Ser 1 5 13027PRTArtificial SequenceSynthetic
peptide 1302Thr Gly Arg Leu Ser Ala Ala 1 5
13037PRTArtificial SequenceSynthetic peptide 1303Val Gly Arg Leu Gln Thr
Thr 1 5 13047PRTArtificial SequenceSynthetic
peptide 1304Asp Gly Pro Ser Cys Val Ile 1 5
13057PRTArtificial SequenceSynthetic peptide 1305Arg Phe Ser Ser Arg Ala
Val 1 5 13067PRTArtificial SequenceSynthetic
peptide 1306His Ala Gly Ser Arg Ala Ser 1 5
13077PRTArtificial SequenceSynthetic peptide 1307Gly Ala Gly Leu Gly Val
Ser 1 5 13087PRTArtificial SequenceSynthetic
peptide 1308Leu Leu Gly Ala Gly Thr Pro 1 5
13097PRTArtificial SequenceSynthetic peptide 1309Leu Leu Ser Ile Leu Lys
Ala 1 5 13107PRTArtificial SequenceSynthetic
peptide 1310Gly Leu Leu Ser Gly Gly Thr 1 5
13117PRTArtificial SequenceSynthetic peptide 1311Leu Ser Val Leu Arg Val
Leu 1 5 13127PRTArtificial SequenceSynthetic
peptide 1312Ser Arg Tyr Thr Leu Arg Ser 1 5
13137PRTArtificial SequenceSynthetic peptide 1313Leu Phe His Thr Arg Ser
Ser 1 5 13147PRTArtificial SequenceSynthetic
peptide 1314Val Ala Arg Ser Ser Phe Arg 1 5
13157PRTArtificial SequenceSynthetic peptide 1315Cys Thr Ala Gly Ser Val
Ser 1 5 13167PRTArtificial SequenceSynthetic
peptide 1316Arg Ala Ala Gly Ser Ala Gly 1 5
13177PRTArtificial SequenceSynthetic peptide 1317His Ala Gly Ser Arg Ala
Ser 1 5 13187PRTArtificial SequenceSynthetic
peptide 1318Gly Ala Gly Leu Gly Val Ser 1 5
13197PRTArtificial SequenceSynthetic peptide 1319Pro Thr Gly Ala Gly Leu
Leu 1 5 13207PRTArtificial SequenceSynthetic
peptide 1320Ala Ser Tyr Ala Gly Leu Val 1 5
13217PRTArtificial SequenceSynthetic peptide 1321Ala Gly Gly Phe Gly Val
Leu 1 5 13227PRTArtificial SequenceSynthetic
peptide 1322Asn Met Ala Gly Gly Gln Glu 1 5
13237PRTArtificial SequenceSynthetic peptide 1323Leu Arg Ala Gly Gly Ser
Tyr 1 5 13247PRTArtificial SequenceSynthetic
peptide 1324Tyr Leu Ala Gly Gly Lys Ala 1 5
13257PRTArtificial SequenceSynthetic peptide 1325Pro Tyr Tyr Asn Gly Val
Arg 1 5 13267PRTArtificial SequenceSynthetic
peptide 1326Ala Gly Gly Phe Gly Val Leu 1 5
13277PRTArtificial SequenceSynthetic peptide 1327Leu Ile Gly Gly Val Leu
His 1 5 13287PRTArtificial SequenceSynthetic
peptide 1328Asp Gly Leu Val Pro Val Ala 1 5
13297PRTArtificial SequenceSynthetic peptide 1329Gly Leu Val Ala Ser Met
Pro 1 5 13307PRTArtificial SequenceSynthetic
peptide 1330Ala Ser Tyr Ala Gly Leu Val 1 5
13317PRTArtificial SequenceSynthetic peptide 1331Leu Val Arg Leu Val Ser
Leu 1 5 13327PRTArtificial SequenceSynthetic
peptide 1332Val Leu Ala Ser Leu Ser Gly 1 5
13337PRTArtificial SequenceSynthetic peptide 1333Gly Ser Ile Thr Gly Gly
Ser 1 5 13347PRTArtificial SequenceSynthetic
peptide 1334Leu Arg Ala Gly Gly Ser Tyr 1 5
13357PRTArtificial SequenceSynthetic peptide 1335Thr Gly Gly Ser Leu Leu
Gly 1 5 13367PRTArtificial SequenceSynthetic
peptide 1336Asp Glu Gly Gly Ser Arg Trp 1 5
13377PRTArtificial SequenceSynthetic peptide 1337Gly Ala Gly Leu Gly Val
Ser 1 5 13387PRTArtificial SequenceSynthetic
peptide 1338Trp Gly Ser Ser Ala Val Lys 1 5
13397PRTArtificial SequenceSynthetic peptide 1339Gln Gly Ser Ser Asn Ser
Val 1 5 13407PRTArtificial SequenceSynthetic
peptide 1340Cys Thr Ala Gly Ser Val Ser 1 5
13417PRTArtificial SequenceSynthetic peptide 1341Ser Val Thr Gly Ser Val
Gly 1 5 13427PRTArtificial SequenceSynthetic
peptide 1342Ser Pro Gly Arg Val Ala Asp 1 5
13437PRTArtificial SequenceSynthetic peptide 1343Asp Ala Val Arg Gly Pro
Ser 1 5 13447PRTArtificial SequenceSynthetic
peptide 1344Gly Ala Gly Leu Gly Val Ser 1 5
13457PRTArtificial SequenceSynthetic peptide 1345Gly Val Ser Gly Thr Val
Ser 1 5 13467PRTArtificial SequenceSynthetic
peptide 1346Ser Gly Val Ser Ile Ser Cys 1 5
13477PRTArtificial SequenceSynthetic peptide 1347Arg Arg Leu Ser Tyr His
Ser 1 5 13487PRTArtificial SequenceSynthetic
peptide 1348Arg Arg Glu Gly Leu Arg Ser 1 5
13497PRTArtificial SequenceSynthetic peptide 1349Glu Arg Val Ser Ala Ala
Val 1 5 13507PRTArtificial SequenceSynthetic
peptide 1350Ala Gly Ser Met Met Glu Phe 1 5
13517PRTArtificial SequenceSynthetic peptide 1351Arg His Gly Pro Gly Val
Leu 1 5 13527PRTArtificial SequenceSynthetic
peptide 1352Gly Leu Arg Arg Asp Asn Gly 1 5
13537PRTArtificial SequenceSynthetic peptide 1353Arg Arg Glu Gly Leu Arg
Ser 1 5 13547PRTArtificial SequenceSynthetic
peptide 1354Glu Arg Val Ser Ala Ala Val 1 5
13557PRTArtificial SequenceSynthetic peptide 1355Val Ala Ala Ser Val Arg
Glu 1 5 13567PRTArtificial SequenceSynthetic
peptide 1356Pro Trp Tyr Asp Gly Ser Val 1 5
13577PRTArtificial SequenceSynthetic peptide 1357Gly Arg Val Thr Leu Glu
Ser 1 5 13587PRTArtificial SequenceSynthetic
peptide 1358Gly Arg Leu Ser Arg Ala Pro 1 5
13597PRTArtificial SequenceSynthetic peptide 1359Ser Arg Leu Ser Tyr Cys
Asn 1 5 13607PRTArtificial SequenceSynthetic
peptide 1360Gln Ala Arg Gly Ser Trp Leu 1 5
13617PRTArtificial SequenceSynthetic peptide 1361Phe Val Pro Arg Gly Ser
Tyr 1 5 13627PRTArtificial SequenceSynthetic
peptide 1362Ala Ala Leu Leu Arg Ala Val 1 5
13637PRTArtificial SequenceSynthetic peptide 1363Leu Ala Gly Arg Ala Ser
Glu 1 5 13647PRTArtificial SequenceSynthetic
peptide 1364Ala Ala Gly Ala Gly Trp Arg 1 5
13657PRTArtificial SequenceSynthetic peptide 1365Ala Asp Leu Gly Ala Gly
Trp 1 5 13667PRTArtificial SequenceSynthetic
peptide 1366Ala Asp Leu Gly Ala Gly Trp 1 5
13677PRTArtificial SequenceSynthetic peptide 1367Gly Gly Ala Gly Arg Gly
Ala 1 5 13687PRTArtificial SequenceSynthetic
peptide 1368Asp Val Trp Val Ala Val Ser 1 5
13697PRTArtificial SequenceSynthetic peptide 1369Ala Ala Leu Leu Arg Ala
Val 1 5 13707PRTArtificial SequenceSynthetic
peptide 1370Asn Leu Arg Val Gly Ala Glu 1 5
13717PRTArtificial SequenceSynthetic peptide 1371Asn Cys Tyr Ser Leu Arg
Ser 1 5 13727PRTArtificial SequenceSynthetic
peptide 1372Leu Ala Gly Ser Arg Val Ser 1 5
13737PRTArtificial SequenceSynthetic peptide 1373Ser Gly Pro Ala Gly Ser
Phe 1 5 13747PRTArtificial SequenceSynthetic
peptide 1374Leu Ala Gly Ser Arg Val Ser 1 5
13757PRTArtificial SequenceSynthetic peptide 1375Gly Gly Ala Gly Arg Gly
Ala 1 5 13767PRTArtificial SequenceSynthetic
peptide 1376Leu Ala Gly Arg Ala Ser Glu 1 5
13777PRTArtificial SequenceSynthetic peptide 1377Val Ala Gly Arg Leu Gln
Met 1 5 13787PRTArtificial SequenceSynthetic
peptide 1378Trp Gly Ala Gly Leu Asp Ala 1 5
13797PRTArtificial SequenceSynthetic peptide 1379Trp Gly Ala Gly Leu Asp
Ala 1 5 13807PRTArtificial SequenceSynthetic
peptide 1380Ala Gly Arg Gly Ala Gly Gly 1 5
13817PRTArtificial SequenceSynthetic peptide 1381Glu Ala Gly Val Arg Leu
Asn 1 5 13827PRTArtificial SequenceSynthetic
peptide 1382Met Gln Leu Arg Gly Ala Val 1 5
13837PRTArtificial SequenceSynthetic peptide 1383Gly Gly Pro Gly Leu Val
Met 1 5 13847PRTArtificial SequenceSynthetic
peptide 1384Gln Gly Leu Val Arg Gly Gly 1 5
13857PRTArtificial SequenceSynthetic peptide 1385Pro Gly Leu Arg Gly Pro
Ala 1 5 13867PRTArtificial SequenceSynthetic
peptide 1386Pro Gly Leu Arg Gly Pro Ala 1 5
13877PRTArtificial SequenceSynthetic peptide 1387Gly Arg Met Leu Val Ser
Gly 1 5 13887PRTArtificial SequenceSynthetic
peptide 1388Glu Ser Ala Arg Gly Ala Leu 1 5
13897PRTArtificial SequenceSynthetic peptide 1389Gln Ala Arg Gly Ser Trp
Leu 1 5 13907PRTArtificial SequenceSynthetic
peptide 1390Gly Gly Gly Ser Gly Gly Gly 1 5
13917PRTArtificial SequenceSynthetic peptide 1391Asn Asn Val Gly Gly Ser
Ser 1 5 13927PRTArtificial SequenceSynthetic
peptide 1392Gly Gly Arg Val Leu Gly Gln 1 5
13937PRTArtificial SequenceSynthetic peptide 1393Gly Gly Arg Val Arg Gly
Gly 1 5 13947PRTArtificial SequenceSynthetic
peptide 1394Gly Gly Arg Val Arg Gly Gly 1 5
13957PRTArtificial SequenceSynthetic peptide 1395Trp Tyr Gly Gly Arg Gly
Asn 1 5 13967PRTArtificial SequenceSynthetic
peptide 1396Cys Val Gly Leu Gly Cys His 1 5
13977PRTArtificial SequenceSynthetic peptide 1397Asn Asn Val Gly Gly Ser
Ser 1 5 13987PRTArtificial SequenceSynthetic
peptide 1398Phe Met Thr Tyr Gly Ser Gly 1 5
13997PRTArtificial SequenceSynthetic peptide 1399Gly Gly Gly Ser Gly Gly
Gly 1 5 14007PRTArtificial SequenceSynthetic
peptide 1400Trp Asp Gln Gly Ser Gly Tyr 1 5
14017PRTArtificial SequenceSynthetic peptide 1401Gly Ser Val Leu Met Arg
Gly 1 5 14027PRTArtificial SequenceSynthetic
peptide 1402Gly Gly Arg Val Leu Gly Gln 1 5
14037PRTArtificial SequenceSynthetic peptide 1403Gly Gly Arg Val Arg Gly
Gly 1 5 14047PRTArtificial SequenceSynthetic
peptide 1404Gly Gly Arg Val Arg Gly Gly 1 5
14057PRTArtificial SequenceSynthetic peptide 1405Tyr Met Tyr His Gly Arg
Val 1 5 14067PRTArtificial SequenceSynthetic
peptide 1406Gly Arg Leu Ser Arg Ala Pro 1 5
14077PRTArtificial SequenceSynthetic peptide 1407Val Ala Gly Arg Leu Gln
Met 1 5 14087PRTArtificial SequenceSynthetic
peptide 1408Ala Pro Gly Arg Leu Gly Pro 1 5
14097PRTArtificial SequenceSynthetic peptide 1409Ala Pro Gly Arg Leu Gly
Pro 1 5 14107PRTArtificial SequenceSynthetic
peptide 1410Arg Asp Leu Ala Gly Pro Ser 1 5
14117PRTArtificial SequenceSynthetic peptide 1411Arg Leu Ser Gly Ala Gly
Asp 1 5 14127PRTArtificial SequenceSynthetic
peptide 1412Leu Gln Arg Gly Val Ala Arg 1 5
14137PRTArtificial SequenceSynthetic peptide 1413Arg Ala Val Gly Arg Gln
Leu 1 5 14147PRTArtificial SequenceSynthetic
peptide 1414Ser Arg Ala Val Ile Arg Leu 1 5
14157PRTArtificial SequenceSynthetic peptide 1415Val Arg Ala Ser Ser Lys
Arg 1 5 14167PRTArtificial SequenceSynthetic
peptide 1416Asp Gly Ala Gly Ser Leu Arg 1 5
14177PRTArtificial SequenceSynthetic peptide 1417Ser Val Ser Gly Ala Gly
Ser 1 5 14187PRTArtificial SequenceSynthetic
peptide 1418Thr Thr Leu Leu Ser Arg Gln 1 5
14197PRTArtificial SequenceSynthetic peptide 1419Val Ala Glu Leu Leu Ser
Met 1 5 14207PRTArtificial SequenceSynthetic
peptide 1420Leu Pro Gly Arg Leu Arg Val 1 5
14217PRTArtificial SequenceSynthetic peptide 1421Leu Lys Ala Gly Leu Arg
Ser 1 5 14227PRTArtificial SequenceSynthetic
peptide 1422His Arg Val Ser Glu Ser Val 1 5
14237PRTArtificial SequenceSynthetic peptide 1423Tyr Tyr Gly Glu Arg Ser
Ser 1 5 14247PRTArtificial SequenceSynthetic
peptide 1424Asp Gly Ala Gly Ser Leu Arg 1 5
14257PRTArtificial SequenceSynthetic peptide 1425Ser Val Ser Gly Ala Gly
Ser 1 5 14267PRTArtificial SequenceSynthetic
peptide 1426Ala Gly Ser Val Tyr Ser Val 1 5
14277PRTArtificial SequenceSynthetic peptide 1427Ser Ala Gly Leu Leu Pro
Ser 1 5 14287PRTArtificial SequenceSynthetic
peptide 1428Leu Lys Ala Gly Leu Arg Ser 1 5
14297PRTArtificial SequenceSynthetic peptide 1429Arg Arg Ala Gly Gly Ser
Val 1 5 14307PRTArtificial SequenceSynthetic
peptide 1430Ser Trp Ala Gly Val Arg Phe 1 5
14317PRTArtificial SequenceSynthetic peptide 1431Ile Tyr Pro Gly Ala Val
Leu 1 5 14327PRTArtificial SequenceSynthetic
peptide 1432Leu Lys Ala Gly Leu Arg Ser 1 5
14337PRTArtificial SequenceSynthetic peptide 1433Ser Leu Val Ser Pro Arg
Thr 1 5 14347PRTArtificial SequenceSynthetic
peptide 1434His Ala Ala Val Glu Pro Ser 1 5
14357PRTArtificial SequenceSynthetic peptide 1435Thr Ala Ala Ala Val Leu
Leu 1 5 14367PRTArtificial SequenceSynthetic
peptide 1436Phe His Phe Gly Gly Ser Gly 1 5
14377PRTArtificial SequenceSynthetic peptide 1437Gly Glu Gly Gly Ser Gly
Gly 1 5 14387PRTArtificial SequenceSynthetic
peptide 1438Arg Arg Ala Gly Gly Ser Val 1 5
14397PRTArtificial SequenceSynthetic peptide 1439Ala Leu Pro Gly Gly Gly
Arg 1 5 14407PRTArtificial SequenceSynthetic
peptide 1440Tyr Val Gly Gly Arg Leu Arg 1 5
14417PRTArtificial SequenceSynthetic peptide 1441Gly Lys Gly Met Gly Leu
Gly 1 5 14427PRTArtificial SequenceSynthetic
peptide 1442Ser Leu Gly Leu Gly Gly Leu 1 5
14437PRTArtificial SequenceSynthetic peptide 1443Asp Gly Gly Leu Asn Asp
Cys 1 5 14447PRTArtificial SequenceSynthetic
peptide 1444Leu Gly Gly Leu Gly Leu Ser 1 5
14457PRTArtificial SequenceSynthetic peptide 1445Phe His Phe Gly Gly Ser
Gly 1 5 14467PRTArtificial SequenceSynthetic
peptide 1446Gly Glu Gly Gly Ser Gly Gly 1 5
14477PRTArtificial SequenceSynthetic peptide 1447Arg Arg Ala Gly Gly Ser
Val 1 5 14487PRTArtificial SequenceSynthetic
peptide 1448Ser Gly Ala Gly Ser Val Ser 1 5
14497PRTArtificial SequenceSynthetic peptide 1449Ala Gly Ser Val Tyr Ser
Val 1 5 14507PRTArtificial SequenceSynthetic
peptide 1450Gly Arg Val Thr Trp Arg Ser 1 5
14517PRTArtificial SequenceSynthetic peptide 1451Leu Pro Gly Arg Leu Arg
Val 1 5 14527PRTArtificial SequenceSynthetic
peptide 1452Tyr Val Gly Gly Arg Leu Arg 1 5
14537PRTArtificial SequenceSynthetic peptide 1453Gly Pro Ser Ser Ala Val
Glu 1 5 14547PRTArtificial SequenceSynthetic
peptide 1454Arg Arg Leu Ser Tyr Arg Glu 1 5
14557PRTArtificial SequenceSynthetic peptide 1455His Thr Arg Ala Val Ser
Glu 1 5 14567PRTArtificial SequenceSynthetic
peptide 1456Asn Val Ser Arg Ala Val Gly 1 5
14577PRTArtificial SequenceSynthetic peptide 1457Pro Arg His Arg Ala Ser
Gln 1 5 14587PRTArtificial SequenceSynthetic
peptide 1458Leu Gly Ala Gly Met Ile Ala 1 5
14597PRTArtificial SequenceSynthetic peptide 1459Ala Val Ser Leu Val Val
Leu 1 5 14607PRTArtificial SequenceSynthetic
peptide 1460His Thr Arg Ala Val Ser Glu 1 5
14617PRTArtificial SequenceSynthetic peptide 1461Glu Leu Gly Leu Arg Val
Pro 1 5 14627PRTArtificial SequenceSynthetic
peptide 1462Gly Arg Ser Ser Val Ser Asp 1 5
14637PRTArtificial SequenceSynthetic peptide 1463Tyr Ala Gly Ser Gly Gln
Leu 1 5 14647PRTArtificial SequenceSynthetic
peptide 1464Ala Gly Arg Phe Gly Ala Arg 1 5
14657PRTArtificial SequenceSynthetic peptide 1465Ala Ile Met Gly Ala Gly
Leu 1 5 14667PRTArtificial SequenceSynthetic
peptide 1466Thr His Val Gly Gly Val Arg 1 5
14677PRTArtificial SequenceSynthetic peptide 1467Gly Val Leu Thr Arg Gly
Asn 1 5 14687PRTArtificial SequenceSynthetic
peptide 1468Glu Leu Gly Leu Arg Val Pro 1 5
14697PRTArtificial SequenceSynthetic peptide 1469Gly Leu Gly Leu Arg Leu
Gly 1 5 14707PRTArtificial SequenceSynthetic
peptide 1470Ile Asp Leu Val Ser Pro Gly 1 5
14717PRTArtificial SequenceSynthetic peptide 1471Gly Gly Ser Thr Val Pro
Gln 1 5 14727PRTArtificial SequenceSynthetic
peptide 1472Gly Leu Gly Leu Arg Leu Gly 1 5
14737PRTArtificial SequenceSynthetic peptide 1473Thr Ala Thr Gly Gly Leu
Leu 1 5 14747PRTArtificial SequenceSynthetic
peptide 1474Gly Ser Asn Gly Ser Ser His 1 5
14757PRTArtificial SequenceSynthetic peptide 1475Leu Gln Gly Ser Gly Ala
Tyr 1 5 14767PRTArtificial SequenceSynthetic
peptide 1476Leu Gln His Leu Gly Ser Gly 1 5
14777PRTArtificial SequenceSynthetic peptide 1477Gly Pro Ser Val Leu Asp
Ile 1 5 14787PRTArtificial SequenceSynthetic
peptide 1478Gly Ala Thr Gly Val Ser Ser 1 5
14797PRTArtificial SequenceSynthetic peptide 1479Thr Arg Leu Ser Phe Arg
His 1 5 14807PRTArtificial SequenceSynthetic
peptide 1480Phe Leu Arg Gly Val Glu Leu 1 5
14817PRTArtificial SequenceSynthetic peptide 1481Asn Ser Val Arg Gly Ser
Arg 1 5 14827PRTArtificial SequenceSynthetic
peptide 1482Asn Arg Ala Val Leu Ser Ala 1 5
14837PRTArtificial SequenceSynthetic peptide 1483Leu Ile Gly Arg Ala Ser
Met 1 5 14847PRTArtificial SequenceSynthetic
peptide 1484Arg Val Gly Ala Gly Ala Phe 1 5
14857PRTArtificial SequenceSynthetic peptide 1485Trp Ile Ser Ala Val Ser
Lys 1 5 14867PRTArtificial SequenceSynthetic
peptide 1486Ser Ala Val Ser Glu Ser Pro 1 5
14877PRTArtificial SequenceSynthetic peptide 1487Arg Val Gly Thr Leu Arg
Val 1 5 14887PRTArtificial SequenceSynthetic
peptide 1488Arg Val Ser Gly Asp Gly Lys 1 5
14897PRTArtificial SequenceSynthetic peptide 1489Arg Ser Gly Arg Val Ser
Asn 1 5 14907PRTArtificial SequenceSynthetic
peptide 1490Arg Val Ser Asn Glu Ala Leu 1 5
14917PRTArtificial SequenceSynthetic peptide 1491Arg Val Ser Ser Asp Pro
Ile 1 5 14927PRTArtificial SequenceSynthetic
peptide 1492Val Arg Ser Ser Gly Val Leu 1 5
14937PRTArtificial SequenceSynthetic peptide 1493Ser Gly Trp Phe Ala Gly
Ser 1 5 14947PRTArtificial SequenceSynthetic
peptide 1494Ala Gly Leu Gly Leu Leu Asp 1 5
14957PRTArtificial SequenceSynthetic peptide 1495Ser Ala Ala Gly Leu Ala
Arg 1 5 14967PRTArtificial SequenceSynthetic
peptide 1496Phe Ala Gly Ala Gly Val Arg 1 5
14977PRTArtificial SequenceSynthetic peptide 1497Val Arg Leu Thr Gly Val
Arg 1 5 14987PRTArtificial SequenceSynthetic
peptide 1498Val Arg Ser Ser Gly Val Leu 1 5
14997PRTArtificial SequenceSynthetic peptide 1499Arg Pro Trp Gly Ala Val
Ala 1 5 15007PRTArtificial SequenceSynthetic
peptide 1500Pro Val Ser Asp Gly Leu Val 1 5
15017PRTArtificial SequenceSynthetic peptide 1501Asn Lys Gly Gly Leu Arg
Gln 1 5 15027PRTArtificial SequenceSynthetic
peptide 1502Gly Gly Phe Leu Leu Val Ser 1 5
15037PRTArtificial SequenceSynthetic peptide 1503Leu Val Pro Leu Val Ser
Gly 1 5 15047PRTArtificial SequenceSynthetic
peptide 1504Ala Arg Gly Gly Glu Ser Ala 1 5
15057PRTArtificial SequenceSynthetic peptide 1505Met Ser Ala Arg Gly Ile
Leu 1 5 15067PRTArtificial SequenceSynthetic
peptide 1506Ala Ser Leu Val Ala Arg Asn 1 5
15077PRTArtificial SequenceSynthetic peptide 1507Arg Val Glu Ala Ala Val
Pro 1 5 15087PRTArtificial SequenceSynthetic
peptide 1508Arg Ala Leu Gly Ala Ala Ser 1 5
15097PRTArtificial SequenceSynthetic peptide 1509Ala Ser Glu Gly Gly Arg
Ala 1 5 15107PRTArtificial SequenceSynthetic
peptide 1510Ile Gly Gly Arg Trp Val Val 1 5
15117PRTArtificial SequenceSynthetic peptide 1511Ala Gly Leu Gly Leu Leu
Asp 1 5 15127PRTArtificial SequenceSynthetic
peptide 1512Leu Gly Gly Leu Ser Glu Arg 1 5
15137PRTArtificial SequenceSynthetic peptide 1513Asn Lys Gly Gly Leu Arg
Gln 1 5 15147PRTArtificial SequenceSynthetic
peptide 1514Leu Val Gly Ser Ser Arg Val 1 5
15157PRTArtificial SequenceSynthetic peptide 1515Tyr Thr Gly Ser Ser Pro
Ser 1 5 15167PRTArtificial SequenceSynthetic
peptide 1516Gly Ser Val Leu Pro Val Leu 1 5
15177PRTArtificial SequenceSynthetic peptide 1517Lys Gly Asp Gly Ser Val
Arg 1 5 15187PRTArtificial SequenceSynthetic
peptide 1518Gly Ser Val Ser His Arg Arg 1 5
15197PRTArtificial SequenceSynthetic peptide 1519Arg Leu Trp Gly Ser Val
Val 1 5 15207PRTArtificial SequenceSynthetic
peptide 1520Met Gln Gly Arg Val Ile Val 1 5
15217PRTArtificial SequenceSynthetic peptide 1521Arg Ser Gly Arg Val Ser
Asn 1 5 15227PRTArtificial SequenceSynthetic
peptide 1522Leu Glu Val Gly Arg Leu Phe 1 5
15237PRTArtificial SequenceSynthetic peptide 1523Ser Gln Phe Gly Pro Ser
Phe 1 5 15247PRTArtificial SequenceSynthetic
peptide 1524Ala Thr Leu Asp Gly Val Ser 1 5
15257PRTArtificial SequenceSynthetic peptide 1525Arg Leu Ser Trp Thr Val
Leu 1 5 15267PRTArtificial SequenceSynthetic
peptide 1526Leu Arg Phe Arg Arg Gly Val 1 5
15277PRTArtificial SequenceSynthetic peptide 1527Ala Arg Gly Arg Gly Ser
Gln 1 5 15287PRTArtificial SequenceSynthetic
peptide 1528Val Leu Arg Gly Ser Thr Pro 1 5
15297PRTArtificial SequenceSynthetic peptide 1529Ala Arg Leu Arg Ala Ser
Arg 1 5 15307PRTArtificial SequenceSynthetic
peptide 1530Arg Ile Gly Ala Gly His Arg 1 5
15317PRTArtificial SequenceSynthetic peptide 1531Trp Leu Leu Ser Ser Glu
Ile 1 5 15327PRTArtificial SequenceSynthetic
peptide 1532Gly Gly Leu Arg Val Gly Gly 1 5
15337PRTArtificial SequenceSynthetic peptide 1533Gly Leu Arg Val Tyr Glu
Pro 1 5 15347PRTArtificial SequenceSynthetic
peptide 1534Tyr Leu Arg Ser Ala Gly Met 1 5
15357PRTArtificial SequenceSynthetic peptide 1535Arg Val Ser Arg Ala Gly
Gly 1 5 15367PRTArtificial SequenceSynthetic
peptide 1536Ala Gly Arg Pro Gly Gly Tyr 1 5
15377PRTArtificial SequenceSynthetic peptide 1537Tyr Gly Ala Leu Ala Gly
Leu 1 5 15387PRTArtificial SequenceSynthetic
peptide 1538Arg Val Ser Arg Ala Gly Gly 1 5
15397PRTArtificial SequenceSynthetic peptide 1539Ser His Thr Ala Gly Gly
Gly 1 5 15407PRTArtificial SequenceSynthetic
peptide 1540Ala Gly Gly Val Arg Asp Leu 1 5
15417PRTArtificial SequenceSynthetic peptide 1541Arg Pro Ala Gly Gly Arg
Thr 1 5 15427PRTArtificial SequenceSynthetic
peptide 1542Gly Gly Val Arg Leu Gly Gly 1 5
15437PRTArtificial SequenceSynthetic peptide 1543Ala Gly Gly Val Arg Asp
Leu 1 5 15447PRTArtificial SequenceSynthetic
peptide 1544Gly Val Leu Gly Cys Asp Gly 1 5
15457PRTArtificial SequenceSynthetic peptide 1545Cys Gly Ala Val Ala Glu
Trp 1 5 15467PRTArtificial SequenceSynthetic
peptide 1546Gly Asp Cys Gly Leu Val Gly 1 5
15477PRTArtificial SequenceSynthetic peptide 1547Gly Gly Leu Arg Val Gly
Gly 1 5 15487PRTArtificial SequenceSynthetic
peptide 1548Gly Leu Arg Val Tyr Glu Pro 1 5
15497PRTArtificial SequenceSynthetic peptide 1549Ala Arg Gly Arg Gly Ser
Gln 1 5 15507PRTArtificial SequenceSynthetic
peptide 1550Gly Gly Arg Glu Leu Lys Ala 1 5
15517PRTArtificial SequenceSynthetic peptide 1551Gly Gly Gly Arg Arg Ala
Leu 1 5 15527PRTArtificial SequenceSynthetic
peptide 1552Arg Pro Ala Gly Gly Arg Thr 1 5
15537PRTArtificial SequenceSynthetic peptide 1553Gly Gly Leu Lys Val Trp
Arg 1 5 15547PRTArtificial SequenceSynthetic
peptide 1554Gly Gly Leu Arg Val Gly Gly 1 5
15557PRTArtificial SequenceSynthetic peptide 1555Gly Gly Leu Pro Val Gln
Met 1 5 15567PRTArtificial SequenceSynthetic
peptide 1556Arg Gln Asp Gly Gly Leu Tyr 1 5
15577PRTArtificial SequenceSynthetic peptide 1557Tyr Ala Thr Leu Gly Ser
Ser 1 5 15587PRTArtificial SequenceSynthetic
peptide 1558Ser Gly Ser Gly Cys Val Phe 1 5
15597PRTArtificial SequenceSynthetic peptide 1559Val Ser Gly Ser Gly Thr
Ala 1 5 15607PRTArtificial SequenceSynthetic
peptide 1560Val Gly Ser Val Lys Ala Ser 1 5
15617PRTArtificial SequenceSynthetic peptide 1561Ala Thr Gly Ser Gly Ser
Val 1 5 15627PRTArtificial SequenceSynthetic
peptide 1562Pro Thr Ser Gly Arg Leu Val 1 5
15637PRTArtificial SequenceSynthetic peptide 1563Leu Ala Cys Arg Gly Pro
Ser 1 5 15647PRTArtificial SequenceSynthetic
peptide 1564Arg Gly Pro Ser Gln Val Leu 1 5
15657PRTArtificial SequenceSynthetic peptide 1565Thr Leu Gly Arg Leu Ser
Ser 1 5 15667PRTArtificial SequenceSynthetic
peptide 1566Ala Gly Asp Arg Gly Val Ala 1 5
15677PRTArtificial SequenceSynthetic peptide 1567Leu Pro Arg Arg Ala Val
Phe 1 5 15687PRTArtificial SequenceSynthetic
peptide 1568Arg Ala Ser Cys Val Trp Arg 1 5
15697PRTArtificial SequenceSynthetic peptide 1569Phe Ser Lys Met Arg Ala
Ser 1 5 15707PRTArtificial SequenceSynthetic
peptide 1570Asp Tyr Val Gly Ala Gly Thr 1 5
15717PRTArtificial SequenceSynthetic peptide 1571Ala Arg Leu Leu Arg Gly
Gly 1 5 15727PRTArtificial SequenceSynthetic
peptide 1572Leu Leu Arg Ser Val Gly Tyr 1 5
15737PRTArtificial SequenceSynthetic peptide 1573His Leu Arg Ser Gly Phe
Ser 1 5 15747PRTArtificial SequenceSynthetic
peptide 1574Leu Leu Arg Ser Val Gly Tyr 1 5
15757PRTArtificial SequenceSynthetic peptide 1575Ala Gly Arg Pro Asp Gly
Val 1 5 15767PRTArtificial SequenceSynthetic
peptide 1576Asp Glu Asn Arg Ala Gly Leu 1 5
15777PRTArtificial SequenceSynthetic peptide 1577Ala Trp Ala Gly Gly Asp
Met 1 5 15787PRTArtificial SequenceSynthetic
peptide 1578Leu Asn Ala Gly Gly Ser Gly 1 5
15797PRTArtificial SequenceSynthetic peptide 1579Asn Met Gly Ala Val Gly
Ser 1 5 15807PRTArtificial SequenceSynthetic
peptide 1580Pro Ile Gly Ala Val Met Asn 1 5
15817PRTArtificial SequenceSynthetic peptide 1581Leu Thr Gly Gly Leu Val
Phe 1 5 15827PRTArtificial SequenceSynthetic
peptide 1582Cys Gly Glu Gly Leu Val Val 1 5
15837PRTArtificial SequenceSynthetic peptide 1583Ser Asp Leu Gly Leu Arg
Arg 1 5 15847PRTArtificial SequenceSynthetic
peptide 1584His Ala Asp Val Leu Val Ser 1 5
15857PRTArtificial SequenceSynthetic peptide 1585Phe Ser Asn Ala Arg Gly
Tyr 1 5 15867PRTArtificial SequenceSynthetic
peptide 1586Ala Ala Val Trp Trp Ala Ala 1 5
15877PRTArtificial SequenceSynthetic peptide 1587Leu Asn Ala Gly Gly Ser
Gly 1 5 15887PRTArtificial SequenceSynthetic
peptide 1588Gly Gly Ser Ala Trp Trp Gly 1 5
15897PRTArtificial SequenceSynthetic peptide 1589Val Tyr Gly Trp Gly Gly
Ser 1 5 15907PRTArtificial SequenceSynthetic
peptide 1590Gly Gly Arg Leu Leu Arg Ala 1 5
15917PRTArtificial SequenceSynthetic peptide 1591Leu Gly Gly Arg Thr Ile
Ser 1 5 15927PRTArtificial SequenceSynthetic
peptide 1592Tyr Leu Gly Leu Gly Gly Leu 1 5
15937PRTArtificial SequenceSynthetic peptide 1593Ser Ile Thr Arg Gly Gly
Leu 1 5 15947PRTArtificial SequenceSynthetic
peptide 1594Leu Thr Gly Gly Leu Val Phe 1 5
15957PRTArtificial SequenceSynthetic peptide 1595Leu Gly Gly Leu Gly Leu
Tyr 1 5 15967PRTArtificial SequenceSynthetic
peptide 1596Gly Ser Ser Glu Leu Ser Arg 1 5
15977PRTArtificial SequenceSynthetic peptide 1597Gly Ser Gly Gly Ala Asn
Leu 1 5 15987PRTArtificial SequenceSynthetic
peptide 1598Val Asp Gly Ser Gly Asp Asp 1 5
15997PRTArtificial SequenceSynthetic peptide 1599Arg Ser Leu Gly Ser Val
Gly 1 5 16007PRTArtificial SequenceSynthetic
peptide 1600Gly Arg Val Lys Pro Gly Ala 1 5
16017PRTArtificial SequenceSynthetic peptide 1601Gly Gly Arg Leu Leu Arg
Ala 1 5 16027PRTArtificial SequenceSynthetic
peptide 1602Gly Arg Leu Trp Tyr Val Ala 1 5
16037PRTArtificial SequenceSynthetic peptide 1603Thr Leu Gly Arg Leu Ser
Ser 1 5 16047PRTArtificial SequenceSynthetic
peptide 1604Gly Val Ser Gly Leu Ser Arg 1 5
16057PRTArtificial SequenceSynthetic peptide 1605Tyr Gly Val Ser Arg Leu
Leu 1 5 16067PRTArtificial SequenceSynthetic
peptide 1606Ser Arg Leu Ser Tyr Arg Ala 1 5
16077PRTArtificial SequenceSynthetic peptide 1607Ile His Arg Gly Val Trp
Gly 1 5 16087PRTArtificial SequenceSynthetic
peptide 1608Tyr Phe Arg Ala Arg Gly Ser 1 5
16097PRTArtificial SequenceSynthetic peptide 1609Gly Ala Gly Arg Phe Pro
His 1 5 16107PRTArtificial SequenceSynthetic
peptide 1610Ser Gly Ala Gly Ala Ala Phe 1 5
16117PRTArtificial SequenceSynthetic peptide 1611Val Asp Val Gly Gly Ala
Gly 1 5 16127PRTArtificial SequenceSynthetic
peptide 1612Ala Ser Ala Gly Ala Val Ser 1 5
16137PRTArtificial SequenceSynthetic peptide 1613Ala Arg Tyr Ser Leu Arg
Ser 1 5 16147PRTArtificial SequenceSynthetic
peptide 1614Arg Leu Arg Ser Tyr Val Ala 1 5
16157PRTArtificial SequenceSynthetic peptide 1615Ser Arg Lys Gly Leu Arg
Ser 1 5 16167PRTArtificial SequenceSynthetic
peptide 1616Ser Val Thr Gly Arg Val Ser 1 5
16177PRTArtificial SequenceSynthetic peptide 1617Ala Gly Ser Ala Phe Trp
Ala 1 5 16187PRTArtificial SequenceSynthetic
peptide 1618Asp Gln Gln Glu Ala Gly Ser 1 5
16197PRTArtificial SequenceSynthetic peptide 1619Phe Ala Ala Gly Ala Gly
Ser 1 5 16207PRTArtificial SequenceSynthetic
peptide 1620Gly Ala Gly Arg Phe Pro His 1 5
16217PRTArtificial SequenceSynthetic peptide 1621Gly Ala Gly Gly Val Asp
Val 1 5 16227PRTArtificial SequenceSynthetic
peptide 1622Ala Ser Ala Gly Ala Val Ser 1 5
16237PRTArtificial SequenceSynthetic peptide 1623Arg Arg Asp Gly Leu Val
Glu 1 5 16247PRTArtificial SequenceSynthetic
peptide 1624Ser Arg Lys Gly Leu Arg Ser 1 5
16257PRTArtificial SequenceSynthetic peptide 1625Gly Asp Ala Thr Leu Val
Ser 1 5 16267PRTArtificial SequenceSynthetic
peptide 1626Gly Asp Ala Thr Leu Val Ser 1 5
16277PRTArtificial SequenceSynthetic peptide 1627Tyr Phe Arg Ala Arg Gly
Ser 1 5 16287PRTArtificial SequenceSynthetic
peptide 1628Asp Arg Gly Leu Gly Met Ser 1 5
16297PRTArtificial SequenceSynthetic peptide 1629Gly Ser Gly Tyr Phe Ile
Thr 1 5 16307PRTArtificial SequenceSynthetic
peptide 1630Ser Val Thr Gly Arg Val Ser 1 5
16317PRTArtificial SequenceSynthetic peptide 1631Val Gly Pro Ser Val His
Leu 1 5 16327PRTArtificial SequenceSynthetic
peptide 1632Glu Gly Val Arg Gly Val Phe 1 5
16337PRTArtificial SequenceSynthetic peptide 1633Gly Asp Arg Gly Val Arg
Gly 1 5 16347PRTArtificial SequenceSynthetic
peptide 1634Met Arg Gly Val Ala Arg Lys 1 5
16357PRTArtificial SequenceSynthetic peptide 1635Lys Arg Ala Val Gly Arg
Met 1 5 16367PRTArtificial SequenceSynthetic
peptide 1636Asp Arg Ala Ser Ser Trp Ala 1 5
16377PRTArtificial SequenceSynthetic peptide 1637Leu Gln Gly Ala Gly Ile
His 1 5 16387PRTArtificial SequenceSynthetic
peptide 1638Trp Leu Leu Arg Gly Phe Gly 1 5
16397PRTArtificial SequenceSynthetic peptide 1639Ala Ser Pro Pro Leu Arg
Ser 1 5 16407PRTArtificial SequenceSynthetic
peptide 1640Arg Val Ser Ser Glu Thr Phe 1 5
16417PRTArtificial SequenceSynthetic peptide 1641Ala Arg Ala Gly Ser Thr
Phe 1 5 16427PRTArtificial SequenceSynthetic
peptide 1642Thr Phe Ala Gly Arg Ser Leu 1 5
16437PRTArtificial SequenceSynthetic peptide 1643Tyr Ala Ala Gly Gly Ser
Thr 1 5 16447PRTArtificial SequenceSynthetic
peptide 1644Glu Gly Val Arg Gly Val Phe 1 5
16457PRTArtificial SequenceSynthetic peptide 1645Gly Asp Arg Gly Val Arg
Gly 1 5 16467PRTArtificial SequenceSynthetic
peptide 1646Pro Gly Val Leu Arg Glu Pro 1 5
16477PRTArtificial SequenceSynthetic peptide 1647Gly Leu Arg Asp Gly Val
Glu 1 5 16487PRTArtificial SequenceSynthetic
peptide 1648Phe Pro Ala Arg Gly Glu Asp 1 5
16497PRTArtificial SequenceSynthetic peptide 1649Met Leu Gly Ser Ala Ser
Leu 1 5 16507PRTArtificial SequenceSynthetic
peptide 1650His Gly Gly Ser Asn Asp Arg 1 5
16517PRTArtificial SequenceSynthetic peptide 1651Tyr Ala Ala Gly Gly Ser
Thr 1 5 16527PRTArtificial SequenceSynthetic
peptide 1652Gln Gly Gly Arg Ser Gly Val 1 5
16537PRTArtificial SequenceSynthetic peptide 1653Trp Thr Val Gly Gly Arg
Val 1 5 16547PRTArtificial SequenceSynthetic
peptide 1654Val Lys Gly Ser Ser Met Arg 1 5
16557PRTArtificial SequenceSynthetic peptide 1655Phe Val Gly Arg Val Gly
Glu 1 5 16567PRTArtificial SequenceSynthetic
peptide 1656Gly Arg Val Gly Arg Asp Gly 1 5
16577PRTArtificial SequenceSynthetic peptide 1657Ser Val Ser Arg Gly Arg
Val 1 5 16587PRTArtificial SequenceSynthetic
peptide 1658Trp Thr Val Gly Gly Arg Val 1 5
16597PRTArtificial SequenceSynthetic peptide 1659Gly Phe Gly Arg Leu Leu
Trp 1 5 16607PRTArtificial SequenceSynthetic
peptide 1660Ala Ala Tyr Trp Gly Pro Ser 1 5
16617PRTArtificial SequenceSynthetic peptide 1661Met Asp Gly Val Ser Thr
Glu 1 5 16627PRTArtificial SequenceSynthetic
peptide 1662Val Tyr Trp Trp Gly Val Ser 1 5
16637PRTArtificial SequenceSynthetic peptide 1663Arg Leu Ser Met Ala Ser
Arg 1 5 16647PRTArtificial SequenceSynthetic
peptide 1664Gly Arg Leu Ser Phe Gly Val 1 5
16657PRTArtificial SequenceSynthetic peptide 1665Gly Leu Ser Arg Gly Val
Leu 1 5 16667PRTArtificial SequenceSynthetic
peptide 1666Leu Arg Gly Ser His Val Ala 1 5
16677PRTArtificial SequenceSynthetic peptide 1667Asn Met Gly Arg Gly Ser
Leu 1 5 16687PRTArtificial SequenceSynthetic
peptide 1668Ser Val Val Arg Arg Gly Ser 1 5
16697PRTArtificial SequenceSynthetic peptide 1669Val Met Gly Ala Gly Val
Gln 1 5 16707PRTArtificial SequenceSynthetic
peptide 1670Pro Leu Leu Arg Gln Gln Leu 1 5
16717PRTArtificial SequenceSynthetic peptide 1671Ser Asn Gly Leu Arg Val
Val 1 5 16727PRTArtificial SequenceSynthetic
peptide 1672Leu Arg Ser Met Ala Val Met 1 5
16737PRTArtificial SequenceSynthetic peptide 1673Val Asp Leu Arg Ser Ala
Phe 1 5 16747PRTArtificial SequenceSynthetic
peptide 1674Phe Arg Val Ser Leu Gly Tyr 1 5
16757PRTArtificial SequenceSynthetic peptide 1675Arg Ser Ser Tyr Ala Pro
Pro 1 5 16767PRTArtificial SequenceSynthetic
peptide 1676Phe Pro Gly Ser Ala Gly Ser 1 5
16777PRTArtificial SequenceSynthetic peptide 1677Phe Ala Gly Arg Ala Pro
Arg 1 5 16787PRTArtificial SequenceSynthetic
peptide 1678Phe Ile Ala Gly Gly Val Gly 1 5
16797PRTArtificial SequenceSynthetic peptide 1679Leu Ile His Ala Gly Gly
Gln 1 5 16807PRTArtificial SequenceSynthetic
peptide 1680Arg Ala Gly Gly Gly Ala Pro 1 5
16817PRTArtificial SequenceSynthetic peptide 1681Thr Trp His Ala Gly Gly
Ile 1 5 16827PRTArtificial SequenceSynthetic
peptide 1682Gly Val Arg Ser Ile Thr Leu 1 5
16837PRTArtificial SequenceSynthetic peptide 1683Gly Leu Ser Arg Gly Val
Leu 1 5 16847PRTArtificial SequenceSynthetic
peptide 1684Arg Val Val Gly Ala Val Leu 1 5
16857PRTArtificial SequenceSynthetic peptide 1685Phe Gly Leu Arg Met Ser
Asn 1 5 16867PRTArtificial SequenceSynthetic
peptide 1686Leu Gly Leu Arg Gly Trp Thr 1 5
16877PRTArtificial SequenceSynthetic peptide 1687Ala Phe Phe Met Gly Leu
Arg 1 5 16887PRTArtificial SequenceSynthetic
peptide 1688Ser Asn Gly Leu Arg Val Val 1 5
16897PRTArtificial SequenceSynthetic peptide 1689Ala Arg Gly Thr Met Thr
Gly 1 5 16907PRTArtificial SequenceSynthetic
peptide 1690Arg Pro Ala Arg Gly Ala Phe 1 5
16917PRTArtificial SequenceSynthetic peptide 1691Ala Ser Leu Pro Met Leu
His 1 5 16927PRTArtificial SequenceSynthetic
peptide 1692Gly Gly Ser Val Glu Gly Gln 1 5
16937PRTArtificial SequenceSynthetic peptide 1693Leu Gly Gly Arg Gln Glu
Ser 1 5 16947PRTArtificial SequenceSynthetic
peptide 1694Asn Gly Gly Arg Val Leu Ser 1 5
16957PRTArtificial SequenceSynthetic peptide 1695Pro Ile Gly Gly Leu Phe
Gly 1 5 16967PRTArtificial SequenceSynthetic
peptide 1696Ala Glu Cys Cys Gly Gly Leu 1 5
16977PRTArtificial SequenceSynthetic peptide 1697Ser Glu Gln Arg Gly Gly
Leu 1 5 16987PRTArtificial SequenceSynthetic
peptide 1698Asp Arg Phe Gly Ser Ser Ala 1 5
16997PRTArtificial SequenceSynthetic peptide 1699Gly His Gly Ser Gly Ser
Arg 1 5 17007PRTArtificial SequenceSynthetic
peptide 1700Gly Gly Ser Val Glu Gly Gln 1 5
17017PRTArtificial SequenceSynthetic peptide 1701Gly Ser Val Val Ser Ser
Trp 1 5 17027PRTArtificial SequenceSynthetic
peptide 1702Asn Gly Gly Arg Val Leu Ser 1 5
17037PRTArtificial SequenceSynthetic peptide 1703Gly Arg Leu Met Pro Gly
Gly 1 5 17047PRTArtificial SequenceSynthetic
peptide 1704Thr Trp Gly Arg Leu Gly Leu 1 5
17057PRTArtificial SequenceSynthetic peptide 1705Ala Val His Ser Gly Arg
Leu 1 5 17067PRTArtificial SequenceSynthetic
peptide 1706Gly Arg Leu Ser Phe Gly Val 1 5
17077PRTArtificial SequenceSynthetic peptide 1707Pro Gln Gly Pro Ser Ser
Val 1 5 17087PRTArtificial SequenceSynthetic
peptide 1708Ala Gly Trp Arg Leu Ser Gln 1 5
17097PRTArtificial SequenceSynthetic peptide 1709Arg Val Asp Arg Gly Ser
Leu 1 5 17107PRTArtificial SequenceSynthetic
peptide 1710Arg Ala Val Cys Glu Trp Asp 1 5
17117PRTArtificial SequenceSynthetic peptide 1711Arg Ala Val Glu Arg Val
Ala 1 5 17127PRTArtificial SequenceSynthetic
peptide 1712Ala Val Phe Arg Ala Ser Arg 1 5
17137PRTArtificial SequenceSynthetic peptide 1713Gly Ala Gly Ser Ser Val
Trp 1 5 17147PRTArtificial SequenceSynthetic
peptide 1714Gly Ala Gly Ser Ser Val Trp 1 5
17157PRTArtificial SequenceSynthetic peptide 1715Trp Leu Leu Arg Ser Trp
Ser 1 5 17167PRTArtificial SequenceSynthetic
peptide 1716Arg Lys Glu Ala Leu Arg Val 1 5
17177PRTArtificial SequenceSynthetic peptide 1717Arg Leu Arg Val Ser Val
Arg 1 5 17187PRTArtificial SequenceSynthetic
peptide 1718Leu Arg Pro Gly Leu Arg Ser 1 5
17197PRTArtificial SequenceSynthetic peptide 1719Gln Arg Tyr His Leu Arg
Ser 1 5 17207PRTArtificial SequenceSynthetic
peptide 1720Trp Leu Leu Arg Ser Trp Ser 1 5
17217PRTArtificial SequenceSynthetic peptide 1721Gly Arg Glu Arg Val Ser
His 1 5 17227PRTArtificial SequenceSynthetic
peptide 1722Arg Val Ser Val Arg Leu Arg 1 5
17237PRTArtificial SequenceSynthetic peptide 1723Gly Ala Gly Ser Ser Val
Trp 1 5 17247PRTArtificial SequenceSynthetic
peptide 1724Gly Ala Gly Ser Ser Val Trp 1 5
17257PRTArtificial SequenceSynthetic peptide 1725Ala Gly Leu Trp Pro Trp
Asn 1 5 17267PRTArtificial SequenceSynthetic
peptide 1726Gly Val Arg Gly Gly Gly Asp 1 5
17277PRTArtificial SequenceSynthetic peptide 1727Gly Leu Val Arg Arg Val
Val 1 5 17287PRTArtificial SequenceSynthetic
peptide 1728Leu Arg Pro Gly Leu Arg Ser 1 5
17297PRTArtificial SequenceSynthetic peptide 1729Trp Ala His Ala Ala Ser
Tyr 1 5 17307PRTArtificial SequenceSynthetic
peptide 1730Asp Gly Gly Gly Arg Val Gly 1 5
17317PRTArtificial SequenceSynthetic peptide 1731Val Gly Val Met Gly Gly
Arg 1 5 17327PRTArtificial SequenceSynthetic
peptide 1732Val Tyr Gly Gly Arg Ser Glu 1 5
17337PRTArtificial SequenceSynthetic peptide 1733Thr Ile Cys Leu Gly Leu
Gly 1 5 17347PRTArtificial SequenceSynthetic
peptide 1734Gly Ala Gly Ser Ser Val Trp 1 5
17357PRTArtificial SequenceSynthetic peptide 1735Gly Ala Gly Ser Ser Val
Trp 1 5 17367PRTArtificial SequenceSynthetic
peptide 1736Asp His Val Ser Gly Ser Val 1 5
17377PRTArtificial SequenceSynthetic peptide 1737Asp Gly Gly Gly Arg Val
Gly 1 5 17387PRTArtificial SequenceSynthetic
peptide 1738Gly Glu Gly Arg Leu Cys Gly 1 5
17397PRTArtificial SequenceSynthetic peptide 1739Gly Val Ala Ile Gly Arg
Leu 1 5 17407PRTArtificial SequenceSynthetic
peptide 1740Phe Gly Val Ser Gln Val His 1 5
17417PRTArtificial SequenceSynthetic peptide 1741Gly Gly Val Ser Arg Met
Arg 1 5 17427PRTArtificial SequenceSynthetic
peptide 1742Gly Arg Ile Arg Leu Ser Phe 1 5
17437PRTArtificial SequenceSynthetic peptide 1743Arg Gly Val Asn Tyr Arg
Ser 1 5 17447PRTArtificial SequenceSynthetic
peptide 1744Thr Glu Gly Thr Arg Gly Val 1 5
17457PRTArtificial SequenceSynthetic peptide 1745Gly Tyr Ala Arg Gly Ser
Gly 1 5 17467PRTArtificial SequenceSynthetic
peptide 1746Gly Val Trp Leu Arg Gly Ser 1 5
17477PRTArtificial SequenceSynthetic peptide 1747Ala Ala Arg Ala Val Trp
Gly 1 5 17487PRTArtificial SequenceSynthetic
peptide 1748Arg Ala Ser Tyr Tyr Gly Val 1 5
17497PRTArtificial SequenceSynthetic peptide 1749Gly Ala Gly Val Glu Tyr
Phe 1 5 17507PRTArtificial SequenceSynthetic
peptide 1750Leu Leu Leu Leu Ser Gly Ser 1 5
17517PRTArtificial SequenceSynthetic peptide 1751Val Leu Leu Ser Ala Gly
Leu 1 5 17527PRTArtificial SequenceSynthetic
peptide 1752Thr Gly Leu Leu Arg Leu Tyr 1 5
17537PRTArtificial SequenceSynthetic peptide 1753Leu Arg Ser Ser Leu Val
Ser 1 5 17547PRTArtificial SequenceSynthetic
peptide 1754Leu Arg Ser Ser Leu Val Ser 1 5
17557PRTArtificial SequenceSynthetic peptide 1755Pro Arg Ser Ser Gly Pro
Met 1 5 17567PRTArtificial SequenceSynthetic
peptide 1756Thr Ala Gly Arg Leu Glu Val 1 5
17577PRTArtificial SequenceSynthetic peptide 1757Ala Gly Leu Glu Asp Leu
Gly 1 5 17587PRTArtificial SequenceSynthetic
peptide 1758Met Pro Ala Gly Leu Gly Val 1 5
17597PRTArtificial SequenceSynthetic peptide 1759Val Leu Leu Ser Ala Gly
Leu 1 5 17607PRTArtificial SequenceSynthetic
peptide 1760Gly Val Arg Trp Asn Trp Ser 1 5
17617PRTArtificial SequenceSynthetic peptide 1761Thr Arg Asp Gly Val Arg
Trp 1 5 17627PRTArtificial SequenceSynthetic
peptide 1762Arg Ala His Gly Leu Val Cys 1 5
17637PRTArtificial SequenceSynthetic peptide 1763Leu Gly Ser Ser Gly Leu
Arg 1 5 17647PRTArtificial SequenceSynthetic
peptide 1764Leu Leu Val Ser Leu Ser Ser 1 5
17657PRTArtificial SequenceSynthetic peptide 1765Leu Arg Ser Ser Leu Val
Ser 1 5 17667PRTArtificial SequenceSynthetic
peptide 1766Leu Val Ser Thr Arg Trp Ala 1 5
17677PRTArtificial SequenceSynthetic peptide 1767Leu Val Ser Tyr Ser Ala
Val 1 5 17687PRTArtificial SequenceSynthetic
peptide 1768Gly Tyr Ala Arg Gly Ser Gly 1 5
17697PRTArtificial SequenceSynthetic peptide 1769Leu Gly Ala Ser Leu Leu
Val 1 5 17707PRTArtificial SequenceSynthetic
peptide 1770Gly Thr Gly Ala Ala Val Phe 1 5
17717PRTArtificial SequenceSynthetic peptide 1771Ala Ala Val Gly Thr Ala
Leu 1 5 17727PRTArtificial SequenceSynthetic
peptide 1772Val Ser Ala Ala Ser Ser Val 1 5
17737PRTArtificial SequenceSynthetic peptide 1773Arg Gly Gly Ser Pro Pro
Val 1 5 17747PRTArtificial SequenceSynthetic
peptide 1774Val Pro Pro Ser Gly Gly Arg 1 5
17757PRTArtificial SequenceSynthetic peptide 1775Gly Leu Gly Ser Cys Ala
Pro 1 5 17767PRTArtificial SequenceSynthetic
peptide 1776Met Pro Ala Gly Leu Gly Val 1 5
17777PRTArtificial SequenceSynthetic peptide 1777Met Pro Gly Ser Ser Arg
Pro 1 5 17787PRTArtificial SequenceSynthetic
peptide 1778Gly Ser Ser Leu Ser Arg Pro 1 5
17797PRTArtificial SequenceSynthetic peptide 1779Arg Leu Gly Ser Ser Gly
Leu 1 5 17807PRTArtificial SequenceSynthetic
peptide 1780Gly Tyr Ala Arg Gly Ser Gly 1 5
17817PRTArtificial SequenceSynthetic peptide 1781Ser Gly Arg Leu Trp Val
Gly 1 5 17827PRTArtificial SequenceSynthetic
peptide 1782Thr Ala Gly Arg Leu Glu Val 1 5
17837PRTArtificial SequenceSynthetic peptide 1783Gly Pro Ser Phe Asp Ala
Lys 1 5 17847PRTArtificial SequenceSynthetic
peptide 1784Ala Cys Thr Gly Val Ser Arg 1 5
17857PRTArtificial SequenceSynthetic peptide 1785Leu Gly Met Gly Arg Gly
Val 1 5 17867PRTArtificial SequenceSynthetic
peptide 1786Met Leu Gly Arg Gly Ser Val 1 5
17877PRTArtificial SequenceSynthetic peptide 1787Pro Arg Ala Ser Ser Thr
Gly 1 5 17887PRTArtificial SequenceSynthetic
peptide 1788Arg Ala Ser Cys Phe Trp Asp 1 5
17897PRTArtificial SequenceSynthetic peptide 1789Arg Ala Ser Cys Phe Trp
Asp 1 5 17907PRTArtificial SequenceSynthetic
peptide 1790Phe Leu Leu Leu Ser His Arg 1 5
17917PRTArtificial SequenceSynthetic peptide 1791Leu Leu Ser Val Thr Ser
Xaa 1 5 17927PRTArtificial SequenceSynthetic
peptide 1792Pro Leu Leu Arg Glu Val Gly 1 5
17937PRTArtificial SequenceSynthetic peptide 1793Leu Arg Val Gly His Ala
Gly 1 5 17947PRTArtificial SequenceSynthetic
peptide 1794Asn Glu Leu Arg Val Cys Arg 1 5
17957PRTArtificial SequenceSynthetic peptide 1795Met Arg Tyr Glu Leu Arg
Ser 1 5 17967PRTArtificial SequenceSynthetic
peptide 1796Arg Val Ser Val Trp Trp Ala 1 5
17977PRTArtificial SequenceSynthetic peptide 1797Phe Ala Gln Arg Arg Val
Ser 1 5 17987PRTArtificial SequenceSynthetic
peptide 1798Ser His His Arg Ser Ser Ile 1 5
17997PRTArtificial SequenceSynthetic peptide 1799Cys Met Ala Gly Ser Gln
Asp 1 5 18007PRTArtificial SequenceSynthetic
peptide 1800Arg Tyr Gly Thr Ala Gly Ser 1 5
18017PRTArtificial SequenceSynthetic peptide 1801Ser Ala Gly Ser His Pro
Ala 1 5 18027PRTArtificial SequenceSynthetic
peptide 1802Pro Asn Ser Ala Gly Ser Val 1 5
18037PRTArtificial SequenceSynthetic peptide 1803Lys Met Arg Ile Ala Gly
Arg 1 5 18047PRTArtificial SequenceSynthetic
peptide 1804Met Glu Arg Val Ala Gly Arg 1 5
18057PRTArtificial SequenceSynthetic peptide 1805Trp Ala Gly Leu Ser Arg
Pro 1 5 18067PRTArtificial SequenceSynthetic
peptide 1806Gly Ala His Gly Val Arg Leu 1 5
18077PRTArtificial SequenceSynthetic peptide 1807Arg Val Pro Thr Gly Val
Arg 1 5 18087PRTArtificial SequenceSynthetic
peptide 1808Arg Gly Ala Val Arg Glu Met 1 5
18097PRTArtificial SequenceSynthetic peptide 1809Phe Asp Pro Gly Gly Leu
Arg 1 5 18107PRTArtificial SequenceSynthetic
peptide 1810Ile Leu Ser Asp Leu Val Ser 1 5
18117PRTArtificial SequenceSynthetic peptide 1811Leu Leu Asn Pro Ala Arg
Gly 1 5 18127PRTArtificial SequenceSynthetic
peptide 1812Trp Trp Ala Ala Val Pro Gly 1 5
18137PRTArtificial SequenceSynthetic peptide 1813Lys Ala Ala Ser Thr Glu
Asp 1 5 18147PRTArtificial SequenceSynthetic
peptide 1814Ser Tyr Met Gly Ala Ala Ser 1 5
18157PRTArtificial SequenceSynthetic peptide 1815Gly Gly Ser Ile Asp Cys
Cys 1 5 18167PRTArtificial SequenceSynthetic
peptide 1816Gly Pro Gly Gly Ser Lys Arg 1 5
18177PRTArtificial SequenceSynthetic peptide 1817Ala Phe Gly Gly Gly Ser
Met 1 5 18187PRTArtificial SequenceSynthetic
peptide 1818Pro Glu Gly Gly Arg Arg Pro 1 5
18197PRTArtificial SequenceSynthetic peptide 1819Gly Gly Leu Glu Gln Asp
Gly 1 5 18207PRTArtificial SequenceSynthetic
peptide 1820Phe Asp Pro Gly Gly Leu Arg 1 5
18217PRTArtificial SequenceSynthetic peptide 1821Leu Phe Gly Ser Ser Val
Ser 1 5 18227PRTArtificial SequenceSynthetic
peptide 1822Trp Asp Gly Ser Ser Val Ser 1 5
18237PRTArtificial SequenceSynthetic peptide 1823Pro Asn Ser Ala Gly Ser
Val 1 5 18247PRTArtificial SequenceSynthetic
peptide 1824Met Leu Gly Arg Gly Ser Val 1 5
18257PRTArtificial SequenceSynthetic peptide 1825Thr Arg Arg Gly Arg Leu
Asp 1 5 18267PRTArtificial SequenceSynthetic
peptide 1826Gly Val Ser Ile Ser Asp Gly 1 5
18277PRTArtificial SequenceSynthetic peptide 1827Gly Val Ser Ile Tyr Asp
Leu 1 5 18287PRTArtificial SequenceSynthetic
peptide 1828Ala Arg Leu Ser Leu Glu Leu 1 5
18297PRTArtificial SequenceSynthetic peptide 1829Arg Leu Arg Leu Ser Ser
Trp 1 5 18307PRTArtificial SequenceSynthetic
peptide 1830Arg Arg Leu Ser Ser Ile Ala 1 5
18317PRTArtificial SequenceSynthetic peptide 1831Ser Arg Leu Ser Tyr Arg
Thr 1 5 18327PRTArtificial SequenceSynthetic
peptide 1832Ala Arg Gly Ser Trp Arg Glu 1 5
18337PRTArtificial SequenceSynthetic peptide 1833Val Arg Leu Arg Ala Val
Phe 1 5 18347PRTArtificial SequenceSynthetic
peptide 1834Arg Ala Ser Arg Ile Gly Leu 1 5
18357PRTArtificial SequenceSynthetic peptide 1835Gly Ala Gly Thr Ser Glu
Gly 1 5 18367PRTArtificial SequenceSynthetic
peptide 1836Leu Leu Ser Thr Val Trp Val 1 5
18377PRTArtificial SequenceSynthetic peptide 1837Glu Leu Arg Arg Leu Leu
Ser 1 5 18387PRTArtificial SequenceSynthetic
peptide 1838Leu Leu Arg Gly Leu Arg Pro 1 5
18397PRTArtificial SequenceSynthetic peptide 1839Ser Leu Leu Arg Arg Leu
Glu 1 5 18407PRTArtificial SequenceSynthetic
peptide 1840Leu Arg Val Ser Arg Gly Leu 1 5
18417PRTArtificial SequenceSynthetic peptide 1841Thr Leu Gly Leu Arg Val
Pro 1 5 18427PRTArtificial SequenceSynthetic
peptide 1842Phe Val Ala Arg Leu Arg Val 1 5
18437PRTArtificial SequenceSynthetic peptide 1843Gly Val Tyr Trp Leu Arg
Ser 1 5 18447PRTArtificial SequenceSynthetic
peptide 1844Ser Phe Trp Trp Leu Arg Ser 1 5
18457PRTArtificial SequenceSynthetic peptide 1845Thr Arg Tyr Ser Leu Arg
Ser 1 5 18467PRTArtificial SequenceSynthetic
peptide 1846Leu Arg Val Ser Arg Gly Leu 1 5
18477PRTArtificial SequenceSynthetic peptide 1847Arg Ser Ser Ser Gly Ser
Gly 1 5 18487PRTArtificial SequenceSynthetic
peptide 1848Thr Arg Ser Ser Leu Thr His 1 5
18497PRTArtificial SequenceSynthetic peptide 1849Thr Gly Arg Ser Ser Phe
Trp 1 5 18507PRTArtificial SequenceSynthetic
peptide 1850Asn Ala Gly Arg Gly Ala Ser 1 5
18517PRTArtificial SequenceSynthetic peptide 1851His Ala Gly Leu Leu Val
Val 1 5 18527PRTArtificial SequenceSynthetic
peptide 1852His Thr Tyr Gly Val Arg Phe 1 5
18537PRTArtificial SequenceSynthetic peptide 1853Gly Ala Val Arg Ser Val
Met 1 5 18547PRTArtificial SequenceSynthetic
peptide 1854Val Leu Val Glu Gly Ala Val 1 5
18557PRTArtificial SequenceSynthetic peptide 1855Leu Leu Arg Gly Leu Arg
Pro 1 5 18567PRTArtificial SequenceSynthetic
peptide 1856Thr Leu Gly Leu Arg Val Pro 1 5
18577PRTArtificial SequenceSynthetic peptide 1857Ala Arg Gly Ser Trp Arg
Glu 1 5 18587PRTArtificial SequenceSynthetic
peptide 1858Gly Leu Trp Ala Ala Val Leu 1 5
18597PRTArtificial SequenceSynthetic peptide 1859Gly Trp Thr Met Ala Ala
Ser 1 5 18607PRTArtificial SequenceSynthetic
peptide 1860Leu Tyr Met Gly Gly Ser His 1 5
18617PRTArtificial SequenceSynthetic peptide 1861Gly Val Gly Gly Arg Gln
Ser 1 5 18627PRTArtificial SequenceSynthetic
peptide 1862Arg Arg Gly Leu Gly Asp Ala 1 5
18637PRTArtificial SequenceSynthetic peptide 1863Thr Gly Gly Leu His Trp
Tyr 1 5 18647PRTArtificial SequenceSynthetic
peptide 1864Gly Ser Gly Ser Ser Ser Arg 1 5
18657PRTArtificial SequenceSynthetic peptide 1865Gly Ser Ser Thr Leu Gln
Trp 1 5 18667PRTArtificial SequenceSynthetic
peptide 1866Arg Ser Ser Ser Gly Ser Gly 1 5
18677PRTArtificial SequenceSynthetic peptide 1867Asp Glu Leu Gly Ser Val
Gln 1 5 18687PRTArtificial SequenceSynthetic
peptide 1868Gly Arg Leu Arg Pro Phe Ser 1 5
18697PRTArtificial SequenceSynthetic peptide 1869Pro Arg Leu Gly Arg Leu
Leu 1 5 18707PRTArtificial SequenceSynthetic
peptide 1870Val Gly Val Ser Gln Glu Trp 1 5
18717PRTArtificial SequenceSynthetic peptide 1871Asp Gly Val Ser Pro Leu
Trp 1 5 18727PRTArtificial SequenceSynthetic
peptide 1872Pro Arg Gly Ser Leu Phe Ala 1 5
18737PRTArtificial SequenceSynthetic peptide 1873Val Ile Val Arg Gly Ser
Leu 1 5 18747PRTArtificial SequenceSynthetic
peptide 1874Gly Asp Arg Ala Val Gly Leu 1 5
18757PRTArtificial SequenceSynthetic peptide 1875Val His Lys Arg Ala Val
Leu 1 5 18767PRTArtificial SequenceSynthetic
peptide 1876Gly Gly Ala Gly Ser Arg Arg 1 5
18777PRTArtificial SequenceSynthetic peptide 1877Arg Leu Glu Thr Leu Leu
Ser 1 5 18787PRTArtificial SequenceSynthetic
peptide 1878Leu Leu Arg Ala Gly Val Arg 1 5
18797PRTArtificial SequenceSynthetic peptide 1879Pro Ala Ile Leu Arg Val
Arg 1 5 18807PRTArtificial SequenceSynthetic
peptide 1880Gly Asp Leu Arg Val Ser Val 1 5
18817PRTArtificial SequenceSynthetic peptide 1881Gly Asp Leu Arg Val Ser
Val 1 5 18827PRTArtificial SequenceSynthetic
peptide 1882Gly Gly Ala Gly Ser Arg Arg 1 5
18837PRTArtificial SequenceSynthetic peptide 1883Ala Gly Ser Val Thr Glu
Gln 1 5 18847PRTArtificial SequenceSynthetic
peptide 1884Ser Ser Ser Leu Ala Gly Ser 1 5
18857PRTArtificial SequenceSynthetic peptide 1885Arg Ser Trp Asn Ala Gly
Arg 1 5 18867PRTArtificial SequenceSynthetic
peptide 1886Ala Gly Leu Pro His Arg Phe 1 5
18877PRTArtificial SequenceSynthetic peptide 1887Arg Asn Ser Arg Ala Gly
Leu 1 5 18887PRTArtificial SequenceSynthetic
peptide 1888Arg Arg Ser Gly Ala Gly Gly 1 5
18897PRTArtificial SequenceSynthetic peptide 1889Ala Gly Gly Pro Ser Ser
Tyr 1 5 18907PRTArtificial SequenceSynthetic
peptide 1890Thr Gly Val Arg Asn Ser Pro 1 5
18917PRTArtificial SequenceSynthetic peptide 1891Leu Leu Arg Ala Gly Val
Arg 1 5 18927PRTArtificial SequenceSynthetic
peptide 1892Ala Leu Val Ser Thr Ile Leu 1 5
18937PRTArtificial SequenceSynthetic peptide 1893Ala Arg Gly Arg Asp Glu
Gly 1 5 18947PRTArtificial SequenceSynthetic
peptide 1894Ala Ser Leu Ser Val Val Ile 1 5
18957PRTArtificial SequenceSynthetic peptide 1895Gly Gly Ser Arg Gly Tyr
Arg 1 5 18967PRTArtificial SequenceSynthetic
peptide 1896Tyr Trp Gly Gly Ser Val Pro 1 5
18977PRTArtificial SequenceSynthetic peptide 1897Gly Gly Arg Pro Val Glu
Arg 1 5 18987PRTArtificial SequenceSynthetic
peptide 1898Gly Gly Arg Ser Gln Glu Gly 1 5
18997PRTArtificial SequenceSynthetic peptide 1899Pro Gly Gly Gly Arg Gly
Arg 1 5 19007PRTArtificial SequenceSynthetic
peptide 1900Phe Ser Leu Gly Ser Ser Pro 1 5
19017PRTArtificial SequenceSynthetic peptide 1901Gly Ser Val Phe Gly Thr
Pro 1 5 19027PRTArtificial SequenceSynthetic
peptide 1902Ala Gly Ser Val Thr Glu Gln 1 5
19037PRTArtificial SequenceSynthetic peptide 1903Tyr Trp Gly Gly Ser Val
Pro 1 5 19047PRTArtificial SequenceSynthetic
peptide 1904Leu Ser Gly Arg Val Ile Val 1 5
19057PRTArtificial SequenceSynthetic peptide 1905Leu Ser Thr Pro Gly Arg
Val 1 5 19067PRTArtificial SequenceSynthetic
peptide 1906Ala Gly Gly Pro Ser Ser Tyr 1 5
19077PRTArtificial SequenceSynthetic peptide 1907Arg Val Met Arg Gly Ser
Leu 1 5 19087PRTArtificial SequenceSynthetic
peptide 1908Arg Ala Ser Cys Val Trp Ala 1 5
19097PRTArtificial SequenceSynthetic peptide 1909Gln Leu Leu Ser Gln Val
Tyr 1 5 19107PRTArtificial SequenceSynthetic
peptide 1910Glu Arg Tyr Tyr Leu Arg Ser 1 5
19117PRTArtificial SequenceSynthetic peptide 1911Gly Leu Val Lys Leu Arg
Ser 1 5 19127PRTArtificial SequenceSynthetic
peptide 1912Gly Arg Leu Ala Ala Gly Ser 1 5
19137PRTArtificial SequenceSynthetic peptide 1913Gly Leu Val Lys Leu Arg
Ser 1 5 19147PRTArtificial SequenceSynthetic
peptide 1914Leu Trp Phe Glu Leu Val Ser 1 5
19157PRTArtificial SequenceSynthetic peptide 1915Ile Gly Ala Ala Ser Trp
Phe 1 5 19167PRTArtificial SequenceSynthetic
peptide 1916Gly Gly Arg Arg Gly Thr Ser 1 5
19177PRTArtificial SequenceSynthetic peptide 1917Arg Asp Leu Gly Gly Arg
Trp 1 5 19187PRTArtificial SequenceSynthetic
peptide 1918Trp Arg Gly Gly Leu Asp Arg 1 5
19197PRTArtificial SequenceSynthetic peptide 1919Gly Arg Trp Thr Gly Ser
Ser 1 5 19207PRTArtificial SequenceSynthetic
peptide 1920Ser Tyr Trp Val Gly Ser Ser 1 5
19217PRTArtificial SequenceSynthetic peptide 1921Gly Arg Leu Ala Ala Gly
Ser 1 5 19227PRTArtificial SequenceSynthetic
peptide 1922Ala Lys Ala Gly Val Ser Arg 1 5
19237PRTArtificial SequenceSynthetic peptide 1923Leu Arg Leu Ser Gly His
Asp 1 5 19247PRTArtificial SequenceSynthetic
peptide 1924Arg Gly Val Gly Ala Lys Ala 1 5
19257PRTArtificial SequenceSynthetic peptide 1925Leu Arg Gly Val Tyr Val
Ala 1 5 19267PRTArtificial SequenceSynthetic
peptide 1926Gly Thr Pro Ala Val Ser Tyr 1 5
19277PRTArtificial SequenceSynthetic peptide 1927Phe Leu Leu Ser Arg Ser
Ala 1 5 19287PRTArtificial SequenceSynthetic
peptide 1928Ala Gly Leu Leu Ser Asp Val 1 5
19297PRTArtificial SequenceSynthetic peptide 1929Leu Arg Val Gly Xaa Pro
Gly 1 5 19307PRTArtificial SequenceSynthetic
peptide 1930Arg Val Ser Gly Ser Pro Val 1 5
19317PRTArtificial SequenceSynthetic peptide 1931Arg Ser Ser Ile Asp Val
Gly 1 5 19327PRTArtificial SequenceSynthetic
peptide 1932Ala Gly Arg Arg Leu Arg Asp 1 5
19337PRTArtificial SequenceSynthetic peptide 1933Trp Arg Leu Ala Gly Leu
Gly 1 5 19347PRTArtificial SequenceSynthetic
peptide 1934Pro Thr Val Ser Ala Gly Leu 1 5
19357PRTArtificial SequenceSynthetic peptide 1935Ala Gly Leu Leu Ser Asp
Val 1 5 19367PRTArtificial SequenceSynthetic
peptide 1936Thr Leu Gly Val Leu Val Thr 1 5
19377PRTArtificial SequenceSynthetic peptide 1937Gly Asp Arg Arg Leu Val
Ser 1 5 19387PRTArtificial SequenceSynthetic
peptide 1938Leu Met Leu Val Ser Gly Lys 1 5
19397PRTArtificial SequenceSynthetic peptide 1939Asp Val His Ala Arg Gly
Asp 1 5 19407PRTArtificial SequenceSynthetic
peptide 1940Arg Glu Gly Gly Ser Asp Thr 1 5
19417PRTArtificial SequenceSynthetic peptide 1941Gly Gly Arg Arg Val Val
Val 1 5 19427PRTArtificial SequenceSynthetic
peptide 1942Asn Val Gly Gly Gly Arg Phe 1 5
19437PRTArtificial SequenceSynthetic peptide 1943Gly Leu Gly Ala Leu Arg
Trp 1 5 19447PRTArtificial SequenceSynthetic
peptide 1944Leu Gly Leu Ser Gly Leu Gly 1 5
19457PRTArtificial SequenceSynthetic peptide 1945Arg Gly Leu Gly Arg Pro
Val 1 5 19467PRTArtificial SequenceSynthetic
peptide 1946Gly Ser Ser Gly Leu Leu Ala 1 5
19477PRTArtificial SequenceSynthetic peptide 1947Leu Gly Ser Ser Ser His
Ile 1 5 19487PRTArtificial SequenceSynthetic
peptide 1948Ile Gly Ser Gly Val Gly Val 1 5
19497PRTArtificial SequenceSynthetic peptide 1949Lys Gly Ser Val Leu Met
Leu 1 5 19507PRTArtificial SequenceSynthetic
peptide 1950Val Pro Ser Gly Ser Val Arg 1 5
19517PRTArtificial SequenceSynthetic peptide 1951Gly Tyr Leu Gly Arg Leu
Pro 1 5 19527PRTArtificial SequenceSynthetic
peptide 1952Ala Val Tyr Val Gly Arg Leu 1 5
19537PRTArtificial SequenceSynthetic peptide 1953Leu Gly Gly Arg Leu Ser
Leu 1 5 19547PRTArtificial SequenceSynthetic
peptide 1954Arg Gly Val Gly Lys Thr Lys 1 5
19557PRTArtificial SequenceSynthetic peptide 1955Leu Gly Gly Ala Arg Gly
Val 1 5 19567PRTArtificial SequenceSynthetic
peptide 1956His Ala Trp Asp Arg Gly Val 1 5
19577PRTArtificial SequenceSynthetic peptide 1957Asp Trp Gly Ser Arg Gly
Val 1 5 19587PRTArtificial SequenceSynthetic
peptide 1958Pro Tyr Arg Arg Gly Ser Cys 1 5
19597PRTArtificial SequenceSynthetic peptide 1959Ala Leu Asn Arg Gly Ser
Arg 1 5 19607PRTArtificial SequenceSynthetic
peptide 1960Thr Phe Arg Gly Ala Gly Val 1 5
19617PRTArtificial SequenceSynthetic peptide 1961Leu Leu Ser Ala Ala Arg
Phe 1 5 19627PRTArtificial SequenceSynthetic
peptide 1962Met Arg Pro Gly Leu Arg Ser 1 5
19637PRTArtificial SequenceSynthetic peptide 1963Pro Arg Val Ser Ala Leu
Val 1 5 19647PRTArtificial SequenceSynthetic
peptide 1964Val Arg Val Ser Leu Asn Ser 1 5
19657PRTArtificial SequenceSynthetic peptide 1965Gly Arg Ser Ser Ala Gly
Pro 1 5 19667PRTArtificial SequenceSynthetic
peptide 1966Leu His Ala Gly Ser Ser Val 1 5
19677PRTArtificial SequenceSynthetic peptide 1967Val Val Met Ile Ala Gly
Ser 1 5 19687PRTArtificial SequenceSynthetic
peptide 1968Asp Thr Pro Ala Gly Arg Leu 1 5
19697PRTArtificial SequenceSynthetic peptide 1969Val Gly Ala Gly Arg Phe
Thr 1 5 19707PRTArtificial SequenceSynthetic
peptide 1970Ala Gly Gly Thr Asp Arg Thr 1 5
19717PRTArtificial SequenceSynthetic peptide 1971Phe Ile Ser Ala Gly Gly
Trp 1 5 19727PRTArtificial SequenceSynthetic
peptide 1972Thr Ile Pro Ala Gly Gly Gly 1 5
19737PRTArtificial SequenceSynthetic peptide 1973Val Gly Arg Ala Gly Gly
Leu 1 5 19747PRTArtificial SequenceSynthetic
peptide 1974Asn Pro Gly Leu Val Trp Asn 1 5
19757PRTArtificial SequenceSynthetic peptide 1975Leu Gly Leu Val His Trp
Val 1 5 19767PRTArtificial SequenceSynthetic
peptide 1976Met Arg Pro Gly Leu Arg Ser 1 5
19777PRTArtificial SequenceSynthetic peptide 1977Ala Arg Gly Asn Val Arg
Phe 1 5 19787PRTArtificial SequenceSynthetic
peptide 1978Leu Gly Gly Ala Arg Gly Val 1 5
19797PRTArtificial SequenceSynthetic peptide 1979Phe Arg Ala Ala Ser Leu
Leu 1 5 19807PRTArtificial SequenceSynthetic
peptide 1980Ala Ala Ser Val Gly Val Ala 1 5
19817PRTArtificial SequenceSynthetic peptide 1981Phe Arg Ala Ala Ser Leu
Leu 1 5 19827PRTArtificial SequenceSynthetic
peptide 1982Pro Val Phe Arg Gly Gly Ser 1 5
19837PRTArtificial SequenceSynthetic peptide 1983Ser Gly Gly Ser Val Gly
Phe 1 5 19847PRTArtificial SequenceSynthetic
peptide 1984Val Arg Ala Asn Gly Gly Ser 1 5
19857PRTArtificial SequenceSynthetic peptide 1985Phe His Ile Trp Gly Gly
Arg 1 5 19867PRTArtificial SequenceSynthetic
peptide 1986Leu Gly Gly Arg Leu Ser Leu 1 5
19877PRTArtificial SequenceSynthetic peptide 1987Ser Gly Gly Arg Phe Val
Pro 1 5 19887PRTArtificial SequenceSynthetic
peptide 1988Gly Gly Gly Leu Pro Val Asp 1 5
19897PRTArtificial SequenceSynthetic peptide 1989Leu Ser Leu Arg Gly Gly
Leu 1 5 19907PRTArtificial SequenceSynthetic
peptide 1990Val Gly Arg Ala Gly Gly Leu 1 5
19917PRTArtificial SequenceSynthetic peptide 1991Ala Asn Gly Ser Ser Lys
Lys 1 5 19927PRTArtificial SequenceSynthetic
peptide 1992Asp Phe Thr Leu Gly Ser Ser 1 5
19937PRTArtificial SequenceSynthetic peptide 1993Leu His Ala Gly Ser Ser
Val 1 5 19947PRTArtificial SequenceSynthetic
peptide 1994Asn Ser Gly Ser Val Val Ser 1 5
19957PRTArtificial SequenceSynthetic peptide 1995Ser Gly Gly Ser Val Gly
Phe 1 5 19967PRTArtificial SequenceSynthetic
peptide 1996Trp Ser Ile Ser Gly Ser Val 1 5
19977PRTArtificial SequenceSynthetic peptide 1997Asp Thr Pro Ala Gly Arg
Leu 1 5 19987PRTArtificial SequenceSynthetic
peptide 1998Leu Gly Gly Arg Leu Ser Leu 1 5
19997PRTArtificial SequenceSynthetic peptide 1999Ala Val Gly Val Ser Ala
Ala 1 5 20007PRTArtificial SequenceSynthetic
peptide 2000Ser Gly Val Ser Asn Pro Gly 1 5
20017PRTArtificial SequenceSynthetic peptide 2001Phe Gly Val Ser Gly Gly
Ser 1 5 20027PRTArtificial SequenceSynthetic
peptide 2002Glu Ser Ala Thr Gly Val Ser 1 5
20037PRTArtificial SequenceSynthetic peptide 2003Ala Ala Ile Val Gly Val
Ser 1 5 20047PRTArtificial SequenceSynthetic
peptide 2004Leu Arg Ser Gly Arg Gly Ser 1 5
20057PRTArtificial SequenceSynthetic peptide 2005Leu Arg Ser Gly Arg Gly
Ser 1 5 20067PRTArtificial SequenceSynthetic
peptide 2006Arg Gly Arg Gly Ser Thr Leu 1 5
20077PRTArtificial SequenceSynthetic peptide 2007Arg Gly Ser Pro Ala Ala
Ala 1 5 20087PRTArtificial SequenceSynthetic
peptide 2008Ser Arg Gly Ser Tyr Gly Ser 1 5
20097PRTArtificial SequenceSynthetic peptide 2009Gly Val Gly Gly Gly Ala
Gly 1 5 20107PRTArtificial SequenceSynthetic
peptide 2010Leu Arg Ser Gly Arg Gly Ser 1 5
20117PRTArtificial SequenceSynthetic peptide 2011Ala Gly Gly Gly Gly Tyr
His 1 5 20127PRTArtificial SequenceSynthetic
peptide 2012Gly Ala Gly Gly Gly Val Gly 1 5
20137PRTArtificial SequenceSynthetic peptide 2013Tyr Arg Ala Leu Ala Gly
Gly 1 5 20147PRTArtificial SequenceSynthetic
peptide 2014Leu Tyr Val Asp Ala Ser Leu 1 5
20157PRTArtificial SequenceSynthetic peptide 2015Gly Glu Gly Ser Gly Ser
Ala 1 5 20167PRTArtificial SequenceSynthetic
peptide 2016Arg Val Arg Gly Val Leu Asp 1 5
20177PRTArtificial SequenceSynthetic peptide 2017Ser Met Arg Gly Val Leu
Ser 1 5 20187PRTArtificial SequenceSynthetic
peptide 2018Glu Ala Gly Pro Arg Gly Val 1 5
20197PRTArtificial SequenceSynthetic peptide 2019Cys Arg Gly Ser Ile Gly
Ala 1 5 20207PRTArtificial SequenceSynthetic
peptide 2020Pro Leu Gln Arg Gly Ser Gly 1 5
20217PRTArtificial SequenceSynthetic peptide 2021Arg Gly Ser Arg Trp Ser
Ser 1 5 20227PRTArtificial SequenceSynthetic
peptide 2022Arg Gly Ser Tyr Val Glu Arg 1 5
20237PRTArtificial SequenceSynthetic peptide 2023Thr Tyr Cys Asp Arg Ala
Val 1 5 20247PRTArtificial SequenceSynthetic
peptide 2024Leu Gly Val Arg Ala Ser Pro 1 5
20257PRTArtificial SequenceSynthetic peptide 2025Trp Arg Ala Ser Pro Gly
Met 1 5 20267PRTArtificial SequenceSynthetic
peptide 2026Pro Arg Ala Ser Asp Ile Leu 1 5
20277PRTArtificial SequenceSynthetic peptide 2027Arg Val Gly Ala Gly Trp
Pro 1 5 20287PRTArtificial SequenceSynthetic
peptide 2028Leu Leu Ser Arg Ala Gln Ala 1 5
20297PRTArtificial SequenceSynthetic peptide 2029Ser Ala Leu Arg Val Gly
Leu 1 5 20307PRTArtificial SequenceSynthetic
peptide 2030Val Gly Leu Arg Val Arg Phe 1 5
20317PRTArtificial SequenceSynthetic peptide 2031Tyr Gly Leu Arg Ser Leu
Val 1 5 20327PRTArtificial SequenceSynthetic
peptide 2032Thr Arg Val Ser Gly Ser Gly 1 5
20337PRTArtificial SequenceSynthetic peptide 2033Val Arg Arg Ser Ser Lys
Phe 1 5 20347PRTArtificial SequenceSynthetic
peptide 2034Thr Phe Ala Gly Leu Ala Gln 1 5
20357PRTArtificial SequenceSynthetic peptide 2035Leu Gly Val Arg Ala Ser
Pro 1 5 20367PRTArtificial SequenceSynthetic
peptide 2036Leu Gly Val Arg Leu Ala Ser 1 5
20377PRTArtificial SequenceSynthetic peptide 2037Pro Trp Gly Ala Gly Val
Arg 1 5 20387PRTArtificial SequenceSynthetic
peptide 2038Gly Val Leu Thr Ile Gly Ala 1 5
20397PRTArtificial SequenceSynthetic peptide 2039Arg Val Arg Gly Val Leu
Asp 1 5 20407PRTArtificial SequenceSynthetic
peptide 2040Ile Gly Trp Gly Val Leu Gly 1 5
20417PRTArtificial SequenceSynthetic peptide 2041Ser Met Arg Gly Val Leu
Ser 1 5 20427PRTArtificial SequenceSynthetic
peptide 2042Gly Ala Val Leu Thr Ser Cys 1 5
20437PRTArtificial SequenceSynthetic peptide 2043Gly Leu Val Ser Thr Leu
Ile 1 5 20447PRTArtificial SequenceSynthetic
peptide 2044Gly Leu Val Gly Trp Gly Ile 1 5
20457PRTArtificial SequenceSynthetic peptide 2045Val Gly Leu Arg Cys Ser
Val 1 5 20467PRTArtificial SequenceSynthetic
peptide 2046Val Gly Leu Arg Val Arg Phe 1 5
20477PRTArtificial SequenceSynthetic peptide 2047Tyr Gly Leu Arg Ser Leu
Val 1 5 20487PRTArtificial SequenceSynthetic
peptide 2048Gly Leu Val Ser Thr Leu Ile 1 5
20497PRTArtificial SequenceSynthetic peptide 2049Pro Arg Gly Met Ala Arg
Gly 1 5 20507PRTArtificial SequenceSynthetic
peptide 2050Arg Gly Gly Ser Asp Glu Ala 1 5
20517PRTArtificial SequenceSynthetic peptide 2051Ala Glu Asp Ser Gly Gly
Arg 1 5 20527PRTArtificial SequenceSynthetic
peptide 2052Gly Gly Arg Cys Gly Ala Glu 1 5
20537PRTArtificial SequenceSynthetic peptide 2053Gly Gly Leu Met Pro Arg
Tyr 1 5 20547PRTArtificial SequenceSynthetic
peptide 2054Gly Ser Ser Val Ser Leu Gly 1 5
20557PRTArtificial SequenceSynthetic peptide 2055Gly Ser Gly Arg Gln Leu
Pro 1 5 20567PRTArtificial SequenceSynthetic
peptide 2056Arg Lys Gly Ser Gly Thr Ala 1 5
20577PRTArtificial SequenceSynthetic peptide 2057Thr Arg Val Ser Gly Ser
Gly 1 5 20587PRTArtificial SequenceSynthetic
peptide 2058Gly Ser Gly Ser Val Arg Thr 1 5
20597PRTArtificial SequenceSynthetic peptide 2059Asp Asp Gly Arg Val His
Arg 1 5 20607PRTArtificial SequenceSynthetic
peptide 2060Asp Leu Val Gly Arg Val Arg 1 5
20617PRTArtificial SequenceSynthetic peptide 2061Trp Gly Arg Leu Glu Ser
Thr 1 5 20627PRTArtificial SequenceSynthetic
peptide 2062Met Gly Pro Ser Ala Arg Trp 1 5
20637PRTArtificial SequenceSynthetic peptide 2063Ile Ser Gly Val Ser Asp
Asp 1 5 20647PRTArtificial SequenceSynthetic
peptide 2064Gly His Ser Glu Arg Leu Ser 1 5
20657PRTArtificial SequenceSynthetic peptide 2065Glu Arg Gly Val Phe Val
Tyr 1 5 20667PRTArtificial SequenceSynthetic
peptide 2066Thr Arg Gly Val Ile Gly Gly 1 5
20677PRTArtificial SequenceSynthetic peptide 2067Arg Gly Ser Phe Gly Leu
Gly 1 5 20687PRTArtificial SequenceSynthetic
peptide 2068Pro Phe His Arg Arg Ala Val 1 5
20697PRTArtificial SequenceSynthetic peptide 2069Val Gly Ile Gly Ala Gly
Gly 1 5 20707PRTArtificial SequenceSynthetic
peptide 2070Ala Val Ser Leu Ala Trp Gln 1 5
20717PRTArtificial SequenceSynthetic peptide 2071Phe Pro Ala Val Ser Thr
Glu 1 5 20727PRTArtificial SequenceSynthetic
peptide 2072Ser Gly Ala Arg Leu Arg Ser 1 5
20737PRTArtificial SequenceSynthetic peptide 2073Ser His Arg Ser Ser Thr
Gly 1 5 20747PRTArtificial SequenceSynthetic
peptide 2074Ser Arg Leu Arg Ala Gly Ser 1 5
20757PRTArtificial SequenceSynthetic peptide 2075Ser Phe Ala Gly Arg Ile
Leu 1 5 20767PRTArtificial SequenceSynthetic
peptide 2076Arg Val Ala Ala Gly Gly Leu 1 5
20777PRTArtificial SequenceSynthetic peptide 2077Val Gly Ile Gly Ala Gly
Gly 1 5 20787PRTArtificial SequenceSynthetic
peptide 2078Val Gly Ile Gly Ala Gly Gly 1 5
20797PRTArtificial SequenceSynthetic peptide 2079Gln Lys Pro Gly Ala Val
Gly 1 5 20807PRTArtificial SequenceSynthetic
peptide 2080Leu Gly Tyr Tyr Gly Ala Val 1 5
20817PRTArtificial SequenceSynthetic peptide 2081Leu Pro Leu Gly Leu Val
Ser 1 5 20827PRTArtificial SequenceSynthetic
peptide 2082Leu Gly Leu Val Phe Thr Arg 1 5
20837PRTArtificial SequenceSynthetic peptide 2083Leu Pro Leu Gly Leu Val
Ser 1 5 20847PRTArtificial SequenceSynthetic
peptide 2084Asn Ser Lys Pro Leu Val Ser 1 5
20857PRTArtificial SequenceSynthetic peptide 2085Thr Asn Arg Phe Ala Arg
Gly 1 5 20867PRTArtificial SequenceSynthetic
peptide 2086Leu Ala Ser Leu Ala Arg Pro 1 5
20877PRTArtificial SequenceSynthetic peptide 2087Leu Gly Gly Ala Ala Val
Arg 1 5 20887PRTArtificial SequenceSynthetic
peptide 2088Ala Ala Ser Pro His Pro Gly 1 5
20897PRTArtificial SequenceSynthetic peptide 2089Leu Ser Lys Gly Gly Ser
Glu 1 5 20907PRTArtificial SequenceSynthetic
peptide 2090Gly Leu Gly Arg Ser Val Asn 1 5
20917PRTArtificial SequenceSynthetic peptide 2091Pro Gly Leu Gly Tyr Ala
Leu 1 5 20927PRTArtificial SequenceSynthetic
peptide 2092Arg Gly Ser Phe Gly Leu Gly 1 5
20937PRTArtificial SequenceSynthetic peptide 2093Gly Arg Asp Trp Gly Gly
Leu 1 5 20947PRTArtificial SequenceSynthetic
peptide 2094Arg Val Ala Ala Gly Gly Leu 1 5
20957PRTArtificial SequenceSynthetic peptide 2095Thr Val Gly Ser Ser Leu
Gly 1 5 20967PRTArtificial SequenceSynthetic
peptide 2096Gly Arg Val Asp Pro Val Asp 1 5
20977PRTArtificial SequenceSynthetic peptide 2097Ser Leu Tyr Arg Gly Arg
Leu 1 5 20987PRTArtificial SequenceSynthetic
peptide 2098Val Ala Leu Gly Val Ser Ser 1 5
20997PRTArtificial SequenceSynthetic peptide 2099Val Ser Val Thr Arg Leu
Ser 1 5 21007PRTArtificial SequenceSynthetic
peptide 2100Ala Gly Ala Thr Arg Gly Ser 1 5
21017PRTArtificial SequenceSynthetic peptide 2101Arg Arg Gly Ser Val Ala
Glu 1 5 21027PRTArtificial SequenceSynthetic
peptide 2102Phe Arg Phe Val Arg Gly Ser 1 5
21037PRTArtificial SequenceSynthetic peptide 2103Thr Arg Gly Ser Gly Ala
Gly 1 5 21047PRTArtificial SequenceSynthetic
peptide 2104Gly Ala Arg Ala Val Ala Pro 1 5
21057PRTArtificial SequenceSynthetic peptide 2105Thr Arg Gly Ser Gly Ala
Gly 1 5 21067PRTArtificial SequenceSynthetic
peptide 2106Glu Ala Val Ser Gly Arg Arg 1 5
21077PRTArtificial SequenceSynthetic peptide 2107Pro Val Arg Arg Val Ser
Ser 1 5 21087PRTArtificial SequenceSynthetic
peptide 2108Ile Arg Val Ser Ala Val Val 1 5
21097PRTArtificial SequenceSynthetic peptide 2109His Val Arg Ser Ser Tyr
Ala 1 5 21107PRTArtificial SequenceSynthetic
peptide 2110Arg Val Arg Ser Ser Leu Ala 1 5
21117PRTArtificial SequenceSynthetic peptide 2111Thr Ala Ala Gly Ser Ser
Phe 1 5 21127PRTArtificial SequenceSynthetic
peptide 2112Gly Ala Gly Ser Gly Arg Thr 1 5
21137PRTArtificial SequenceSynthetic peptide 2113Pro Ala Val Ala Gly Ser
Thr 1 5 21147PRTArtificial SequenceSynthetic
peptide 2114Ala Gly Arg His Leu Asp Ala 1 5
21157PRTArtificial SequenceSynthetic peptide 2115Asp Arg Gln Leu Ala Gly
Arg 1 5 21167PRTArtificial SequenceSynthetic
peptide 2116Leu Gly Val Arg Glu Val Gly 1 5
21177PRTArtificial SequenceSynthetic peptide 2117Val Ala Val Gly Val Arg
Ser 1 5 21187PRTArtificial SequenceSynthetic
peptide 2118Ser Phe Gly Val Leu Ser Gly 1 5
21197PRTArtificial SequenceSynthetic peptide 2119Thr Ser Gly Ala Val Ala
Pro 1 5 21207PRTArtificial SequenceSynthetic
peptide 2120Gly Leu Arg Glu Val Gln Asp 1 5
21217PRTArtificial SequenceSynthetic peptide 2121Ser Leu Val Ser Glu Arg
Ala 1 5 21227PRTArtificial SequenceSynthetic
peptide 2122Ser Val His Leu Val Ser Gly 1 5
21237PRTArtificial SequenceSynthetic peptide 2123Thr Gln Val Glu Ala Arg
Gly 1 5 21247PRTArtificial SequenceSynthetic
peptide 2124Gly Gly Arg Pro Thr Val Thr 1 5
21257PRTArtificial SequenceSynthetic peptide 2125Val Val Gly Gly Arg Arg
Thr 1 5 21267PRTArtificial SequenceSynthetic
peptide 2126Gly Val Gly Gly Leu Ser Ser 1 5
21277PRTArtificial SequenceSynthetic peptide 2127Thr Ala Ala Gly Ser Ser
Phe 1 5 21287PRTArtificial SequenceSynthetic
peptide 2128Thr Arg Gly Ser Gly Ala Gly 1 5
21297PRTArtificial SequenceSynthetic peptide 2129Arg Arg Gly Ser Val Ala
Glu 1 5 21307PRTArtificial SequenceSynthetic
peptide 2130Gly Ser Val Leu His Val Ser 1 5
21317PRTArtificial SequenceSynthetic peptide 2131Ser Gly Arg Val Phe Arg
Phe 1 5 21327PRTArtificial SequenceSynthetic
peptide 2132Trp Ser Ala Thr Gly Val Ser 1 5
21339PRTArtificial SequenceSynthetic peptide 2133Cys Ala Gly Leu Ser Gly
Gly Thr Cys 1 5 21349PRTArtificial
SequenceSynthetic peptide 2134Cys Ser Gly Ile Gly Ser Gly Gly Cys 1
5 21359PRTArtificial SequenceSynthetic peptide
2135Cys Ser Ser Gly Gly Val Leu Gly Cys 1 5
21369PRTArtificial SequenceSynthetic peptide 2136Cys Ser Trp Gly Ser
Gly Gly Ser Cys 1 5 21379PRTArtificial
SequenceSynthetic peptide 2137Cys Thr Leu Val Leu Gly Gly Ser Cys 1
5 21389PRTArtificial SequenceSynthetic peptide
2138Cys Arg Phe Glu Ser Ser Gly Gly Cys 1 5
21399PRTArtificial SequenceSynthetic peptide 2139Cys His Val Ser Gly
Gly Ser Gly Cys 1 5 21409PRTArtificial
SequenceSynthetic peptide 2140Cys Thr Gly Gly Ser Leu Gly Ala Cys 1
5
User Contributions:
Comment about this patent or add new information about this topic:
People who visited this patent also read: | |
Patent application number | Title |
---|---|
20160134092 | STRAIN RELIEF DEVICE FOR LOW FRICTION DROP CABLE |
20160134091 | ELECTRICAL BOX RECEPTACLE MOUNT |
20160134090 | SHIELD STRUCTURE FOR WIRE HARNESS |
20160134089 | WIRE TRAY FOR A WIRE HARNESS ASSEMBLY |
20160134088 | SWITCHGEAR ASSEMBLY, AND SUBMERSIBLE ELECTRICAL ENCLOSURE AND METHOD OF MANUFACTURING A SUBMERSIBLE ELECTRICAL ENCLOSURE THEREFOR |